

Annual Report 2008

OOA

Address

Oncology Graduate School Amsterdam OOA
VU medisch centrum
Kamer CCA 3.36
De Boelelaan 1117
1081 HV Amsterdam

phone : 020-4444054
e-mail : e.ruhe@vumc.nl
website : www.ooa-graduateschool.nl

Contents

Preface		5
1	Management structure	9
2	General report	13
3	Educational activities	19
4	PhD research program	25
5	Awards	43
Annex 1	Faculty and staff	47
Annex 2	International visitors	59
Annex 3	PhD theses completed	63
Annex 4	Scientific publications	71



preface

Preface

The mission of the Oncology Graduate School Amsterdam (Onderzoekschool Oncologie Amsterdam - OOA) is to educate graduate students in basic and clinical cancer research, and to ensure proper supervision and mentoring of graduate students in the Amsterdam region. OOA's graduate students are scientist-in-training who receive additional theoretical and practical education on various subjects related to cancer.

OOA is a joint venture of the Netherlands Cancer Institute (Nederlands Kanker Instituut - NKI) and the medical faculties VU Medical Center (VUmc) and Amsterdam Medical Center (AMC) of the Free University Amsterdam (Vrije Universiteit - VU) and the University of Amsterdam (Universiteit van Amsterdam- UvA), respectively. These organizations strive for excellence in research and education in oncology, the realization of which is promoted by their participation in OOA.

The OOA research program ranges from basic molecular biology to clinical bedside research. It includes, for instance, fundamental studies on cellular signal transduction and the control of gene expression, but also clinical trials of new immunotherapeutic approaches and the development

of new tools to evaluate the quality of life in cancer patients. OOA organizes a range of educational activities, including specialized training courses, meet-the-expert sessions and an annual graduate student retreat.

This report describes the activities and scientific output of OOA in 2008. It includes detailed listings of our educational activities, such as training programs, and an overview of the scientific output, including listings of PhD theses completed and scientific papers published throughout the year 2008.

Executive Directors,

Prof.dr. G.A. Meijer (VU)
Prof.dr. T.K. Sixma. (NKI)
Prof.dr. J.P. Medema (UvA)

board and organization

1

1. Management structure

Board

Prof.dr. A. Berns, chairman
Prof.dr. S. Rodenhuis
Prof.dr. H.M. Pinedo, til 30 September
Prof. dr. C.J.L.M. Meijer, from 1 October
Prof.dr. P. Postmus
Prof.dr. C.E.E. Konings
Pof.dr. D.J. Richel

Executive directors

Prof.dr. G.A. Meijer, chairman
Prof.dr. T.K. Sixma
Prof.dr. J.P. Medema

Participating institutes

Free University Amsterdam (VU)/ VU Medical Center (VUmc)
Administrative center
Contact / secretariat: dr. E.M. Ruhé-Hoogervorst
De Boelelaan 1117
1081 HV Amsterdam
phone : 020-4444054
fax : 020-4442964
email : e.ruhe@vumc.nl

University of Amsterdam (UvA)/ Academic Medical Center (AMC)
Contact / secretariat: dr. Y. Donselaar
Meibergdreef 15
1105 AZ Amsterdam
phone : 020-5668502
fax : 020-5669165
email : y.e.donselaar@amc.uva.nl

Netherlands Cancer Institute. (NKI)
Contact / secretariat: Ms. F. Manuputty
Plesmanlaan 121
1066 CX Amsterdam
phone : 020 512 1950
fax : 0 20 512 1954
email : f.manuputty@nki.nl

Faculty and staff

The complete list of founding institutes' faculty and staff involved in educational activities and research projects conducted by OOA is provide in Annex 1.

The background features a large, abstract graphic composed of several overlapping, semi-transparent gray shapes. These shapes are geometric, including triangles and polygons, and they overlap in a way that creates a sense of depth and movement. The overall effect is a modern, minimalist design.

general report

2

2. General report

Educational activities

The core activity of OOA is training PhD students in conducting cancer research. For this purpose, OOA has developed a high-quality curriculum. In 2008, OOA organized various graduate training courses and an Annual Graduate Student Retreat.

All courses were evaluated by means of standardized evaluation procedures. In this way, OOA carefully monitors the quality of its courses. Based on the outcome of these evaluations, the training programs are being improved continuously.

A detailed description of all training courses offered in 2008 is provided in chapter 3 of this Annual Report.

Research program

Research projects at OOA's institutes can be clustered under two main themes. The theme 'Experimental biology' covers 'Oncogenesis' and 'Tumor cell biology' as the main lines of research. The second main theme is 'Experimental clinical research' and covers 'Diagnosis of cancer' and 'Prevention and therapy of cancer'. Chapter 4 provides listings of all individual PhD projects conducted within these main themes. More detailed descriptions of these research programs and their output are provided in the annual reports of the founding institutes.

Theme 1: Experimental biology

The development of cancer is frequently associated with aberrations in cell signalling and signal transduction pathways. Transformation of a normal cell into a fully malignant cell requires multiple (sequential) genetic alterations affecting key genes controlling essential cellular pathways involved in cell division, proliferation, and apoptosis. Studying the genes and proteins involved in these pathways should result in a better understanding of the processes of tumorigenesis and tumor progression and should contribute to the development of novel diagnostic tools and better treatment strategies.

By applying innovative research tools, novel components of the major cancer-relevant pathways may be discovered. Tools applied in research projects include high-throughput methods for genetic, epigenetic, transcriptomic and proteomic analyses. Examples are gain-of-function

genetic screens with retroviral cDNA expression libraries, and loss-of-function genetic screens with RNA interference libraries. In addition, advanced mouse models have been developed for the genetic dissection of cancer.

At the cellular level, processes like cell-cell communication, cell-cell adhesion, cell migration and proliferation are being studied. Metastasis, the spread of tumor cells to distant sites in the body, is the main cause of cancer lethality. The mechanisms of cancer metastasis are being investigated. Important mechanisms in the pathogenesis of cancer are studied including genetic susceptibility, viral oncogenesis, oncogene induced senescence, genomic instability, tumor stroma interactions and anti tumor immune responses.

Theme 2: Experimental clinical research

This theme focuses on the identification of new methods for the diagnosis, prognosis and individualized treatment of cancer. Early detection of cancer greatly increases the chance of a favourable outcome.

The emerging and rapidly growing fields of molecular imaging and genomics provide new opportunities to study the unique biology of a specific malignant disease in an individual patient. Combining an integrated research approach with clinical data collection and evaluation allows for the development of highly valuable indicators for the diagnosis and prediction of disease outcome in the individual patient. In our research, modern state-of-the-art CT and MRI machines enable imaging of anatomical details with high precision. In addition, imaging techniques like SPECT, PET, PET-CT and MRI, provide non-invasive methods to obtain unique molecular and biological information at the tissue level in vivo. For the purpose of molecular imaging studies, novel reporter probes are being developed and evaluated in (pre)clinical studies. In addition, by using (advanced) mouse models available at the OOA institutes, new clinical strategies for molecular imaging are being developed.

High-throughput tools are being applied to measure genetic variation and improve the criteria for disease classification. These tools include expression micro-arrays and CGH arrays for human and mouse studies. Quantitative mass spectrometry is being applied in the search for proteins capable of distinguishing between diseased and disease-free states with high sensitivity and specificity. The newly identified

proteins may be used as specific cancer markers for routine non-invasive tests.

Cancer therapy is another important focus within this theme. This program includes research lines focused on targeted therapy, both by medical and radiotherapeutic means. Patient-tailored therapy should ensure that the benefits of a treatment are optimized and that patients who are unlikely to benefit, are spared the side-effects of treatment. The research projects include preclinical evaluation and clinical application of the new generation of molecular targeted therapies and anti-angiogenic agents against novel cellular targets in the tumor and its environment. The pharmacological optimization of conventional cytotoxic drugs is another line of research that is being studied.

The theme "Experimental clinical research" also focuses on passage of the blood-brain barrier by drugs. Inadequate passage of the blood-brain barrier is generally considered a major cause of the lack of efficacy of systemic chemotherapy against intracranial malignancies.

Yet another research line is focused on immune therapy. New immunotherapeutic approaches for the treatment of malignant disorders are being investigated. The impact of vaccination in the adjuvant and primary treatment settings is being explored.

Projects focused on radiotherapy and surgery is directed at the clinical implementation and optimization of 4-dimensional, image-guided approaches to improve local disease control by radiation treatment and to reduce toxicity to normal tissue.

In the gene therapy area, clinical trials are evaluating gene therapy in malignancy with the current focus on optimal targeting of tumors and improving viral vector efficacy.

PhD projects and students

Overall, 356 PhD projects were actively elaborated throughout 2008. The names of the PhD students at the three OOA institutes and the projects in which they participated are listed in chapter 4.

Of all PhD projects, 17% was funded by the participating institutes themselves (primary funding; 'eerste geldstroom'); 19% was financed by public funds (secondary funding; 'tweede geldstroom'), 44% by research contracts from external organisations including cancer charity and industrial funds (tertiary funding; 'derde geldstroom') and 20% was financed by other funds (quaternary funding; 'vierde geldstroom').

A total of 48 students completed and defended their PhD thesis and obtained their PhD degree in 2008. Annex 3 provides the complete list of PhD students who obtained their degree in 2008 with details of their theses and graduation.

International visitors

Training of PhD students can be stimulated and enhanced by having scientific interactions between students and foreign experts operating in the field of the students' research projects. OOA is part of a large international network of cancer researchers and, therefore, international guests from other research institutes visit OOA's institutes frequently to interact with OOA students and staff.

Throughout 2008, we welcomed 83 international experts in various settings (Annex 2).

Awards

Several PhD students and staff of the OOA institutes won prestigious awards and honors - scientific or otherwise - in 2008. Chapter 5 provides a listing of these awards and honors.

OOA has an excellent (inter)national status, as demonstrated by, amongst others, the large number of research projects granted in open national and international calls. Recent examples include 3 CTMM projects and 7 TI Pharma strategic Research Programmes next to multiple EU, KNAW and NWO grants, like the 'vernieuwingsimpuls'.

Scientific publications

The OOA international reputation is also evident by the high quality of the published output of the three institutions in top scientific journals.

Research highlights in 2008, also reflecting current status of relevant research, were amongst others, the results of a study published by the research group of Ruud Brakenhoff (VUmc) in the J. Natl. Cancer Inst. Showing that HPV does not play a major role in squamous cell carcinogenesis in Fanconi anemia patients. Furthermore it was shown that the Fanconi anemia squamous cell carcinomas (SCC) are genetically similar to sporadic SCCs despite having a different etiology. Tom Wurdinger (VUmc) demonstrated, in collaboration with collaborators at Harvard Medical School, that a small regulatory microRNA, miR-296, has a major role in the upregulation of growth factor receptors on endothelial cells which is a key step in angiogenesis in e.g. glioma. Inhibition of miR-296 with antagomirs reduces angiogenesis in tumor xenografts in vivo (Cancer Cell).

Ben Slotman (VUmc) et al published in collaboration with University Medical Center Groningen in the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination with chemotherapy or surgery (Journal of Clinical Oncology).

Studying the mechanism of oncogene-induced senescence, a cellular process protecting against cancer, Daniel Peeper's (NKI) group described in collaboration with Wolter Mooi (VUmc) in Cell an

unexpected role for interleukins. They observed that these cytokines have an essential role in protecting cells against the proliferation-stimulating effects of activating oncogene mutations.

The group of Reuven Agami used a novel genetic screening approach to select micro RNAs (miRNAs) that target any gene of interest. This revealed that miR-221 promotes cancerous growth of glioblastomas by restricting the expression of the tumor suppressor p27. They also identified miR-372 and miR-373 as miRNAs that stimulate cellular migration, invasion and metastasis of breast tumors and uncovered the the function of Dead End (DND1), a gene essential for germ cell survival and protection from germ-cell cancer (Nature Cell Biology).

The group of Bas van Steensel published their mapping of some 1,300 large domains that associate with Lamin (LADs) in Nature. These LADs represent a repressive chromatin environment, demonstrating that the human genome is divided into large, discrete domains that are units of chromosome organization within the nucleus. Anthony Uren and Jaap Kool in collaboration with the groups of Lodewyk and David Adams (Sanger centre, UK), highlighted the power of high throughput insertional mutagenesis screens as a cancer gene network discovery platform in cancer-predisposed p19ARF and p53 deficient mice in a paper in Cell.

Constitutional gene defects predispose to cancer in children. Such tumor predisposition syndromes can be recognized by specific patterns of morphological abnormalities. Johannes Merks published in JAMA that pediatric patients with cancer show a significantly higher prevalence of morphological abnormalities compared with controls. Specific patterns of morphological abnormalities indicate possible unrecognized tumor predisposition syndromes, but validation in an independent sample is needed.

Understanding how cells maintain genome integrity when challenged with (DSBs) is of major importance, particularly since the discovery of multiple links of DSBs with genome instability and cancer-predisposition disorders. Ionizing radiation is the agent of choice to produce DSBs in cells; however, targeting DSBs and monitoring changes in their position over time can be difficult. The research group of Jacob Aten published in Nature Genetics a procedure for induction of easily recognizable linear arrays of DNA double-strand breaks (DSBs) in nuclei of adherent eukaryotic cells by exposing the cells to alpha particles from a small Americium source (Box1).

The group of JP Medema showed that spheroid cultures of colon cancer stem cells (CSCs) contain expression of CD133, CD166, CD44, CD29, CD24, Lgr5, and nuclear beta-catenin, which have all been suggested to mark the (cancer) stem cell population. More importantly, by using these spheroid cultures or freshly isolated tumor cells from multiple colon carcinomas, they provided compelling evidence to indicate that the capacity to propagate a tumor with all differentiated

progeny resides in a single CSC. Single-cell-cloned CSCs can form an adenocarcinoma on xenotransplantation but do not generate the stroma within these tumors. Moreover, they can self-renew and are capable of multilineage differentiation. Further analysis indicated that the lineage decision is dictated by phosphoinositide 3-kinase (PI3K) signaling in CSCs.

A total of 1257 publications have been published (with participation) by researchers from the three institutes combined. Of these, 53 papers were published jointly by researchers from different participating institutes in OOA. Annex 4 provides the complete list of scientific publications in 2008.

Facilities

The main goal of all research activities of the 3 OOA institutes is to better understand the development of cancer and to improve the perspectives of cancer patients. For this purpose, many state-of-the-art technologies are present and new initiatives have been developed. Information about innovative technologies is communicated at many occasions, including courses and the OOA retreat, and these technologies are open to PhD students within OOA. As a result, the OOA PhD students often have early access to novel techniques and can apply these in research.

State-of-the-art facilities are:

- Microarray facilities with high resolution oligonucleotide array and CGH arrays for mouse and human studies (VUmc, NKI)
- Oncoproteomics laboratory for protein and glycan profiling using mass spectrometry (VUmc, AMC)
- (Molecular) Imaging facilities (cyclotrons, GMP facilities, animal and clinical PET/CT-cameras and MRI-machines) enabling imaging of anatomical details with high precision (VUmc)
- Tissue microarray facility (VUmc)
- Robotics and screening facility, including high content imaging (NKI)
- Microscopy facility, including extensive confocal and electron microscopy (NKI, AMC)
- Flow cytometry facility (NKI, AMC)
- Extensive animal facilities (NKI)
- Tissue and Serum biobanks (NKI, VUmc)
- New animal facility (ARIA) (AMC)
- Genomics: MPS GS-FLEX sequencer (AMC)
- Lentiviral library for RNA-silencing for human and mouse (AMC)
- Mass spectrometry facility (AMC)

In addition, new initiatives are:

- Imaging Center (including training center) (VUmc)
- Central Clinical Trial Support (office) (VUmc, AMC)
- Phase I/II unit for clinical trials (VUmc)
- Biobanking (VUmc, AMC)
- Human monoclonal antibody phage display facility (VUmc)
- Mouse Clinic (NKI)
- Protein Expression Facility (NKI)

educational activities

3

3. Educational activities

In line with its mission, i.e. providing graduate students education in oncology research, OOA organizes several advanced courses in the field of oncology annually. The educational program is drawn up by the Board of Directors based upon evaluations of previous courses, contemporary developments in cancer research, and educational needs expressed by PhD students as well as initiatives from the OOA faculty. OOA offers courses focused on a wide variety of topics.

In 2008, 7 courses and 5 Meet-the-Expert sessions were organized. Courses are usually restricted to about 15-20 graduate students to ensure optimal interaction between students and faculty. Courses are advertised on the OOA website and announced by e-mail to the PhD students. Courses included lectures given by (inter)national experts, demonstrations and practical training. In addition, the Annual Graduate Student Retreat was organized again in 2008.

Besides the specialized oncological courses mentioned below, the graduate students followed several general courses such as on biostatistics and epidemiology, on laboratory animal technology and on writing and (poster)presentations techniques in scientific English. These courses were organized by the AMC, VUmc and NKI.

HPV: Secondary prevention and the new era

Meet the Expert session with prof. dr. L. Gissmann and prof. dr. M. Stanley

Organization: Prof. dr. C.J.L.M. Meijer
Date: 16 January
Location: VUmc

This session, organized as part of a symposium was focussed on an in depth discussion with 2 experts on this field. Prof. Gissmann (German Cancer Research Center, Heidelberg, Germany) has excellent expertise on the development of optimized methods for the induction of immune responses against the early proteins of HPV 16, the prototype of cancer-related papillomaviruses.

Prof. Stanley (University of Cambridge, Cambridge, UK) leads a research group focusing on the prevention and treatment of human papillomavirus infection, which causes cervical cancer. Understanding the ways in which the immune system develops a response to the human papillomavirus is important if effective vaccines against viral-associated disease are to be produced. A search for the cellular and viral changes that could control the progression of neoplastic disease forms another area of research focus.

This session was attended by 14 PhD students. The overall evaluation rate was 8.4 (scale 1-10).

Replication Stress and Genome Maintenance

Organization: prof. dr. H.P.J. te Riele
dr. J. de Winter
Date: 11 - 23 February
Location: NKI, VUmc

During cell division, cells need to faithfully transmit their genetic information to daughter cells. In particular during S phase, the integrity of the genetic information is challenged e.g. by misincorporation of nucleotides by replicative or translesion polymerases or by stalling of replication forks at sites of DNA damage. In cancer cells deregulated cell cycle control leads to replication stress, which may be caused by inappropriate coordination of replication origin firing. The course focused on DNA damage that can occur during DNA replication and provided an overview of the cellular responses to replication stress. During the course, 8 speakers of international reputation gave a seminar. In addition, participants had an in-depth discussion with the speaker of the day. Discussions were chaired by two participants who prepared for this by reading two papers of the speaker.

Cellular Oncology: Translating Basic Knowledge into Clinical Application

Organization: Prof. dr. G.A. Meijer
Date: 5 - 8 March
Location: VUmc

The genomic and proteomic revolution continues to have a tremendous impact on cancer and has provided unprecedented insights into its basic mechanisms. The current challenge to the medical-scientific community is to carry these new insights further and to translate these into new clinical applications. Ultimately, investigations will have to result in the identification of novel diagnostics and prognostic markers and of therapeutic targets towards prevention and clinical management of pathological conditions caused by aberrations of cell growth and homeostasis. During this 4-day meeting a broad range of topics were covered, including cancer biology, detection, diagnosis and therapeutic management.

A total number of 44 PhD students attended this symposium.

The Microscopic, Macroscopic and Pathologic Anatomy of the Mouse

Organization: Prof. dr. R. van Noorden
Prof. dr. W. Lamers
Date: 17 - 20 March
Location: AMC

Most biomedical PhD students perform animal experiments at some stage of their research career, but most students have never received practical instructions with respect to the anatomy, histology and pathological anatomy of experimental animals. For this reason, experimental animals are usually not subjected to a thorough and systematic inspection to assess whether, besides the local (expected) effects in the organ(s) under study, other organs are affected as well.

This annual course aims at providing insight(s) into the anatomy and histology of the mouse, presently the most frequently used animal species in cancer research. In addition, the course focused on the recognition of pathological changes in the mouse. During the course each student dissected either a male or a female mouse, to become acquainted with the topographic anatomy of this species. The microscopy part of the course focused on studying the architecture of normal and pathologically altered mouse tissues. During the practical part, recognition of cell and tissue types, and changes in architecture of tissues as a result of pathological processes, were studied microscopically.

In addition to standard staining techniques, functional staining techniques were demonstrated. This year the practical part of the microscopical anatomy has been done with computerized sections and computer assisted magnifications.

Of the total number of 25 participants, 18 were PhD students of the OOA, 1 assistant professor, 1 biotechnician, 1 medical practitioner and 4 master oncology students.
The overall evaluation rate was 7.0 (scale 1-10).

Clinical Oncology

Organization: Prof. dr. J.P. Medema
Prof. dr. D. Richel
Date: 16 - 20 June
Location: AMC

During this course, a detailed insight into the epidemiology, screening, diagnosis and treatment of cancer, with an emphasis on breast and colorectal cancer was given. The course was designed to provide a framework for laboratory scientists (molecular biologists, chemists, biologists) on the day-to-day reality of cancer treatment in the clinic. It involved presentations on the current and future possibilities in diagnosis and treatments, on cancer epidemiology and screening. Moreover, this course was unique in that it allowed students to participate in multidisciplinary patient discussions where treatment regimens of patients are discussed, to witness an endoscopy demonstration and to sit in at a patient policlinical visit. The program was spread out over 5 days, but in

parts of the program participants were divided (poli visit, multidisciplinary discussions). In effect the course was thus be a 3 day course for the participants. Importantly, it also included a meet-the professor session (see below).

A total of 11 students participated in the course. The overall evaluation rate was 8.0 (scale 1-10), including meet-the-expert session.

Low-penetrance genes for colorectal cancer

Meet the Expert with prof. dr.

I. Tomlinson

Organization: Prof. dr. J.P. Medema
Prof. dr. D. Richel
Date: 18 June
Location: AMC

Prof. dr. Tomlinson (Molecular and Population Genetics Laboratory, Cancer Research UK, London Research Institute, UK) has outstanding expertise in the area of colorectal tumorigenesis. His research focuses on the discovery of genes that predispose to colorectal cancer and the roles of mutation and selection in tumorigenesis, with emphasis on the Wnt pathway. He has contributed to a large number of publications in high ranked journals.

This master class was part of the topical course, but could be attended by other PhD students as well. It will started with a seminar by professor Tomlinson himself and was followed by in depth discussions with the attendees.

A total of 16 students participated in this session.

Basic Microscopy Course "In the Footsteps of Antoni van Leeuwenhoek"

Organization: Dr. J.A.M. Beliën
Dr. L. Brocks
Dr. W.A. van Cappellen
Prof. dr. TWJ Gadella
Dr. A.B. Houtsmuller
Dr. K. Jalink
Prof. dr. C.J. van Noorden
Dr. L. Oomen
Prof. dr. P.J. Peters
Dr. E.A.J. Reits
Time: 5 - 9 September
Location: VUmc, AMC

This 5-day basic course covered a wide range of aspects of microscopy, starting with a short history of microscopy and basic principles of various forms of microscopy. Lectures, hands-on sessions covered the basics of image analysis and image processing, image measurement, TyhConfocal microscopy, confocal microscopy (live cell imaging), Fluorescence microscopy, electron microscopy. During the course samples were prepared and examined. The participants could bring their own purified proteins solutions after consulting with the organization first.

In the journal club key review papers were discussed on the theme 'The use of fluorescence in cell biology'. The papers were read by the students. Summaries of (parts of) the papers are given by students in the journal club.

A total of 20 students participated in the course. The overall evaluation rate was 3.8 (scale 1-5).

Annual Graduate Student Retreat

Organization: Prof.dr. T. Sixma
M. van der Velde
F. Manuputty
Time: 3 - 5 October
Location: Texel

A highlight of the educational program is the Annual Graduate Student Retreat. This three-day retreat focuses entirely on research conducted by the graduate students themselves. At the retreat, students not only present their work as a poster in the first year of their participation and as an oral presentation in subsequent years, they are also in charge of chairing sessions, discussions. In recent years, students participated in peer review of presentations given by others in order to award the prize for the best poster and best presentation. In this manner, the retreat trains important skills in presentation and interaction but it also provides an overview of research conducted within OOA at an early stage of the student's career, contributing significantly to the interaction between different groups.

A total of 93 students participated in this retreat. The overall evaluation rate was 3.5 (scale 1-5).

Drug Discovery and Development

Organization: Prof. dr. J.J. Neefjes
Dr. B. Rodenko
dr. H. Ovaa
Time: 3 - 10 October
Location: NKI

Chemical compounds are central in the treatment of disease. Novel compounds are entering the clinic and this will continue. How are such drugs generated and what can be expected in the future?

In this course, the development of drugs, including biologicals, is described from target discovery to chemical lead-optimization of potential drugs, toxicology and pharmacology, approval and final market-launch. This course will be given in collaboration with internationally recognized speakers from academia and industry.

Friday prior to the course (October 3) it was possible to join a crashcourse basic principles "chemical synthesis".

A total of 30 students participated in the course. The overall evaluation rate was 8.0 (scale 1-10).

Somatic genome alteration in human prostatic carcinoma

Meet the Expert with prof. dr.

B. Nelson

Organization: Prof. dr. P. Snijders
Date: 31 October
Location: VUmc

This session was organized as part of the CCA Translational Oncology Symposium 2008 on October 30.

Prof. dr. B. Nelson (The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins) has discovered the most common known somatic genome alteration in human prostatic carcinoma cells. The DNA lesion, hypermethylation of deoxycytidine nucleotides in the promoter of a carcinogen-defense enzyme gene, appears to result in inactivation of the gene and a resultant increased vulnerability of prostatic cells to carcinogens. Another major interest pursued in his laboratory is the role of chronic or recurrent inflammation as a cause of prostate cancer.

During the 'Meet the Expert Session' participants discussed several papers of Prof. Nelson.

A total of 8 students participated in this session. The overall evaluation rate was 7.0 (scale 1-10).

Mouse Models for Colorectal Cancer Research

Meet the Expert with prof. dr.

B. Cormier

Organization: dr. R.J.A. Fijneman
Date: 10 November
Location: VUmc

Prof. dr. R.T. Cormier (University of Minnesota, Dept. of Biochemistry & Molecular Biology, Medical School Duluth, MN, USA) has outstanding expertise in the area of mouse models to investigate development of colorectal cancer (CRC). Research in his lab has focused on functional characterization of genetic modifiers of CRC. While identifying these genes directly in humans is difficult, mouse models can be used to clone cancer susceptibility genes whose human homologues can be evaluated clinically. The Min (Multiple Intestinal Neoplasia) mouse, which carries a dominant mutation in the Apc gene, has been shown to be a valuable model of human CRC. Projects in the lab include the use of transgenesis and targeted mutagenesis to study the role of (genetic) modifiers of Min such as Pla2g2a, PPARgamma, MUC2, EphA2, and MCT1; understanding how altered DNA methylation affects Min tumorigenesis; and identification of genes critical for intestinal cancer metastasis using transposon mediated mutagenesis.

During the 'Meet the Expert Session' participants were given the opportunity to discuss several papers with Prof. Cormier that focus on current high-throughput techniques to identify new cancer genes using in vivo mouse models of tumor development.

The seminar by dr. Cormier was part of a Mini-symposium on Mouse Models for Human Cancer Research.

A total of 7 students participated in this session. The overall evaluation rate was 8.5 (scale 1-10).

Advanced Microscopy Course “In the Footsteps of Antoni van Leeuwenhoek”

Organization: Dr. J.A.M. Beliën
Dr. L. Brocks
Dr. W.A. van Cappellen
Prof. dr. TWJ Gadella
Dr. A.B. Houtsmuller
Dr. K. Jalink
Prof. dr. C.J. van Noorden
Dr. L. Oomen
Prof. dr. P.J. Peters
Dr. E.A.J. Reits

Time: 3 - 12 November

Location: VUmc, AMC, NKIParticipants of this advanced course attended 6 of 11 optional topics.

These topics included:

Quality control and characterization of confocal microscopes, Intracellulair protein labeling and visualization by confocal and correlative EM, Calculation of Confocal FRET from Images of Sensitized Emission, Fluorescence life-time determination by time-correlated single-photon counting (TCSPC), Large-Scale Imaging scanner (LSI), Frequency-domain fluorescence lifetime imaging microscopy (FLIM), Spectral imaging microscopy and CLEM, Total internal reflection fluorescence (TIRF) and Spinning disk microscopy , 4Pi microscopy , Fluorescent redistribution after photobleaching (FRAP) and CRYO-Electron Microscopy and Tomography of biological sections: Bridging the gap between EM and X-ray.

A total of 20 students participated in this session. The overall evaluation rate was 8.5 (scale 1 - 10).

Chromosomal instability pathways in gastric cancer

Meet the Expert with prof. dr. O. Monni and prof. dr. H. Grabsch

Organization: Dr. B. Carvalho
Dr. N. van Grieken
Prof. dr. G.A. Meijer

Time: 15 December

Location: VUmc

This session was part of a symposium “Etiology of Gastic Cancers”. An in depth discussion with the experts was focus of this session.

Prof. dr. O. Monni is leader of the gastrointestinal research group of the Section of Pathology and Tumour Biology (Leeds Institute of Molecular Medicine, Leeds University). Aim is to improve the outcome of patients with cancer of the upper or lower gastrointestinal (GI) tract using knowledge derived from large clinical trials/population based studies.

Research of Prof. dr. O. Monni is primary focused is on head and neck squamous cell carcinoma, gastric cancer and breast cancer. Integrated analyses of copy number and gene expression in clinical tumors and cell lines have illustrated that deregulation of hundreds of genes is associated with genomic losses and amplifications across the genome. A number of frequent tumor type specific copy number and gene expression alterations have been identified but the biological and pathophysiological significance of these alterations is still largely unknown. Interest is now to dissect the functional role of the genes that have been identified as deregulated due to genomic aberration in epithelial cancers.

A total of 7 students attended this session. The overall evaluation rate was 7.8 (scale 1-10).

PhD research program

4

4. PhD research program

This chapter describes the 356 PhD projects conducted within the two main themes of the OOA research programs, with the names of the PhD students involved and their supervisor(s). Graduate students who obtained their PhD degree in 2008 are marked by means of an asterisk added to their name.

Funding

- 1 Financed by participating OOA institute ("eerste geldstroom")
- 2 Financed by public funds ("tweede geldstroom")
- 3-4 Financed by private funds ("derde / vierde geldstroom")

Theme 1 Experimental Biology

Biochemistry (NKI)

A.C. Faesen	3D repertoire	Sixma	2005	2
J. Hausmann	Structural studies of autotaxium	Sixma	2008	3
F. Mattioli	Structural and functional analysis of a novel E3 ubiquitin ligase consisting of the pcp's BMI1 and ING1B	Sixma	2006	3
A. Reumer	LI & Alu elements: Structural and functional analysis of human non-LTR retrotransposons	Sixma	2005	2
J.J. Smit	Ubiquitin conjugation	Sixma	2007	4
M. Vargas	Structural analysis of the mechanism of ubiquitin conjugation	Sixma	2004	2

Cell Biology I (NKI)

J.I. van den Bout*	The role of $\alpha\beta 1$ integrin in the development and pathophysiology of the glomerulus	Sonnenberg	2000	3
Q. le Duc	The role of actomyosin contraction in the down-regulation of E-cadherin mediated cell adhesion	De Rooij	2007	3
S. Ellenbroek	Tiam1/Rac signaling and wnt/beta-catenin-induced tumorigenicity	Collard	2004	3
D. Elouarrat	Regulation of sirt1 and downstream targets by phosphoinositides	Moolenaar	2005	3
E. Frijns	Controlling hemidesmosome dynamics by phosphorylation of residues on the integrin beta4	Sonnenberg	2007	4
A. Hajdo-Milasinovic	Ras en Rho signaling networks and epithelial-mesenchymal transition	Collard	2001	3
A. Houben	Autotaxin, a secreted lyso PLD: role in tumor progression	Moolenaar	2006	3
S. Huveneers*	Cooperation between the SRC oncogene and integrin $\alpha\beta 3$ in oncogenic transformations of epithelial cells	Danen	2003	3
M. Ketema	Analysis of the function of a novel nuclear envelope protein, nesprin 3 in anchoring the nucleus to the intermediate filament system	Sonnenberg	2005	2
C. Margadant	Generation of a mouse model for EBS-MD	Sonnenberg	2006	4
J. Meijer	Role of the chemokine SDF-1 and its receptor CXCR4 in carcinoma and melanoma metastasis	Roos	2003	3
S. Mertens	Initiation and progression of lymphomas and skin carcinogenesis in Tiam1 mutant mice	Collard	2001	3
B. Ponsioen	LPA receptor signaling	Moolenaar	2003	3
T. Rygiel	Function based screening for genes involved in invasion of epithelial tumor cells	Collard	2002	3
N. Sachs	Function of integrin-CD151 complexes in tumor cell invasion and metastasis	Sonnenberg	2004	3
D. Visser	TRPM7: a novel regulator of cytoskeletal tension: implications for cancer progression, invasion and metastasis	Moolenaar	2007	3

L. van Zeijl	Cell-cell connexin signalling: suppression of cell transformation	Moolenaar	2000	3
Cell Biology II (NKI)				
H. Albers	Modulation of antitoxin activity by small molecules	Ovaa	2007	2
C. Berkers	Chemistry-based functional proteomics, new tools for cancer biology	Oova	2004	1
S. van Deventer	Kinome and phosphatome knock-down	Neefjes	2008	4
T. van den Hoorn	Defining the MHC class II microdomain to understand immune responses	Neefjes	2004	3
R. Hoppes	MHC synthesis	Ovaa	2007	2
D. Houben	Pathways of antigen presentation by CD1 a,b and c	Peters	2006	2
M. Jongasma	Manipulating the MHC class II system to control immune responses in auto immunity	Neefjes	2007	2
R. van der Kant	Manipulating the MHC class II system to control immune responses in auto immunity	Neefjes	2007	2
M. Kedde	Studying tumorigenesis using RNAi	Neefjes	2003	3
R. de Leeuw			2007	4
R. Nagel	Nuclear receptors in targeted cancer therapy Genome wide search for DNA damage checkpoint functions in humans	Michalides Neefjes	2005	4
J. Neijssen*	Peptidases and improving the MHC class I response	Neefjes	2002	2/1
B. Pang	Manipulation of phagosomal pathways	Neefjes	2006	2
P. Paul	Drugs for therapy	Neefjes	2006	2
J. Pierson	EG immunoprion immunological and structural studies of prion diversities	Peters	2006	4
I. Salomon	Microban	Neefjes	2005	4
N. Sousa Rocha*	Structure elucidation of cord7 and complexe	Neefjes	2001	1
Y. Souwer	The role of HLA-DO and HLA-DM in effective MHC class II mediated immune activation	van Ham / Neefjes	2001	2
W. Zwart	Molecular basis of resistance to anti-estrogens	Michalides	2003	1
Gene regulation (NKI)				
A. Bos	Genetic screens to identify cancer related functions of human microRNAs	Agami	2008	3
U. Braunschweig	Genome-wide analysis of chromatin structure	van Lohuizen	2005	2
J. Drost	Identification and characterization of human tumor suppressor genes in the p53 pathway	Agami	2005	3
J. Duijse	Genome wide screens for DNA-damage check point in human cells	Agami	2005	4
A. Duursma*	Activated proteolysis in response to DNA damage	Agami	2001	1
D. Engelsma*	Synthetic transport signals to predict and regulate nucleocytoplasmic transport	Fornierod	2002	1
F. Frederiks	The role of histone methylation in the regulation of gene expression	van Leeuwen	2004	4
J. Hendriksen*	Role of the nuclear pore complex in β -type catenin nuclear signalling	Fornierod	2001	2
B. Kalverda	The role of RamBP3 in beta cetenin dependent nuclear signaling and oncogenesis	Fornierod	2004	3
M. van Kouwenhove	Role of miRNA genes in etiology of germ cell tumors and derived malignant tumors	Agami	2007	2
D. Peric-Hupkes	Chromatin Profiling of Human gene silencing complexes	van Lohuizen	2004	3
C. le Sage*	Activated proteolysis, a novel rapid response to DNA damage	Agami	2002	2
K. Verzijlbergen	The role of histone methylation in gene silencing and transcriptional memory	van Leeuwen	2005	2

M. Vogel*	Functional Genomics of Gene Regulation by heterochromatin proteins	van Steensel	2002	3
Immunology (NKI)				
S. Ariotti	Introvital imaging of epidermal immune phenomena in virus infections and DNA tattooing	Schumacher	2007	1
A.H. Bakker	Analysis and manipulation of tumor specific T cell immunity	Schumacher	2002	2
M. Coccoris	Dissecting virus-specific cytotoxic T cell immunity	Kruisbeek	2000	2
C. Gerlach	Cellular barcoding and dissection of T cell differentiation	Schumacher	2005	1
M. Heideman	Role of translesion DNA synthesis in Immunity and Cancer Development	Borst	2005	2
J. van Heijst	Tracing lineage relationships by cellular barcoding	Schumacher	2004	3
M. Hogenbirk	A Cancer Genome Atlas of the activation induced cytidine deaminase novel insights into the pathogenesis and prognosis of B cell lymphoma	Jacobs	2008	3
A. Jorritsma*	Analysis of vaccine-induced melanoma specific T-cell immunity: a combined human + mouse study	Haanen	2002	3
A.M. Keller*	Cellular and molecular basis of effector and memory T cell responses	Borst	2002	1
B. van de Kooij	A novel type of ubiquitination regulates apoptosis signaling by BH3 only protein Bid	Borst	2008	2
P. Krijger	The role of post replication repair in lymphoma development and somatic hypermutation	Jacobs	2006	2
P. Langerak*	Complementation tagging and lymphocyte development	Borst	2003	4
C. Linnemann	Preclicinal development of TLR gene therapy for prostate carcinoma	Schumacher	2008	2
C. Maas	Apoptosis signalling of BH3-only protein Bid, mechanisms of action and modes	Borst	2004	3
K. Oosterhuis	Treatment of HBP positive penile and cervical cancer by introduction of NPV7 special TCI	Schumacher	2006	2
V. Peperzak	The role of CD27/CD70-regulated cell survival in shaping effector and memory T cell responses	Borst	2004	2
R. Rooswinkel	Improvement of chemoradiotherapy in head and neck cancer by small molecule inhibitors of Bcl-2	Verheij	2008	3
E. Veraar	TNF ligands in cancer: CD70	Borst	2006	4
I. Verbrugge	Tumor therapy with ionizing radiation and death ligand Trail efficacy and key mol. determinants	Borst/ Verheij	2004	3
N. Wit	A cancer Genome Atlas of the activation induced cytidine deaminase	Jacobs	2008	3
M. Witte*	Induction of T-cell immunity through adoptive transfer of T cell receptors	Borst	2003	2
Molecular Biology (NKI)				
M. Aarts	High-throughput gene modification by single-stranded DNA oligonucleotides	Te Riele	2004	4
S. Bakker	Significance of the Fanconi Anemia caretaker pathway in development and treatment of cancer	Te Riele	2007	2
J. van Bommel	Multi-gene chromatin domains	Te Riele	2007	2
R. Drost	Therapy responses of BRCA-mutated tumors and role of PALB2 in mammary tumorigenesis	Jonkers	2005	3
B. Evers	Mammary tumorigenesis in conditional tumor suppressor gene knockout mice	Berns	2003	2
T. van Harn	Role of the G2 restriction point in tumor development and behaviour	Te Riele	2007	2
H. Holstege	The role of BRCA1 and BRCA2 loss-of-function in breast cancer	Berns	2002	3

H. Horlings	Genetic classification of breast cancer	van de Vijver	2006	2
D. Iusuf	OATP1A/1B(SLCO1A/1B) drug uptake transporters in anticancer drug pharmacokinetics and toxicity risks; possible strategy	Schinkel	2008	3
J. Jaspers	The role of tumor-initiating cells in cancer metastasis and drug resistance	Jonkers / Rottenberg	2008	2
C. Klijn	Dissection of the role of E-cadherin loss-of-function in breast cancer development and metastasis	Jonkers	2007	2
R. Koornstra	Predicting hormonal treatment sensitivity in breast cancer	Linn	2007	4
R. Leitner	Characterization of the physiological roles of multidrug resistance protein (MRP) 1-6 by screening for their subtract in vivo	Te Riele	2008	?
R. van Leuken*	Roles of human Cyclin-dependent kinase subunits HsCks1 and HsCks2 in mitotic progress	Bernards	2003	3
J. de Ronde	CTMM - Breastcare	Rodenhuis	2008	2
E. van der Steeg	The impact of OATP drug carriers on in vivo pharmacology toxicology & physiology	Beijnen	2004	4
M. Vollebergh	Predicting therapy responses in breast and lung cancer	Rodenhuis	2007	3
T. Vormer	The identification of oncogenic events collaborating with loss of function of the retinoblastoma gene family in tumor development and progression	Te Riele	2003	3
E. Wielders	Subtle gene modification to study the role of the mismatch repair complex Msh2/Msh5 in mutation avoid	Te Riele	2004	3
S. Zanders	Mechanisms of chemotherapy resistance of spontaneous mammary tumors in genetically-engineered mouse models	Te Riele	2007	2
Molecular Carcinogenesis (NKI)				
L. Clijsters	Targeting protein destruction during cell division	Bernards	2007	3
M. Epping*	Molecular basis of anti-cancer activity of HDAC inhibitors	Bernards	2002	4
A. Fabius	Molecular barcode screens to identify genetic interactions with protein kinases in mammalian cells	Beijersbergen	2004	3
E. Geutjes	The role of deubiquitinating enzymes in apoptotic signalling pathways	Bernards	2006	2
G. Heynen	Determinants of the breast cancer stem cell phenotypes	Bernards	2008	2
R. Kortlever*	Senescence rescue screens	Bernards	2002	1
H.J. Kuiken	HCD/HT using RNAi technology	Bernards	2005	4
J. Mullenders	High throughput functional screens for stable loss-of-function phenotypes	Bernards	2003	3
J. Nijwening	Development & application of shRNA in cell based screening technologies	Bernards	2005	4
E. Voets	Divergent control of Cyclin B1-Cdk1 in cancer cells: a key role in therapy	Wolthuis	2008	3
W. van Zon	Control of Mitosis by regulated protein destruction	Wolthuis	2004	1
Molecular Genetics (NKI)				
A. Alendar	Identification of the PIM regulatory network by microarray analysis and high throughput retroviral tagging	Berns	2002	3
I. Bejaoui	The role of class I HDACs in development and tumorigenesis	Bernards	2007	3
E. Boutsma	Functional analysis of BMI-ring finger interacting proteins and application of microarray technology to identify BMI-1 response genes	Bernards	2000	3
S. Bruggeman*	Characterisation of oncogenic potential and mechanism of gene repression of TBX2	van Lohuizen	2003	3
T. Geiger*	Oncogenic function of human DRIL1	Berns	2003	3

J. Kaplon	The relationship between cell metabolism, senescence and cancer	Peeper	2007	2
T. Kuilman	Novel functional genomic screens to identify pathways that protect mouse & human cells against oncogenic transformation by mutant RAS	Berns	2003	2
C. Michaloglou	Senescence-like replicative arrest in melanocytic naevi: a melanoma-suppressive mechanism?	Peeper	2003	1
E.H.M. van Montfort	Development of a mouse model to study the genetic basis of malignant mesothelioma	Berns	2000	3
M. Peuscher	Novel factors involved in chromosome protection by telomeres	Berns	2007	3
M. Smit	The role of the neurotrophic tyrosine kinase receptor	Berns	2005	3
P. Taghavi	Functional analysis of BMI1-ring finger interacting proteins and application of microarray technology to identify BMI1-responsive genes	van Lohuizen	2000	3
J. van der Torre	Novel factors involved in chromosome end protection by telomeres	Berns	2006	3
Y. van der Velden	The role of Ikb1 in tissue morphogenesis and cancer zebrafish	Haramis	2006	2
J. Vissers	Regulation of histone H2A monoubiquitination by Ring 1b/Bmi1 and USP3 in DNA damage responses	van Lohuizen	2006	4
L. Vredeveld	The role and mechanism of escape from Ras induced senescence in oncogenesis	Peeper	2002	3
A. Zwaagstra	Identification of novel mammary tumor progression genes	Hilkens	2005	3
Clinical Genetics (VUmc)				
N. Ameziane	Role of Fanconi anemia genes in familial and sporadic breast cancer	Joenje / Pals	2004	2
S. Bakker	The Achillesheel of tumours with the Fanconi anemia phenotype	Joenje / te Riele	2005	1
M. Corbin	Human Genes essential for the defense against oxygen toxicity	Joenje / Dorsman	2008	3
C.J. Dommering	Retinoblastoom en erfelijkheid	Meijers	2006	1
A. Haitjema	Proteins interacting with FANCI and PALB2	Joenje / Dorsman	2008	3
M. Massink	Molecular classification of familial breast cancer	Joenje / Waisfisz	2008	2
B.M. Mol	Molecular carcinogenesis of retinoblastoma	Dorsman / Cloos	2008	3
C. Stoepker	The Fanconi anemia/BRCA pathway in oral squamous cell carcinomas	Joenje / de Winter	2008	1
P. van der Lelij	The role of sister chromatid cohesion in the maintenance of genetic stability	Joenje / de Winter	2006	1
Medical Oncology (VUmc)				
J.J. Lindenberg	Adenovirus-based and CD40-targeted in vivo tumor vaccination	de Gruijl	2006	2
Molecular Cellbiology and Immunology (VUmc)				
E.M. van Beek	SIRP-alpha-CD47 interactions in viral and tumor immunity	van den Berg	2003	1
Nuclear Medicine and PET Research (VUmc)				
P. Cheebsumon	Effects of image reconstruction, heterogeneity and F18-FDG kinetics on oncological response evaluation with PET	Boellaard / Smit	2008	3
Obstetrics and Gynaecology (VUmc)				
B. Hermsen*	Risk assessment and preventive measures in women at high risk of developing breast and ovarian cancer	von Mensdorff-Pouilly	2002	4
M.E. Nowee	Oncogenic factors in ovarian and tubal carcinoma	Verheijen	2002	4
Oral and Maxillofacial Surgery and Pathology (VUmc)				
J.F. Bremmer	Diagnosis and therapy of genetically altered mucosal lesions in the oral cavity and oropharynx	van der Waal / Brakenhoff	2002	1

Otolaryngology/Head and Neck Surgery (VUmc)

P.K.E. Börjesson	Detection and therapy of head and neck cancer with radiolabeled anti-CD44v6 monoclonal antibodies	van Dongen / de Bree	2000	1
A.P. Graveland	Molecular diagnosis of head and neck squamous cell carcinoma (HNSCC)	Brakenhoff	2005	3
S.R. de Kemp	Functional characterization of stem cells and signal transduction pathways in head and neck squamous cell carcinoma	Braakhuis / Brakenhoff	2007	1
M. Moreno*	Study of MUC1 as target for the immunotherapy of patients with breast and ovarian carcinomas	van Dongen / de Bree	2000	1
S. Smeets	Multi-step head and neck carcinogenesis	Brakenhoff	2003	1
B.M. Schaij-Visser	A quantitative proteome progression model for squamous cell cancer	Brakenhoff	2004	4
M. van der Plas	Identification of oncogenic microRNAs and classical cancer genes involved in head and neck squamous cell carcinoma by a functional genomics approach	Brakenhoff / Braakhuis	2008	3
H.J.T. van Zeeburg	Innovative therapies of precancerous lesions in the oral cavity and oropharynx	Brakenhoff	2004	1

Pathology (VUmc)

M. Bierkens	Genetic profiling of CIN 3 lesions diagnosed in the subsequent screening round following screening by HPV testing and cytology	Snijders / Steenbergen	2007	1
L.J.W. Bosch	Methylation for Early Colorectal Cancer Detection	Meijer	2005	4
N.W.J. Bulkman*	HPV-BOB	Snijders / Meijer	2001	2
S.A.G.M. Cillessen*	Functional analysis of apoptosis signaling pathways in B-cell lymphomas	Oudejans / Meijer	2003	3
A. Hardebol	Functional characterization of chromosome 20q amplified genes suitable for CRC screening	Meijer	2005	4
F.E. Henken	Defining the essential molecular pathways involved in cervical carcinogenesis	Snijders	2005	1
A.T. Hesselink*	High-risk human papillomavirus testing in cervical screening which assay?	Snijders / Meijer	2002	1
E.K. Hoebe	Role of soluble BART1 oncoprotein in Epstein-Barr virus driven carcinogenesis and its functional inhibition by antibodies	Middeldorp	2007	3
P.A.J. Krijnen	Epstein-Barr virus LMP1,2 specific immunoreactivity and immunotherapy in Hodgkin's Disease	Middeldorp	2005	3
R.M. Overmeer	TSLC1 silencing, a marker for risk assessment of cervical cancer	Meijer	2005	3
E. Reinen	Genetic profiling for risk assessment of preneoplastic endobronchial lesions	Snijders / Smit	2007	3
D. Rijkaart	Stratifying high-risk HPV positive women for risk of CIN 3 and cervical carcinoma by HPV transcript analysis	Snijders / Meijer	2006	3
M. Scherpenisse	Immunity against Human Papilloma Virus	Meijer	2008	3
A. Turksma	Towards adjuvant immunotherapy for squamous cell carcinoma	Hooijberg / Meijer / Leemans	2007	3
R. van de Ven	ABC Transporters in dendritic cell function	Scheffer / de Gruijl	2003	3
J. de Wilde	Cervical carcinogenesis: unraveling of the multistep pathways using well-defined clinical material and in vitro cell culture model systems	Snijders / Steenbergen	2002	1
M. de Wit	Molecular imaging of colorectal cancer	Meijer / Fijneman	2006	4

Urology (Vumc)

A. Mol	New experimental markers for early detection of high-risk prostate cancer	Van Moorselaar / Geldoff	2006	3
--------	---	--------------------------	------	---

Cell Biology & Histology (AMC/UvA)

J.M.E.D.Gillis	When protein degradation fails	Reits/ van Noorden	2005	2
H.A.G. Krol	Role of peptidases in polyglutamine disorders	Reits/ van Noorden	2004	1
P. Krawczyk	Double strands DNA breaks and their repair	Aten/ van Noorden	2003	3

Center for Experimental Molecular Medicine (AMC/UvA)

S.A. Bleumink	Morphostasis of the adult gastrointestinal tract	Peppelenbosch/ van Deventer	2002	1
T. Borovski	Chromosomal aberrations and cancer stem cells	Medema	2006	3
H. Braat	Innovative feedingintervention in patients with chronic inflammation	van Deventer	1999	3
S.H. Diks	Tissue factor-dependent signalling	van Deventer	1999	2
F.F. van Doormaal	The association between hemostasis and cancer	Buller/ Richel	2006	1
K. Kemper	The role of cancer stem cells in tumorigenesis and metastasis in colon cancer	Medema	2006	1
A.M. Rygiel*	Follow-up study of a cohort of Barrett's oesophagus patients by brush cytology and fish	van Deventer	2003	2
J.B. Tuynman	A phase II study on the effects of celecoxib on several pharmacodynamic endpoints, including activity of the Wnt/b-catenin pathway, apoptosis, proliferation, and angiogenesis in sporadic colorectal polyps and colorectal cancer in human	Richel/ van Deventer	2002	3
I. Vermeulen	Wnt signalling and cancer stem cells	Medema	2006	2
G.Hardenberg*	The role of APRIL and its receptors in tumour growth and immune regulation	Medema	2003	3
F.B. Mullauer	Inventory of the anti-cancer efficacy of the plant-derived compound Betulinic acid and the clarification of the mechanisms underlying its induction of tumor-specific apoptosis	Medema	2005	3

Clinical chemistry (AMC/UvA)

O.G. Besancon	Preclinical screening of drug combinations for neuroblastoma	Kuilenburg	2008	3
---------------	--	------------	------	---

Gastroenterology (AMC/UvA)

A.L. Davelaar	Markers en moleculen in darm oncologie	Krishnadath	2008	1 and 2
---------------	--	-------------	------	---------

Hematology (AMC/UvA)

R. Mous*	Studies on the immune system in CLL	van Oers / van Lier	2004	3
----------	-------------------------------------	---------------------	------	---

Human Genetics (AMC/UvA)

A.C.J. Ammerlaan	Genetic profiling of gliomas and their recurrences for improvement of diagnosis and prognosis	Hulsebos / Versteeg	2002	3
J. Bunt	The role of OTX2 in medulloblastoma	Versteeg/ Kool	2005	1
H.J. Gierman	The human genome: understanding functional nuclear organisation from landmarks in the human transcriptome	Versteeg	2003	1
T. van Groningen	The role of Notch signalling in Neuroblastoma	Versteeg	2008	2
A. Koppen*	Gene silencing by Myc-oncogenes	Versteeg	2001	3
I.M. Revet	The role of the MEIS homeobox genes in neuroblastoma pathogenesis	Versteeg	2003	3

Medical Oncology (AMC/UvA)

T. Niers*	Coagulation angiogenesis and cancer	Richel / van Noorden	2004	1
-----------	-------------------------------------	----------------------	------	---

Pathology (AMC/UvA)

D. Gorter*	Functional and molecular analysis of HGF/Met signaling in germinal center B cells and B cell neoplasia	Pals	2000	3
M. van Keimpema	The role of the forkhead transcription factor FOXP1 in B-cell non-Hodgkin lymphoma	Pals	2008	3
R. Reijmers	The role of heparan sulfate proteoglycans in B cells and Multiple Myeloma	Pals	2003	2

Theme 2: Experimental Clinical Research

Clinical Oncology (NKI)

R. Keizer	Population pharmacokinetics and pharmacodynamics of investigational anti-cancer agents	Schellens/Beijnen	2006	4
S. Mook	Prognostic profiling in breast cancer	Van 't Veer	2006	2

Experimental therapy (NKI)

J. Hannemann*	Micro array analysis of breast cancer as a diagnostic tool to guide optimal treatment	van de Vijver	2002	3
M. de Jong	Prediction of local control after radiotherapy in head and neck cancer	Begg	2007	3
S. Joosse	Specific chromosomal imbalance in breast carcinomas as a marker for breast cancer susceptibility	Nederlof	2007	3
M. Kok	Molecular prediction of therapy outcome in breast cancer	Van 't Veer	2004	4
J. Lagas	Impact of the multidrug transporters p-glycoprot., MRP2 and BCRP on the behaviour of anti-cancer drugs	Schinkel	2004	4
S. Neijenhuis	Determinants of radiosensitivity	Begg	2003	3
R. Oostendorp	Preclinical and clinical pharmacology of oral drugs	Schellens/Beijnen	2004	4
J. Pramana	Gene expression profiling to predict outcome after chemoradiation in head and neck cancer	Begg	2005	3
I. Seeman	The role of endoglin in induction and repair of cardiovascular damage after radiation alone or in combination with trast	Stewart / v. Leeuwen / Mummery	2008	3
S. Veltkamp*	Clinical Pharmacology of oral gemcitabine and other (oral) anti-cancer agents	Schellens/Beijnen	2003	4
C. Verhagen	Fanconi anemia pathway defects in HNSCC	Begg	2008	1
C. Vermeulen	Determinants of radiosensitivity	Begg	2002	3
M. Vlaming	Compound Mrp2 (Abcc2) and other drug transporter knockout mice to study determinants ...	Schinkel	2003	3
A. Vrieling*	The IGF system in breast and colorectal carcinogenesis: dietary intervention and mol. Studies	van Leeuwen	2002	3
R. van Waterschoot	Generation and validation of cytochrome P450 3A knockout and transgenic mice as tools for...	Beijnen	2005	2

Medical Oncology (NKI)

D. Boss	Clinical pharmacology of anticancer drugs	Schellens	2005	4
J. Bueno de Mesquita	Predictive and prognostic factors in breast cancer	Linn/v.d. Vijver	2003	4
M. Deenen	Clinical pharmacology and pharmacogenetics of fluoropyrimidine anti-cancer agents	Schellens/Beijnen	2006	4
L. Devriese	Pharmacodynamics of anti cancer treatment	Schellens	2008	4

A. Dubbelman	ADME and man balance of anticancer drugs	Schellens/Beijnen	2008	3
E. de Jongh	Effectivity anti-cancer therapy	Schellens	2007	4
I. Kuppens	Improvement of oral pharmacology of anticancer drugs	Schellens/Beijnen	2002	4
S. Leijen	Development of combination therapy with anti cancer drugs	Schellens / Beijnen	2008	4
J. Meulenaar	Drug formulation and clinical testing of anticancer drugs	Schellens / Beijnen	2008	4
J. Moes	Oral Taxanes: pharmaceutical and clinical development group pilot programme transletinal onderzoek	Schellens/Beijnen	2007	4
M. Schwellengrebel	Optimizing peri-operative treatment of rectal cancer	Cats/Marijnen	2008	4
W. Uyterlinde	Supportive care in the treatment of NSCLC	v.d. Heuvel	2008	4
Pharmacy and Pharmacology (NKI)				
E. Brouwers	Bioanalyse van metalen (i.h.b. Platina) in biologische matrices m.b.v. ICP-MS	Beijnen	2003	4
C. Ekhart*	Genotyping as tool for dose individualization in high-dose chemotherapy	Huitema	2006	3
J. Engwegen	Clinical proteomics	Beijnen	2003	4
M.C. Gast	Proteomics in Oncology	Beijnen	2003	4
M. Klous	Pharmaceutical development of diacetylmorphine formulations	Beijnen	2001	4
S. Koolen	Oral administration of anti-cancer agents	Schellens/ Beijnen	2006	4
S. van der Schoot	Pharmaceutical development of anti cancer agents	Beijnen	2002	1
L. Tran	High-dose 121I-labelled rituximab in the treatment of non-Hodgkin lymphomas	Beijnen	2006	4
A. Zandvliet	Population pharmacokinetics & pharmacodynamics of investigational anticancer drugs	Beijnen	2003	4
Psychosocial Research and Epidemiology (NKI)				
S. v.d. Belt-Dusebout	Risk of second malignancy and cardiovascular disease after treatment for testicular cancer	van Leeuwen	2003	3
N. Boekel	Cardiovascular morbidity and mortality in breast cancer survivors	van Leeuwen	2008	3
K. Douma	Long-term psychosocial impact of genetic testing among familial adenomatous polyposis families	Aaronson	2004	3
W. Eijzinga	Identification of psychosocial problems and perceived need for support in cancer genetics	Bleiker	2008	3
M. Hoening*	Long term risk of second cancers following treatment of Hodgkin's disease, testicular cancer and breast	van Leeuwen	2000	3
C. Lammens	LFS-VHI-study -> Psychosocial aspects of genetic testing in families at high risk of multiple tumors	Aaronson	2005	3
W. van Lent	Improving the efficiency of oncologic hospital care process with business etc	Van Harten	2006	4
A. Pijpe	Gene-environment interactions in BRCA1/2 breast/ovarian cancer families	Floor van Leeuwen	2004	3
V. Retèl	Constructive Technology Assessment of gene expression profiling for breast cancer patients	Van Harten	2006	4
A. van Rosmalen**	The role of early life-style factors in the etiology of breast cancer	Rookus	2001	4
C. Schilder	Behavioral and Psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients	Schagen	2003	4

J. Verloop	Physical activity and breast cancer risk	Van Leeuwen	1997	3
M. Wevers	Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients	Aaronson	2008	4
Radiotherapy (NKI)				
J. de Boer	image guided correction strategies to optimize the precision of RT	Sonke	2006	3
R. Bohoslavsky	Probabilistic based treatment planning with biological objectives for high dose high-precision RT of prostate cancer	van Herk	2008	3
H. Dees-Ribbers	High precision image guided RT for bladder cancer	Remeijer / Hulshof	2008	3
G. Borst	Optimization of conformal radiation therapy of non-small cell lung cancer by advanced 3-D planning	Lebesque	2003	3
S. van Kranen	High precision radiotherapy in the presence of anatomical deformations	Van Herk	2005	3
M. Smitsmans	On-line tomographic guidance for RT of the prostate	Bartelink	2003	4
J. Wolthaus	Optimization of conformal RT of non-small cell lung cancer by advanced 3-D planning	Bartelink	2003	3
Gastroenterology (VUmc)				
F.A. Oort	Colorectal polyps and cancer in Amsterdam	Mulder / Craanen	2007	4
J.S. Terhaar sive Droste	Colorectal polyps and cancer in Amsterdam	Craanen	2005	3
J.M.W. van de Water	Predicting T-cell lymphoma development in refractory coeliac disease patients by profiling of apoptosis pathways in intestinal T-lymphocytes	Mulder / Meijer	2007	1
Obstetrics and Gynaecology (VUmc)				
E.M. Davelaar	Serum tumour markers in cervical carcinoma	Verstraeten	2004	2
M. Verbruggen	Clinical and molecular aspects of borderline ovarian tumours	Dorsman	2002	1
Hematology (VUmc)				
C. Alhan	Role of flow cytometry in the diagnosis and prognostication of myelodysplastic syndromes	v.d. Loosdrecht	2008	4
C. Hess	The nature of minimal residual disease in acute myeloid leukemia	Schuurhuis / Ossenkoppele	2002	3
M. Terwijn	Detection of residual leukemic stem cells during minimal residual disease in AML	Schuurhuis / Ossenkoppele	2006	3
W. van den Ancker	Optimizing strategies in dendritic cell vaccination in myeloid leukaemia	v.d. Loosdrecht / Ossenkoppele	2006	1
M. van Luijn	Regulation of MHC class-II in acute myeloid leukemia and its impact on immunosurveillance	v.d. Loosdrecht / Ossenkoppele	2006	3
A. van Rhenen*	The nature of primitive clonogenic aml cells and the role in emergence of minimal residual disease in AML	Schuurhuis / Ossenkoppele	2002	4
M.J. Wondergem	Can transformation of indolent lymphoma be detected at an early stage by PET scanning?	Huijgens / Hoekstra	2006	1
J. Zijlstra-Baalbergen*	Response monitoring in non-Hodgkin's lymphoma using Positron Emission Tomography	Huijgens / Lammertsma	2003	1
Medical Oncology (VUmc)				
A. Adema	Development of novel strategies to optimize cytotoxic and targeted therapy	Peters	2003	4
K. Azijli	TNF ligands in cancer: TRIAL for cancer therapy	Peters	2008	3
M.N.A. Bijman	Docetaxel: its role in the inhibition of angiogenesis and the mechanism for	Boven / Hoekman	2001	3

	induction of apoptosis			
I. Bijnsdorp	Enhancement of trifluorothymidine cytotoxicity by docetaxel	Peters	2005	3
H. van Cruijssen	Clinical trials with receptor tyrosine kinase inhibitors in patients with advanced cancer	Hoekman	2004	3
M.I. Gallegos Ruiz*	Mutational and functional analysis of the EGFR pathway in NSCLC patients: correlation with prognosis and response to small molecule EGFR inhibitors	Giaccone	2005	3
E. Giovannetti	Correlation of cytidine deaminase and DNA repair genes polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients	Peters	2007	4
K.J. Gotink	Sensitivity and resistance of tumor cells to the antiangiogenic tyrosine kinase inhibitor sunitinib	Verheul	2008	3
C. Lemos*	Folate supplementation in chemotherapy: increase of efficacy versus induction of drug resistance	Peters	2005	3
J. Sigmond	Interaction of gemcitabine with novel molecular targets	Peters	2002	4
J. Voortman*	Efficacy and mechanism of combination therapy with proteasome inhibitor PS-341 (Velcade™) in NSCLC	Kruyt / Giaccone	2003	4
L. Vroling	Circulating endothelial cells as markers for anti-angiogenic therapy	Broxterman	2005	3
M. Walraven	Underlying mechanisms of antiangiogenic treatment related clinical toxicities	Verheul	2008	3
Medical Psychology (VUmc)				
J. van Dijk*	Psychosocial functioning and quality of life of retinoblastoma survivors and parents in the Netherlands	Imhof	2004	3
Neurology (VUmc)				
I. Bosma	Health-related quality of life and neurocognitive functioning of long-term surviving high-grade glioma patients / Synchronized brain activity and neurocognitive function in brain tumor patients: a MEG study / Efficacy and toxicity of cerebral glioma treatment	Klein / Stam / Postma	2004	4
L. Douw	Changes in functional connectivity after tumor resection in brain tumor patients: a magnetoencephalography study	Stam / Reijneveld	2008	3
S. Toering	Correlation between SV2A expression in tumour tissue and efficacy of levetiracetam in glioma patients with epilepsy	Reijneveld / Heimans / Klein	2007	3/4
Neurosurgery (VUmc)				
C. Badr	Bioluminescence imaging for discovery and characterization of novel glioma therapeutics	Würdinger / Noske	2008	1
V. Caretti	Brainstem tumors: development of anti-tumor drugs for convection enhanced delivery	Kaspers / Vandertop	2008	3
S. Idema	Improving oncolytic viral therapy for glioma	Dirven / Lamfers	2003	4
Nuclear Medicine (VUmc)				
W. Direcks	Experimental and clinical studies using positron emission tomography (PET) for monitoring response to chemotherapy in (locally) advanced breast cancer	Molthoff / vd Wall	2003	3

J. Emmering	Towards a rational use of PET in breast cancer patients	Teule	2003	1
A.J. de Langen	Evaluating therapeutic impact of induction therapy for locally advanced NSCLC with molecular imaging	Hoekstra	2005	1
A.A.M. van der Veldt	PET imaging of [11C]docetaxel kinetics: part I, the role of bioavailability of [11C]docetaxel in predicting response in breast cancer	Hendrikse	2007	3
Orthopaedics				
J. Posthuma de Boer	Treatment of osteosarcoma lung metastasis through targeted therapy	Kaspers / van Beusechem	2008	4
Otolaryngology / Head and Neck Surgery (VUmc)				
J. Brouwer*	Investigation into cost-effectiveness of diagnostic algorithms of patients with head and neck cancer to prevent unnecessary treatments	Leemans	2000	1
R. Cohen	The selective targeting of angiogenesis and of tumour stroma	Van Dongen / de Bree / Leemans	2008	2
G.B. Flach	The sentinel node procedure in head and neck cancer: clinical value and potential technical improvements / Aspiration cytology and sentinel node biopsy in the detection of occult lymph node metastases of early oral and oropharyngeal cancer	De Bree / Van Dongen	2007	3
C.D.L. van Gogh	Voice therapy for patients with voice problems after treatment for early glottic cancer / Voice after laryngectomy by means of a sound-producing tracheoesophageal shunt valve	Mahieu	2002	2
A.M. Lo Galbo	Hypothyroidism after treatment for laryngeal cancer	Leemans	2005	1
D. Heuveling	Improvement of the sentinel node procedure in head and neck cancer by PET-CT lymphoscintigraphy, optical techniques and minimal invasive surgery. Molecular targeting of intracellular proteins in cancer	De Bree / Van Dongen	2008	4
I.M. Oskam	Health related quality of life in head and neck cancer patients	Leemans	2004	1
L.R. Perk	Molecular imaging with PET using long-lived positron emitters	van Dongen	2003	2
L. van der Putten	FDG-PET for avoidance of futile direct laryngoscopies under general anaesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapy	Leemans	2005	3
A. Senft	Screening for distant metastases and second primary tumors with FDG-PET (the school study)	Leemans	2002	2
B.M. Tijink	Antibody-based therapy with emphasis on head and neck cancer	Van Dongen / de Bree / Leemans	2003	3
M.J.W.D. Vosjan	Development of dual-specific nanobodies for cancer diagnosis and treatment	Van Dongen	2008	2
Pathology (VUmc)				
T. Buffart*	Predicting lymph node status in gastric cancer by DNA-based genomic profiling for stratifying surgical therapy	vd Velde / Meijer	2004	3
E.A. Greijer	Early pathogenesis and intervention in Epstein-Barr virus (EBV) driven post-transplant lymphoproliferative disease (PTLD) in stem cell (SCT) and solid organ transplant (SOT) recipients	Middeldorp	2005	3

J.C. Haan	Prediction of response to drug therapy in advanced colorectal cancer based on DNA copy number profiles of primary tumors	Meijer / Ylstra	2007	3
A. Hardebol	CRC screening by faeces DNA based testing using chromosome 20q genes	G.A. Meijer	2005	4
I. van Houdt*	Involvement of resistance to apoptotic cell death in the response to immunotherapy	Kummer / van den Eertwegh	2003	1
J. Molling*	Anti-tumor effector functions of skewed natural killer T cells	Scheper / von Blomberg	2002	3
S. Santegoets*	Dendritic and T cell functions in patients with metastatic hormone-refractory prostate cancer treated with Prostate GVAX cancer immunotherapy and Ipilimumab	de Gruijl	2002	3
Q.J.M. Voorham	Increasing sensitivity for detection of high risk flat adenomas in population screening for colorectal cancer	G.A. Meijer	2006	3
S.M. Wilting	Distinction of early, intermediate and late cervical intraepithelial neoplasia grade III (CIN III) lesions by micro-array analysis	Snijders / Steenberg	2003	3
Pediatrics (VUmc)				
C. Bachas	Characterization of relapsed acute myeloid leukemia	Cloos/ Schuurhuis	2007	1
K.I. Braam	Silicone gel sheet to improve cosmetic outcome of the scar after removal of an implantable central venous access device (ICVAD) in childhood cancer survivors	Van Dulmen-den Broeder/Kaspers	2007	4
N. Franke	Drug resistance in childhood leukemia	Cloos / Kaspers	2006	4
I. Hubeek	Tyrosine phosphatases as new targets in childhood cancer	Cloos	2005	3
W.A. Kors	Retinoblastoma	Cloos	2005	1
M. Luttjeboer	Ex vivo radiosensitivity and modification by anticancer agents in pediatric brain tumors	Kaspers / Sminia	2002	4
S.E. Mir	Therapeutic potential of histone deacetylase inhibitors in the treatment of Medulloblastomas: from anticancer drugs to neuroprotective agents / Role HDACs in childhood brain tumors	Kaspers / Cloos	2007	2
S. Mostert	Compliance with chemotherapy in childhood acute lymphoblastic leukemia in a developing country	Veerman	2003	4
A. Overbeek	Reproductive function, ovarian reserve, and risk of premature menopause in female childhood cancer survivors: a nationwide study	Voskuil	2008	3
J. Vink	Glucocorticoid-induced apoptosis and glucocorticoid resistance in lymphoid malignancies and autoimmune diseases	Kaspers	2001	3/4
D.G. van Vuurden	Targeted therapy in pediatric brain tumors	Kaspers	2005	1
Pulmonology (Vumc)				
E. Phernambucq	Multimodality treatment in NSCLC	Smit	2008	3
R. van den Berg	The use of molecular biomarkers in early lung cancer	Snijders / Smit	2003	2
Radiology (VUmc)				
P. de Graaf	Clinical and experimental high resolution	Castelijns	2006	3

R. Ljumanovic	ocular MR Imaging: towards improved detection of retinoblastoma tumor extent Prognostic value of MRI-determined lymph node parameters in development of distant metastases in head and neck carcinoma	Castelijns	2003	3
J.H. Weijs	Optimization of US selection criteria of lymph nodes (size, laterality, aspect and behaviour) to perform USgFNAC in follow-up of patients's oral cavity or oropharyngeal carcinoma	Castelijns	2005	2
Radiotherapy (VUmc)				
K.A. van Nifterik	Malignant glioma genetics and related chemo-radiosensitivity as guidance for individualized therapy	Sminia / Hulsebos	2002	1/3
Reumatology (VUmc)				
C.S.E. Verbrugge	Proteasome inhibitor targeting of the (immuno)proteasome: effects on immune effector cells and therapeutic consequences for cancer and chronic inflammatory diseases	Dijkmans / Jansen	2008	1
Surgery (VUmc)				
R.P.M. Brosens	Tumor profiling for prediction of clinical outcome in colorectal cancer patients	Cuesta / G.A. Meijer	2006	3
H. Fabry	Strategy and results in early breast cancer	Meijer	2003	1
G. Melis	Quantifications of the generation of arginine in the kidney during liver surgery	Van Leeuwen	2001	2
M.P.C. Siroen	ADMA clearing after liverresection for metastatic cancer	Van Leeuwen/van der Sijp	2002	2
M. Westerterp	The role of FDG PET in esophageal cancer staging and monitoring the response to neoadjuvant therapy	Molthoff	2005	2
Gastro-enterology & Hepatology (AMC/UvA)				
M.A. van Geer	Development of infectivity enhanced conditionally replicating adenovirus vectors for gene therapy of pancreatic cancer	Oude Elferink	2002	3
T. de Wijkerslooth	Population screening for colorectal cancer by colonoscopy or CT-colonography in the Netherlands	Fockens / Bossuyt	2008	2
Hematology (AMC/UvA)				
D. Hallaert*	Novel therapeutic approaches to attack the microenvironment in Chronic Lymphocytic Leukemia	Van Oers/ Eldering	2004	3
M. Jak	Immunotherapy for B-CLL in human CD20 transgenic mice	Van Oers/ van Lier	2007	4
Human Genetics (AMC/UvA)				
E.E. Santo	FOXO3 in neuroblastoma	Koster	2007	1
Medical Oncology (AMC/UvA)				
F.F. van Doormaal	The association between hemostatis and cancer	Buller / Richel	2006	1
S.J. de Kort	Ethical aspects of palliative cancer chemotherapy	Willems/ Richel	2003	3
Pathology (UvA/AMC)				
L. Kuipers	Cancer therapy with the proteasome inhibitor Bortezomib and the death ligand TRAIL for non-small cell lung cancer	Peters	2008	3
W.W.J. de Leng	Carcinogenesis in het Peutz-Jehgers syndroom	Offerhaus	2002	3

Pediatric Oncology (AMC/UvA)

E.J. Aukema	Late consequences and needs of young survivors of a brain tumor and their parents	Last/Schouten/Grootenhuis	2006	1
M. Cardous-Ubbink	Excess mortality and morbidity following treatment of childhood cancer; Assessment of risks and options for secondary prevention			
R. Cuperus	Modulation of Fenecitinide induced apoptosis in Neuroblastoma cells	van Leeuwen / Caron Caron	1998 2004	3 3
N. van Eijkelenburg	Vroege fase geneesmiddelen studies bij kinderen met kanker	Caron	2007	3
V. Engelen	QLIC-ON quality of life in childhood oncology	Versteeg/ van Nes	2005	3
J.J. Molenaar	Delineating the biological and clinical importance of CyclinD1 in neuroblastoma	Caron	2000	1
H. van der Pal	Cardiovascular disease after treatment for childhood cancer	Caron / van Leeuwen	2008	3
E. Sieswerda	new drug development, clinical trials and late effects	Caron/ Kremer	2007	3
J. Stutterheim	MRD monitoring at children with neuroblastoma	Caron/ Tytgat	2006	3
Psychosocial department (UvA/AMC)				
E. Aukema	Late consequences and needs of young survivors of a brain tumor and their parents	Last / Schouten	2006	3
M. de Ruiter	Pediatric research on improving speed, memory and attention	Caron	2008	3
Radiotherapy (UvA/AMC)				
S. Hovingh	Investigation of a gene set classifier for late radiation toxicity in prostate cancer patients	Medema / Stalpers	2008	3
Surgery (AMC/UvA)				
M.C. Janssen	Locale ablatie van levertumoren: het effect van radiofrequente thermoablatie, interstitiele lasercoagulatie en cryoablatie op de acute fase immuunreactie en stollingsactivatie in de rat	Van Gulik	2001	3
Urology (AMC/UvA)				
P. Beemster	Cryosurgery of small renal tumors	De la Rosette/ Laguna/ Wijkstra	2005	1

The image features a minimalist design with overlapping grey geometric shapes. A large, light grey triangle is positioned on the left side. A darker grey shape, resembling a stylized arrow or a trapezoid, points from the left towards the right. The word "awards" is printed in a black, sans-serif font within the darker grey shape. Below the word, a large, bold black number "5" is displayed. The overall composition is clean and modern.

awards

5

5. Awards

This chapter lists awards and honors won by staff and students involved in OOA throughout 2008. The lists are in alphabetical order of the recipients' last name.

Faculty and staff members of the OOA fulfilled numerous functions in national and international organizations, on scientific boards of scientific journals, as members of study sections, and as organizers or co-organizers of scientific meetings, workshops and congresses.

Scientific awards and honors

Faculty and staff

H. Bartelink (NKI) received a doctorate honoris causa from the Academia of Medicine in Gdansk, Poland.

I.E.M. Bultink (VUmc) won the NVLE award 2008.

B.A.C. Dijkmans (VUmc) received the Clemmensen lecture Award Denmark.

B.A.C. Dijkmans (VUmc) was awarded with lecture 'Interventions in very early stages of heumatoid arthritis invited lecture' Istanbul Turkey.

J. Haanen (NKI) was appointed as Professor of Translational Immunotherapy of Cancer at the Leiden University.

G.J.L. Kaspers (VUmc) received the Nijbakker-Morra studentenprijs for Eily Schaafsma.

D. Peeper (NKI) was appointed as professor of Functional Oncogenomics at the Free University in Amsterdam.

D. Peeper (NKI) was elected as EMBO member.

D.M. Pegtel (VUmc) received a VENI Grant.

G.J. Peters (VUmc) won Eminent scientist of the year 2007 Europe in January 2008.

P.H.M. Savelkoul (VUmc) won the First Amsterdam Invention Award (Amsterdam Topstad).

T. Sixma (NKI) became member of the Royal Netherlands (Dutch) Academy of Arts and Sciences.

B. van Steensel (NKI) was elected as EMBO member.

I. van der Waal (VUmc) was awarded with the Honorary Membership of the Nederlandse

Vereniging voor Mondziekten, Kaak- en Aangezichtschirurgie Amsterdam.

I. van der Waal (VUmc) won The Scientific Award of the Spanish Society of Oral Medicine, Bilbao (Spain).

C.M.J.E. Vandenbroucke-Grauls (VUmc) won the APUA (Alliance for the Prudent use of Antibiotics) Leadership Award for exemplary leadership in controlling hospital infections and antibiotic resistance, Washington (USA).

PhD students

F.E. Henken (VUmc) received a KWF/Dutch cancer society travel grant

J. Hodzic (VUmc) won the AACR-AstraZeneca Scholar-in-Training Award in San Diego (USA).

I. Ouwehand (VUmc) received the Travel Award Kobe (Japan).

S.J.A.M. Santegoets (VUmc) received a KWF/Dutch cancer society travel grant.

S.J.A.M. Santegoets (VUmc) won the AACR-PCF Prostate Cancer Research Recognition Award for Research Excellence in San Diego (USA).

L. van Baarsen (VUmc) won The VU-wetenschapsprijs 2008.

J. Voorman (VUmc) was awarded with a Visiting Fellow Award National Cancer Institute by National Institutes of Health, Bethesda (USA).

W. Zwart (NKI) won the AvL-prize 2008 for young, promising NKI-scientists.



faculty and staff

annex

1

Annex 1.

Faculty and staff of OOA

FACULTY

Prof.dr. N.K. Aaronson (Theme 2)
Department of Psychosocial Research and
Epidemiology
Netherlands Cancer Institute

Dr. R. Agami (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Dr. J.A. Aten (Theme 1)
Department of Cell Biology and Histology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. A. Begg (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. R. Beijersbergen (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. R. Bernards (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. A.J.M. Berns (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. J.H. Beijnen (Theme 2)
Division of Pharmacology
Netherlands Cancer Institute

Prof.dr. J.G. Borst (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Prof.dr. P. Borst (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. R.H. Brakenhoff (Theme 1 and 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof.dr. H. N. Caron (Theme 1 and 2)
Pediatric Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. J.G.N.M. Collard (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. J. Crezee (Theme 2)
Department of Department of Radiation Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.A.M.S. van Dongen (Theme 1 and 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Dr. E.F. Eldering (Theme 1)
Department of Experimental Immunology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. D. Geerts (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. W.R. Gerritsen (Theme 2)
Department of Medical Oncology
VU University Medical Center

Prof.dr. D.J. Gouma (Theme 2)
Department of Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Dr M. A. Grootenhuys (Theme 2)
Department of Pediatrics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. T.M. van Gulik (Theme 2)
Department of Experimental Surgery
Academic Medical Centre / Universiteit van
Amsterdam

Prof. Dr. A. Hagenbeek (Theme 1 and 2)
Department of Hematology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. J. Haanen (Theme 1 and 2)
Department of Immunology
Netherlands Cancer Institute

Prof. Dr. M. van Herk (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof.dr. O.S. Hoekstra (Theme 2)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. P.C. Huijgens (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Dr T.J.M. Hulsebos (Theme 1)
Department of Neurogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Dr. K. Jalink (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. H. Joenje (Theme 1)
Department of Human Genetics
VU University Medical Center

Dr. J. Jonkers (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. G.J. Kaspers (Theme 2)
Department of Paediatrics
VU University Medical Center

Prof.dr. C.C.E. Koning (Theme 2)
Department of Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Dr. M. Kool (Theme 1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. Y. van Kooyk (Theme 1 and 2)
Department of Molecular Biology and Immunology
VU University Medical Center

Dr. K.K. Krishnadath (Theme 1)
Department of Gastroenterology and Hepatology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. A. B.P. van Kuilenburg (Theme 1 and 2)
Department of Clinical Chemistry
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. A.A. Lammertsma (Theme 2)
Department of Nuclear Medicine
VU University Medical Center

Prof.dr. Ch.R. Leemans (Theme 2)
Department of Otolaryngology-Head & Neck
Surgery
VU University Medical Center

Prof. dr. A.G.J.M. van Leeuwen (Theme 2)
LaserCenter
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. F.E. van Leeuwen (Theme 2)
Psychosocial Research and Epidemiology
Netherlands Cancer Institute

Dr. F. van Leeuwen (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. M. van Lohuizen (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Dr. R.M. Luiten (Theme 2)
Department of Immunology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J.P. Medema (Theme 1)
Laboratory of Experimental Oncology and
Radiotherapy
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. C.J.L.M. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. G.A. Meijer (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. S. Meijer (Theme 2)
Department of Surgical oncology
VU University Medical Center

Prof.dr. H. Meijers-Heijboer (Theme 1)
Department of Clinical Genetics
VU University Medical Center

Prof. dr. W.H. Moolenaar (Theme 1)
Department of Cellular Biochemistry
Netherlands Cancer Institute

Prof.dr. J.M. Middeldorp (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Prof.dr. J.J.C. Neefjes (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof. dr. C.J.M. van Noesel (Theme 1)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Prof. dr. M.H.J. van Oers (Theme 1 and 2)
Department of Hematology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. G.J. Ossenkoppele (Theme 1 and 2)
Department of Haematology
VU University Medical Center

Prof.dr. S.T. Pals (Theme 1 and 2)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. A. Perrakis (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Dr. D. Peeper (Theme 1)
Department of Molecular Genetics
Netherlands Cancer Institute

Prof.dr. G.J. Peters (Theme 2)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. P.J. Peters (Theme 1)
Department of Tumor Biology
Netherlands Cancer Institute

Prof.dr. P. Postmus (Theme 2)
Department of Pulmonology
VU University Medical Center

Prof.dr. D.J. Richel (Theme 1 and 2)
Department of Medical Oncology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. H.P.J. te Riele (Theme 1)
Department of Molecular Biology
Netherlands Cancer Institute

Prof.dr. S. Rodenhuis (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Dr. E. Roos (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Prof.dr. J.J.M.C.H. de la Rosette (Theme 2)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. J.H.M. Schellens (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof.dr. R.J. Scheper (Theme 1 and 2)
Department of Pathology
VU University Medical Center

Dr. A. Schinkel (Theme 1)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. J.H. Schornagel (Theme 2)
Department of Internal Medicine
Netherlands Cancer Institute

Prof. Dr. T. Schumacher (Theme 1)
Department of Immunology
Netherlands Cancer Institute

Dr. G.J. Schuurhuis (Theme 2)
Department of Hematology
VU University Medical Center

Prof.dr. S. Senan (Theme 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. T.K. Sixma (Theme 1)
Department of Molecular Carcinogenesis
Netherlands Cancer Institute

Prof.dr. B.J. Slotman (Theme 1 and 2)
Department of Radiation Oncology
VU University Medical Center

Prof.dr. E.F. Smit (Theme 2)
Department of Pulmonology
VU University Medical Center

Dr. A. Sonnenberg (Theme 1)
Department of Cell Biology
Netherlands Cancer Institute

Dr. M. Spaargaren (Theme 1)
Department of Pathology
Academic Medical Centre / Universiteit van
Amsterdam

Dr. C.A. Spek (Theme 1 and 2)
Department of Experimental and Molecular
Medicine
Academic Medical Centre / Universiteit van
Amsterdam

Dr. B. van Steensel (Theme1)
Department of Molecular Biology
Netherlands Cancer Institute

Dr. L. van 't Veer (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. L.J. Valentijn (Theme1)
Department of Human Genetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof.dr. W.P. Vandertop (Theme 2)
Department of Neurosurgery
VU University Medical Center

Prof.dr. A.J.P. Veerman (Theme 2)
Department of Paediatrics
VU University Medical Center

Dr. M. Verheij (Theme 2)
Department of Radiotherapy
Netherlands Cancer Institute

Prof. dr. H. Verheul (Theme 2)
Department of Clinical Oncology
VU University Medical Center

Prof.dr. R.H.M. Verheijen (Theme 2)
Dept. of Obstetrics & Gynaecology
VU University Medical Center

Prof.dr. R. Versteeg (Theme 1 and 2)
Department of Antropogenetics
Academic Medical Centre / Universiteit van
Amsterdam

Prof. dr. M. van de Vijver (Theme 2)
Department of Experimental Therapy
Netherlands Cancer Institute

Dr. H. Wijkstra (Theme 2)
Department of Urology
Academic Medical Centre / Universiteit van
Amsterdam

STAFF

Netherlands Cancer Institute

Cell Biology

Dr. J.G. Collard
Dr. C. Jalink
Dr. E. Roos
Dr. A. Sonnenberg

Molecular Carcinogenesis

Prof.dr. R. Bernards
Dr. R. Beijersbergen
Dr. A. Perrakis
Prof.dr. T.K. Sixma

Cellular Biochemistry

Dr. W.J. van Blitterswijk
Dr. N. Divecha
Dr. F. van Leeuwen
Prof.dr. W.H. Moolenaar
Dr. H. Ovaa
Dr. M. Verheij

Immunology

Prof.dr. J. Borst
Dr. J.B.A.G. Haanen
Dr. H. Jacobs
Prof.dr. T.N.M. Schumacher
Dr. F.A. Vyth-Dreese

Molecular Biology

Prof.dr. P. Borst (honorary staff member)
Dr. J. Jonkers
Dr. H. van Luenen
Prof.dr. H. te Riele
Dr. B. van Steensel

Tumor Biology

Dr. R. Agami
Dr. M. Fornerod
Dr. R.J.A.M. Michalides
Prof.dr. J.J. Neefjes
Prof.dr. P.J. Peters

Molecular Genetics

Prof.dr. A.J.M. Berns
Dr. J. Hilkens
Dr. P. Krimpenfort
Prof.dr. M. van Lohuizen
Dr. M. Snoek
Dr. M.A. van der Valk

Experimental therapy

Prof.dr. A.C. Begg
Dr. A. Schinkel
Dr. F.A. Stewart
Prof.dr. M.J. van de Vijver
Dr. L.J. van 't Veer

Radiotherapy

B.M.P. Aleman
Prof.dr. G.M.M. Bartelink
Dr. J.S.A. Belderbos
Dr. R.W. de Boer
Dr. M. Boersma

Dr. I. Bruinvis
B.N.F.M. van Bunningen
Dr. E.M.F. Damen
Dr. L.G.H. Dewit
Dr. R.L.M. Haas
Dr. A.A.M. Hart
Dr. W. Heemsbergen
Dr. M. van Herk
Dr. E.P.M. Jansen
Dr. J.V. Lebesque
Dr. C.A.M. Marijnen
E.A.H. Masselink
Dr. B.J. Mijnheer
Dr. L.M.F. Moonen
Dr. C.R.N. Rasch
Dr. P. Remeijer
Dr. N.S. Russell
J.G. Salverda
Dr. C. Schneider
Dr. J. Stroom
Dr. J.C.M. Theuvs
Dr. C. van Vliet-Vroegindeweij
Dr. C. Vrieling
Dr. F.W. Wittkämper

Medical Oncology

Dr. J.W. Baars
Dr. P. Baas
Drs. E.M. Bais
Prof.dr. J.H. Beijnen
Dr. J.P. de Boer
Dr. W.W. ten Bokkel Huinink
Dr. W. Boogerd
Dr. H. Boot
Dr. J.A. Burgers
Dr. A. Cats
Prof.dr. G.C. de Gast
L. Gualthérie van Weezel
Dr. J.B.A.G. Haanen
Dr. A. Huitema
Dr. J.M. Kerst
Dr. S.C. Linn
Dr. A. Lukas
Dr. H. Neering
Prof.dr. S. Rodenhuis
Dr. J.H.M. Schellens
Dr. J.H. Schornagel
Dr. M. Smits
Dr. B.G. Taal
Dr. M. van der Weide
Dr. N. van Zandwijk

Surgical Oncology

Prof.dr. B.B.R. Kroon
Dr. A.J.M. Balm
Dr. A. Bex
Dr. M.W.M. van den Brekel
Dr. D.R. Buitelaar
Prof.dr. M.P.M. Burger
Dr. J. ten Cate
Dr. F. van Coevorden
Dr. M.P. Copper
Dr. W. van Driel
Dr. G. Fons

Dr. S. Gonggrijp
Dr. J.J. Hage
Prof.dr. F.J.M. Hilgers
Prof.dr. S. Horenblas
Dr. H. Huitink
Dr. C. Keijzer
H. Klomp
Dr. F.H.M. Kroon
Dr. P.J.F.M. Lohuis
Dr. M.A.C. Lubsen
Dr. W. Meinhardt
Dr. O.E. Nieweg
Dr. H.S.A. Oldenburg
Dr. H.G. van der Poel
Dr. M. de Rie
J.M. Runday
Dr. E.J.Th. Rutgers
Dr. P.F.E. Schutte
Dr. M. Scraméek
Dr. M. Slot
Dr. L.E. Smeele
Dr. T. Stoppa
Dr. I.B. Tan
Dr. A.P. Timmers
Dr. V.J. Verwaal
Dr. M.J. Vrancken Peeters
L.A.E. Woerdeman
Dr. F.A.N. Zoetmulder

Psychosocial Research and Epidemiology

Prof.dr. N.K. Aaronson
Prof.dr. F.S.A.M. van Dam
Prof.dr. W.J. van Harten
Prof.dr. F.E. van Leeuwen
Dr. M.A. Rookus

Pathology

Dr. T. Alderliesten
Dr. J.M. G. Bonfrer
Dr. H. van Boven
Dr. M.P.W. Gallee
Dr. K. Gilhuijs
Dr. C.A. Hoefnagel
Dr. F.B.L. Hogervorst
Dr. D. de Jong
Dr. J. Kluijt
Dr. W. Koops
Dr. R. Kröger
Dr. C. Loo
Dr. W.J. Mooi
S.H. Muller
Dr. P.M. Nederlof
Dr. W.J. Nooijen
F.A. Pameijer
Dr. R. van Pel
Dr. J.L. Peterse
Dr. W. Prevoo
Dr. M. Sinaasappel
Dr. F. Sivo
Dr. J. Teertstra
Dr. O. van Tellingen
Dr. R.A. Valdès Olmos
Dr. L. van 't Veer
Dr. M.L.F. van Velthuijsen
Dr. S. Verhoef

Prof.Dr. M. van de Vijver
Dr. J. Wesseling

Radiology

A.P.E. Besnaard
W. Koops
Dr. R. Kröger

VU University Medical Center

Anaesthesiology

Prof.dr. W.W.A. Zuurmond

Clinical Genetics

Dr. S. Agarwal
Prof.dr. H. Joenje
Dr. F. Menko
Prof.dr. H. Meijers-Heijboer
Dr. G. Pals
Dr. Q. Waisfisz
Dr. J. de Winter

Clinical Chemistry

Dr. C.B.M. Oudejans
Prof.dr. M.A. Blankenstein

Gastro-enterology

Dr. M. Craanen
Prof.dr. C Mulder

Haematology

M.E.D. Chamuleau
Dr. A. Dräger
Prof.dr. P.C. Huijgens
Dr. J.J.W.M. Janssen
Prof. dr. G.J. Ossenkoppele
Dr. G.J. Schuurhuis
Dr. L. Smit
Dr. A.A. van de Loosdrecht
Dr. O. Visser
Dr. S. Zweegman
Dr. J.M. Zijlstra

Medical Psychology

Prof.dr.P.T. Cohen-Kettenis
Dr. J. Huisman
Dr. M. Klein
Prof.dr.H.M. Ploeg

Molecular Cell Biology

Prof.dr. R.H.J. Beelen
Prof.dr. G. Kraal
Prof.dr. Y. van Kooyk

Medical Oncology

Dr. P.J.M. Bakker
Prof.dr. E. Boven
Dr. H.J. Broxterman
Dr. J. Buter
Dr. T.D. de Gruijl
Dr. R.J.A. Fijneman
Dr. W.R. Gerritsen
Dr. B.N. Hangalapura
Dr. K. Hoekman
Dr. R. Honeywell
Dr. M.L. Janmaat
Dr. C.R. Jimenez
Dr. F.A.E. Kruyt
Prof.dr. J. Lankelma
Dr. P. Noordhuis
Dr. D. Oosterhoff
Prof.dr. G.J. Peters
Dr. T.V. Pham
Dr. S. Piersma

Dr. J.A. Rodriguez
Dr. M.P. van den Tol
Dr. C.J. van Groenigen
Dr. V.W. van Beusechem
Dr. H.P. van den Berg
Dr. A.J.M. van den Eertwegh
Dr. J.J. van der Vliet
Prof.dr. H. Verheul
Dr. C. Vermeulen

Neurosurgery

Dr. J.C. Baaijen
Dr. C.M.F. Dirven
Dr. M.L.M. Lamfers
Dr. D.P. Noske
Prof.dr. W.P. Vandertop
Dr. T. Würdinger

Neurology

Prof.dr. J.J. Heimans
Dr. T. Postma
Dr. J.C. Reijneveld

Nuclear Medicine

Dr. R. Boellaard
Dr. E.F.I. Comans
Dr. A.A. Geldof
Dr. N.H. Hendrikse
Dr. J.D.M. Herscheid
Prof.dr. O.S. Hoekstra
Prof.dr. A.A. Lammertsma
Dr. M. Lubberink
Dr. C.F.M. Molthoff
Dr. H.J. Pijpers
Dr. P. Raijmakers
Prof.dr G.A.M.S. van Dongen
Dr. G.W.M. Visser
Dr. A.D. Windhorst
Dr. J.M. Zijlstra

Obstetrics and Gynaecology

Dr. J.C. Dorsman
Prof.dr. P. Kenemans
Dr. S. von Mensdorff-Pouilly
Prof.dr. R.H.M. Verheijen

Ophthalmology

Dr. S. Imhoff
Dr. A. Moll

Oral and maxillofacial surgery and pathology

Prof.dr. I. van der Waal

Otolaryngology / Head and Neck Surgery

Dr. P.A. Borggreven
Dr. B.J.M. Braakhuis
Prof.dr. R.H. Brakenhoff
Dr. R. de Bree
Dr. F. Dijk
Dr. J.M. Festen
Dr. D.J. Kuik
Prof.dr. Dr. Ch.R. Leemans
Prof.dr. H.F. Mahieu
Dr. R.N.P.M. Rinkel

Dr. I. Verdonck-de Leeuw
Prof.dr. G.A.M.S. van Dongen
Dr. D. Vugts

Pathology

Dr. J. Beliën
Prof. dr. E. Bloemena
Dr. H.J. Bontkes
Dr. C.L. Bos
Dr. B. Carvalho
Dr. J.B.A. Crusius
Dr. B. Diosdado
Dr. A.E. Greijer
Dr. D.A.M. Heideman
Dr. E. Hooijberg
Dr. F.J. van Kemenade
Dr. P. Krijnen
Prof.dr. C.J.L.M. Meijer
Prof.dr. G.A. Meijer
Prof.dr. J.M. Middeldorp
Prof.dr. W.J. Mooi
Dr. S.A. Morré
Dr. J.J. Oudejans
Prof.dr. A.S. Peña
Dr. G.L. Scheffer
Prof.dr. R.J. Scheper
Dr. P.J.F. Snijders
Dr. R. Steenbergen
Dr. M. van de Wiel
Prof.dr. P.J. van den Elsen
Dr. P. van den Ijssel
Dr. A.H. van Hattum
Dr. B.M.E. von Blomberg-van der Flier
Dr. B. Ylstra

Paediatrics

Dr. F. Abbink
Dr. C.J.M. Broers

Dr. J. Cloos
Dr. V. de Haas
Dr. E. Dulmen-den Broeder
Dr. I. Hubeek
Prof.dr. G.J. Kaspers
Dr. M.H. van der Berg
Dr. A.M. van Furth
Dr. M.A. Veening
Prof. Dr. A.J.P. Veerman

Pulmonology

Prof.dr. P.E. Postmus
Prof.dr. E.F. Smit
Dr. T.G. Sutedja

Radiology

Prof.dr. J.A. Castelijns

Radiation Oncology

Dr. F.J. Lagerwaard
Dr. M.V.M. Lafleur
Prof.dr. S. Senan
Prof.dr. B.J. Slotman
Dr. P. Sminia
Dr. B. van Triest

Surgical Oncology

Prof.dr. M.A. Cuesta
Prof.dr. S. Meijer
Prof.dr. P.A.M. van Leeuwen

Medical Oncology

Urology

Dr. E.C. de Boer
Dr. A.A. Geldof
Dr. R.J.A. Moorselaar

University of Amsterdam

Medical Biochemistry
Prof.dr. J.M.F.G. Aerts

Cell Biology & Histology
Dr. J.A. Aten
Prof. dr. C.J.F. van Noorden
Dr. A. Sonnenberg

Experimental Internal Medicine
Dr. C.A. Spek

Gastro-enterology & Hepatology
Prof.dr. R.P.J. Oude Elferink
Dr. K.K. Krishnadath

Genetic Metabolic Diseases
Dr. A.B.P. van Kuilenburg

Human Genetics
Dr. H.A.M. Geerts
Dr. L.J. Valentijn
Prof.dr. R. Versteeg
Dr. M. Kool

Hematology
Dr. M.J. Kersten
Dr. H. Koene
Prof. dr. M.H.J. van Oers

Immunology
Dr. E.F. Eldering
Dr. R.M. Luiten

LaserCenter
Dr. M.C. Aalders
Prof. dr. A.G.J.M. van Leeuwen

Medical Biochemistry
Prof. dr. J.M.F.G. Aerts

Medical Oncology
Dr. P.J.M. Bakker
Prof.dr. D.J. Richel
Dr. A.M. Westermann
Dr. H. Wilmink

Neurogenetics
Dr. Th.J.M. Hulsebos

Pathology
Prof.dr. S.T. Pals
Dr. M. Spaargaren
Prof. dr. C.J.M. van Noesel

Pediatric Oncology
Dr. H. van den Berg
Prof.dr. H.N. Caron
Dr. A.B.P. van Kuilenburg
Dr. J. de Kraker
Dr. J.H. Merks
Dr. A.Y.N. Schouten-van Meeteren
Prof. dr. G.A.M. Tytgat
Dr. A.C. Verschuur
Dr. M.D. van de Wetering

Dr. J. Zsiros

Radiotherapy
Dr. C. van Bree
Dr. N.A.P. Franken
Prof.dr. C.C.E. Koning
Prof.dr. J.P. Medema

Surgery
Prof.dr. D.J. Gouma
Prof.dr. T.M. van Gulik

Urology
Prof.dr. J.J.M.C.H. de la Rosette
Dr.Ir. H. Wijkstra

international visitors

annex 2

Annex 2.

International visitors

Alberts B., USA
Allavena P., Italy
Auwerx J., Switzerland

Bernstein B., USA
Bonnet D., UK
Brummelkamp T., USA
Brunsveld L., Germany
Bulavin D., Singapore
Burke B., USA
Bussemaker H., USA

Carneiro F., Portugal
Carette J., UK
Chalmes A., UK
Christofori G., Switzerland
Cormier R.T., USA

d'Adda di Fagagna F., Italy
Darby S., UK
Darwin H., USA
Dutta A., USA

Fersht A., UK
France Poupon M., France
Fulda S., Germany

Grabsch H., UK

Hahn W., USA
Haibe-Kains B., Belgium
Hall A., USA
Hanash S., USA
Helin K., Denmark
Helleday T., UK
Hickson I., UK

Ince T., USA
Innocenti M., Germany

Jakobs S., Germany
Jentsch S., Germany
Jiricny J., Switzerland

Kauppinen S., Denmark
Kerem B., Israel
Klein B., France
Krogan N., USA
Kuhn P., USA

Lehmann A., UK

Lehtio J., Sweden

Mahmood U., USA
Makela T., Finland
Marangoni E., France
May E., Germany
McColl K.E.L., Scotland
McMahon M., USA
Monni O., Finland
Muir T., USA

Naldini L., Italy
Nelson W.G., USA
Nilsson J., Sweden

Oliveira C., Portugal

Paolo di Fiore P., Italy
Patel K.J., UK
Peters J.M., Austria
Peto R., UK
Pfeifer R., USA
Ploegh H., USA
Ponten F., Sweden

Rando O., USA
Reddy Junutula J., USA
Reis e Sousa C., UK
Rotem-Yehudar R., Israel

Schoenberger S.P., USA
Segal E., Israel
Seruca R., Portugal
Sherwood D., USA
Skog J., USA
Spits H., USA
Sundberg J., USA
Szostak J., USA

Taylor S., UK
Thames H.D., USA
Tomlinson I., UK

Valdimarsdottir H., USA
Vallee R., USA
Van Ginderachter J., Belgium
van Kasteren S., UK
van Oudenaarden A., USA
Vasilieva L., USA

Weinberg R., USA

PhD theses completed

annex 3

Annex 3.

Theses completed

In 2008, 48 graduate students completed their graduate training and obtained a PhD degree. Their names, thesis titles, supervisors and institutes are listed below. The institute at which the research described in the theses was carried out is mentioned between brackets and may differ from the university where the PhD graduation took place.

Name	:	van der Bij, G.J. (VUmc)
Title	:	The impact of microenvironment and surgery on colon carcinoma metastasis; new concepts in development and therapy
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Meyer S., Beelen R.M.J. and Van Egmond M.
Date	:	07-11-2008
Name	:	van den Bout I. (NKI)
Title	:	Identification and functional analysis of genes regulated by B1 and B3 integrins
University	:	Universiteit van Amsterdam
(co)Promotors	:	Berns A.J.M.
Date	:	27-03-2008
Name	:	Brouwer J. (VUmc)
Title	:	Diagnostic imaging in detecting recurrent and metastatic head and neck cancer
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Leemans C.R., De Bree R., Castelijns J.A. and Comans E.F.I.
Date	:	30-09-2008
Name	:	Bruggeman S. (NKI)
Title	:	Polycomb group genes in brain development and cancer Ink4a/ecf and beyond
University	:	Universiteit van Amsterdam
(co)Promotors	:	van Lohuizen, M.
Date	:	07-02-2008
Name	:	Buffart T.E. (VUmc)
Title	:	DNA copy number profiling of gastric cancer and its clinical implications
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Meijer G.A., Van der Velde C.J.H., Van Grieken N.C.T. and Pinto Morais de Carvalho B.
Date	:	16-12-08
Name	:	Bulkmans N.W.J. (VUmc)
Title	:	Primary hrHPV testing in cervical screening: the arguments
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Meijer C.J.L.M., Snijders P.J.F., Rozendaal L and Berkhof J.
Date	:	15-01-2008
Name	:	Cilllessen S.A.G.M. (VUmc)
Title	:	Apoptosis in diffuse large B-cell lymphomas: from mechanisms to applications
University	:	Vrije Universiteit Amsterdam
(co)Promotors	:	Meijer C.J.L.M. and Oudejans J.J.
Date	:	11-06-2008

Name : **van Dijk J. (VUmc)**
Title : Quality of life and psychosocial functioning of Retinoblastoma survivors in the Netherlands
University : Vrije Universiteit Amsterdam
(co)Promotors : Cohen-Kettenis P.T., Huisman J., Imhof S.M. and Moll A.C.
Date : 5-12-2008

Name : **Duursma A.M. (NKI)**
Title : Molecular dissection of Cdc6 and the miR-148 family : two stories with common themes
University : Universiteit Leiden
(co)Promotors : Neefjes J.J. and Agami R.
Date : 14-05-2008

Name : **Ekhart G.C. (NKI)**
Title : Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy
University : Universiteit van Utrecht
(co)Promotors : Beijnen, J.H., Rodenhuis S. and Huitema A.D.R.
Date : 22-09-2008

Name : **Engelsma D. (NKI)**
Title : Nuclear Export Signals:Small Domains with Large Impact
University : Universiteit Leiden
(co)Promotors : Neefjes J.
Date : 10-10-2008

Name : **Epping M. (NKI)**
Title : Functional Genetic screens as tools to discover signaling pathways targeted by cancer drugs
University : Universiteit van Utrecht
(co)Promotors : Bernards R.
Date : 18-03-2008

Name : **van Galen J.C. (VUmc)**
Title : Expression analysis of stress-induced apoptosis pathway regulating genes in B-cell lymphomas
University : Vrije Universiteit Amsterdam
(co)Promotors : Meijer C.J.L.M., Oudejans J.J. and Raaphorst F.M.M.
Date : 19-11-2008

Name : **Gallegos Ruiz M.I. (VUmc)**
Title : Therapeutic Targets and Biomarkers in Lung Cancer
University : Vrije Universiteit Amsterdam
(co)Promotors : Giaccone G., Smit E.F., Rodriguez J.A. and Ylstra B.
Date : 22-04-2008

Name : **Geiger T. (NKI)**
Title : Oncogenic and Metastatic Functions of the Neurotrophic Receptor TRKB
University : Universiteit van Amsterdam
(co)Promotors : Berns A.J.M. and Peeper D.S.
Date : 19-12-2008

Name : **de Gorter D.J.J (AMC)**
Title : Signaling pathways involved in B cell differentiation and disease. The role of Ral, Btk and Met.
University : Universiteit van Amsterdam
(co)Promotors : Pals S.T., Spaargaren M.
Date : 03-04-2008

Name : **Hallaert D.Y.H. (AMC)**
Title : 'From the cradle to the grave' Novel therapeutic approaches to attack the microenvironment in Chronic Lymphocytic Leukemia.
University : Universiteit van Amsterdam
(co)Promotors : van Oers M.H. and Eldering E.
Date : 15-10-2008

Name : **Hannemann J. (NKI/AMC)**
 Title : Gene expression profiling in breast cancer. A link between biology and clinical decision making.
 University : Universiteit van Amsterdam
 (co)Promotors : van de Vijver M. J. and Rodenhuis S.
 Date : 03-07-2008

Name : **Hardenberg G. (AMC)**
 Title : The role of APRIL in immunity and tumorigenicity
 University : Universiteit van Amsterdam
 (co)Promotors : Medema J.P.
 Date : 24-04-2008

Name : **Hendriksen J. (NKI)**
 Title : Intracellular routing of bet-catenin
 University : Universiteit Leiden
 (co)Promotors : Moolenaar W.
 Date : 19-06-2008

Name : **Hesselink A.T.H. (VUmc)**
 Title : High-risk human papillomavirus testing in cervical screening: which assay?
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Snijders P.J.F., Meijer C.J.L.M. and Heideman D.A.M.
 Date : 15-01-2008

Name : **Hermesen B.B.J. (VUmc)**
 Title : Risk profile of women at hereditary high risk for breast and ovarian cancer
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Verheijen R.H.M. and Kenemans P.
 Date : 16-04-2008

Name : **Hooning M. (NKI)**
 Title : Adverse effects of treatment in long-term survivors of breast cancer
 University : Universiteit Leiden
 (co)Promotors : van Leeuwen F.
 Date : 9-1-2008

Name : **van Houdt I.S. (VUmc)**
 Title : Cellular immune response in human melanoma, insights for a patient tailored therapy
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Meijer C.J.L.M., Oudejans J.J. and Hooijberg E.
 Date : 14-05-2008

Name : **Huveneers S. (NKI)**
 Title : The regulation of Rho and Src signaling
 University : Universiteit van Amsterdam
 (co)Promotors : Berns A.J.M.
 Date : 30-10-2008

Name : **Jorritsma, A. (NKI)**
 Title : Immunotherapy of melanoma : toward clinical application
 University : Universiteit Leiden
 (co)Promotors : Schumacher T.N.M. and Haanen B.A.G.
 Date : 04-09-2008

Name : **Keller A.M. (NKI)**
 Title : The role of CD70/CD27 interactions at the dendritic cell/T cell interface
 University : Universiteit van Amsterdam
 (co)Promotors : Borst J.
 Date : 23-05-2008

Name : **Koppen A. (AMC)**
 Title : Gene regulation by MYCN in neuroblastoma
 University : Universiteit van Amsterdam
 (co)Promotors : Versteeg R. and Valentijn L. J.
 Date : 25-03-2008

Name : **Kortlever R. (NKI)**
 Title : Escaping Growth Arrest in Cancer
 University : Universiteit van Utrecht
 (co)Promotors : Bernards R.
 Date : 24-06-2008

Name : **Langerak, P. (NKI)**
 Title : DNA Damage Tolerance: From Error Free UV-Damage Bypass to mutagenesis of Immunoglobulin Genes
 University : Universiteit van Amsterdam
 (co)Promotors : Borst J.
 Date : 01-02-2008

Name : **Lemos C. (VUmc)**
 Title : Folate supplementation in chemotherapy: increase of efficacy versus induction of drug resistance.
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Calhau C., Azevedo I. and Peters G.J.
 Date : 10-10-2008

Name : **Le Sage C. (NKI)**
 Title : Identifying Cancer-Causing Noncoding RNAs
 University : Universiteit Leiden
 (co)Promotors : Neefjes J.
 Date : 10-01-2008

Name : **Leuken, R.J. van**
 Title : Ubiquitination and deubiquitination involved in cell cycle progression
 University : Universiteit Utrecht
 (co)Promotors : Medema, R.H.; Wolthuis, R.M.F.
 Date : 18-09-2008

Name : **Molling J.W. (VUmc)**
 Title : Invariant natural killer T cells and immunotherapy of cancer
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Scheper R.J., van den Eertwegh A.J.M., von Blomberg B.M.E., Bontkes H.J.
 Date : 23-05-2008

Name : **Moreno Jauge M. (VUmc)**
 Title : Innate and adaptive tumour immunity: Role of invariant natural killer T cells.
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Verheijen R.H.M., Scheper R.J., von Mensdorff-Pouilly S.C.T. and Bontkes H.J.
 Date : 26-09-2008

Name : **Mous R. (AMC)**
 Title : Studies on the immune system in CLL
 University : Universiteit van Amsterdam
 (co)Promotors : van Oers M.H.J. and van Lier R.A.W.
 Date : 03-10-2008

Name : **Neijssen J. (NKI)**
 Title : The Fate of Intracellular Peptides and MHC class I Antigen Presentation
 University : Universiteit Leiden
 (co)Promotors : Neefjes J.
 Date : 6-2-2008

Name : **Niers T.H.M. (AMC)**
 Title : Coagulation, angiogenesis and cancer
 University : Universiteit van Amsterdam
 (co)Promotors : Büller H.R., Spek, C.A., Richel, D.J. and van Noorden C.J.F.
 Date : 17-06-2008

Name : **van Rhenen A. (VUmc)**
 Title : Detection and characterization of leukemic stem cells
 University : Vrije Universiteit Amsterdam
 (co)Promotors : P.C. Huijgens
 Date : 25-04-2008

Name : **De Sousa Rocha N. (NKI)**
 Title : Moleculair basis for the control of motor-based transport of MHC class II compartments
 University : Universiteit Leiden
 (co)Promotors : Neefjes J.
 Date : 8-10-2008

Name : **Rygiel A.M. (AMC)**
 Title : Genetic markers in malignant progression of Barrett's esophagus
 University : Universiteit van Amsterdam
 (co)Promotors : Peppelenbosch M.P., Fockens P., Krishnadath K.K., Bergman J.J.G.H.M.
 Date : 18-01-2008

Name : **Santegoets S.J.A.M. (VUmc)**
 Title : Characterization of a human dendritic cell line; a prelude to allogeneic dendritic cell-based tumor vaccination.
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Scheper R.J., de Gruijl T.D. and Van den Eertwegh A.J.M..
 Date : 12-03-2008

Name : **Veltkamp S. (NKI)**
 Title : Clinical pharmacological and translation research on novel formulations of anticancer drugs
 University : Universiteit van Utrecht
 (co)Promotors : Schellens J.H.M.
 Date : 05-03-2008

Name : **Vogel M.J. (NKI)**
 Title : Genomic mapping of heterochromatin components using DamID.
 University : Universiteit van Amsterdam
 (co)Promotors : van Lohuizen M.M.S.
 Date : 31-10-2008

Name : **Voortman J. (VUmc)**
 Title : The proteasome a viable target in non-small cell lung cancer?
 University : Vrije Universiteit Amsterdam,
 (co)Promotors : Giaccone G.
 Date : 18-04-2008

Name : **Vrieling A. (NKI)**
 Title : The Insuline-like Growth Factor (IGF) system in breast and colorectal carcinogenesis: dietary intervention and molecular
 University : Universiteit Leiden
 (co)Promotors : van Leeuwen F.
 Date : 17-1-2008

Name : **Witte M. (NKI)**
 Title : Adoptive Transfer of Tumor-and Minor antigen-specific T cell reactivity in mouse models
 University : Universiteit Leiden
 (co)Promotors : Schumacher
 Date : 29-5-2008

Name : **Zijlstra J.M. (VUmc)**
 Title : FDG PET Response Monitoring in Malignant Lymphoma
 University : Vrije Universiteit Amsterdam
 (co)Promotors : Huijgens P.C. and Hoekstra O.S.
 Date : 03-07-2008

scientific publications

annex 4

Annex 4.

Scientific publications

1. Aalbers AGJ, Biere SSAY, van Berge Henegouwen MI, Bemelman WA. Hand-assisted or laparoscopic-assisted approach in colorectal surgery: a systematic review and meta-analysis. *Surg Endoscopy and other Intervent Techn* 2008; 22(8): 1769-1780. (AMC)
2. Aarnoudse CA, Bax M, Sanchez-Hernandez M, Garcia-Vallejo JJ, van Kooyk Y. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. *Int J Cancer* 2008; 122(4): 839-846 (VUmc)
3. Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JBAG, Schumacher TNM, Rosenberg SA, Restifo NP, Morgan RA. T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. *J Immunother* 2008; 31: 1-6 (NKI)
4. Abbink FC, Laarman CA, Braam KI, van Wijk JA, Kors WA, Bouman AA, Spreeuwenberg MD, Stoffel-Wagner B, Bokenkamp A. Beta-trace protein is not superior to cystatin C for the estimation of GFR in patients receiving corticosteroids. *Clin Biochem* 2008; 41(4-5): 299-305 (VUmc)
5. Abdallah AM, Savage ND, van Zon M, Wilson L, Vandenbroucke-Grauls CMJE, van der Wel NN, Ottenhoff TH, Bitter W. The ESX-5 secretion system of *Mycobacterium marinum* modulates the macrophage response. *J Immunol* 2008; 181(10): 7166-7175 (NKI / VUmc)
6. Acquadro C, Conway K, Hareendran A, Aaronson N, European Regulatory Issues and Quality of Life Assessment (ERIQA) Group. Literature review of methods to translate health-related quality of life questionnaires for use in multinational clinical trials. *Value Health* 2008; 11: 509-21 (NKI)
7. Agner T, Andersen KE, Brandao FM, Bruynzeel DP, Bruze M, Frosch P, Goncalo M, Goossens A, Le Coz CJ, Rustemeyer T, White IR, Diepgen T. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. *Contact Dermatitis* 2008; 59(1): 43-47 (VUmc)
8. Al Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. *Int J Radiat Oncol Biol Phys* 2008; 72: 980-8 (NKI)
9. Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, Mulder JA, Fijen CA, Maten W, Vandenbroucke-Grauls CMJE, Savelkoul PHM. Extended-spectrum-beta-lactamase production in a *Salmonella enterica* serotype Typhi strain from the Philippines. *J Clin Microbiol* 2008; 46(8): 2794-2795 (VUmc)
10. Aleksunes LM, Augustine LM, Scheffer GL, Cherrington NJ, Manautou JE. Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. *Toxicology* 2008; 250(2-3): 82-88 (VUmc)
11. Aletaha D, Ladewe R, Karonitsch T, Bathon J, Boers M, Bombardier C, Bombardieri S, Choi H, Combe B, Dougados M, Emery P, Gomez-Reino J, Keystone E, Koch G, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Michaud K, O'Dell J, Paulus H, Pincus T, Richards P, S. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. *Arthritis Rheum* 2008; 59(10): 1371-1377 (VUmc)
12. Allard RH, Eekhoff EM, Lips PT, van Merkesteyn JPR, van der Waal I. Kaakbotnecrose bij oncologische patiënten die met intraveneuze bisfosfonaten zijn of worden behandeld: een overzicht. *Ned Tijdschr Oncol* 2008; 5: 218-224 (VUmc)
13. Al-Toma AB, Verbeek WHM, Mulder C.J.J. Update on the Management of Refractory Coeliac Disease in: Fasano A, Troncone R, Branski D, (eds): *Frontiers in Celiac Disease*. Basel, Karger. 2008; : 123-132 (VUmc)
14. Alvarez B, Stroeken PJ, Edel MJ, Roos E. Integrin Cytoplasmic domain-Associated Protein-1 (ICAP-1) promotes migration of myoblasts and affects focal adhesions. *J Cell Physiol* 2008; 214: 474-82 (NKI)
15. Ameziane N, Errami A, Leveille F, Fontaine C, de Vries Y, van Spaendonk RM, de Winter JP, Pals G, Joenje H. Genetic subtyping of Fanconi anemia by comprehensive mutation screening. *Hum Mutat* 2008; 29(1): 159-166 (VUmc)
16. Ammerlaan ACJ, Ararou A, Houben MPWA, Baas F, Tijssen CC, Teepe JLJM, Wesseling P, Hulsebos TJM. Long-term survival and transmission of INI1-mutation via nonpenetrant males in a

family with rhabdoid tumour predisposition syndrome. *Br J Cancer* 2008; 98(2): 474-479. (AMC)

17. Ammerlaan ACJ, Houben MPWA, Tijssen CC, Wesseling P, Hulsebos TJM. Secondary meningioma in a long-term survivor of atypical teratoid/rhabdoid tumour with a germline INI1 mutation. *Childs Nervous System* 2008; 24(7): 855-857. (AMC)

18. Andriessen MJ, van der Peet DL, Cuesta MA. Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer (*Br J Surg* 2008; 95: 191-194). *Br J Surg* 2008; 95(10): 1305-1306 (VUmc)

19. Anten S, Heddema ER, Visser O, Zweegman AS. Images in haematology. Cerebral fungal abscess in a patient with acute promyelocytic leukaemia. *Br J Haematol* 2008; 140(3): 253 (VUmc)

20. Antoniou AC, Spurdle AB, Sinilnikova OM, Healey S, Pooley KA, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Hofmann W, Sutter C, Niederacher D, Deissler H, Caldes T, Kämpjärvi K, Nevanlinna H, Simard J, Beesley J, Chen X, Neuhausen SL, Rebbeck TR, Wagner T, Lynch HT, Isaacs C, Weitzel J, Ganz PA, Daly MB, Tomlinson G, Olopade OI, Blum JL, Couch FJ, Peterlongo P, Manoukian S, Barile M, Radice P, Szabo CI, Pereira LHM, Greene MH, Rennert G, Lejbkowitz F, Barnett-Griness O, Andrulis IL, Ozcelik H, Gerdes AM, Caligo MA, Laitman Y, Kaufman B, Milgrom R, Friedman E, Domchek SM, Nathanson KL, Osorio A, Llort G, Milne RL, Benítez J, Hamann U, Hogervorst FBL, Manders P, Ligtenberg MJL, van den Ouweland AMW, Peock S, Cook M, Platte R, Evans DG, Eeles R, Pichert G, Chu C, Eccles D, Davidson R, Douglas F, Godwin AK, Barjhoux L, Mazoyer S, Sobol H, Bourdon V, Eisinger F, Chompret A, Capoulade C, Bressac-de Paillerets B, Lenoir GM, Gauthier-Villars M, Houdayer C, Stoppa-Lyonnet D, Chenevix-Trench G, Easton DF, CIMBA. Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *Am J Hum Genet* 2008; 82: 937-48 (NKI)

21. Appel IM, Kazemier KM, Boos J, Lanvers C, Huijman J, Veerman AJP, van Wering E, den Boer ML, Pieters R. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. *Leukemia* 2008; 22(9): 1665-1679 (VUmc)

22. Appelmelk BJ, den Dunnen JT, Driessen NN, Ummels R, Pak M, Nigou J, Larrouy-Maumus G, Gurcha SS, Movahedzadeh F, Geurtsen J, Brown EJ, Eysink Smeets MM, Besra GS, Willemsen PT, Lowary TL, van Kooyk Y, Maaskant JJ, Stoker NG, van der Ley P, Puzo G, Vandenb. The mannose cap of mycobacterial lipoarabinomannan does not dominate the Mycobacterium-host interaction. *Cell Microbiol* 2008; 10(4): 930-944 (VUmc)

23. Appels NMGM, Bolijn MJ, Chan K, Stephens TC, Hochtin-Boes G, Middleton M, Beijnen JH, de

Bono JS, Harris AL, Schellens JHM. Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer. *Br J Cancer* 2008; 98: 1951-8 (NKI)

24. Appledorn DM, Patial S, McBride A, Godbehere S, van Rooijen N, Parameswaran N, Amalfitano A. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. *J Immunol* 2008; 181(3): 2134-2144 (VUmc)

25. Arentsen HC, Langbein S, de La Rosette JJMCH, Pelger RCM, Bos SD, Fernandes JG, de Reijke TM. The nuclear matrix protein 22 (NMP22) bladdercheck test for the detection of bladder cancer. *Urologia Polska* 2008; 61: 24-27. (AMC)

26. Atwal GS, Rabadán R, Lozano G, Strong LC, Ruijs MWG, Schmidt MK, van 't Veer LJ, Nevanlinna H, Tommiska J, Ki K, Bougeard G, Frebourg T, Levine AJ, Bond GL. An information-theoretic analysis of genetics, gender and age in cancer patients. *PLoS ONE* 2008; 3: e1951 (7pp) (NKI)

27. Baas P, Szczesna A, Albert I, Milanowski J, Juhasz E, Sztancsik Z, Von Pawel J, Oyama R, Burgers S. Phase I/II study of a 3 weekly oral taxane (DJ-927) in patients with recurrent, advanced non-small cell lung cancer. *J Thorac Oncol* 2008; 3: 745-50 (NKI)

28. Backer R, van Leeuwen F, Kraal G, den Haan JMM. CD8-dendritic cells preferentially cross-present *S. cerevisiae* antigens. *Eur J Immunol* 2008; 38: 370-80 (NKI)

29. Backer R, van Leeuwen FE, Kraal G, den Haan JMM. CD8- dendritic cells preferentially cross-present *Saccharomyces cerevisiae* antigens. *Eur J Immunol* 2008; 38(2): 370-380 (VUmc)

30. Bakker AH, Hoppes R, Linnemann C, Toebes M, Rodenko B, Berkers CR, Hadrup SR, van Esch WJ, Heemskerk MH, Ovaas H, Schumacher TNM. Conditional MHC class I ligands and peptide exchange technology for the human MHC gene products HLA-A1, -A3, -A11, and -B7. *Proc Natl Acad Sci U S A* 2008; 105: 3825-30 (NKI)

31. Bakx R, Visser O, Jossen J, Meijer S, Slors JF, van Lanschot JJ. Management of recurrent rectal cancer. A population based study in greater Amsterdam. *World J Gastroenterol* 2008; 14(39): 6018-6023 (VUmc)

32. Baldanzi G, Cutrupi S, Chianale F, Gnocchi V, Rainero E, Porporato P, Filigheddu N, Van Blitterswijk WJ, Parolini O, Bussolino F, Sinigaglia F, Graziani A. Diacylglycerol kinase- α phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility. *Oncogene* 2008; 27: 942-56 (NKI)

33. Balgobind BV, van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJL, Pieters R, Zwaan CM, van den Heuvel-

- Eibrink MM, Meijerink JP. Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis. *Blood* 2008; 111(8): 4322-4328 (VUmc)
34. Balm AJM, Smeele LE, Lohuis PJ. Optimizing exposure of the posterolateral maxillary and pterygoid region: The lower cheek flap. *Eur J Surg Oncol* 2008; 34: 699-703 (AMC / NKI)
35. Bardin A, Vaccarella S, Clifford GM, Lissowska J, Rekosz M, Bobkiewicz P, Kupryjanczyk J, Krynicki R, Jonska-Gmyrek J, nska-Bidzinska A, Snijders PJF, Meijer CJLM, Zatonski W, Franceschi S. Human papillomavirus infection in women with and without cervical cancer in Warsaw, Poland. *Eur J Cancer* 2008; 44(4): 557-564 (VUmc)
36. Barendrecht MM, Abrams P, Schumacher H, de La Rosette Jean JJMCH, Michel MC. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? *Neurourol Urodynam* 2008; 27(3): 226-230. (AMC)
37. Barlesi F, Giaccone G, Gallegos-Ruiz MI, Span SW, Lefesvre P, Kruyt FA, Rodriguez JA. Genotype analysis of the VNTR polymorphism in the SMYD3 histone methyltransferase gene: lack of correlation with the level of histone H3 methylation in NSCLC tissues or with the risk of NSCLC. *Int J Cancer* 2008; 122(6): 1441-1442 (VUmc)
38. Bartelink H. Progress in radiotherapy for early breast cancer. *Ann Oncol* 2008; 19 Suppl 5: v117-v121 (NKI)
39. Beeker A, Boven E, Lefesvre P, Golding R, van Groeningen CJ. Retroperitoneal mature teratoma after orchidectomy for a stage IB pure embryonal testicular carcinoma. *Int J Clin Oncol* 2008; 13(1): 71-73 (VUmc)
40. Beemster P, Phoa S, Wijkstra H, de la Rosette J, Laguna P. Follow-up of renal masses after cryosurgery using computed tomography; enhancement patterns and cryolesion size. *BJU Internat* 2008; 101(10): 1237-1242. (AMC)
41. Beemster PWT, Lagerveld BW, Witte LPW, de La Rosette JJMCH, Pes M, Laguna P, Wijkstra H. The performance of 17-gauge cryoprobes in vitro. *Technol Cancer Res Treatm* 2008; 7(4): 321-327. (AMC)
42. Beijnen JH, Van Der Schoot SC, Nuijen B, Flesch FM, Gore A, Mirejovsky D, Lenaz L. Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin. *Drug Dev Ind Pharm* 2008; 34: 1130-9 (NKI)
43. Bekker J, Meijer S. [The historical perspective of the sentinel lymph node concept]. *Ned Tijdschr Geneesk* 2008; 152(1): 38-45 (VUmc)
44. Belderbos JSA, Kepka L, Spring Kong FM, Martel MK, Videtic GM, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: non-small-Cell lung cancer (NSCLC). *Int J Radiat Oncol Biol Phys* 2008; 72: 335-42 (NKI)
45. Beljaards RC, Kirtschig G, Boersma DM. Expression of neural cell adhesion molecule (CD56) in basal and squamous cell carcinoma. *Dermatol Surg* 2008; 34(11): 1577-1579 (VUmc)
46. Bem RA, Bos AP, Bots M, Wolbink AM, van Ham MS, Medema JP, Lutter R, van Woensel JBM. Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. *Pediatric Res* 2008; 63(6): 650-655. (AMC)
47. Bem RA, Farnand AW, Wong V, Koski A, Rosenfeld ME, van Rooijen N, Frevert CW, Martin TR, Matute-Bello G. Depletion of resident alveolar macrophages does not prevent Fas-mediated lung injury in mice. *Am J Physiol Lung Cell Mol Physiol* 2008; 295(2): L314-L325 (VUmc)
48. Bergs JWJ, ten Cate R, Haveman J, Medema JP, Franken NAP, van Bree C. Chromosome Fragments have the Potential to Predict Hyperthermia-induced Radio-sensitization in Two Different Human Tumor Cell Lines. *J Rad Res* 2008; 49(5): 465-472. (AMC)
49. Berhane K, Hauptmann M, Langholz B. Using tensor product splines in modeling exposure-time-response relationships: application to the Colorado Plateau Uranium Miners cohort. *Stat Med* 2008; 27: 5484-96 (NKI)
50. Berkhof J, Meijer CJLM. Human papillomavirus DNA versus papanicolaou screening tests for cervical cancer. *N Engl J Med* 2008; 358(6): 642 (VUmc)
51. Bernardo D, van Hoogstraten I, Verbeek WHM, Pena AS, Mearin ML, Arranz E, Garrote JA, Scheper RJ, Schreurs MW, Bontkes HJ, Mulder CJJ, von Blomberg BME. Decreased circulating iNKT cell numbers in refractory coeliac disease. *Clin Immunol* 2008; 126(2): 172-179 (VUmc)
52. Bernards R. RNAi Delivers Insights into Liver Cancer [Comment]. *Cell* 2008; 135: 793-5 (NKI)
53. Bertaccini EJ, Lindahl E, Sixma T, Trudell JR. Effect of cobratoxin binding on the normal mode vibration within acetylcholine binding protein. *J Chem Inf Model* 2008; 48: 855-60 (NKI)
54. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Wittteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet* 2008; 371(9613): 651-659 (VUmc)
55. Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Wittteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck. [Probiotic prophylaxis in patients with predicted

- severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial]. *Ned Tijdschr Geneeskd* 2008; 152(12): 685-696 (VUmc)
56. Beukers SM, Rustemeyer T, Bruynzeel DP. Cheilitis due to olive oil. *Contact Dermatitis* 2008; 59(4): 253-255 (VUmc)
57. Bex A, Haanen JBAG, Vyth-Dreese FA, Horenblas S, de Gast GC. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis. *Urol Int* 2008; 80: 367-71 (NKI)
58. Bex A. Review: treatment of small cell carcinoma of the urinary bladder: can we learn from small cell lung cancer? *Clin Adv Hematol Oncol* 2008; 6: 385-6 (NKI)
59. Bhatti P, Struewing JP, Alexander BH, Hauptmann M, Bowen L, Mateus-Pereira LH, Pineda MA, Simon SL, Weinstock RM, Rosenstein M, Stovall M, Preston DL, Linet MS, Doody MM, Sigurdson AJ. Polymorphisms in DNA repair genes, ionizing radiation exposure and risk of breast cancer in U.S. Radiologic technologists. *Int J Cancer* 2008; 122: 177-82 (NKI)
60. Biewenga P, Buist MR, Moerland PD, van Thernaat Ver Loren E, van Kampen AHC, ten Kate FJW, Baas F. Gene expression in early stage cervical cancer. *Gyn Onc* 2008; 108(3): 520-526. (AMC)
61. Bijlsma MF, Leenders PJA, Janssen BJA, Peppelenbosch MP, ten Cate H, Spek CA. Endogenous hedgehog expression contributes to myocardial ischemia-reperfusion-induced injury. *Exp Biol Med* 2008; 233(8): 989-996. (AMC)
62. Bijlsma MF, Peppelenbosch MP, Spek CA, Roelink H. Leukotriene synthesis is required for hedgehog-dependent neurite projection in neuralized embryoid bodies but not for motor neuron differentiation. *Stem Cells* 2008; 26(5): 1138-1145. (AMC)
63. Bijlsma MF, Peppelenbosch MP, Spek CA. (Pro-)vitamin D as treatment option for hedgehog-related malignancies. *Med Hypotheses* 2008; 70(1): 202-203. (AMC)
64. Bijman MN, Hermelink CA, van Berkel MP, Laan AC, Janmaat ML, Peters GJ, Boven E. Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels. *Biochem Pharmacol* 2008; 75(2): 427-437 (VUmc)
65. Bijman MN, van Berkel MP, van Nieuw Amerongen GP, Boven E. Interference with actin dynamics is superior to disturbance of microtubule function in the inhibition of human ovarian cancer cell motility. *Biochem Pharmacol* 2008; 76(6): 707-716 (VUmc)
66. Bijnsdorp IV, de Bruin M, Laan AC, Fukushima M, Peters GJ. The role of platelet-derived endothelial cell growth factor/thymidine phosphorylase in tumor behavior. *Nucleosides Nucleotides Nucleic Acids* 2008; 27(6): 681-691 (VUmc)
67. Bijnsdorp IV, Kruyt FA, Fukushima M, Peters GJ. Trifluorothymidine induces cell death independently of p53. *Nucleosides Nucleotides Nucleic Acids* 2008; 27(6): 699-703 (VUmc)
68. Bijnsdorp IV, Kruyt FA, Gokoel S, Fukushima M, Peters GJ. Synergistic interaction between trifluorothymidine and docetaxel is sequence dependent. *Cancer Sci* 2008; 99(11): 2302-2308 (VUmc)
69. Bijnsdorp IV, Peters GJ. The hollow fibre assay. In: *Encyclopedia of Cancer*, 2nd edition (ed. M. Schwab), Part 8, Springer Berlin Heidelberg, Germany. 2008; : 1404-1406 (VUmc)
70. Bijnsdorp IV, Schwendener RA, Schott H, Schott S, Fichtner I, Honeywell RJ, Losekoot N, Laan AC, Peters GJ. In vitro activity and mechanism of action of a duplex and multidrug of ethynylcytidine and 5-fluorodeoxyuridine. *Nucleic Acids Symp Ser (Oxf)* 2008; (52): 651 (VUmc)
71. Birks EJ, Latif N, Enesa K, Folkvang T, Luong le A, Sarathchandra P, Khan M, Ovaas H, Terracciano CM, Barton PJ, Yacoub MH, Evans PC. Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. *Cardiovasc Res* 2008; 79: 472-80 (NKI)
72. Bitter W, Houben ENG, Luirink J. Specialised protein secretion systems of mycobacteria in: Parish T, Brown AS, (eds): *Mycobacterium: Genomics and Molecular Biology*. Norfolk UK, Caister Academic Press. 2008; : 193-209 (VUmc)
73. Blanco S, Forne M, Lacoma A, Prat C, Cuesta MA, Latorre I, Viver JM, Fernandez G, Molinos S, Dominguez J. Comparison of stool antigen immunoassay methods for detecting *Helicobacter pylori* infection before and after eradication treatment. *Diagn Microbiol Infect Dis* 2008; 61(2): 150-155 (VUmc)
74. Blanco S, Lacoma A, Prat C, Cuesta MA, Fuenzalida L, Latorre I, Dominguez J. Detection of *Legionella* antigen in nonconcentrated and concentrated urine samples by a new immunochromatographic assay. *Eur J Clin Microbiol Infect Dis* 2008; 27(12): 1249-1251 (VUmc)
75. Bleeker MC, Heideman DAM, Snijders PJF, Horenblas S, Dillner J, Meijer CJLM. Penis kanker: van risicofactoren tot moleculaire pathogenese. *Ned Tijdschr Oncol* 2008; 5: 243-251 (VUmc)
76. Bleeker MC, Snijders PJF, Voorhorst FJ, Meijer CJLM. Flat penile lesions in the sexual transmission of human papillomavirus. *Ned Tijdschr Geneeskd* 2008; 152(17): 993-998 (VUmc)
77. Bleiker EMA, Hendriks JHCL, Otten JDM, Verbeek ALM, Van Der Ploeg HM. Personality factors and breast cancer risk: A 13-year follow-up. *J Natl Cancer Inst* 2008; 100: 213-8 (NKI)

78. Bloem EF, van Zuuren FJ, Koeneman MA, Rapkin BD, Visser MRM, Koning CCE, Sprangers Mirjam AG. Clarifying quality of life assessment: do theoretical models capture the underlying cognitive processes? *Qual Life Res* 2008; 17(8): 1093-1102. (AMC)
79. Bloemena E. Kanker en oncogenese. *Ned Tijdschr Tandheelkd* 2008; 115: 180-185 (VUmc)
80. Blok CS, Gauw S, Mooij MJ, Gibbs S, de Boer EM, Gaastra MTW. Gekweekte autologe huid behandeling: alternatief voor chronische, niet spontaan genezende wonden. *Ned Tijdschr Derm Venereol* 2008; 18: 411-414 (VUmc)
81. Blumer RM, van Vonderen MG, Sutinen J, Hassink E, Ackermans M, van Agtmael MA, Yki-Jarvinen H, Danner SA, Reiss P, Sauerwein HP. Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy. *AIDS* 2008; 22(2): 227-236 (VUmc)
82. Bobardt MD, Cheng G, de Witte L, Selvarajah S, Chatterji U, Sanders-Bear BE, Geijtenbeek TBH, Chisari FV, Gallay PA. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. *Proc Natl Acad Sci U S A* 2008; 105(14): 5525-5530 (VUmc)
83. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, Arends B, Verzijlbergen FJ, Zijlstra JM, Paans AM, Comans EFI, Pruim J. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. *Eur J Nucl Med Mol Imaging* 2008; 35(12): 2320-33 (VUmc)
84. Boers M. A call for pragmatic treatment trials in rheumatoid arthritis. *Nat Clin Pract Rheumatol* 2008; 4(6): 292-293 (VUmc)
85. Boers M. COBRA combination therapy in daily practice--getting back to the future. *Rheumatology (Oxford)* 2008; 47(1): 1-2 (VUmc)
86. Boers M. Missing data in trials: do we have to keep carrying the last observation forward?. *Arthritis Rheum* 2008; 59(1): 2-3 (VUmc)
87. Boers M. Pathophysiology of rheumatoid arthritis: split or lump?. *Arthritis Rheum* 2008; 58(10): 2925-2927 (VUmc)
88. Bontkes HJ, Kramer D, Ruizendaal JJ, Meijer CJLM, Hooijberg E. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. *Clin Immunol* 2008; 127(3): 375-384 (VUmc)
89. Booi KAC, van Eeden S, Ghazi Hosseini E, ten Kate FJW, Aronson DC. Een ongebruikelijke manifestatie van een periappendiculair infiltraat. *NTVG* 2008; 152(39): 2133-2137. (AMC)
90. Booman M, Szuhai K, Rosenwald A, Hartmann E, Kluin-Nelemans H, de Jong D, Schuurin E, Kluin P. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. *J Pathol* 2008; 216: 209-17 (NKI)
91. Boone J, ten Kate FJW, Offerhaus GJA, van Diest PJ, Rinkes Borel IHM, van Hillegersberg R. Mtor in squamous cell carcinoma of the oesophagus: a potential target for molecular therapy? *J Clin Path* 2008; 61(8): 909-913. (AMC)
92. Boone J, van Hillegersberg R, van Diest PJ, Offerhaus GJA, Rinkes Borel IHM, ten Kate FJW. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. *Virchows Arch* 2008; 452(5): 507-514. (AMC)
93. Boparai KS, Dekker E, van Eeden S, Polak MM, Bartelsman JFWM, Mathus-Vliegen EMH, Keller JJ, van Noesel CJM. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. *Gastroenterol* 2008; 135(6): 2014-2018. (AMC)
94. Borensztajn K, Peppelenbosch MP, Spek CA. Factor Xa: at the crossroads between coagulation and signaling in physiology and disease. *Trends in Mol Med* 2008; 14(10): 429-440. (AMC)
95. Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease-activated receptor-2 activation. *American J Pathol* 2008; 172(2): 309-320. (AMC)
96. Borensztajn KS, Spek CA. Protease-activated receptors, apoptosis and tumor growth. *Pathophysiol Haemostasis and Thrombosis* 2008; 36(3-4):137-147. (AMC)
97. Borgemeester MC, van den Brekel MW M, van Tinteren H, Smeele LE, Pameijer FA, van Velthuysen MF, Balm AJM. Ultrasound-guided aspiration cytology for the assessment of the clinically N0 neck: factors influencing its accuracy. *Head and Neck-J Sciences Specialties of The Head and Neck* 2008; 30(11): 1505-1513. (AMC / NKI)
98. Borm ME, van Bodegraven AA, Mulder CJJ, Kraal G, Bouma G. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. *Genes Immun* 2008; 9(3): 274-278 (VUmc)
99. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? *Cell Cycle* 2008; 7: 1353-9 (NKI)
- 100.
101. Borst P, Sabatini R. Base J: discovery, biosynthesis, and possible functions. *Annu Rev Microbiol* 2008; 62: 235-51 (NKI)
102. Borst P, Van De Wetering K, Schlingemann R. Does the absence of ABCC6 (multidrug resistance protein 6) in patients with Pseudoxanthoma elasticum prevent the liver from providing sufficient vitamin K to the periphery? *Cell Cycle* 2008; 7: 1575-9 (NKI)
103. Bos R, van Duikeren S, Morreau H, Franken K, Schumacher TNM, Haanen JB, van der Burg SH,

- Melief CJM, Offringa R. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. *Cancer Res* 2008; 68: 8446-55 (NKI)
104. Bos WH, Bartelds GM, Wolbink GJ, de Koning MH, van de Stadt RJ, van Schaardenburg D, Dijkmans BAC, Nurmohamed MT. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. *J Rheumatol* 2008; 35(10): 1972-1977 (VUmc)
105. Bos WH, Nielen MM, Dijkmans BAC, van Schaardenburg D. Duration of pre-rheumatoid arthritis anti-cyclic citrullinated peptide positivity is positively associated with age at seroconversion. *Ann Rheum Dis* 2008; 67(11): 1642 (VUmc)
106. Bos WH, Ursum J, de Vries N, Bartelds GM, Wolbink GJ, Nurmohamed MT, van der Horst-Bruinsma IE, van de Stadt RJ, Crusius JBA, Tak PP, Dijkmans BAC, van Schaardenburg D. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. *Ann Rheum Dis* 2008; 67(9): 1347-1350 (VUmc)
107. Bosma I, Douw L, Bartolomei F, Heimans JJ, van Dijk BW, Postma TJ, Stam CJ, Reijneveld JC, Klein M. Synchronized brain activity and neurocognitive function in patients with low-grade glioma: a magnetoencephalography study. *Neuro Oncol* 2008; 10(5): 734-744 (VUmc)
108. Bosma I, Stam CJ, Douw L, Bartolomei F, Heimans JJ, van Dijk BW, Postma TJ, Klein M, Reijneveld JC. The influence of low-grade glioma on resting state oscillatory brain activity: a magnetoencephalography study. *J Neurooncol* 2008; 88(1): 77-85 (VUmc)
109. Boss DS, Valdés Olmos RA, Sinaasappel M, Beijnen JH, Schellens JHM. Application of PET/CT in the development of novel anti-cancer drugs: a review. *Oncologist* 2008; 13: 25-38 (NKI)
110. Bossema E, Stiggelbout A, Baas-Thijssen M, van de Velde C, Marijnen C. Patients' preferences for low rectal cancer surgery. *Eur J Surg Oncol* 2008; 34: 42-8 (NKI)
111. Bossema ER, Marijnen CAM, Baas-Thijssen MCM, Van De Velde CJH, Stiggelbout AM. Evaluation of the treatment tradeoff method in rectal cancer patients: Is surgery preference related to outcome utilities? *Med Decis Making* 2008; 28: 888-98 (NKI)
112. Bots M, Medema JP. Serpins in T cell immunity. *J Leukocyte Biol* 2008; 84(5): 1238-1247. (AMC)
113. Boutsma E, Noback S, van Lohuizen M. The Polycomb protein and E3 ubiquitin ligase Ring1B harbors an IRES in its highly conserved 5' UTR. *PLoS ONE* 2008; 3: e2322 (NKI)
114. Bouwman P, Jonkers J. Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility. *Cell Cycle* 2008; 7: 2647-53 (NKI)
115. Boven E, Honkoop AH, van Tinteren H, van der Wilt CL, van Leeuwen-Stok AE. BOOG onderzoekt in ATX-studie bevacizumab in combinatie met chemotherapie bij gemetastaseerd mammacarcinoom. *Medische Oncologie* 2008; 11: 29-31 (VUmc)
116. Bozikas A, Marsman WA, Rosmolen WD, van Baal JWPM, Kulik W, ten Kate FJW, Krishnadath KK, Bergman JJGHM. The effect of oral administration of ursodeoxycholic acid and high-dose proton pump inhibitors on the histology of Barrett's esophagus. *Dis Esophag* 2008; 21(4): 346-354. (AMC)
117. Braaf B, Nadort A, Faber DJ, ter Wee R, van Leeuwen TG, Aalders MCG. Blood oxygen saturation of frozen tissue determined by hyper spectral imaging. In: Farkas DL, Nicolau DV, Leif RC (red.): *Imaging Manipulation & Analysis of Biomolecules, cells and tissue VI*. 2008. p.1-2. (AMC)
118. Braam SR, Zeinstra L, Litjens S, Ward-van Oostwaard D, van den Brink S, van Laake L, Lebrin F, Kats P, Hochstenbach R, Passier R, Sonnenberg A, Mummery CL. Recombinant Vitronectin is a Functionally Defined Substrate that Supports Human Embryonic Stem Cell Self Renewal via $\alpha_5\beta_1$ Integrin. *Stem Cells* 2008; 26: 2257-65 (NKI)
119. Bramsen I, van der Linden MH, Eskens FJ, Bijvank EM, van Groenigen CJ, Kaufman HJ, Aaronson NK. Evaluation of a face-to-face psychosocial screening intervention for cancer patients: Acceptance and effects on quality of life. *Patient Educ Couns* 2008; 70: 61-8 (NKI)
120. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. *Lancet Oncol* 2008; 9(5): 453-461 (NKI/ VUmc)
121. Bremer E, ten Cate B, Samplonius DF, Mueller N, Wajant H, Stel AJ, Chamuleau MED, van de Loosdrecht AA, Stieglmaier J, Fey GH, Helfrich W. Superior activity of fusion protein scFvRit: sFasL over cotreatment with rituximab and Fas agonists. *Cancer Res* 2008; 68(2): 597-604 (VUmc)
122. Bremmer JF, Braakhuis BJM, Brink A, Broeckaert MA, Beliën JAM, Meijer GA, Kuik DJ, Leemans CR, Bloemena E, van der Waal I, Brakenhoff RH. Comparative evaluation of genetic assays to identify oral pre-cancerous fields. *J Oral Pathol Med* 2008; 37(10): 599-606 (VUmc)
123. Broekhuizen CA, de Boer L, Schipper K, Jones CD, Qadir S, Vandenbroucke-Grauls CMJE, Zaat SA. Staphylococcus epidermidis is cleared from biomaterial implants but persists in peri-implant tissue in mice despite rifampicin/vancomycin treatment. *J Biomed Mater Res A* 2008; 85(2): 498-505 (VUmc)

124. Broekhuizen CA, Schultz MJ, van der Wal AC, Boszhard L, de Boer L, Vandenbroucke-Grauls CMJE, Zaat SA. Tissue around catheters is a niche for bacteria associated with medical device infection. *Crit Care Med* 2008; 36(8): 2395-2402 (VUmc)
125. Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FBL, van 't Veer LJ. The spectrum of ATM missense variants and their contribution to contralateral breast cancer. *Breast Cancer Res Treat* 2008; 107: 243-8 (NKI)
126. Bron JL, Mooi WJ, Saouti R, Wuisman PI. A slow-growing prepatellar mass in a 31-year-old woman. *Clin Orthop Relat Res* 2008; 466(6): 1511-1515 (VUmc)
127. Bronner MB, Knoester H, Bos AP, Last BF, Grootenhuis MA. Follow-up after paediatric intensive care treatment: parental posttraumatic stress. *Acta Paediatr* 2008; 97(2): 181-186. (AMC)
128. Bronner MB, Knoester H, Bos AP, Last BF, Grootenhuis MA. Posttraumatic stress disorder (PTSD) in children after paediatric intensive care treatment compared to children who survived a major fire disaster. *Child & Adolescent Psychiatry and Mental Health* 2008; 2(1): 9. (AMC)
129. Brouwer J, de Bree R, Comans EFI, Akarriou M, Langendijk JA, Castelijns JA, Hoekstra OS, Leemans CR. Improved detection of recurrent laryngeal tumor after radiotherapy using (18)FDG-PET as initial method. *Radiother Oncol* 2008; 87(2): 217-220 (VUmc)
130. Brouwer J, Hooft L, Hoekstra OS, Riphagen II, Castelijns JA, de Bree R, Leemans CR. Systematic review: accuracy of imaging tests in the diagnosis of recurrent laryngeal carcinoma after radiotherapy. *Head Neck* 2008; 30(7): 889-897 (VUmc)
131. Brouwers EEM, Huitema ADR, Beijnen JH, Schellens JHM. Long-term platinum retention after treatment with cisplatin and oxaliplatin. *BMC Clin Pharmacol* 2008; 8: 7 (10pp) (NKI)
132. Brouwers EEM, Huitema ADR, Schellens JHM, Beijnen JH. The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry. *Anticancer Drugs* 2008; 19: 621-30 (NKI)
133. Brouwers EEM, Tibben M, Rosing H, Schellens JHM, Beijnen JH. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research. *Mass Spectrom Rev* 2008; 27: 67-100 (NKI)
134. Brouwers EEM, Tibben MM, Pluim D, Rosing H, Boot H, Cats A, Schellens JHM, Beijnen JH. Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin. *Anal Bioanal Chem* 2008; 391: 577-85 (NKI)
135. Brüggemann LW, Versteeg HH, Niers TM, Reitsma PH, Spek CA. Experimental melanoma metastasis in lungs of mice with congenital coagulation disorders. *J Cell Mol Med* 2008; 12(6B): 2622-2627. (AMC)
136. Brüggemann LW, Versteeg HH, Reitsma PH, Spek CA. High factor viia levels do not promote tumor metastasis. *Thrombosis and Haemostasis* 2008; 99(4): 787-788. (AMC)
137. Brune V, Tiacci E, Pfeil I, Doering C, Eckerle S, van Noesel CJM, Klapper W, Falini B, von Heydebreck A, Metzler D, Braeuninger A, Hansmann M, Kueppers R. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. *J Experimental Med* 2008; 205(10): 2251-2268. (AMC)
138. Bruynzeel DP. Epicutaan allergologisch onderzoek in: Bruynzeel-Koomen, van Wijk, Knulst, de Monchy, (eds): *Handboek Allergologie*. Utrecht, De Tijdstroom. 2008; : 27-36 (VUmc)
139. Bryer SC, Fantuzzi G, van Rooijen N, Koh TJ. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. *J Immunol* 2008; 180(2): 1179-1188 (VUmc)
140. Buffart TE, Israeli D, Tijssen M, Vosse SJ, Mrcic A, Meijer GA, Ylstra B. Across array comparative genomic hybridization: a strategy to reduce reference channel hybridizations. *Genes Chromosomes Cancer* 2008; 47(11): 994-1004 (VUmc)
141. Buffart TE, Overmeer RM, Steenbergen RDM, Tijssen M, van Grieken NC, Snijders PJF, Grabsch HI, van d, V, Carvalho B, Meijer GA. MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. *Br J Cancer* 2008; 99(11): 1802-1807 (VUmc)
142. Buis DR, Dirven CM, Lagerwaard FJ, Mandl ES, Lycklama a Nijeholt GJ, Eshghi DS, van den Berg R, Baayen JC, Meijer OW, Slotman BJ, Vandertop WP. Radiosurgery of brain arteriovenous malformation in children. *J Neurol* 2008; 225(4): 551-560 (VUmc)
143. Buitelaar D, Huitink J, Oldenburg H, Rutgers E, Schutte P, Van Tinteren H. Field block: An additional technique of potential value for breast surgery under general anaesthesia [6]. *Eur J Anaesthesiol* 2008; 25: 253-5 (NKI)
144. Bulk S, Rozendaal L, Zielinski GD, Berkhof J, Daalmeijer NC, Snijders PJF, van Kemenade FJ, Meijer CJLM. High-risk human papillomavirus is present in cytologically false-negative smears: an analysis of "normal" smears preceding CIN2/3. *J Clin Pathol* 2008; 61(3): 385-389 (VUmc)
145. Bultink IEM, Dijkmans BAC, Voskuyl AE. Comorbidity in systemic lupus erythematosus: Aspects of cardiovascular disease, osteoporosis and

- infections in: Seward TI, (ed): Progress in systemic lupus erythematosus research. Hauppauge, USA, Nova Science Publishers. 2008; : 77-103 (VUmc)
146. Bultink IEM, Turkstra F, Diamant M, Dijkmans BAC, Voskuyl AE. Prevalence of and risk factors for the metabolic syndrome in women with systemic lupus erythematosus. *Clin Exp Rheumatol* 2008; 26(1): 32-38 (VUmc)
147. Bultink IEM, Turkstra F, Dijkmans BAC, Voskuyl AE. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. *J Rheumatol* 2008; 35(6): 1053-1057 (VUmc)
148. Bultink IEM. Complicaties bij systemische lupus erythematosus. *Ned Tijdschr Reum* 2008; 3: 21-24 (VUmc)
149. Burger MPM. Over schoonheid en plastische chirurgie. *Ned Tijdschr Obstet & Gyn* 2008; 121: 121-127. (AMC)
150. Burgers JA, Kunst PW, Koolen MG, Willems LN, Burgers JS, van den Heuvel M. Pleural drainage and pleurodesis; implementation of the Dutch guidelines in four hospitals. *Eur Respir J* 2008; 32: 1321-7 (NKI)
151. Buskens CJ, ten Kate FJW, Obertop H, Izbicki JR, van Lanschot JJB. Analysis of micrometastatic disease in histologically negative lymph nodes of patients with adenocarcinoma of the distal esophagus or gastric cardia. *Dis Esophagus* 2008; 21(6): 488-495. (AMC)
152. Buter J. [Medical treatment of solid tumours]. *Ned Tijdschr Tandheelkd* 2008; 115(4): 201-202 (VUmc)
153. Bystrom J, Evans I, Newson J, Stables M, Toor I, van Rooijen N, Crawford M, Colville-Nash P, Farrow S, Gilroy DW. Resolution-phase macrophages possess a unique inflammatory phenotype that is controlled by cAMP. *Blood* 2008; 112(10): 4117-4127 (VUmc)
154. Campbell SJ, Zahid I, Losey P, Law S, Jiang Y, Bilgen M, van Rooijen N, Morsali D, Davis AE, Anthony DC. Liver Kupffer cells control the magnitude of the inflammatory response in the injured brain and spinal cord. *Neuropharmacology* 2008; 55(5): 780-787 (VUmc)
155. Champion SN, Johnson R, Aleksunes LM, Goedken MJ, van Rooijen N, Scheffer GL, Cherrington NJ, Manautou JE. Hepatic Mrp4 induction following acetaminophen exposure is dependent on Kupffer cell function. *Am J Physiol Gastrointest Liver Physiol* 2008; 295(2): G294-G304 (VUmc)
156. Cantaert T, Kolln J, Timmer T, van der Pouw-Kraan CTM, Vandooren B, Thurlings RM, Canete JD, Catrina AI, Out T, Verweij CL, Zhang Y, Tak PP, Baeten D. B lymphocyte autoimmunity in rheumatoid synovitis is independent of ectopic lymphoid neogenesis. *J Immunol* 2008; 181(1): 785-794 (VUmc)
157. Capelle LG, de Vries AC, Looman CW, Casparie MK, Boot H, Meijer GA, Kuipers EJ. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. *Eur J Cancer* 2008; 44: 2470-6 (NKI / VUmc)
158. Cardoso F, van't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: The MINDACT trial. *J Clin Oncol* 2008; 26: 729-35 (NKI)
159. Ceelen M, van Weissenbruch MM, Roos JC, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Body composition in children and adolescents born after in vitro fertilization or spontaneous conception. *J Clin Endocrinol Metab* 2007; 92: 3417-23 (NKI)
160. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Growth and development of children born after in vitro fertilization. *Fertil Steril* 2008; 90: 1662-73 (NKI)
161. Ceelen M, van Weissenbruch MM, Vermeiden JP, van Leeuwen FE, Delemarre-van de Waal HA. Pubertal development in children and adolescents born after IVF and spontaneous conception. *Hum Reprod* 2008; 23: 2791-8 (NKI)
162. Ceelen M, van Weissenbruch MM, Vermeiden JPW, van Leeuwen FE, Delemarre-Van De Waal HA. Cardiometabolic differences in children born after in vitro fertilization: Follow-up study. *J Clin Endocrinol Metab* 2008; 93: 1682-8 (NKI)
163. Celia A, Zeccolini G, Guazzoni G, Pansadoro V, Disanto V, Porpiglia F, Milani C, Abbou C, Gaston R, Janetschek G, Soomroo Naem A, Fornara P, Breda A, Schulam PG, de la Rosette J, Laguna Pilar M, Palou J, Breda G. Laparoscopic nephron sparing surgery: a multi-institutional European survey of 592 cases. *Archivio Italiano Di Urologia, Andrologia* 2008; 80(3): 85-91. (AMC)
164. Celie JWAM, Reijmers RM, Slot EM, Beelen RHJ, Spaargaren M, ter Wee PM, Florquin S, van den Born J. Tubulointerstitial heparan sulfate proteoglycan changes in human renal diseases correlate with leukocyte influx and proteinuria. *Am J Physiol-Renal Physiology* 2008; 294(1): F253-F263. (AMC / VUmc)
165. Chamuleau MED, van de Loosdrecht AA, Hess CJ, Janssen JJWM, Zevenbergen A, Delwel R, Valk PJ, Lowenberg B, Ossenkoppele GJ. High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. *Haematologica* 2008; 93(12): 1894-1898 (VUmc)
166. Cheng Q, Aleksunes LM, Manautou JE, Cherrington NJ, Scheffer GL, Yamasaki H, Slitt AL. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. *Mol Pharm* 2008; 5(1): 77-91 (VUmc)
167. Chodick G, Bekiroglu N, Hauptmann M, Alexander BH, Freedman DM, Doody MM, Cheung LC, Simon SL, Weinstock RM, Bouville A, Sigurdson AJ. Risk of cataract after exposure to low doses of

- ionizing radiation: A 20-year prospective cohort study among US radiologic technologists. *Am J Epidemiol* 2008; 168: 620-31 (NKI)
168. Choi B, Tabatabaei S, Bachmann A, Collins E, de la Rosette J, Gomez Sancha F, Muir G, Reich O, Woo H. Greenlight HPS 120-w laser for benign prostatic hyperplasia: Comparative complications and technical recommendations. *Eur Urol Supplements* 2008; 7(4): 384-392. (AMC)
169. Cillessen SAGM, Reed JC, Welsh K, Pinilla C, Houghten R, Hooijberg E, Deurhof J, Castricum KC, Kortman P, Hess CJ, Ossenkoppele GJ, Meijer CJLM, Oudejans JJ. Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. *Blood* 2008; 111(1): 369-375 (VUmc)
170. Claes A, Gambarota G, Hamans B, van Tellingen O, Wesseling P, Maass C, Heerschap A, Leenders W. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment. *Int J Cancer* 2008; 122: 1981-6 (NKI)
171. Cleton-Jansen AM, van Eijk R, Lombaerts M, Schmidt MK, van't Veer LJ, Philippo K, Zimmerman RME, Peterse JL, Smit VTBH, van Wezel T, Cornelisse CJ. ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: Absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. *BMC Cancer* 2008; 8: 105 (12pp) (NKI)
172. Coccoris M, Swart E, De Witte MA, van Heijst JW, Haanen JBAG, Schepers K, Schumacher TNM. Long-term functionality of TCR-transduced T cells in vivo. *J Immunol* 2008; 180: 6536-43 (NKI)
173. Codacci-Pisanelli G, Noordhuis P, van der Wilt CL, Peters GJ. Selective protection by uridine of growth inhibition by 5-fluorouracil (5FU) mediated by 5FU incorporation into RNA, but not the thymidylate synthase mediated growth inhibition by 5FU-leucovorin. *Nucleosides Nucleotides Nucleic Acids* 2008; 27(6): 733-739 (VUmc)
174. Coe BP, Macaulay C, Lam WL, Ylstra B, Carvalho B, Meijer GA. Comment re: a comparison of DNA copy number profiling platforms. *Cancer Res* 2008; 68(10): 4010 (VUmc)
175. Coffa J, van de Wiel MA, Diosdado B, Carvalho B, Schouten J, Meijer GA. MLPAnalyzer: data analysis tool for reliable automated normalization of MLPA fragment data. *Cell Oncol* 2008; 30(4): 323-335 (VUmc)
176. Cohen SX, Ben Jelloul M, Long F, Vagin A, Knipscheer P, Lebbink J, Sixma TK, Lamzin VS, Murshudov GN, Perrakis A. ARP/wARP and molecular replacement: the next generation. *Acta Crystallogr D Biol Crystallogr* 2008; 64: 49-60 (NKI)
177. Coiffier B, Lepretre S, Pedersen LM, Gadeberg O, Fredriksen H, van Oers MHJ, Wooldridge J, Kloczko J, Holowiecki J, Hellmann A, Walewski J, Flensburg M, Petersen J, Robak T. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. *Blood* 2008; 111(3): 1094-1100. (AMC)
178. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W, Mueller RP, Kurtz J, Morgan DAL, Dubois JB, Salamon E, Mirimanoff R, Bolla M, Van Der Hulst M, Rodenhuis CC, Bartelink H, EORTC Radiation Oncology Group. Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer - A study based on the EORTC trial 22881-10882 'boost versus no boost'. *Eur J Cancer* 2008; 44: 2587-99 (NKI)
179. Concalo M, Bruynzeel DP. Mechanisms in cutaneous drug hypersensitivity reactions in: Marzulli, Maibach, (eds): *Marzulli and Maibach's dermatotoxicology*. Boca Raton, CRC Press. 2008; : 259-268 (VUmc)
180. Corjon S, Wortmann A, Engler T, van Rooijen N, Kochanek S, Kreppel F. Targeting of adenovirus vectors to the LRP receptor family with the high-affinity ligand RAP via combined genetic and chemical modification of the pIX capsomere. *Mol Ther* 2008; 16(11): 1813-1824 (VUmc)
181. Costa JL, Meijer GA, Ylstra B, Caldas C. Array comparative genomic hybridization copy number profiling: a new tool for translational research in solid malignancies. *Semin Radiat Oncol* 2008; 18(2): 98-104 (VUmc)
182. Coupe VM, Berkhof J, Bulkman NW, Snijders PJF, Meijer CJLM. Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. *Br J Cancer* 2008; 98(3): 646-651 (VUmc)
183. Crosetto N, Bienko M, Hibbert RG, Perica T, Ambrogio C, Kensche T, Hofmann K, Sixma TK, Dikic I. Human Wrnip1 is localized in replication factories in a ubiquitin-binding zinc finger-dependent manner. *J Biol Chem* 2008; 283: 35173-85 (NKI)
184. Crusius JBA, Canzian F, Capella G, Pena AS, Pera G, Sala N, Agudo A, Rico F, del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martin. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). *Ann Oncol* 2008; 19(11): 1894-1902 (VUmc)
185. Csikós T, Reijmers RM, Uren AG, Spaargaren M, Pals ST. Instant conditional transgenesis in the mouse hematopoietic compartment. *J Immunol Meth* 2008; 339: 259-63 (NKI)
186. Csikós T, Reijmers RM, Uren AG, Spaargaren M, Pals ST: Instant conditional transgenesis in the mouse hematopoietic compartment. *J Immunol Methods* 2008; 339(2): 259-263. (AMC)

187. Cunningham AL, Carbone F, Geijtenbeek TBH. Langerhans cells and viral immunity. *Eur J Immunol* 2008; 38(9): 2377-2385 (VUmc)
188. Cuperus R, Tytgat GAM, Leen R, Brites P, Bras J, Caron HN, van Kuilenburg ABP. Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. *Int J Oncol* 2008; 32(5): 1011-1019. (AMC)
189. Curvers W, Baak L, Kiesslich R, van Oijen A, Rabenstein T, Ragnath K, Rey JF, Scholten P, Seitz U, ten Kate F, Fockens P, Bergman J. Chromoendoscopy and narrow-band imaging compared with high-resolution magnification endoscopy in Barrett's esophagus. *Gastroenterol* 2008; 134(3): 670-679. (AMC)
190. Curvers WL, Peters FP, Elzer B, Schaap AJCM, Baak LC, van Oijen A, Mallant-Hent RM, ten Kate F, Krishnadath KK, Bergman JJGHM. Quality of Barrett's surveillance in The Netherlands: a standardized review of endoscopy and pathology reports. *Eur J Gastroenterol Hepatol* 2008; 20(7): 601-607. (AMC)
191. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJLM. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. *Vaccine* 2008; 26 Suppl 10: K29-K41 (VUmc)
192. Damen CW, Rosing H, Schellens JHM, Beijnen JH. Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry. *J Pharm Biomed Anal* 2008; 46: 449-55 (NKI)
193. Damen CW, Rosing H, Tibben MM, van Maanen MJ, Lagas JS, Schinkel AH, Schellens JHM, Beijnen JH. A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci* 2008; 868: 102-9 (NKI)
194. Davelaar EM, van de Lande J, von Mensdorff-Pouilly S, Blankenstein MA, Verheijen RHM, Kenemans P. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer. *Tumour Biol* 2008; 29(1): 9-17 (VUmc)
195. de Boer JP, Hiddink RF, Raderer M, Antonini N, Aleman BMP, Boot H, de Jong D. Dissemination patterns in non-gastric MALT lymphoma. *Haematologica* 2008; 93: 201-6 (NKI)
196. de Boer NK, Jharap B, Mulder CJJ, van Bodegraven AA. Low and adequately dosed 6-thioguanine: not so bad after all. *Inflamm Bowel Dis* 2008; 14(8): 1166-1167 (VUmc)
197. de Boer NK, Tuynman H, Bloemena E, Westerga J, van der Peet DL, Mulder CJJ, Cuesta MA, Meuwissen SG, van Nieuwkerk CMJ, van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. *Scand J Gastroenterol* 2008; 43(5): 604-608 (VUmc)
198. de Boer NK, van Bodegraven AA, de Graaf P, van der Hulst RW, Zoetekouw L, van Kuilenburg AB. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. *Ther Drug Monit* 2008; 30(3): 390-393 (VUmc)
199. de Boer NK, Zondervan PE, Gilissen LP, den Hartog GJ, Westerveld BD, Derijks LJ, Bloemena E, Engels LG, van Bodegraven AA, Mulder CJJ. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. *Dig Liver Dis* 2008; 40(2): 108-113 (VUmc)
200. De Boer NKH, van Bodegraven AA, de Graaf P, van der Hulst RWM, Zoetekouw L, van Kuilenburg ABP. Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. *Ther Drug Monitoring* 2008; 30(3): 390-393. (AMC)
201. De Bree E, Rosing H, Filis D, Romanos J, Melissourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: A clinical and pharmacokinetic study. *Ann Surg Oncol* 2008; 15: 1183-92 (NKI)
202. de Bree R, Flach GB, Hoekstra OS, Bloemena E, Castelijns JA, Uyl-de Groot CA, van der Waal I, Leemans CR. SNUS-studie: echogelegeide dunne naald aspiratie cytologie en de schildwachtklierprocedure bij de detectie van occulte lymfekliermetastasen van kleine mondholte- en oropharynxcarcinomen. *Ned Tijdschr Oncol* 2008; 5: 80-82 (VUmc)
203. de Bree R, Flach GB, Hoekstra OS, Bloemena E, van der Waal I, Leemans CR. Toepassingen van de schildwachtklierprocedure bij mondholtecarcinomen. *Ned Tijdschr Tandheelkd* 2008; 115: 674-677 (VUmc)
204. de Bree R, Hoekstra OS, Bloemena E, van der Waal I, Leemans CR. De schildwachtklierprocedure bij mondholtecarcinomen: routine onderzoek?. *Ned Tijdschr Oncol* 2008; 5: 45-50 (VUmc)
205. de Bree R, Leemans CR. How to reconstruct small tongue and floor of mouth defects? in: Cernea CR, Disa FL, Fliss D, Lima RA, Myers EN, Wei WI, (eds): *Pearls and pitfalls in head and neck surgery*. Basel, Karger. 2008; : 60-61 (VUmc)
206. de Bree R, Lips P, Leemans CR. The need for patients' endocrine function vigilance following treatment of head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg* 2008; 16(2): 154-157 (VUmc)
207. de Bree R, Moll AC, Imhof SM, Buter J, Leemans CR. Subsequent tumors in retinoblastoma

- survivors: the role of the head and neck surgeon. *Oral Oncol* 2008; 44(10): 982-985 (VUmc)
208. de Bree R, Rinaldo A, Genden EM, Suarez C, Rodrigo JP, Fagan JJ, Kowalski LP, Ferlito A, Leemans CR. Modern reconstruction techniques for oral and pharyngeal defects after tumor resection. *Eur Arch Otorhinolaryngol* 2008; 265(1): 1-9 (VUmc)
209. de Bree R, Verdonck-de Leeuw IM, Keizer AL, Houffelaar A, Leemans CR. Touch screen computer-assisted health-related quality of life and distress data collection in head and neck cancer patients. *Clin Otolaryngol* 2008; 33(2): 138-142 (VUmc)
210. de Bree R, Verduijn W, Keizer AL, Houffelaar A, Leemans CR. Kwaliteit van leven bij hoofd-halskankerpatiënten: verzamelen van gegevens op een touch screen computer. *Ned Tijdschr Oncol* 2008; 5: 299-303 (VUmc)
211. de Bree R. Hoofd-halskanker en welzijn: zijn psychosociale interventies gewenst?. *Psychosoc Oncol* 2008; 16: 26 (VUmc)
212. De Bruin EC, Medema JP. Apoptosis and non-apoptotic deaths in cancer development and treatment response. *Cancer Treatm Rev* 2008; 34(8): 737-749. (AMC)
213. De Bruin EC, van de Velde CJH, van Krieken JHJM, Marijnen CAM, Medema JP. Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. *Clin Cancer Res* 2008; 14(4): 1073-1079. (AMC)
214. De Bruin EC, Van De Velde CJH, Van Krieken JHJM, Marijnen CAM, Medema JP. Epithelial human leukocyte antigen-DR expression predicts reduced recurrence rates and prolonged survival in rectal cancer patients. *Clin Cancer Res* 2008; 14: 1073-9 (NKI)
215. De Bruin ML, Huisbrink J, Hauptmann M, Kuenen MA, Ouwens GM, van 't Veer MB, Aleman BMP, van Leeuwen FE. Treatment-related risk factors for premature menopause following Hodgkin's lymphoma. *Blood* 2008; 111: 101-8 (NKI)
216. De Fost M, Out TA, de Wilde FA, Tjin EPM, Pals ST, van Oers MHJ, Boot RG, Aerts JFMG, Maas M, vom Dahl S, Hollak CEM. Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. *Ann Hematol* 2008; 87(6): 439-449. (AMC)
217. De Fost M, van Noesel CJM, Aerts JFMG, Maas M, Pöll RG, Hollak CEM. Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. *Haematologica-The Hematol J* 2008; 93(7): 1119-1120. (AMC)
218. De Gorter DJJ, Reijmers RM, Beuling EA, Naber HPH, Kuil A, Kersten MJ, Pals ST, Spaargaren M. The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. *Blood* 2008; 111(7): 3364-3372. (AMC)
219. de Graaf P, de Boer NK, Jharap B, Mulder CJJ, van Bodegraven AA, Veldkamp AI. Stability of thiopurine metabolites: a potential analytical bias. *Clin Chem* 2008; 54(1): 216-218 (VUmc)
220. De Groot A, Stoof TJ, de Beer H, von Blomberg BME, Conemans J, Jonkman M, Mulder CJJ. Dermatitis herpetiformis. Aanbevelingen uit de Richtlijn. *Ned Tijdschr Derm Venereol* 2008; 18: 422-423 (VUmc)
221. de Gruijl TD, van den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. *Cancer Immunol Immunother* 2008; 57(10): 1569-1577 (VUmc)
222. De Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadavec-Zaletel L, Grajkowska W, Perek M, Osterheld M, Ellison D, Baas F, Versteeg R, Kool M. Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. *Clin Cancer Res* 2008; 14(13): 4154-4160. (AMC)
223. de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. *J Intern Med* 2008; 264: 528-36 (NKI)
224. de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbe E, Casparie MK, van Leeuwen FE. Anaplastic large-cell lymphoma in women with breast implants. *JAMA* 2008; 300: 2030-5 (NKI)
225. de Jong MAWP, de Witte L, Bolmstedt A, van Kooyk Y, Geijtenbeek TBH. Dendritic cells mediate herpes simplex virus infection and transmission through the C-type lectin DC-SIGN. *J Gen Virol* 2008; 89(Pt 10): 2398-2409 (VUmc)
226. de Jong MAWP, de Witte L, Oudhoff MJ, Gringhuis SI, Gallay P, Geijtenbeek TBH. TNF-alpha and TLR agonists increase susceptibility to HIV-1 transmission by human Langerhans cells ex vivo. *J Clin Invest* 2008; 118(10): 3440-3452 (VUmc)
227. de Jong Z, Munneke M, Vilim V, Zwiderman AH, Kroon HM, Runday HK, Lems WF, Dijkmans BAC, Breedveld FC, Vliet Vlieland TP, Hazes JM, Degroot J. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study. *Rheumatology (Oxford)* 2008; 47(6): 868-871 (VUmc)
228. de Jonge HJ, Weidenaar AC, ter Elst A, Boezen HM, Scherpen FJ, Bouma-Ter Steege JC, Kaspers GJL, Goemans BF, Creutzig U, Zimmermann M, Kamps WA, de Bont ES. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. *Clin Cancer Res* 2008; 14(3): 924-930 (VUmc)
229. de Jongh CM, John SM, Bruynzeel DP, Calkoen F, van Dijk FJ, Khrenova L, Rustemeyer T, Verberk MM, Kezic S. Cytokine gene polymorphisms and susceptibility to chronic irritant contact

- dermatitis. *Contact Dermatitis* 2008; 58(5): 269-277 (VUmc)
230. de Jongh CM, Khrenova L, Kezic S, Rustemeyer T, Verberk MM, John SM. Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. *Contact Dermatitis* 2008; 58(5): 263-268 (VUmc)
231. De Keersmaecker K, Rocnik JL, Bernad R, Lee BH, Leeman D, Gielen O, Verachtert H, Folens C, Munck S, Marynen P, Fornerod M, Gilliland DG, Cools J. Kinase activation and transformation by NUP214-ABL1 is dependent on the context of the nuclear pore. *Mol Cell* 2008; 31: 134-42 (NKI)
232. De Kraker J, Hoefnagel KA, Verschuur AC, van Eck B, van Santen HM, Caron HN. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age. *Eur J Cancer* 2008; 44(4): 551-556. (AMC / NKI)
233. De Kruif MD, Setiati TE, Mairuhu ATA, Koraka P, Aberson HA, Spek CA, Osterhaus ADME, Reitsma PH, Brandjes DPM, Soemantri A, van Gorp ECM. Differential Gene Expression Changes in Children with Severe Dengue Virus Infections. *Plos Neglected Tropical Dis* 2008; 2(4): 215. (AMC)
234. De la Rosette JJ MCH. Editorial Comment: Holmium Laser Enucleation of the Prostate-Outcomes Independent of Prostate Size? *J Urol* 2008; 180(6): 2435. (AMC)
235. De la Rosette JJMCH, Collins E, Bachmann A, Choi B, Muir G, Reich O, Gomez Sancha F, Tabatabaei S, Woo H. Historical aspects of laser therapy for benign prostatic hyperplasia. *Eur Urol Suppl* 2008; 7(4): 363-369. (AMC)
236. De La Rosette JJMCH, Gravas S, Fitzpatrick JM. Minimally Invasive Treatment of Male Lower Urinary Tract Symptoms. *Urologic Clinics Of North America* 2008; 35(3): 505-518. (AMC)
237. De La Rosette JJMCH, Laguna MP, Rassweiler JJ, Conort P. Training in Percutaneous Nephrolithotomy-A Critical Review. *Eur Urol* 2008; 54(5): 994-1003. (AMC)
238. De la Rosette JJMCH, Rassweiler J. Editorial: innovative approaches in endoscopic surgery. *J Endourol* 2008; 22(4): 743-744. (AMC)
239. De La Rosette JJMCH, Rassweiler JJ. Bipolar TURP treatment for BPH refractory to medication: the past, present, and future surgical reference standard. *J Endourol* 2008; 22(9): 2111-2, discussion 2123. (AMC)
240. De La Rosette JJMCH, Rassweiler JJ. Rebuttal. *J Endourol* 2008; 22(9): 2121-2122. (AMC)
241. De la Rosette JJMCH, Rioja Zuazu J, Tsakiris P, Elsakka A M, Zudaire JJ, Laguna MP, de Reijke ThM. Prognostic Factors and Percutaneous Nephrolithotomy Morbidity: A Multivariate Analysis of a Contemporary Series Using the Clavien Classification. *J Urol* 2008; 180(6): 2489-2493. (AMC)
242. De La Rosette JJMCH, Tsakiris P, Ferrandino MN, Elsakka AM, Rioja J, Preminger GM. Beyond Prone Position in Percutaneous Nephrolithotomy: A Comprehensive Review. *Eur Urol* 2008; 54(6): 1262-1269. (AMC)
243. De La Rosette JJMCH, van Poppel H, Sternberg C: Future directions. In: de La Rosette JJMCH, van Poppel H, Sternberg C (red.): *Renal Cell Cancer: Diagnosis and Therapy*, London: Springer-Verlag, 2008. p.567-568. (AMC)
244. De La Rosette JJMCH, van Poppel Hein, Sternberg C. (red.): *Renal Cell Cancer: Diagnosis and Therapy*. London : Springer-Verlag, 2008. 582p. ISBN 978-1-84628-385-7. (AMC)
245. De La Rosette JJMCH. Editorial Comment on: Endoscopic Combined Intrarenal Surgery in Galdakao-Modified Supine Valdivia Position: A New Standard for Percutaneous Nephrolithotomy? *Eur Urol* 2008; 54(6): 1400-1401. (AMC)
246. De la Rosette JJMCH: Facing the challenges of benign prostatic hyperplasia management. *Cur Opin Urol* 2008; 18(1): 9-10. (AMC)
247. de Langen AJ, Lubberink M, Boellaard R, Spreeuwenberg MD, Smit EF, Hoekstra OS, Lammertsma AA. Reproducibility of Tumor Perfusion Measurements Using 15O-Labeled Water and PET. *J Nucl Med* 2008; 49(11): 1763-1768 (VUmc)
248. de Langen AJ, van den Boogaard V, Marcus JT, Lubberink M. Use of H2(15)O-PET and DCE-MRI to measure tumor blood flow. *Oncologist* 2008; 13(6): 631-644 (VUmc)
249. de Mulder PH, Haanen JB, Sleijfer S, Kruit WH, Gietema JA, Richel DJ, Groenewegen G, Voest EE, van den Eertwegh AJM, Osanto S, Jansen RL, Mulders PF. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus]. *Ned Tijdschr Geneesk* 2008; 152(7): 371-375 (AMC / VUmc)
250. de Reijke TM, Battermann JJ, van Moorselaar RJA, de Jong I, Visser AP, Burgers JS. [Practice guideline 'Prostate cancer: diagnosis and treatment']. *Ned Tijdschr Geneesk* 2008; 152(32): 1771-1775 (VUmc)
251. De Soet JJ, van Gemert-Schriks MC, Laine ML, van Amerongen WE, Morre SA, van Winkelhoff AJ. Host and microbiological factors related to dental caries development. *Caries Res* 2008; 42(5): 340-347 (VUmc)
252. de Visscher JG, van der Meij EH, van der Waal I. Mondkanker: diagnostiek en behandeling. *ACTA Quality Practice* 2008; 4: 34-43 (VUmc)
253. de Visser KE. Spontaneous immune responses to sporadic tumors: tumor-promoting, tumor-protective or both? *Cancer Immunol Immunother* 2008; 57: 1531-9 (NKI)

254. de Vreeze RSA, de Jong D, Haas RL, Stewart F, van Coevorden F. Effectiveness of Radiotherapy in Myxoid Sarcomas is Associated with a Dense Vascular Pattern. *Int J Radiat Oncol Biol Phys* 2008; 72: 1480-7 (NKI)
255. de Vreeze RSA, Koops W, Haas RL, van Coevorden F. An unusual case of hemosiderotic fibrohistiocytic lipomatous lesion: correlation of MRI and pathologic findings. *Sarcoma* 2008; 2008: 893918 (4pp) (NKI)
256. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, Kuipers EJ. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. *Gastroenterology* 2008; 134(4): 945-952 (VUmc)
257. de Vries HJ, van der Bij AK, Fennema JS, Smit C, de Wolff F, Prins M, Coutinho RA, Morre SA. Lymphogranuloma venereum proctitis in men who have sex with men is associated with anal enema use and high-risk behavior. *Sex Transm Dis* 2008; 35(2): 203-208 (VUmc)
258. de Vries MA, van Litsenburg RR, Huisman J, Grootenhuis MA, Versluys BA, Kaspers GJL, Gemke RJ. Effect of dexamethasone on quality of life in children with acute lymphoblastic leukaemia: a prospective observational study. *Health Qual Life Outcomes* 2008; 6(1): 103 (AMC / VUmc)
259. de Vries MK, van der Horst-Bruinsma IE, Wolbink GJ. Adalimumab in juvenile rheumatoid arthritis. *N Engl J Med* 2008; 359(23): 2496-2497 (VUmc)
260. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Runday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BAC, Huizinga TW, Allaart CF. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. *Arthritis Rheum* 2008; 58(5): 1293-1298 (VUmc)
261. de Wilde J, De-Castro AJ, Snijders PJF, Meijer CJLM, Rosl F, Steenbergen RDM. Alterations in AP-1 and AP-1 regulatory genes during HPV-induced carcinogenesis. *Cell Oncol* 2008; 30(1): 77-87 (VUmc)
262. de Wilde J, Wilting SM, Meijer CJLM, van de Wiel MA, Ylstra B, Snijders PJF, Steenbergen RDM. Gene expression profiling to identify markers associated with deregulated hTERT in HPV-transformed keratinocytes and cervical cancer. *Int J Cancer* 2008; 122(4): 877-888 (VUmc)
263. de Wit E, Braunschweig U, Greil F, Bussemaker HJ, van Steensel B. Global chromatin domain organization of the Drosophila genome. *PLoS Genet* 2008; 4: e1000045 (NKI)
264. De Witt Hamer PC, Van Tilborg AA, Eijk PP, Sminia P, Troost D, van Noorden CJ, Ylstra B, Leenstra S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. *Oncogene* 2008; 27(14): 2091-2096 (AMC / VUmc)
265. de Witte L, de Vries RD, van d, V, Yuksel S, Litjens M, de Swart RL, Geijtenbeek TBH. DC-SIGN and CD150 have distinct roles in transmission of measles virus from dendritic cells to T-lymphocytes. *PLoS Pathog* 2008; 4(4): e1000049 (VUmc)
266. de Witte L, Nabatov A, Geijtenbeek TBH. Distinct roles for DC-SIGN+-dendritic cells and Langerhans cells in HIV-1 transmission. *Trends Mol Med* 2008; 14(1): 12-19 (VUmc)
267. De Witte MA, Bendle GM, van den Boom MD, Coccoris M, Schell TD, Tevethia SS, Van Tinteren H, Mesman EM, Song JY, Schumacher TNM. TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. *J Immunol* 2008; 181: 2563-71 (NKI)
268. De Witte MA, Jorritsma A, Kaiser A, van den Boom MD, Dokter M, Bendle GM, Haanen JBAG, Schumacher TNM. Requirements for effective antitumor responses of TCR transduced T cells. *J Immunol* 2008; 181: 5128-36 (NKI)
269. De Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JBAG, Rooney CM, Schumacher TNM. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. *J Immunol* 2008; 180: 6365-73 (NKI)
270. de Wolf C, Jansen R, Yamaguchi H, de Haas M, Van De Wetering K, Wijnholds J, Beijnen J, Borst P. Contribution of the drug transporter ABCG2 (breast cancer resistance protein) to resistance against anticancer nucleosides. *Mol Cancer Ther* 2008; 7: 3092-102 (NKI)
271. Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJWM, Sonneveld P, van Marwijk KM, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Lowenberg B, Ossenkop. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. *Blood* 2008; 111(5): 2581-2588 (VUmc)
272. den Dulk M, Krijnen P, Marijnen CAM, Rutten HJ, van de Poll-Franse LV, Putter H, Meershoek-Klein Kranenbarg E, Jansen-Landheer ML, Coebergh JWW, Van De Velde CJH. Improved overall survival for patients with rectal cancer since 1990: The effects of TME surgery and pre-operative radiotherapy. *Eur J Cancer* 2008; 44: 1710-6 (NKI)
273. Den Otter W, Jacobs JJ, Battermann JJ, Hordijk GJ, Krastev Z, Moiseeva EV, Stewart RJ, Ziekman PG, Koten JW. Local therapy of cancer with free IL-2. *Cancer Immunol Immunother* 2008; 57(7): 931-950 (VUmc)
274. den Uyl D, Geusens P, Bijlsma JW, Laan RFJM, Huisman AM, Nijs RNJ, Lems WF. Glucocorticoid Induced Osteoporosis, nieuwe inzichten in pathogenese, epidemiologie en

- behandeling. *Ned Tijdschr Reum* 2008; : 23-31 (VUmc)
275. Derijks-Engwegen JYMN, Cats A, Smits ME, Schellens JHM, Beijnen JH. Improving colorectal cancer management: The potential of proteomics. *Biomarkers Med* 2008; 2: 253-89 (NKI)
276. Derks S, Postma C, Carvalho B, van den Bosch SM, Moerkerk PT, Herman JG, Weijenberg MP, de Bruine AP, Meijer GA, van Engeland M. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. *Carcinogenesis* 2008; 29(2): 434-439 (VUmc)
277. Devos SA, Constandt L, Tupker RA, Noz KC, Lucker GP, Bruynzeel DP, Schuttelaar ML, Kruyswijk MR, van Zuuren EJ, Vink J, Coenraads PJ, Kiemeny LA, van d, V. Relevance of positive patch-test reactions to fragrance mix. *Dermatitis* 2008; 19(1): 43-47 (VUmc)
278. Diederens BM, Kluytmans JA, Vandenbroucke-Grauls CMJE, Peeters MF. Utility of real-time PCR for diagnosis of Legionnaires' disease in routine clinical practice. *J Clin Microbiol* 2008; 46(2): 671-677 (VUmc)
279. Dijkmans BAC. The diagnostic accuracy of anti-citrulline antibody assessment in the diagnosis of patients suspected of rheumatoid arthritis by a general practitioner. *Ned Tijdschr Geneesk* 2008; 152(24): 1400 (VUmc)
280. Direcks WG, Berndsen SC, Proost N, Peters GJ, Balzarini J, Spreeuwenberg MD, Lammertsma AA, Molthoff CFM. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. *Br J Cancer* 2008; 99(3): 481-487 (VUmc)
281. Direcks WG, van Gelder M, Lammertsma AA, Molthoff CFM. A new rat model of human breast cancer for evaluating efficacy of new anti-cancer agents in vivo. *Cancer Biol Ther* 2008; 7(4): 532-537 (VUmc)
282. Dirven R, Hilgers FJ, Plooij JM, Maal TJ, Berge SJ, Verkerke GJ, Marres HA. 3D stereophotogrammetry for the assessment of tracheostoma anatomy. *Acta Otolaryngol* 2008; 128: 1248-54 (NKI)
283. Dobben AC, Felt-Bersma RJF, ten Kate FJW, Stoker J. Cross-sectional imaging of the anal sphincter in fecal incontinence. *Am J Roentgenol* 2008; 190(3): 671-682. (AMC)
284. Doedens RA, van der Sar AM, Bitter W, Scholvinck EH. Transmission of *Mycobacterium marinum* from fish to a very young child. *Pediatr Infect Dis J* 2008; 27(1): 81-83 (VUmc)
285. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkh TUYA S, Kommos F, Wentzensen N, Snijders PJF, Meijer CJLM, Franceschi S, Pawlita M. Human papillomavirus infection in Ulaanbaatar, Mongolia: a population-based study. *Cancer Epidemiol Biomarkers Prev* 2008; 17(7): 1731-1738 (VUmc)
286. Dorlo TPC, Hillebrand MJX, Rosing H, Eggelte TA, de Vries PJ, Beijnen JH. Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci* 2008; 865: 55-62 (NKI)
287. Dorlo TPC, Van Thiel PPAM, Huitema ADR, Keizer RJ, De Vries HJC, Beijnen JH, de Vries PJ. Pharmacokinetics of miltefosine in old world cutaneous leishmaniasis patients. *Antimicrob Agents Chemother* 2008; 52: 2855-60 (NKI)
288. Douma KFL, Aaronson NK, Vasen HFA, Bleiker EMA. Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. *Psychooncology* 2008; 17: 737-45 (NKI)
289. Doumont G, de Visser KE, Derksen PW, Jonkers J. Models for angiogenesis: from fundamental mechanisms to anticancer treatment research. *Drug Discov Today* 2008; 4: 75-82 (NKI)
290. Douw L, Baayen H, Bosma I, Klein M, Vandertop P, Heimans JJ, Stam K, de Munch J, Reijneveld JC. Treatment-related changes in functional connectivity in brain tumor patients: a magnetoencephalography study. *Exp Neurol* 2008; 212(2): 285-290 (VUmc)
291. Draijer MJ, Hondebrink E, van Leeuwen TG, Steenbergen W. (red.): Connecting laser Doppler perfusion imaging and laser speckle contrast analysis in GL Cote & AV Priezzhev (eds.). 2008. (SPIE Conference Proceedings; 68630C). (AMC)
292. Dunlop DC, Ulrich A, Appelmeik BJ, Burton DR, Dwek RA, Zitzmann N, Scanlan CN. Antigenic mimicry of the HIV envelope by AIDS-associated pathogens. *AIDS* 2008; 22(16): 2214-2217 (VUmc)
293. Dunn MJ, Gil C, Kleinhammer C, Lottspeich F, Pennington S, Sanchez JC, Albar JP, Bini L, Corrales F, Corthals GL, Fountoulakis MM, Hoogland C, James P, Jensen ON, Jimenez CR, Jorin-Novo J, Kraus HJ, Meyer H, Noukakis D, Palagi PM, Penque D, Quinn A, Rabi. EuPA achieves visibility - an activity report on the first three years. *J Proteomics* 2008; 71(1): 11-18 (VUmc)
294. Duursma AM, Kedde M, Schrier M, le Sage C, Agami R. miR-148 targets human DNMT3b protein coding region. *RNA* 2008; 14: 872-7 (NKI)
295. Edele F, Molenaar R, Gutle D, Dudda JC, Jakob T, Homey B, Mebius RE, Hornef M, Martin SF. Cutting edge: instructive role of peripheral tissue cells in the imprinting of T cell homing receptor patterns. *J Immunol* 2008; 181(6): 3745-3749 (VUmc)
296. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernardis R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by

- the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. *Cancer Res* 2008; 68: 9221-30 (NKI)
297. Ekhart C, Doodeman VD, Rodenhuis S, Smits PH, Beijnen JH, Huitema ADR. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. *Pharmacogenet Genomics* 2008; 18: 515-23 (NKI)
298. Ekhart C, Rodenhuis S, Beijnen JH, Huitema ADR. Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. *Cancer Chemother Pharmacol* 2008; 63: 543-7 (NKI)
299. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema ADR. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. *Pharmacogenet Genomics* 2008; 18: 1009-15 (NKI)
300. El Sharouni SY, Aerts JG, Senan S, de Ruyscher D, Groen HJ, Smit EF, Vonk EJA, Verhagen AF, Schramel FM. Behandeling van patiënten met niet-kleincellig longcarcinoom stadium III: gelijktijdig hooggedoseerde chemotherapie en radiotherapie. *Ned Tijdschr Geneesk* 2008; 152: 2714-2717 (VUmc)
301. Elkon R, Agami R. Removal of AU bias from microarray mRNA expression data enhances computational identification of active microRNAs. *PLoS Comput Biol* 2008; 4: e1000189 (NKI)
302. Emberton M, Marberger M, de la Rosette J. Understanding patient and physician perceptions of benign prostatic hyperplasia in Europe: The Prostate Research on Behaviour and Education (PROBE) Survey. *Internat J Clin Pract* 2008; 62(1): 18-26. (AMC)
303. Emmering J, Krak NC, van der Hoeven JJ, Spreeuwenberg MD, Twisk JW, Meijer S, Pinedo HM, Hoekstra OS. Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology. *Ann Oncol* 2008; 19(9): 1573-1577 (VUmc)
304. Engel DR, Maurer J, Tittel AP, Weisheit C, Cavlar T, Schumak B, Limmer A, van Rooijen N, Trautwein C, Tacke F, Kurts C. CCR2 mediates homeostatic and inflammatory release of Gr1(high) monocytes from the bone marrow, but is dispensable for bladder infiltration in bacterial urinary tract infection. *J Immunol* 2008; 181(8): 5579-5586 (VUmc)
305. Engelsma D, Valle N, Fish A, Salome N, Almendral JM, Fornerod M. A supraphysiological nuclear export signal is required for parvovirus nuclear export. *Mol Biol Cell* 2008; 19: 2544-52 (NKI)
306. Engwegen JYMN, Alberts A, Knol JC, Jimenez CR, Depla ACTM, Tuynman H, van Heukelem HA, Snel P, Smits ME. Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer. *Prot Clin Applic* 2008; 2(6): 936-945 (NKI / VUmc)
307. Engwegen JYMN, Depla ACTM, Smits ME, Cats A, Tuynman H, van Heukelem HA, Snel P, Meuleman W, Wessels LFA, Schellens JHM, Beijnen JH. Detection of colorectal cancer by serum and tissue protein profiling: A prospective study in a population at risk. *Biomarker Insights* 2008; 375-85 (NKI)
308. Enokizono J, Kusuhara H, Ose A, Schinkel AH, Sugiyama Y. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds. *Drug Metab Dispos* 2008; 36: 995-1002 (NKI)
309. Epping MT, Hart AAM, Glas AM, Krijgsman O, Bernards R. PRAME expression and clinical outcome of breast cancer. *Br J Cancer* 2008; 99: 398-403 (NKI)
310. Epstein J, van der Waal I. Oral cancer in: Greenberg MS, Glick M, Ship JA, (eds): *Burket's Oral Medicine*. Hamilton, BC Decker Inc. 2008; : 153-189 (VUmc)
311. Erdogan D, Kloek JJ, ten Kate FJW, Rauws EAJ, Busch ORC, Gouma DJ, van Gulik TM. Immunoglobulin G(4)-related sclerosing cholangitis in patients resected for presumed malignant bile duct strictures. *Br J Surg* 2008; 95(6): 727-734. (AMC)
312. Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MAG, Bossuyt PMM, van Milligen de Wit AWM, Crolla RMPH, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AMCJ, Davids PHP, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieveerse RJ, van der Zaag ES, Houben MHMG, Vecht J, Pierik REGJM, van Ditzhuijsen TJM, Prins HA, Marsman WA, Stockmann HB, Brink MA, Consten ECJ, van der Werf SDJ, Marinelli AWKS, Jansen JM, Gerhards MF, Bolwerk CJM, Stassen LPS, Spanier BWM, Bilgen Spillenaar EJ, van Berkel AM, Cense HA, van Heukelem HA, van de Laar A, Bruins Slot W, Eijsbouts QA, van Ooteghem NAM, van Wagenveld B, van den Brande JMH, van Geloven AAW, Bruin KF, Maring JK, Oldenburg B, van Hillegersberg R, de Jong DJ., Bleichrodt R, van der Peet DL, Dekkers PEP, Goei TH, Stokkers PCF. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). *BMC Surgery* 2008; 8(1): 15. (AMC)
313. Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MAG, Gouma DJ, Bemelman WA. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. Open ileocolic resection for Crohn's disease: a comparative study. *Dis Colon & Rectum* 2008; 51(6): 858-867. (AMC)
314. Evers B, Drost R, Schut E, de Bruin M, van der Burg E, Derksen PW, Holstege H, Liu X, van Drunen E, Beverloo HB, Smith GC, Martin NM, Lau A, O'Connor MJ, Jonkers J. Selective inhibition of BRCA2-deficient mammary tumor cell growth by

- AZD2281 and cisplatin. *Clin Cancer Res* 2008; 14: 3916-25 (NKI)
315. Faber DJ, Aalders MC, Drexler W, van Leeuwen TG. (red.): Using low coherent light for spectroscopic information from tissue. In: *Optical Coherence Tomography; Technology and Applications*. Danvers : Springer, 2008. (*Optical Coherence Tomography*). (AMC)
316. Fachiroh J, Prasetyanti PR, Paramita DK, Prasetyawati AT, Anggrahini DW, Haryana SM, Middeldorp JM. Dried-blood sampling for epstein-barr virus immunoglobulin G (IgG) and IgA serology in nasopharyngeal carcinoma screening. *J Clin Microbiol* 2008; 46(4): 1374-1380 (VUmc)
317. Farber K, Synowitz M, Zahn G, Vossmeier D, Stragies R, van Rooijen N, Kettenmann H. An alpha5beta1 integrin inhibitor attenuates glioma growth. *Mol Cell Neurosci* 2008; 39(4): 579-585 (VUmc)
318. Feller N, Kelder A, Westra G, Ossenkoppele GJ, Schuurhuis GJ. Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants. *Cytometry B Clin Cytom* 2008; 74(1): 9-16 (VUmc)
319. Fijneman RJA, Cormier RT. The roles of sPLA2-IIA (Pla2g2a) in cancer of the small and large intestine. *Front Biosci* 2008; 13: 4144-4174 (VUmc)
320. Fijneman RJA, Peham JR, van de Wiel MA, Meijer GA, Matise I, Velcich A, Cormier RT. Expression of Pla2g2a prevents carcinogenesis in Muc2-deficient mice. *Cancer Sci* 2008; 99(11): 2113-2119 (VUmc)
321. Fitton I, Steenbakkens RJ, Gilhuijs K, Duppen JC, Nowak PJ, van Herk M, Rasch CRN. Impact of Anatomical Location on Value of CT-PET Co-Registration for Delineation of Lung Tumors. *Int J Radiat Oncol Biol Phys* 2008; 70: 1403-7 (NKI)
322. Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, Dogliotti L, Conti G, Turesson I, James N, Heidenreich A, Solsona E, Guillem V, Herchenhorn D, Moul J, van Moorselaar J, Coetzee LJ, Wilson A, Bamias A, De Wit R, Chrisofos M. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. *Crit Rev Oncol Hematol* 2008; 68(suppl 1): S9-S22 (VUmc)
323. Foijer F, Simonis M, van Vliet M, Wessels L, Kerkhoven R, Sorger PK, Te Riele H. Oncogenic pathways impinging on the G(2)-restriction point. *Oncogene* 2008; 27: 1142-54 (NKI)
324. Fornerod M, Clarke PR. To the centre of the volcano. Workshop on the mechanisms of nucleocytoplasmic transport. *EMBO Rep* 2008; 9: 419-24 (NKI)
325. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, Bauersachs J. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. *Hypertension* 2008; 51(4): 905-914 (VUmc)
326. Francipane MG, Alea Mileidys P, Lombardo Y, Todaro M, Medema JP, Stassi G. Crucial role of interleukin-4 in the survival of colon cancer stem cells. *Cancer Res* 2008; 68(11): 4022-4025. (AMC)
327. Franke NE, Vink J, Cloos J, Kaspers GJL. Proteasome and protease inhibitors in: Kaspers GJL, Coiffier B, Heinrich MC, Estey E, (eds): *Innovative Leukemia and Lymfoma Therapy*. New York, Informa Healthcare. 2008; : 469-489 (VUmc)
328. Franken SM, Stoof TJ, Starink TM. Staphylococcal Scalded Skin Syndrome bij een 90-jarige patiënt. *Ned Tijdschr Derm Venereol* 2008; 18: 395-397 (VUmc)
329. Frederiks F, Tzouros M, Oudgenoeg G, van Welsem T, Fornerod M, Krijgsveld J, van Leeuwen F. Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states. *Nat Struct Mol Biol* 2008; 15: 550-7 (NKI)
330. Funel N, Giovannetti E, del Chiaro M, Mey V, Pollina LE, Nannizzi S, Boggi U, Ricciardi S, del Tacca M, Bevilacqua G, Mosca F, Danesi R, Campani D. Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma. *Lab Invest* 2008; 88(7): 773-784 (VUmc)
331. Fux M, van Rooijen N, Owens T. Macrophage-independent T cell infiltration to the site of injury-induced brain inflammation. *J Neuroimmunol* 2008; 203(1): 64-72 (VUmc)
332. Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS, Krichevsky AM. MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. *Mol Cell Biol* 2008; 28(17): 5369-5380 (VUmc)
333. Galea I, Felton LM, Waters S, van Rooijen N, Perry VH, Newman TA. Immune-to-brain signalling. The role of cerebral CD163-positive macrophages. *Neurosci Lett* 2008; 448(1): 41-46 (VUmc)
334. Gallegos-Ruiz MI, Floor K, Roepman P, Rodriguez JA, Meijer GA, Mooi WJ, Jassem E, Niklinski J, Muley T, van Zandwijk N, Smit EF, Beebe K, Neckers L, Ylstra B, Giaccone G. Integration of gene dosage and gene expression in non-small cell lung cancer, identification of HSP90 as potential target. *PLoS ONE* 2008; 3(3): e0001722 (NKI / VUmc)
335. Gambarota G, Leenders W, Maass C, Wesseling P, van der Kogel B, van Tellingen O, Heerschap A. Characterisation of tumour vasculature in mouse brain by USPIO contrast-enhanced MRI. *Br J Cancer* 2008; 98: 1784-9 (NKI)
336. Ganesan K, Ivanova T, Wu Y, Rajasegaran V, Wu J, Lee MH, Yu K, Rha SY, Chung HC, Ylstra B, Meijer GA, Lian KO, Grabsch H, Tan P. Inhibition of gastric cancer invasion and metastasis by PLA2G2A, a novel beta-catenin/TCF target gene. *Cancer Res* 2008; 68(11): 4277-4286 (VUmc)

337. Ganesh Sivanandam V, Stephen SL, Hernandez-Alcoceba R, Alzuguren P, Zabala M, van Rooijen N, Qian C, Berger I, Gross ML, Prieto J, Kochanek S. Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1. *J Gene Med* 2008; 10(10): 1083-1091 (VUmc)
338. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, Richesson DA, Bojesen SE, Nordestgaard BG, Axelsson CK, Arias JI, Milne RL, Ribas G, Gonzalez-Neira A, Benitez J, Zamora P, Brauch H, Justenhoven C, Hamann U, Ko YD, Bruening T, Haas S, Dork T, . Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. *PLoS Genet* 2008; 4(4): e1000054 (VUmc)
339. Garcia-Vallejo JJ, van Liempt E, da Costa MP, Beckers C, van het Hof B, Gringhuis SI, Zwaginga JJ, van Dijk W, Geijtenbeek TBH, van Kooyk Y, van Die IM. DC-SIGN mediates adhesion and rolling of dendritic cells on primary human umbilical vein endothelial cells through LewisY antigen expressed on ICAM-2. *Mol Immunol* 2008; 45(8): 2359-2369 (VUmc)
340. Gast MCW, Engwegen JY, Schellens JHM, Beijnen JH. Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling. *BMC Med Genomics* 2008; 1: 4 (12 pp) (NKI)
341. Gast MCW, Van Tinteren H, Bontenbal M, van Hoesel RQGM, Nooij MA, Rodenhuis S, Span PN, Tjan-Heijnen VCG, de Vries EGE, Harris N, Twisk JW, Schellens JHM, Beijnen JH. Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. *BMC Cancer* 2008; 8: 389 (15pp) (NKI)
342. Gaudart N, Ekpo P, Pattanapanyasat K, van Kooyk Y, Engering A. *Leptospira interrogans* is recognized through DC-SIGN and induces maturation and cytokine production by human dendritic cells. *FEMS Immunol Med Microbiol* 2008; 53(3): 359-367 (VUmc)
343. Gedik GK, Hoefnagel CA, Bais E, Valdés Olmos RA. 131I-MIBG Therapy in metastatic pheochromocytoma and paraganglioma. *Eur J Nucl Med Mol Imaging* 2008; 35: 725-33 (NKI)
344. Gehring K, Sitskoorn MM, Aaronson NK, Taphoorn MJ. Interventions for cognitive deficits in adults with brain tumours. *Lancet Neurol* 2008; 7: 548-60 (NKI)
345. Geiben-Lynn R, Greenland JR, Frimpong-Boateng K, van Rooijen N, Hovav AH, Letvin NL. CD4+ T lymphocytes mediate in vivo clearance of plasmid DNA vaccine antigen expression and potentiate CD8+ T-cell immune responses. *Blood* 2008; 112(12): 4585-4590 (VUmc)
346. Genden EM, Ferlito A, Rinaldo A, Silver CE, Fagan JJ, Suarez C, Langendijk JA, Lefebvre JL, Bradley PJ, Leemans CR, Chen AY, Jose J, Wolf GT. Recent changes in the treatment of patients with advanced laryngeal cancer. *Head Neck* 2008; 30(1): 103-110 (VUmc)
347. Getts DR, Terry RL, Getts MT, Muller M, Rana S, Shrestha B, Radford J, van Rooijen N, Campbell IL, King NJ. Ly6c+ "inflammatory monocytes" are microglial precursors recruited in a pathogenic manner in West Nile virus encephalitis. *J Exp Med* 2008; 205(10): 2319-2337 (VUmc)
348. Geusens P, Lems WF. Efficacy and tolerability of lumiracoxib, a highly selective cyclooxygenase-2 (COX2) inhibitor, in the management of pain and osteoarthritis. *Ther Clin Risk Manag* 2008; 4(2): 337-344 (VUmc)
349. Geusens PP, Roux CH, Reid DM, Lems WF, Adami S, Adachi JD, Sambrook PN, Saag KG, Lane NE, Hochberg MC. Drug Insight: choosing a drug treatment strategy for women with osteoporosis-an evidence--based clinical perspective. *Nat Clin Pract Rheumatol* 2008; 4(5): 240-248 (VUmc)
350. Gibbs S. The diagnosis and treatment of tungiasis. *Br J Dermatol* 2008; 159(4): 981 (VUmc)
351. Gilijamse M, Smeele LE. Een raadselachtige zwelling in het hoofd-halsgebied. *Ned Tijdschr KNO-heelk* 2008; : 97-100 (VUmc)
352. Giovannetti E, Backus HH, Wouters D, Peters GJ. Functional inactivity and mutations of p53 differentially affect sensitivity to 5-fluorouracil and antifolate inhibitors of thymidylate synthase (TS) by altering TS levels in colorectal cancer cells. *Nucleosides Nucleotides Nucleic Acids* 2008; 27[6]: 740-745 (VUmc)
353. Giovannetti E, Laan AC, Vasile E, Tibaldi C, Nannizzi S, Ricciardi S, Falcone A, Danesi R, Peters GJ. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.. *Nucleosides Nucleotides Nucleic Acids* 2008; 27: 720-725 (VUmc)
354. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, Ricciardi S, Danesi R, Giaccone G, Peters GJ. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. *Mol Pharmacol* 2008; 73(4): 1290-1300 (VUmc)
355. Giovannetti E, Ugrasena DG, Supriyadi E, Vroling L, Azzarello A, de Lange D, Peters GJ, Veerman AJP, Cloos J. Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. *Leuk Res* 2008; 32(1): 19-24 (VUmc)
356. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Der Maazen RV, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P. The conundrum of hodgkin lymphoma nodes: To be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. *Radiother Oncol* 2008; 88: 202-10 (NKI)

357. Go AT, Visser A, van Dijk M, Mulders MA, Eijk P, Ylstra B, Blankenstein MA, van Vugt JM, Oudejans CBM. A novel method to identify syncytiotrophoblast-derived RNA products representative of trisomy 21 placental RNA in maternal plasma. *Methods Mol Biol* 2008; 444: 291-302 (VUmc)
358. Godsave SF, Wille H, Kujala P, Latawiec D, Dearmond SJ, Serban A, Prusiner SB, Peters PJ. Cryo-Immunogold Electron Microscopy for Prions: Toward Identification of a Conversion Site. *J Neurosci* 2008; 28: 12489-99 (NKI)
359. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeven D, Kerstens PJ, Hazes JM, Zwinderman AH, Roodman HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, Dijkmans BAC. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis Rheum* 2008; 58(2 Suppl): S126-S135 (VUmc)
360. Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJL. Outcome for children with relapsed acute myeloid leukemia in the Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only?. *Haematologica* 2008; 93(9): 1418-1420 (VUmc)
361. Goemans BF, Zwaan CM, Cloos J, Kaspers GJL. Type 1 mutations in pediatric acute myeloid leukemia. *Ann Hematol* 2008; 87[S1]: S62-S64 (VUmc)
362. Goemans BF, Zwaan CM, Vijverberg SJ, Loonen AH, Creutzig U, Hahlen K, Reinhardt D, Gibson BE, Cloos J, Kaspers GJL. Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. *Leukemia* 2008; 22(12): 2284-2285 (VUmc)
363. Goessling W, North TE, Lord AM, Ceol C, Lee S, Weidinger G, Bourque C, Strijbosch R, Haramis AP, Puder M, Clevers H, Moon RT, Zon LI. APC mutant zebrafish uncover a changing temporal requirement for wnt signaling in liver development. *Dev Biol* 2008; 320: 161-74 (NKI)
364. Gondrie JJ, Pouw RE, Sondermeijer CMT, Peters FP, Curvers WL, Rosmolen WD, Krishnadath KK, ten Kate F, Fockens P, Bergman JJ. Stepwise circumferential and focal ablation of Barrett's esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. *Endoscopy* 2008; 40(5): 359-369. (AMC)
365. Gondrie JJ, Pouw RE, Sondermeijer CMT, Peters FP, Curvers WL, Rosmolen WD, ten Kate F, Fockens P, Bergman JJ. Effective treatment of early Barrett's neoplasia with stepwise circumferential and focal ablation using the HALO system. *Endoscopy* 2008; 40(5): 370-379. (AMC)
366. Graat HC, van Beusechem VW, Schagen FH, Witlox MA, Kleinerman ES, Helder MN, Gerritsen WR, Kaspers GJL, Wuisman PI. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. *Mol Cancer* 2008; 7: 9 (VUmc)
367. Greijer AE, is-van Diemen PM, Fijneman RJA, Giles RH, Voest EE, van Hinsbergh V, Meijer GA. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. *Virchows Arch* 2008; 452(5): 535-544 (VUmc)
368. Greillier L, Baas P, Welch JJ, Hasan B, Passiukov A. Biomarkers for malignant pleural mesothelioma: Current status. *Mol Diagn Ther* 2008; 12: 375-90 (NKI)
369. Gremmer R, Schroder ML, Ten Bokkel Huinink WW, Brandsma D, Boogerd W. Successful management of brain metastasis from malignant germ cell tumours with standard induction chemotherapy. *J Neurooncol* 2008; 90: 335-9 (NKI)
370. Grietschnig CG, Scheltens P, van der Waal I. [Atypical pain in the mandible caused by trigeminal neuralgia]. *Ned Tijdschr Tandheelkd* 2008; 115(1): 41-43 (VUmc)
371. Grietschnig CG, Scheltens P, van der Waal I. Een patiënt met een atypische pijnklacht in de onderkaak. *Ned Tijdschr Tandheelkd* 2008; 115: 43-45 (VUmc)
372. Groen RWJ, Oud MECM, Schilder-Tol EJM, Overdijk MB, ten Berge D, Nusse R, Spaargaren M, Pals ST. Illegitimate WNT pathway activation by beta-catenin mutation or autocrine stimulation in T-cell malignancies. *Cancer Res* 2008; 68(17): 6969-6977. (AMC)
373. Gronwald J, Pijpe A, Byrski T, Huzarski T, Stawicka M, Cybulski C, van Leeuwen F, Lubinski J, Narod SA. Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. *Breast Cancer Res Treat* 2008; 112: 581-4 (NKI)
374. Guelen L, Pagie L, Brassat E, Meuleman W, Faza MB, Talhout W, Eussen BH, de Klein A, Wessels L, de Laat W, van Steensel B. Domain organization of human chromosomes revealed by mapping of nuclear lamina interactions. *Nature* 2008; 453: 948-51 (NKI)
375. Guijarro LG, Mate J, Gisbert JP, Perez-Calle JL, Marin-Jimenez I, Arriaza E, Olleros T, Delgado M, Castillejo MS, Prieto-Merino D, Gonzalez L, V, Pena AS. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. *World J Gastroenterol* 2008; 14(18): 2851-2857 (VUmc)
376. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BAC, Allaart CF, Lems WF. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis* 2008; 67(6): 823-828 (VUmc)

377. Gundy CM, Aaronson NK. The influence of proxy perspective on patient-proxy agreement in the evaluation of health-related quality of life: An empirical study. *Med Care* 2008; 46: 209-16 (NKI)
378. Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH., de Jong D, Eldering E, van Oers MHJ, Mellink CHM, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. *J Mol Diagn* 2008; 10(5): 442-451. (AMC / NKI)
379. Haarman EG, Kaspers GJL, Pieters R, Rottier MM, Veerman AJP. Circumvention of glucocorticoid resistance in childhood leukemia. *Leuk Res* 2008; 32(9): 1417-1423 (VUmc)
380. Haasbeek CJ, Senan S, Smit EF, Lagerwaard FJ. CT-guided pulmonary radiofrequency ablation. *Radiology* 2008; 246(1): 334-335 (VUmc)
381. Haasbeek CJ, Senan S, Smit EF, Paul MA, Slotman BJ, Lagerwaard FJ. Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. *Oncologist* 2008; 13(3): 309-319 (VUmc)
382. Haasbeek CJ, Spoelstra FO, Lagerwaard FJ, van Sornsen de Koste JR, Cuijpers JP, Slotman BJ, Senan S. Impact of audio-coaching on the position of lung tumors. *Int J Radiat Oncol Biol Phys* 2008; 71(4): 1118-1123 (VUmc)
383. Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJF, Mulder CJJ, Meuwissen SG, Pena AS, van Bodegraven AA. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. *World J Gastroenterol* 2008; 14(20): 3183-3187 (VUmc)
384. Hage JJ, Woerdeman LAE. The design of the lateral thoracodorsal flap. *Ann Plast Surg* 2008; 61: 302-5 (NKI)
385. Hage JJ. Heraklas on knots: Sixteen surgical nooses and knots from the first century A.D. *World J Surg* 2008; 32: 648-55 (NKI)
386. Hage JJ. On the origin and evolution of the Roeder knot and loop: a geometrical review. *Surg Laparoscop Endosc Percutan Tech* 2008; 18: 1-7 (NKI)
387. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, Link BK, Robak T, Wojtukiewicz M, Pfreundschuh M, Kneba M, Engert A, Sonneveld P, Flensburg M, Petersen J, Losic N, Radford J. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. *Blood* 2008; 111(12): 5486-5495. (AMC)
388. Hagenbeek A, Kluin PM, Schouten HCM: Non-Hodgkin lymfomen [hfdstk 29]. In: Löwenberg B, Ossenkoppele GJ (red.): *Handboek Hematologie*. Utrecht: De Tijdstroom, 2008. p.405-442. (AMC)
389. Hagenbeek A. Monoclonal antibodies (novel): Humax-CD20, Ofatumumab. *Hematol Meetings Rep* 2 2008; 79-80. (AMC)
390. Hagenbeek A. Monoclonal antibodies (update): CD20, Rituximab. *Hematol Meetings Rep* 2 2008; 50-51. (AMC)
391. Hagenbeek A. Response: Multiple administrations of the fully human monoclonal antibody Ofatumumab. *Blood* 2008; 112(6): 2585. (AMC)
392. Hagenbeek TJ, Spits H. T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus. *Leukemia* 2008; 22: 608-19 (NKI)
393. Haibe-Kains B, Desmedt C, Piette F, Buyse M, Cardoso F, van't Veer L, Piccart M, Bontempi G, Sotiropoulos C. Comparison of prognostic gene expression signatures for breast cancer. *BMC Genomics* 2008; 9: 394 (NKI)
394. Halebian G, Kijviki K, de la Rosette J, Premingert G. Ureteral stenting and urinary stone management: A systematic review. *J Urol* 2008; 179(2): 424-430. (AMC)
395. Hallaert DYH, Jaspers A, van Noesel CJ, van Oers MHJ, Kater AP, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. *Blood* 2008; 112(13): 5141-5149. (AMC)
396. Hardenberg G, Fernandez L, Hendriks J, Chebli K, Jacquet C, Sitbon M, Hahne M, Medema JP. APRIL facilitates viral-induced erythroleukemia but is dispensable for T cell immunity and lymphomagenesis. *J Leukocyte Biol* 2008; 84(2): 380-388. (AMC)
397. Hardenberg G, van Bostelen L, Hahne M, Medema JP. Thymus-independent class switch recombination is affected by APRIL. *Immunol Cell Biol* 2008; 86(6): 530-534. (AMC)
398. Hardenberg G, van der Sluijs K, van der Poll T, Medema JP. APRIL affects antibody responses and early leukocyte infiltration, but not influenza A viral control. *Mol Immunol* 2008; 45(11): 3050-3058. (AMC)
399. Harmsen S, Koster AS, Beijnen JH, Schellens JHM, Meijerman I. Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction. *Drug Metab Dispos* 2008; 36: 1166-71 (NKI)
400. Hartog H, van der Graaf WTA, Wesseling J, van der Veer E, Boezen HM. Measurement of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 after delayed separation of whole blood samples. *Clin Biochem* 2008; 41: 636-9 (NKI)
401. Hasemann MS, Damgaard I, Schuster MB, Theilgaard-Monch K, Sorensen AB, Mrcic A, Krugers T, Ylstra B, Pedersen FS, Nerlov C, Porse BT. Mutation of C/EBPalpha predisposes to the development of myeloid leukemia in a retroviral

- insertional mutagenesis screen. *Blood* 2008; 111(8): 4309-4321 (VUmc)
402. Hatzis P, van der Flier LG, van Driel MA, Guryev V, Nielsen F, Denissov S, Nijman IJ, Koster J, Santo EE, Welboren W, Versteeg R, Cuppen E, van de Wetering M, Clevers H, Stunnenberg HG. Genome-wide pattern of TCF7L2/TCF4 chromatin occupancy in colorectal cancer cells. *Mol Cell Biol* 2008; 28(8): 2732-2744. (AMC)
403. Hatzmann J, Heymans HSA, Ferrer-I-Carbonell A, van Praag BMS, Grootenhuus MA. Hidden Consequences of Success in Pediatrics: Parental Health-Related Quality of Life-Results From the Care Project. *Pediatrics* 122(5), 2008, p.E1030-E1038. (AMC)
404. Hava DL, van der Wel N, Cohen N, Dascher CC, Houben D, Leon L, Agarwal S, Sugita M, van Zon M, Kent SC, Shams H, Peters PJ, Brenner MB. Evasion of peptide, but not lipid antigen presentation, through pathogen-induced dendritic cell maturation. *Proc Natl Acad Sci U S A* 2008; 105: 11281-6 (NKI)
405. Hawkins TA, Haramis AP, Etard C, Prodromou C, Vaughan CK, Ashworth R, Ray S, Behra M, Holder N, Talbot WS, Pearl LH, Strähle U, Wilson SW. The ATPase-dependent chaperoning activity of Hsp90a regulates thick filament formation and integration during skeletal muscle myofibrillogenesis. *Development* 2008; 135: 1147-56 (NKI)
406. Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AAM, Van De Rijn M, Linn SC. Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. *Am J Surg Pathol* 2008; 32: 1513-22 (NKI)
407. Heideman DAM, Snijders PJF, Berkhof J, Verheijen RHM, Helmerhorst TJ, Meijer CJLM. Vaccination against HPV: indications for women and the impact on the cervical screening programme. *BJOG* 2008; 115(8): 938-946 (VUmc)
408. Heideman DAM, Snijders PJF, Meijer CJLM. Deel B: mucosaal hoogrisico HPV en cervixcarcinogenese. *SOA-AIDS magazine* 2008; 5(2): 8-10 (VUmc)
409. Heij HA, Verschuur AC, Kaspers GJL, van Rijn RR, Adam JA, Aronson DC. Is aggressive local treatment necessary for diffuse liver involvement in patients with progression of stage 4s neuroblastoma to stage 4?. *J Pediatr Surg* 2008; 43(9): 1630-1635 (VUmc)
410. Helgason HH, Mallo HA, Droogendijk H, Haanen JBAG, van der Veldt AA, van den Eertwegh AJ, Boven E. Brain metastases in patients with renal cell cancer receiving new targeted treatment. *J Clin Oncol* 2008; 26: 152-4 (NKI)
411. Helgason HH, Mallo HA, Droogendijk H, Haanen JG, van der Veldt AAM, van den Eertwegh AJM, Boven E. Brain metastases in patients with renal cell cancer receiving new targeted treatment. *J Clin Oncol* 2008; 26(1): 152-154 (VUmc)
412. Hendrikse NH, Luurtsema G, van der Veldt AA, Lubberink M. Positron emission tomography for modeling pathophysiological processes in vivo. *Curr Opin Drug Discov Devel* 2008; 11: 717-725 (VUmc)
413. Hendriksen J, Jansen M, Brown CM, van der Velde H, van Ham M, Galjart N, Offerhaus GJ, Fagotto F, Fornerod M. Plasma membrane recruitment of dephosphorylated beta-catenin upon activation of the Wnt pathway. *J Cell Sci* 2008; 121: 1793-802 (NKI)
414. Hendry JH, Akahoshi M, Wang LS, Lipshultz SE, Stewart FA, Trott KR. Radiation-induced cardiovascular injury. *Radiat Environ Biophys* 2008; 47: 189-93 (NKI)
415. Hennink S, Wouters MW, Klomp HM, Baas P. Necrotizing pneumonitis caused by postoperative pulmonary torsion. *Interact Cardiovasc Thorac Surg* 2008; 7: 144-5 (NKI)
416. Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, Bernards R, Eilers M. Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. *EMBO J* 2008; 27: 2851-61 (NKI)
417. Hess CJ, Ameziane N, Schuurhuis GJ, Errami A, Denkers F, Kaspers GJL, Cloos J, Joenje H, Reinhardt D, Ossenkoppele GJ, Zwaan CM, Waisfisz Q. Hypermethylation of the FANCC and FANCL promoter regions in sporadic acute leukaemia. *Cell Oncol* 2008; 30(4): 299-306 (VUmc)
418. Hess CJ, Errami A, Berkhof J, Denkers F, Ossenkoppele GJ, Nygren AO, Schuurhuis GJ, Waisfisz Q. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. *Leuk Lymphoma* 2008; 49(6): 1132-1141 (VUmc)
419. Hesselink AT, van Ham MA, Heideman DAM, Groothuismink ZM, Rozendaal L, Berkhof J, van Kemenade FJ, Massuger LA, Melchers WJ, Meijer CJLM, Snijders PJF. Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia. *J Clin Microbiol* 2008; 46(10): 3215-3221 (VUmc)
420. Hijmans CT, van Oirschot MM, Heijboer H, Peters M, Hendriks CJ, Last BF, Oosterlaan J, Grootenhuus MA, Fijnvandraat K. Neuropsychological dysfunction in children with sickle cell disease: the AANPAK project. *Pediatric Clinics Amsterdam* 2008; 19: 10-12. (AMC)
421. Hilarius DL, Kloeg PH, Gundy CM, Aaronson NK. Use of health-related quality-of-life assessments in daily clinical oncology nursing practice: a community hospital-based intervention study. *Cancer* 2008; 113: 628-37 (NKI)

422. Hilgers FJM, Soolsma J, Ackerstaff AH, Balm FJM, Tan IB, van den Brekel MWM. A Thin Tracheal Silicone Washer to Solve Periprosthetic Leakage in Laryngectomies: Direct Results and Long-Term Clinical Effects. *Laryngoscope* 2008; 118(4): 640-645. (AMC / NKI)
423. Hilgers FJM, Van den Brekel M. Practical tips for voice rehabilitation after pharyngolaryngectomy. In: Cernea CR, editor. *Pearls and pitfalls in head and neck surgery: practical tips to minimize complications*. Basel: Karger, 2008: 96-97 (NKI)
424. Hillebrand-Haverkort ME, Budding AE, bij d, V, van Agtmael MA. Mycoplasma pneumoniae infection with incomplete Stevens-Johnson syndrome. *Lancet Infect Dis* 2008; 8(10): 586-587 (VUmc)
425. Hinoul P, Ombelet WU, Burger MP, Roovers JP. A prospective study to evaluate the anatomic and functional outcome of a transobturator mesh kit (Prolift Anterior) for symptomatic cystocele repair. *J Minimally Invas Gynecol* 2008; 15(5): 615-620. (AMC)
426. Hippen KL, Harker-Murray P, Porter SB, Merkel SC, Londer A, Taylor DK, Bina M, Panoskaltis-Mortari A, Rubinstein P, van Rooijen N, Golovina TN, Suhoski MM, Miller JS, Wagner JE, June CH, Riley JL, Blazar BR. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. *Blood* 2008; 112(7): 2847-2857 (VUmc)
427. Ho LL, Kench JG, Handelsman DJ, Scheffer GL, Stricker PD, Grygiel JG, Sutherland RL, Henshall SM, Allen JD, Horvath LG. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. *Prostate* 2008; 68(13): 1421-1429 (VUmc)
428. Ho VKY, van der Heiden-van der Loo, Rutgers EJT, van Diest PJ, Hobbelenk MGG, Tjan-Heijnen VCG, Dirx MJM, Reedijk AMJ, van Dijck JAAM, Poll-Franse LV, Schaapveld M, Peeters PHM. Implementation of sentinel node biopsy in breast cancer patients in the Netherlands. *Eur J Cancer* 2008; 44: 683-91 (NKI)
429. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing Radiation Therapy and Immunotherapy for Curing Incurable Cancers Opportunities and Challenges. *Oncology* 2008; 22: 1064-70 (NKI)
430. Hoebe RA, van der Voort HTM, Stap J, van Noorden CJF, Manders EMM. Quantitative determination of the reduction of phototoxicity and photobleaching by controlled light exposure microscopy. *J Microscopy-Oxford* 2008; 231(Part 1): 9-20. (AMC)
431. Hoebbers FJP, Kartachova M, de Bois J, Van Den Brekel MWM, Van Tinteren H, van Herk M, Rasch CRN, Valdes Olmos RA, Verheij M. (99m)Tc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. *Eur J Nucl Med Mol Imaging* 2008; 35: 509-18 (NKI)
432. Hoebbers FJP, Pameijer FA, de Bois J, Heemsbergen W, Balm AJM, Schornagel JH, Rasch CRN. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma. *Head And Neck-J The Sciences And Specialties Of The Head And Neck* 2008; 30(9): 1216-1223. (AMC)
433. Hoebbers FJP, Pameijer FA, de Bois J, Heemsbergen W, Balm AJM, Schornagel JH, Rasch CRN. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma. *Head Neck* 2008; 30: 1216-23 (NKI)
434. Hoebbers FJP, Pluim D, Hart AAM, Verheij M, Balm AJM, Fons G, Rasch CRN, Schellens JHM, Stalpers LJA, Bartelink H, Begg AC. Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. *Cancer Chemother Pharmacol* 2008; 61(6): 1075-1081. (AMC / NKI)
435. Hoefnagel CA, Sivo F. Radionucliden therapie. In: Van den Broek W, Barneveld P, Lemstra C, Van Urk P, editors. *Leerboek Nucleaire geneeskunde*. Elsevier, 2008: 559-577 (NKI)
436. Hofmann M, Stoss O, Shi D, Büttner R, Van De Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. *Histopathology* 2008; 52: 797-805 (NKI)
437. Hofstra RM, Spurdle AB, Eccles D, Foulkes WD, de Wind N, Hoogerbrugge N, Hogervorst FBL, IARC Unclassified Genetic Variants Working Group. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. *Hum Mutat* 2008; 29: 1292-303 (NKI)
438. Hogenkamp A, Isohadouten N, Reemers SS, Romijn RA, Hemrika W, White MR, Tefsen B, Vervelde L, van Eijk M, Veldhuizen EJ, Haagsman HP. Chicken lung lectin is a functional C-type lectin and inhibits haemagglutination by influenza A virus. *Vet Microbiol* 2008; 130(1-2): 37-46 (VUmc)
439. Holm C, Kok M, Michalides R, Fles R, Koornstra R, Wesseling J, Hauptmann M, Neefjes J, Peterse J, Stal O, Landberg G, Linn S. Phosphorylation of the oestrogen receptor alpha at serine 305 and prediction of tamoxifen resistance in breast cancer. *J Pathol* 2008; 217: 372-9 (NKI)
440. Hommes DW, Erkelens W, Ponsioen C, Stokkers P, Rauws E, van der Spek M, ten Kate F, van Deventer SJ. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. *J Clin Gastroenterol* 2008; 42(5): 522-526. (AMC)
441. Hooft L, van der Veldt AAM, Hoekstra OS, Boers M, Molthoff CFM, van Diest PJ. Hexokinase III, cyclin A and galectin-3 are overexpressed in

- malignant follicular thyroid nodules. *Clin Endocrinol (Oxf)* 2008; 68(2): 252-257 (VUmc)
442. Hoogendoorn WE, Hollema H, van Boven HH, Bergman E, Leeuw-Mantel G, Platteel I, Fles R, Nederlof PM, Mourits MJ, van Leeuwen FE. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. *Breast Cancer Res Treat* 2008; 112: 99-108 (NKI)
443. Hooning MJ, Aleman BMP, Hauptmann M, Baaijens MH, Klijn JG, Noyon R, Stovall M, van Leeuwen FE. Roles of Radiotherapy and Chemotherapy in the Development of Contralateral Breast Cancer. *J Clin Oncol* 2008; 26: 5561-8 (NKI)
444. Hoopman R, Terwee CB, Aaronson NK. Translated COOP/WONCA charts found appropriate for use among Turkish and Moroccan ethnic minority cancer patients. *J Clin Epidemiol* 2008; 61: 1036-48 (NKI)
445. Hoopman R, Terwee CB, Muller MJ, Ory FG, Aaronson NK. Methodological challenges in quality of life research among Turkish and Moroccan ethnic minority cancer patients: translation, recruitment and ethical issues. *Ethn Health* 2008; 1-16 (NKI)
446. Hopman EG, Le Cessie S, von Blomberg BME, Mearin ML. Nutritional management of the gluten-free diet in young people with celiac disease in The Netherlands. *Ned Tijdschr voor Voeding en Dietetiek* 2008; 63(2): s1-s8 (VUmc)
447. Hopman EG, von Blomberg ME, Batstra MR, Morreau H, Dekker FW, Koning F, Lamers CB, Mearin ML. Gluten tolerance in adult patients with celiac disease 20 years after diagnosis?. *Eur J Gastroenterol Hepatol* 2008; 20(5): 423-429 (VUmc)
448. Horenblas S, Kroon BK, Valdés Olmos RA, Nieweg OE. Dynamic sentinel lymph node biopsy in penile carcinoma. In: Mariani G, Giuliano AE, Strauss HW, editors. *Radioguided Surgery: A Comprehensive Team Approach*. Springer, 2009: 111-119 (NKI)
449. Horenblas S, Kroon BK. Cancer of the penis and scrotum. In: Nargund VH, Raghavan D, Sandler HM, editors. *Urological oncology*. New York: Springer, 2008: 566-575 (NKI)
450. Horlings HM, Bergamaschi A, Nordgard SH, Kim YH, Han W, Noh DY, Salari K, Joosse SA, Reyal F, Lingjaerde OC, Kristensen VN, Børresen-Dale AL, Pollack J, van de Vijver MJ. ESR1 gene amplification in breast cancer: a common phenomenon? *Nature Genetics* 2008; 40(7): 807-8, author reply 810-2. (AMC)
451. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, van't Veer LJ, de Jong D. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. *J Clin Oncol* 2008; 26: 4435-41 (NKI)
452. Horn KP, Busch SA, Hawthorne AL, van Rooijen N, Silver J. Another barrier to regeneration in the CNS: activated macrophages induce extensive retraction of dystrophic axons through direct physical interactions. *J Neurosci* 2008; 28(38): 9330-9341 (VUmc)
453. Horne PH, Zimmerer JM, Fisher MG, Lunsford KE, Nadasdy G, Nadasdy T, van Rooijen N, Bumgardner GL. Critical role of effector macrophages in mediating CD4-dependent alloimmune injury of transplanted liver parenchymal cells. *J Immunol* 2008; 181(2): 1224-1231 (VUmc)
454. Houtenbos I, Ossenkoppele GJ, van de Loosdrecht AA. Active specific immunization by the use of leukemic dendritic cell vaccines in: Kaspers GJL, Coiffier B, Heinrich MC, Estey E, (eds): *Innovative Leukemia and Lymphoma Therapy*. Informa Healthcare USA Inc. 2008; : 329-351 (VUmc)
455. Hoving S, Heeneman S, Gijbels MJJ, te Poele JAM, Russell NS, Daemen MJ, Stewart FA. Single-dose and fractionated irradiation promote initiation and progression of atherosclerosis and induce an inflammatory plaque phenotype in ApoE(-/-) mice. *Int J Radiat Oncol Biol Phys* 2008; 71: 848-57 (NKI)
456. Hovius JW, de Jong MAWP, den Dunnen JT, Litjens M, Fikrig E, van der Poll T, Gringhuis SI, Geijtenbeek TBH. Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization. *PLoS Pathog* 2008; 4(2): e31 (VUmc)
457. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, Gimotty PA, Katsaros D, Coukos G, Zhang L, Pure E, Agami R. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. *Nat Cell Biol* 2008; 10: 202-10 (NKI)
458. Huang Y, Cen LP, Luo JM, Wang N, Zhang MZ, van Rooijen N, Pang CP, Cui Q. Differential roles of phosphatidylinositol 3-kinase/akt pathway in retinal ganglion cell survival in rats with or without acute ocular hypertension. *Neuroscience* 2008; 153(1): 214-225 (VUmc)
459. Huang Y, Li Z, Wang N, van Rooijen N, Cui Q. Roles of PI3K and JAK pathways in viability of retinal ganglion cells after acute elevation of intraocular pressure in rats with different autoimmune backgrounds. *BMC Neurosci* 2008; 9: 78 (VUmc)
460. Hubeek I, Comijn EM, van der Wilt CL, Merriman RL, Padron JM, Kaspers GJL, Peters GJ. CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo. *Oncol Rep* 2008; 19(6): 1517-1523 (VUmc)
461. Hubeek I, Giovannetti E, Broekhuizen AJ, Pastor-Anglada M, Kaspers GJL, Peters GJ. Immunocytochemical detection of hENT1 and hCNT1 in normal tissues, lung cancer cell lines, and NSCLC patient samples. *Nucleosides Nucleotides Nucleic Acids* 2008; 27[6]: 787-793 (VUmc)

462. Hubeek I, Hoorweg K, Cloos J, Kaspers GJL. Tyrosine phosphatases as new treatment targets in acute myeloid leukemia in: Kaspers GJL, Coiffier B, Heinrich MC, Estey E, (eds): *Innovative Leukemia and Lymphoma Therapy*. New York, Informa Healthcare. 2008; : 449-468 (VUmc)
463. Huijbers EJ, Baars JW, Schutte PF, Schellens JHM, Beijnen J. Propofol extravasation in a breast cancer patient. *J Oncol Pharm Pract* 2008; 14: 195-8 (NKI)
464. Huisman C, Mallo H, van Riel C, Hulshoff A, van Steijn J. Immunotargeted therapie in de hemato- / oncologische zorg (MO). Maarssen: Elsevier Gezondheidszorg, 2008 (NKI)
465. Huisman J, Aukema EJ, Deijen JB, van Coeverden SC, Kaspers GJL, van der Pal HJ, Delemarre-van de Waal HA. The usefulness of growth hormone treatment for psychological status in young adult survivors of childhood leukaemia: an open-label study. *BMC Pediatr* 2008; 8: 25 (VUmc)
466. Hunt KA, Zhernakova A, Turner G, Heap GA, Franke L, Bruinenberg M, Romanos J, Dinesen LC, Ryan AW, Panesar D, Gwilliam R, Takeuchi F, McLaren WM, Holmes GK, Howdle PD, Walters JR, Sanders DS, Playford RJ, Trynka G, Mulder CJJ, Mearin ML, Verbeek WHM, Trim. Newly identified genetic risk variants for celiac disease related to the immune response. *Nat Genet* 2008; 40(4): 395-402 (VUmc)
467. Huvneers S, Arslan S, van de Water B, Sonnenberg A, Danen EH. Integrins uncouple Src-induced morphological and oncogenic transformation. *J Biol Chem* 2008; 283: 13243-51 (NKI)
468. Huvneers S, Truong H, Fassler R, Sonnenberg A, Danen EH. Binding of soluble fibronectin to integrin alpha5 beta1 - link to focal adhesion redistribution and contractile shape. *J Cell Sci* 2008; 121: 2452-62 (NKI)
469. Iden S, Collard JG. Crosstalk between small GTPases and polarity proteins in cell polarization. *Nat Rev Mol Cell Biol* 2008; 9: 846-59 (NKI)
470. Ifergan I, Jansen G, Assaraf YG. The reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation: RFC as a double edged sword in folate homeostasis. *J Biol Chem* 2008; 283(30): 20687-20695 (VUmc)
471. Israels T, Chirambo C, Caron H, de Kraker J, Molyneux E, Reis R. The guardians' perspective on paediatric cancer treatment in Malawi and factors affecting adherence. *Pediatric Blood & Cancer* 2008; 51(5): 639-642. (AMC)
472. Israels T, Chirambo C, Caron HN, Molyneux EM. Nutritional status at admission of children with cancer in Malawi. *Pediatric Blood & Cancer* 2008; 51(5): 626-628. (AMC)
473. Jakubzick C, Tacke F, Ginhoux F, Wagers AJ, van Rooijen N, Mack M, Merad M, Randolph GJ. Blood monocyte subsets differentially give rise to CD103+ and C. *J Immunol* 2008; 180(5): 3019-3027 (VUmc)
474. Jansen APD, van Hout HPJ, Nijpels G, van Marwijk HWJ, Gundy C, De Vet HCW, Stalman WAB. Self-reports on the IQCODE in older adults: A psychometric evaluation. *J Geriatr Psychiatry Neurol* 2008; 21: 83-92 (NKI)
475. Jansen JM, Bartelsman JF. Fulminant *Clostridium difficile* colitis. *Gut* 2008; 57(1): p.15-+. (AMC)
476. Jansen M, Harting J, Ebben N, Kroon B, Stappers J, Van Engelshoven E, de Vries N. The concept of sustainability and the use of outcome indicators. A case study to continue a successful health counselling intervention. *Fam Pract* 2008; 25 Suppl 1: i32-i37 (NKI)
477. Jansen MC, van Wanrooy S, van Hillegersberg R, Rijken AM, van Coevorden F, Prevoo W, van Gulik TM. Assessment of systemic inflammatory response (SIR) in patients undergoing radiofrequency ablation or partial liver resection for liver tumors. *Eur J Surg Oncol* 2008; 34: 662-7 (NKI)
478. Jansen NC, Kingma A, Schuitema A, Bouma A, Veerman AJP, Kamps WA. Neuropsychological outcome in chemotherapy-only-treated children with acute lymphoblastic leukemia. *J Clin Oncol* 2008; 26(18): 3025-3030 (VUmc)
479. Janssen SP, Comans EH, Voskuyl AE, Wisselink W, Smulders YM. Giant cell arteritis: heterogeneity in clinical presentation and imaging results. *J Vasc Surg* 2008; 48(4): 1025-1031 (VUmc)
480. Jayasekara H, Rajapaksa LC, Aaronson NK. Quality of life in cancer patients in South Asia: psychometric properties of the Sinhala version of the EORTC QLQ-C30 in cancer patients with heterogeneous diagnoses. *Qual Life Res* 2008; 17: 783-91 (NKI)
481. Jenab M, McKay JD, Ferrari P, Biessy C, Laing S, Munar GM, Sala N, Pena S, Crusius JBA, Overvad K, Jensen MK, Olsen A, Tjonneland A, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulos A, Georgila C, Psaltopoulou. CDH1 gene polymorphisms, smoking, *Helicobacter pylori* infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Eur J Cancer* 2008; 44(6): 774-780 (VUmc)
482. Jensch S, de Vries AH, Peringa J, Bipat S, Dekker E, Baak LC, Bartelsman JF, Heutinck A, Montauban van Swijndregt AD, Stoker J. CT colonography with limited bowel preparation: performance characteristics in an increased-risk population. *Radiology* 2008; 247(1): 122-132. (AMC)
483. Jeremic B, Koning C. Induction chemotherapy before chemoradiation in locally advanced non-small-cell lung cancer: Failure after failure, again and again. *J Clin Oncol* 2008; 26(10): E1-E2. (AMC)

484. Ji BT, Blair A, Shu XO, Chow WH, Hauptmann M, Dosemeci M, Yang G, Lubin J, Gao YT, Rothman N, Zheng W. Occupation and breast cancer risk among Shanghai women in a population-based cohort study. *Am J Ind Med* 2008; 51: 100-10 (NKI)
485. Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M. Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. *Cancer Res* 2008; 68(8): 2841-2849 (VUmc)
486. Joenje H, Dorsman JC, Waisfisz Q, de Winter JP. Fanconi-anemie, DNA-herstel en kanker. *Tijdschrift Kanker* 2008; 32: 24-27 (VUmc)
487. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, Van De Vijver M, Berns A. A Conditional Mouse Model for Malignant Mesothelioma. *Cancer Cell* 2008; 13: 261-71 (NKI)
488. Joosten J, Bertholet J, Keemers-Gels M, Barendregt W, Ruers T. Pulmonary resection of colorectal metastases in patients with or without a history of hepatic metastases. *Eur J Surg Oncol* 2008; 34: 895-9 (NKI)
489. Joosten K, Cohen SX, Emsley P, Mooij W, Lamzin VS, Perrakis A. A knowledge-driven approach for crystallographic protein model completion. *Acta Crystallogr D Biol Crystallogr* 2008; 64: 416-24 (NKI)
490. Joosten LA, Heinhuis B, bdollahi-Roodsaz S, Ferwerda G, Lebourhis L, Philpott DJ, Nahori MA, Popa C, Morre SA, van der Meer JW, Girardin SE, Netea MG, van den Berg WB. Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. *Proc Natl Acad Sci U S A* 2008; 105(26): 9017-9022 (VUmc)
491. Jorritsma A, Bins AD, Schumacher TNM, Haanen JBAG. Skewing the T-cell repertoire by combined DNA vaccination, host conditioning, and adoptive transfer. *Cancer Res* 2008; 68: 2455-62 (NKI)
492. Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, Hyman J, Chen K, Piechocka-Trocha A, Brander C, Hooijberg E, Vignali DA, Walker BD, Goldstein H. Lentiviral vectors encoding human immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert peripheral blood CD8 T lymphocytes into cytotoxic T lymphocytes with potent in vitro and in vivo HIV-1-specific inhibitory activity. *J Virol* 2008; 82(6): 3078-3089 (VUmc)
493. Kaas R, Muller SH, Hart AAM, Rutgers EJT. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk. *Eur J Surg Oncol* 2008; 34: 501-7 (NKI)
494. Kakarlapudi N, Vernooy JH, Quan L, Fijneman RJA, Demant P. Control of lymphocyte infiltration of lung tumors in mice by host's genes: mapping of four Lynf (lymphocyte infiltration) loci. *Cancer Immunol Immunother* 2008; 57(2): 217-225 (VUmc)
495. Kalverda B, Roling MD, Fornerod M. Chromatin organization in relation to the nuclear periphery. *FEBS Lett* 2008; 582: 2017-22 (NKI)
496. Kanters E, van Rijssel J, Hensbergen PJ, Hondius D, Mul FP, Deelder AM, Sonnenberg A, van Buul JD, Hordijk PL. Filamin B mediates ICAM-1-driven leukocyte transendothelial migration. *J Biol Chem* 2008; 283: 31830-9 (NKI)
497. Kaparakis M, Walduck AK, Price JD, Pedersen JS, van Rooijen N, Pearse MJ, Wijburg OL, Strugnell RA. Macrophages are mediators of gastritis in acute *Helicobacter pylori* infection in C57BL/6 mice. *Infect Immun* 2008; 76(5): 2235-2239 (VUmc)
498. Kappers I, Belderbos JSA, Burgers JA, Van Zandwijk N, Groen HJ, Klomp HM. Non-small cell lung carcinoma of the superior sulcus: Favourable outcomes of combined modality treatment in carefully selected patients. *Lung Cancer* 2008; 59: 385-90 (NKI)
499. Kappers I, Klomp HM, Burgers JA, Van Zandwijk N, Haas RL, van Pel R. Neoadjuvant (induction) erlotinib response in stage IIIA non-small-cell lung cancer. *J Clin Oncol* 2008; 26: 4205-7 (NKI)
500. Kapur R, Ebeling S, Hagenbeek A. B-cell involvement in chronic graft-versus-host disease. *Haematologica-The Hematol J* 2008; 93(11): 1702-1711. (AMC)
501. Karagozoglu KH, van der Waal I. Polyacrylamide soft tissue filler nodule mimicking a mucoepidermoid carcinoma. *Int J Oral Maxillofac Surg* 2008; 37(6): 578-580 (VUmc)
502. Karim RB, de Lint CA, van Galen SR, van Rozelaar L, Nieuwkerk PT, Askarizadeh E, Hage JJ. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients. *Aesthetic Plast Surg* 2008; 32: 873-8 (NKI)
503. Karimi O, Crusius JBA, Coucousi C, Heijmans R, Sambuelli AM, Pena AS, Koutroubakis IE. JAK2 V617F mutation is not involved in thromboembolism in IBD. *Inflamm Bowel Dis* 2008; 14(11): 1606-1607 (VUmc)
504. Karimi O, Pena AS. Indications and challenges of probiotics, prebiotics, and synbiotics in the management of arthralgias and spondyloarthropathies in inflammatory bowel disease. *J Clin Gastroenterol* 2008; 42 Suppl 3 Pt 1: S136-S141 (VUmc)
505. Karonitsch T, Aletaha D, Boers M, Bombardieri S, Combe B, Dougados M, Emery P, Felson D, Gomez-Reino J, Keystone E, Kvien TK, Martin-Mola E, Matucci-Cerinic M, Richards P, van Riel PL, Siegel J, Smolen JS, Sokka T, van der Heijde D, van Vollenhoven R, War. Methods of

- deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis. *Ann Rheum Dis* 2008; 67(10): 1365-1373 (VUmc)
506. Karperien M, Roelen B, Poelmann R, Gittenbergen-de Groot A, Hierck B, DeRuiter M, Gibbs S. Chapter 2-Morphogenesis, generation of tissue in the embryo in: van Blitterswijk C, Thomsen P, Lindahl A, Hubbell J, Williams DF, Cancedda R, de Bruijn JD, Sohier J, (eds): *Tissue Engineering*. 2008; : 27-72 (VUmc)
507. Kartachova MS, Valdes Olmos RA, Haas RL, Hoebers FJP, Herk M, Verheij M. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. *Nucl Med Commun* 2008; 29: 39-44 (NKI)
508. Kartachova MS, Verheij M, Van Eck BL, Hoefnagel CA, Valdés Olmos RA. Radionuclide imaging of apoptosis in malignancies: promise and pitfalls of 99m Tc-Hynic-rh-annexin V imaging. *Clin Med Oncol* 2009; 1: 319-25 (NKI)
509. Kaspers GJL. Acute myeloide leukemie bij kinderen in: Lowenberg B, Ossenkoppele GJ, de Witte Th, Boogaerts MA, (eds): *Handboek hematologie*. Utrecht, De Tijdstroom. 2008; : 443-452 (VUmc)
510. Kater AP, van Oers MHJ. De plaats van alemtuzumab bij de behandeling van chronische lymfatische leukemie. *Nederl Tijdschr Hematol* 2008; 5(6): 236-244. (AMC)
511. Kedde M, Agami R. Interplay between microRNAs and RNA-binding proteins determines developmental processes. *Cell Cycle* 2008; 7: 899-903 (NKI)
512. Keijzer C, Perez RS, de Lange JJ. Inspiratory carbon monoxide and compound A concentrations during desflurane and sevoflurane anesthesia in humans: An observational study. *Open Anesthesiology Journal* 2009; 2: 26-9 (NKI)
513. Keller AM, Schildknecht A, Xiao Y, van den Broek M, Borst J. Expression of Costimulatory Ligand CD70 on Steady-State Dendritic Cells Breaks CD8(+) T Cell Tolerance and Permits Effective Immunity. *Immunity* 2008; 29: 934-46 (NKI)
514. Kelly MM, McNagny K, Williams DL, van Rooijen N, Maxwell L, Gwozd C, Mody CH, Kubes P. The lung responds to zymosan in a unique manner independent of toll-like receptors, complement, and dectin-1. *Am J Respir Cell Mol Biol* 2008; 38(2): 227-238 (VUmc)
515. Kempf W, Ostheeren-Michaelis S, Paulli M, Lucioni M, Wechsler J, Audring H, Assaf C, Rudiger T, Willemze R, Meijer CJLM, Berti E, Cerroni L, Santucci M, Hallermann C, Berneburg M, Chimenti S, Robson A, Marschalko M, Kazakov DV, Petrella T, Freitag S, Carl. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization For Research and Treatment of Cancer (EORTC). *Arch Dermatol* 2008; 144(12): 1609-1617 (VUmc)
516. Kerkhoven RM, Sie D, Nieuwland M, Heimerikx M, De Ronde J, Brugman W, Velds A. The T7-primer is a source of experimental bias and introduces variability between microarray platforms. *PLoS ONE* 2008; 3: e1980 (NKI)
517. Khorvash F, Keshteli AH, Salehi H, Szeredi L, Morre SA. Unusual transmission route of Lymphogranuloma venereum: following sexual contact with a female donkey. *Int J STD AIDS* 2008; 19(8): 563-564 (VUmc)
518. Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, Frost EH, Savelkoul PHM, Nicholson B, van den Berg RJ, Kato H, Sambol SP, Zukowski W, Woods C, Limbago B, Gerding DN, McDonald LC. Comparison of seven techniques for typing international epidemic strains of *Clostridium difficile*. *J Clin Microbiol* 2008; 46(2): 431-437 (VUmc)
519. Kim HM, Lee YW, Lee KJ, Kim HS, Cho SW, van Rooijen N, Guan Y, Seo SH. Alveolar macrophages are indispensable for controlling influenza viruses in lungs of pigs. *J Virol* 2008; 82(9): 4265-4274 (VUmc)
520. Kirtschig G, Khumalo N, Venning VA, Wojnarowska F. Acquired subepidermal bullous diseases in: Williams H, Bigby M, (eds): *Evidence based dermatology*. Blackwell publishing. 2008; : (VUmc)
521. Kirtschig G, Wojnarowska F. Lichen sclerosis and mechanisms in: Lang F, (ed): *Encyclopedia of Molecular Mechanism of Disease*. Springer. 2008; : (VUmc)
522. Kirtschig G, Wojnarowska F. Mucous membrane pemphigoid in: Lebowitz, (ed): *Treatment of skin disease*. Elsevier. 2008; : (VUmc)
523. Klein M, Reijneveld JC, Heimans JJ. Subjective ratings vs. objective measurement of cognitive function in regard to Van Beek et al (*Int J Radiat Oncol Biol Phys* 2007; 68: 986-991). *Int J Radiat Oncol Biol Phys* 2008; 70(3): 961-962 (VUmc)
524. Klijn C, Holstege H, Ridder JD, Liu X, Reinders M, Jonkers J, Wessels L. Identification of cancer genes using a statistical framework for multiexperiment analysis of nondiscretized array CGH data. *Nucleic Acids Res* 2008; 36: e13 (16pp) (NKI)
525. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. *Clin Dev Immunol* 2008; 2008: 271363 (VUmc)
526. Kloek JJ, ten Kate FJ, Busch ORC, Gouma DJ, van Gulik TM. Surgery for extrahepatic cholangiocarcinoma: predictors of survival. *HPB: The Official Journal Of The International Hepato Pancreato Biliary Association* 2008; 10(3): 190-195. (AMC)

527. Kloek JJ, van Delden OM, Erdogan Da, ten Kate FJ, Rauws EA, Busch OR, Gouma DJ, van Gulik TM. Differentiation of malignant and benign proximal bile duct strictures: The diagnostic dilemma. *World J Gastroenterol* 2008; 14(32): 5032-5038. (AMC)
528. Knijnenburg TA, Wessels LFA, Reinders MJT. Combinatorial influence of environmental parameters on transcription factor activity. *Bioinformatics* 2008; 24: i172-i181 (NKI)
529. Knijnenburg TA, Wessels LFA, Reinders MJT. Creating gene set activity profiles with time-series expression data. *Int J Bioinform Res Appl* 2008; 4: 306-23 (NKI)
530. Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann M, Sixma TK, Pichler A. Ubc9 sumoylation regulates SUMO target discrimination. *Mol Cell* 2008; 31: 371-82 (NKI)
531. Knoester H, Bronner MB, Bos AP, Grootenhuis MA. Quality of life in children three and nine months after discharge from a paediatric intensive care unit: a prospective cohort study. *Health And Quality Of Life Outcomes* 2008; 6(1): 21. (AMC)
532. Knoops L, de Jong D. The role of the p53 pathway in the treatment of follicular lymphoma. *Cell Cycle* 2008; 7: 436-9 (NKI)
533. Knops AM, Goossens A, Burger MPM, Stalpers LJA, Ubbink DT. Simplifying the communication of evidence on treatment benefit and harm to the patient. Anonymous A. (red.): Proceedings of the 6th biennial Joanna Briggs Colloquium in association with the 12th international Nursing Research Conference. Conference Handbook. Cordoba (Spain): 2008.p.86. (AMC)
534. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H, Klutmann S, Knapp WH, Zijlstra JM, Bockisch A, Weckesser M, Lorenz R, Schreckenberger M, Bares R, Eich HT, Mueller RP, Fuchs M, Borchmann P, Schicha H, Diehl V, Engert A. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. *Blood* 2008; 112(10): 3989-3994 (VUmc)
535. Kodach LL, Bleuming SA, Musler AR, Peppelenbosch MP, Hommes DW, van den Brink GR, van Noesel CJM, Offerhaus GJA, Hardwick JCH. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. *Cancer* 2008; 112(2): 300-306. (AMC)
536. Kodach LL, Wiercinska E, de Miranda NFCC, Bleuming SA, Musler AR, Peppelenbosch MP, Dekker E, van den Brink GR, van Noesel CJM, Morreau H, Hommes DW, ten Dijke P, Offerhaus GJA, Hardwick JCH. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. *Gastroenterol* 2008; 134(5): 1332-1341. (AMC)
537. Kodach VM, Faber DJ, van Leeuwen TG. Wavelength swept Ti : sapphire laser. *Optics Communications* 2008; 281(19): 4975-4978. (AMC)
538. Koh AY, Kohler JR, Coggsall KT, van Rooijen N, Pier GB. Mucosal damage and neutropenia are required for *Candida albicans* dissemination. *PLoS Pathog* 2008; 4(2): e35 (VUmc)
539. Kolkman RGM, Brands PJ, Steenbergen W, van Leeuwen TG. Real-time in vivo photoacoustic and ultrasound imaging. *J Biomed Optics* 2008; 13(5): 050510. (AMC)
540. Kolkman RGM, Mulder MJ, Glade CP, Steenbergen W, van Leeuwen TG. Photoacoustic imaging of port-wine stains. *Lasers In Surg Med* 2008; 40(3): 178-182. (AMC)
541. Kolkman RGM, Thumma KK, ten Brinke GA, Siphanto RI, van Neck H, Steenbergen W, van Leeuwen TG. (red.): Photoacoustic imaging of tumor angiogenesis. In AA Oraevsky & LV Wang (Eds.). *Proc SPIE 685602, 2008. (Photons Plus Ultrasound: Imaging and Sensing 2008; 685602)*. (AMC)
542. Konstantinov SR, Smidt H, de Vos WM, Bruijns SC, Singh SK, Valence F, Molle D, Lortal S, Altermann E, Klaenhammer TR, van Kooyk Y. S layer protein A of *Lactobacillus acidophilus* NCFM regulates immature dendritic cell and T cell functions. *Proc Natl Acad Sci U S A* 2008; 105(49): 19474-19479 (VUmc)
543. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, van Sluis P, Troost D, Meeteren NS, Caron HN, Cloos J, Mrcic A, Ylstra B, Grajkowska W, Hartmann W, Pietsch T, Ellison D, Clifford SC, Versteeg R. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. *PLoS ONE* 2008; 3(8): e3088 (AMC / VUmc)
544. Koorstra JBM, Maitra A, Morsink FHM, Drillenburger P, ten Kate FJW, Hruban RH, Offerhaus JA. Undifferentiated carcinoma with osteoclastic giant cells (UCOCCG) of the pancreas associated with the familial atypical multiple mole melanoma syndrome (FAMMM). *Am J Surg Pathol* 2008; 32(12): 1905-1909. (AMC)
545. Kootstra J, Hoekstra-Weebers JE, Rietman H, de Vries J, Baas P, Geertzen JH, Hoekstra HJ. Quality of Life After Sentinel Lymph Node Biopsy or Axillary Lymph Node Dissection in Stage I/II Breast Cancer Patients: A Prospective Longitudinal Study. *Ann Surg Oncol* 2008; 15: 2533-41 (NKI)
546. Koppel EA, Litjens M, van den Berg V, van Kooyk Y, Geijtenbeek TBH. Interaction of SIGNR1 expressed by marginal zone macrophages with marginal zone B cells is essential to early IgM responses against *Streptococcus pneumoniae*. *Mol Immunol* 2008; 45(10): 2881-2887 (VUmc)
547. Koppen A, Ait-Aissa R, Koster J, Øra I, Bras J, van Sluis PG, Caron H, Versteeg R, Valentijn LJ. Dickkopf-3 expression is a marker for neuroblastic

- tumor maturation and is down-regulated by MYCN. *Int J Cancer* 2008; 122(7): 1455-1464. (AMC)
548. Koppers-Lalic D, Verweij MC, Lipinska AD, Wang Y, Quinten E, Reits EA, Koch J, Loch S, Rezende MM, Daus F, Bienkowska-Szewczyk K, Osterrieder N, Mettenleiter TC, Heemskerk MH, Tampe R, Neefjes JJ, Chowdhury SI, Rensing ME, Rijsewijk FA, Wiertz EJ. Varicellovirus UL 49.5 proteins differentially affect the function of the transporter associated with antigen processing, TAP. *PLoS Pathog* 2008; 4: e1000080 (NKI)
549. Kortlenhorst MS, Zahurak M, Shabbeer S, Kachhap S, Galloway N, Parmigiani G, Verheul HM, Carducci MA. A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors. *Clin Cancer Res* 2008; 14(21): 6886-6894 (VUmc)
550. Kortlever RM, Brummelkamp TR, Van Meeteren LA, Moolenaar WH, Bernards R. Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. *Mol Cancer Res* 2008; 6: 1452-60 (NKI)
551. Kortlever RM, Nijwening JH, Bernards R. TGFbeta requires its target plasminogen activator inhibitor-1 for cytostatic activity. *J Biol Chem* 2008; 283: 24308-3313 (NKI)
552. Kortmann W, van Agtmael MA, van Diessen J, Kanen BL, Jakobs C, Nanayakkara PW. 5-Oxoproline as a cause of high anion gap metabolic acidosis: an uncommon cause with common risk factors. *Neth J Med* 2008; 66(8): 354-357 (VUmc)
553. Kraal G. Antigens take the shuttle. *Nat Immunol* 2008; 9(1): 11-12 (VUmc)
554. Krak N, van der Hoeven J, Hoekstra OS, Twisk J, van der Wall E, Lammertsma A. Blood flow and glucose metabolism in stage IV breast cancer: heterogeneity of response during chemotherapy. *Mol Imaging Biol* 2008; 10: 356-363 (VUmc)
555. Krak NC, Hoekstra OS, Lammertsma AA. Measuring response to chemotherapy in locally advanced breast cancer: methodological considerations. In: *Breast Cancer: Nuclear Medicine in Diagnosis and Therapeutic Options*, E. Bombardieri, G. Bonadonna, L. Gianni (eds). Springer-Verlag, Heidelberg. 2008; : 169-180 (VUmc)
556. Kraus M, Malenke E, Gogel J, Muller H, Ruckrich T, Overkleef H, Ovaa H, Koscielniak E, Hartmann JT, Driessen C. Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis. *Mol Cancer Ther* 2008; 7: 1940-8 (NKI)
557. Krawczyk PM, Stap J, Aten JA. Visualization of DNA double-strand break repair: From molecules to cells. *Current Medical Imaging Reviews* 2008; 4(3): 202-211. (AMC)
558. Krawczyk PM, Stap J, Hoebe RA, van Oven CH, Kanaar R, Aten JA. Analysis of the mobility of DNA double-strand break-containing chromosome domains in living Mammalian cells. *Methods In Mol Biol (Clifton, N.J.)* 2008; 463: 309-320. (AMC)
559. Kreike B, Hart AAM, van de Velde T, Borger J, Peterse H, Rutgers E, Bartelink H, van de Vijver MJ. Continuing Risk of Ipsilateral Breast Relapse After Breast-Conserving Therapy at Long-Term Follow-up. *Int J Radiat Oncol Biol Phys* 2008; 71: 1014-21 (AMC / NKI)
560. Kreukels BPC, Hamburger HL, de Ruiter MB, van Dam FSAM, Ridderinkhof KR, Boogerd W, Schagen SB. ERP amplitude and latency in breast cancer survivors treated with adjuvant chemotherapy. *Clin Neurophysiol* 2008; 119: 533-41 (NKI)
561. Kreukels BPC, van Dam FSAM, Ridderinkhof KR, Boogerd W, Schagen SB. Persistent neurocognitive problems after adjuvant chemotherapy for breast cancer. *Clin Breast Cancer* 2008; 8: 80-7 (NKI)
562. Kriege M, Seynaeve C, Meijers-Heijboer HE, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland AM, van Geel B, Brekelmans CT, Klijn JG. Distant disease-free interval, site of first relapse and post-relapse survival in B. *Breast Cancer Res Treat* 2008; 111(2): 303-311 (VUmc)
563. Krol HA, Krawczyk PM, Bosch KS, Aten JA, Hol EM, Reits EA. Polyglutamine expansion accelerates the dynamics of ataxin-1 and does not result in aggregate formation. *Plos One* 2008; (1): 1503. (AMC)
564. Kroon BBR, Noorda EM, Vrouwenraets BC, van Slooten GW, Nieweg OE. Isolated limb perfusion for melanoma. *Surg Oncol Clin N Am* 2008; 17: 785-94, viii (NKI)
565. Kroon BK, Leijte JAP, van Boven H, Wessels LFA, Velds A, Horenblas S, van't Veer LJ. Microarray gene-expression profiling to predict lymph node metastasis in penile carcinoma. *BJU Int* 2008; 102: 510-5 (NKI)
566. Kruse A-J, Skaland I, Munk AC, Janssen E, Gudlaugsson E, Baak JPA. Low p53 and retinoblastoma protein expression in cervical intraepithelial neoplasia grade 3 lesions is associated with coexistent adenocarcinoma in situ. *Hum Pathol* 2008; 39: 573-578 (VUmc)
567. Kruyt FA. TRAIL and cancer therapy. *Cancer Lett* 2008; 263(1): 14-25 (VUmc)
568. Kuijl C, Tuin AW, Overkleef H, Neefjes J. Reciprocal chemical genetics for swift lead and target identification. *Mol Biosyst* 2008; 4: 1001-8 (NKI)
569. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ, Aarden LA, Mooi WJ, Peeper DS. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. *Cell* 2008; 133(6): 1019-1031 (NKI / VUmc)
570. Kuiper EJ, van Nieuwenhoven FA, de Smet MD, van Meurs JC, Tanck MW, Oliver N, Klaassen I,

- van Noorden CJF, Goldschmeding R, Schlingemann RO. The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy. *Plos One* 2008; 3(7): 2675. (AMC)
571. Kuiper EJ, van Zijderveld R, Roestenberg P, Lyons KM, Goldschmeding R, Klaassen I, van Noorden CJF, Schlingemann RO. Connective tissue growth factor is necessary for retinal capillary basal lamina thickening in diabetic mice. *J Histochem Cytochem* 2008; 56(8): 785-792. (AMC)
572. Kuipers HF, Biesta PJ, Montagne LJ, van Haastert ES, van der Valk P, van den Elsen PJ. CC chemokine receptor 5 gene promoter activation by the cyclic AMP response element binding transcription factor. *Blood* 2008; 112(5): 1610-1619 (VUmc)
573. Kümmerlin I, ten Kate F, Smedts F, Horn T, Algaba F, Trias I, de la Rosette J, Laguna MP. Core biopsies of renal tumors: a study on diagnostic accuracy, interobserver, and intraobserver variability. *Eur Urol* 2008; 53(6): 1219-1225. (AMC)
574. Kümmerlin IPED, Laguna MP, de La Rosette JJMCH, Bossuyt PMM. Epidemiology of renal cell carcinoma. In: de La Rosette JJMCH, van Poppel H, Sternberg C (red.): *Renal Cell Cancer: Diagnosis and Therapy*. London: Springer-Verlag, 2008. p.1-8. (AMC)
575. Kümmerlin IPED, ten Kate FJW, Wijkstra H, de La Rosette JJMCH, Laguna MP. Changes in the stage and surgical management of renal tumours during 1995-2005: an analysis of the Dutch national histopathology registry. *BJU International* 2008; 102(8): 946-951. (AMC)
576. Kümmerlin IPED, ten Kate FJW. Biopsies and Cytological Punctures. In: de La Rosette JJMCH., van Poppel H, Sternberg C (red.): *Renal Cell Cancer: Diagnosis and Therapy*. London: Springer-Verlag, 2008. p.137-148. (AMC)
577. Kunkler IH, Canney P, van Tienhoven G, Russell NS, MRC/EORTC (BIG 2-04) SUPREMO Trial Management Group. Elucidating the Role of Chest Wall Irradiation in 'Intermediate-risk' Breast Cancer: the MRC/EORTC SUPREMO Trial. *Clin Oncol* 2008; 20: 31-4 (NKI)
578. Kunst PW, Postmus PE, Sutedja TG. Therapeutic bronchoscopy for palliation of lung tumors in: Hansen HH, (ed): *Textbook of lung cancer*. Informa Healthcare. 2008; : 210-217 (VUmc)
579. Kwakman PH, Van den Akker JP, Guclu A, Aslami H, Binnekade JM, de Boer L, Boszhard L, Paulus F, Middelhoek P, te Velde AA, Vandenbroucke-Grauls CMJE, Schultz MJ, Zaat SA. Medical-grade honey kills antibiotic-resistant bacteria in vitro and eradicates skin colonization. *Clin Infect Dis* 2008; 46(11): 1677-1682 (VUmc)
580. Kweekel DM, Gelderblom H, Van der Straaten T, Antonini NF, Punt CJA, Guchelaar HJ. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. *Br J Cancer* 2008; 99: 275-82 (NKI)
581. Kweekel DM, Koopman M, Antonini NF, Van der Straaten T, Nortier JW, Gelderblom H, Punt CJA, Guchelaar HJ. GSTP1 Ile105Val polymorphism correlates with progression-free survival in MCRC patients treated with or without irinotecan: a study of the Dutch Colorectal Cancer Group. *Br J Cancer* 2008; 99: 1316-21 (NKI)
582. Lagarde SM, de Boer JD, ten Kate FJW, Busch ORC, Obertop H, van Lanschot JJB. Postoperative complications after esophagectomy for adenocarcinoma of the esophagus are related to timing of death due to recurrence. *Ann Surg* 2008; 247(1): 71-76. (AMC)
583. Lagarde SM, Reitsma JB, ten Kate FJW, Busch ORC, Obertop H, Zwinderman AH, Moons J, van Lanschot JJB, Lerut T. Predicting Individual Survival After Potentially Curative Esophagectomy for Adenocarcinoma of the Esophagus or Gastroesophageal Junction. *Ann Surg* 2008; 248(6): 1006-1013. (AMC)
584. Lagarde SM, Ver Loren van Themaat PE, Moerland PD, Gilhuijs-Pederson LA, ten Kate FJW, Reitsma PH, van Kampen AHC, Zwinderman AH, Baas F, van Lanschot JJB. Analysis of Gene Expression Identifies Differentially Expressed Genes and Pathways Associated with Lymphatic Dissemination in Patients with Adenocarcinoma of the Esophagus. *Ann Surg Oncol* 2008; 15(12): 3459-3470. (AMC)
585. Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain penetration and toxicity of an anionic drug, the antibiotic salinomycin. *Antimicrob Agents Chemother* 2008; 52: 1034-9 (NKI)
586. Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2008; 70(3): 685-692 (VUmc)
587. Lange MM, Maas CP, Marijnen CAM, Wiggers T, Rutten HJ, Kranenbarg EK, Van de Velde CJ. Urinary dysfunction after rectal cancer treatment is mainly caused by surgery. *Br J Surg* 2008; 95: 1020-8 (NKI)
588. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. *J Clin Oncol* 2008; 26(22): 3770-3776 (NKI / VUmc)
589. Langer CJ, Wakelee H, Schiller J, Choy H, Shepherd F, Vokes EE, Adjei AA, Baas P, Saijo N, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? *Clin Lung Cancer* 2008; 9: 85-91 (NKI)
590. Langer G, Cohen SX, Lamzin VS, Perrakis A. Automated macromolecular model building for X-

- ray crystallography using ARP/wARP version 7. *Nat Protoc* 2008; 3: 1171-9 (NKI)
591. Le Poole IC, Luiten RM. Autoimmune etiology of generalized vitiligo. *Curr Dir Autoimmunity* 2008; 10: 227-243. (AMC)
592. Lee CH, Espinosa I, Vrijaldenhoven S, Subramanian S, Montgomery KD, Zhu S, Marinelli RJ, Peterse JL, Poulin N, Nielsen TO, West RB, Gilks CB, Van De Rijn M. Prognostic significance of macrophage infiltration in leiomyosarcomas. *Clin Cancer Res* 2008; 14: 1423-30 (NKI)
593. Lee CW, Martin J, MacRae R, Tsao MS, Nguyen E, Johnston M, Baas P, Laurie S, Feld R, Murray N, Shepherd FA. Malignant mesothelioma: Canadian perspective and research directions. *Curr Oncol* 2008; 15: 104-11 (NKI)
594. Lee P, de Bree R, Broxk HA, Leemans CR, Postmus PE, Sutedia TG. Primary lung cancer after treatment of head and neck cancer without lymph node metastasis: Is there a role for autofluorescence bronchoscopy?. *Lung Cancer* 2008; 62(3): 309-15 (VUmc)
595. Lee P, Sutedia TG. Population screening for lung cancer using CT. *Thorax* 2008; 63(1): 87 (VUmc)
596. Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E, van Rooijen N, Moldawer L, Satoh M, Reeves WH. A novel type I IFN-producing cell subset in murine lupus. *J Immunol* 2008; 180(7): 5101-5108 (VUmc)
597. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, Scholten RJ, Hooft L, Bijlmer HA, Reitsma JB, Bossuyt PM, Vandenbroucke-Grauls CMJE. Galactomannan detection for invasive aspergillosis in immunocompromized patients. *Cochrane Database Syst Rev* 2008; (4): CD007394 (VUmc)
598. Lehembre F, Yilmaz M, Wicki A, Schomber T, Strittmatter K, Ziegler D, Kren A, Went P, Derksen PWB, Berns A, Jonkers J, Christofori G. NCAM-induced focal adhesion assembly: A functional switch upon loss of E-cadherin. *EMBO J* 2008; 27: 2603-15 (NKI)
599. Leijte JAP, Gallee M, Antonini N, Horenblas S. Evaluation of Current TNM Classification of Penile Carcinoma. *J Urol* 2008; 180: 933-8 (NKI)
600. Leijte JAP, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. *Eur Urol* 2008; 54: 161-9 (NKI)
601. Leijte JAP, Oddens JR, Lock TMTW. Holmium laser lithotripsy for ureteral calculi: Predictive factors for complications and success. *J Endourol* 2008; 22: 257-60 (NKI)
602. Leijte JAP, Valdés Olmos RA, Nieweg OE, Horenblas S. Anatomical Mapping of Lymphatic Drainage in Penile Carcinoma with SPECT-CT: Implications for the Extent of Inguinal Lymph Node Dissection. *Eur Urol* 2008; 54: 885-92 (NKI)
603. Lemos C, Jansen G, Peters GJ. Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors. *Br J Cancer* 2008; 98(5): 857-862 (VUmc)
604. Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ. Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. *Int J Cancer* 2008; 123(7): 1712-1720 (VUmc)
605. Leter EM, Koopmans AK, Gille JJP, van Os TA, Vittoz GG, David EF, Jaspars EH, Postmus PE, van Moorselaar RJA, Craanen ME, Starink TM, Menko FH. Birt-Hogg-Dube syndrome: clinical and genetic studies of 20 families. *J Invest Dermatol* 2008; 128(1): 45-49 (VUmc)
606. Li KW, Jimenez CR. Synapse proteomics: current status and quantitative applications. *Expert Rev Proteomics* 2008; 5(2): 353-360 (VUmc)
607. Li WW, Visser O, Ubbink DT, Klomp HM, Kloek JJ, de Mol BA. The influence of provider characteristics on resection rates and survival in patients with localized non-small cell lung cancer. *Lung Cancer* 2008; 60: 441-51 (NKI)
608. Lidbury BA, Rulli NE, Suhrbier A, Smith PN, McColl SR, Cunningham AL, Tarkowski A, van Rooijen N, Fraser RJ, Mahalingam S. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus. *J Infect Dis* 2008; 197(11): 1585-1593 (VUmc)
609. Lind JS, Herder GJ, Smit EF. Nieuwe middelen voor de behandeling van gemetastaseerd bronchuscarcinoom: remmers van de epidermale groeifactorreceptor en van de angiogenese. *Ned Tijdschr Geneesk* 2008; 152: 928-932 (VUmc)
610. Lind JS, Smit EF, Grunberg K, Senan S, Lagerwaard FJ. Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. *J Thorac Oncol* 2008; 3(9): 1050-1053 (VUmc)
611. Linn SC, Bueno-de-Mesquita JM, van de Vijver MJ. Are gene signatures better than traditional clinical factors? - Authors' reply. *Lancet Oncol* 2008; 9(3): 198-199. (AMC)
612. Linthorst Homan MW, de Korte J, Grootenhuis MA, Bos JD, Sprangers MAG, van der Veen JP. Impact of childhood vitiligo on adult life. *Br J Dermatol* 2008; 159: 915-20 (AMC / NKI)
613. Ljumanovic R, Langendijk JA, Hoekstra OS, Knol DL, Leemans CR, Castelijns JA. Pre- and post-radiotherapy MRI results as a predictive model for response in laryngeal carcinoma. *Eur Radiol* 2008; 18(10): 2231-2240 (VUmc)
614. Llamas MA, Mooij MJ, Sparrius M, Vandenbroucke-Grauls CMJE, Ratledge C, Bitter W. Characterization of five novel *Pseudomonas aeruginosa* cell-surface signalling systems. *Mol Microbiol* 2008; 67(2): 458-472 (VUmc)
615. Lois N, Dawson R, Townend J, McKinnon AD, Smith GC, van 't Hof R, van Rooijen N, Forrester JV. Effect of short-term macrophage depletion in

- the development of posterior capsule opacification in rodents. *Br J Ophthalmol* 2008; 92(11): 1528-1533 (VUmc)
616. Loken MR, van de Loosdrecht AA, Ogata K, Orfao A, Wells DA. Flow cytometry in myelodysplastic syndromes: report from a working conference. *Leuk Res* 2008; 32(1): 5-17 (VUmc)
617. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, van der Holt B, Martin H, Barge R, Bertsch U, Schlenzka J, Bos GMJ, Croockewit S, Zweegman S, Breitskreuz I, Joosten P, Scheid C, van Marwijk-Kooy M, Salwender HJ, van Oers MHJ, Schaafsma R, Naumann R, Sinnige H, Blau I, Verhoef G, de Weerd O, Wijermans P, Wittebol S, Duersen U, Vellenga E, Goldschmidt H. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. *Haematologica-The Hematol J* 2008; 93(1): 124-127. (AMC)
618. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, Peeters Vrancken MJ, Gilhuijs KGA. Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results. *Am J Roentgenol* 2008; 191(5): 1331-1338. (AMC / NKI)
619. Loonen MP, Hage JJ, Kon M. Plastic Surgery Classics: characteristics of 50 top-cited articles in four Plastic Surgery Journals since 1946. *Plast Reconstr Surg* 2008; 121: 320e-7e (NKI)
620. Lordick F, Ruers T, Aust DE, Collette L, Downey RJ, Hajjam ME, Flamen P, Haustermans K, Ilson D, Julié C, Krause BJ, Newiger H, Ott K, Roth A, Cutsem EV, Weber WA, Lutz MP. European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. *Eur J Cancer* 2008; 44: 1807-19 (NKI)
621. Los AP, de Widt J, Van Blitterswijk WJ, Divecha N. Is there a role for diacylglycerol kinase-zeta in cell cycle regulation? *Adv Enzyme Regul* 2008; 48: 31-9 (NKI)
622. Louropoulou A, van d, V, Schoenmaker T, Catsburg A, Savelkoul PHM, Loos BG. Mannose-binding lectin gene polymorphisms in relation to periodontitis. *J Clin Periodontol* 2008; 35(11): 923-930 (VUmc)
623. Lubberink M, Abdul Fatah S, Brans B, Hoekstra OS, Teule GJ. The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma. *Q J Nucl Med Mol Imaging* 2008; 52(1): 30-36 (VUmc)
624. Luijnenburg SE, Hanlo PW, Han KS, Kors WA, Witkamp TD, Verbeke JI. Postoperative hemicerebellar inflammation mimicking recurrent tumor after resection of a medulloblastoma. Case report. *J Neurosurg Pediatrics* 2008; 1(4): 330-333 (VUmc)
625. Luiten RM. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? *Commentary* 5. *Exp Dermatol* 2008; 17(2): 155-156. (AMC)
626. Lukas C, Sharp JT, Angwin J, Boers M, Duryea J, Hall JR, Kauffman JA, Landewe R, Langs G, Bernelot Moens HJ, Peloschek P, van der Heijde D. Automated measurement of joint space width in small joints of patients with rheumatoid arthritis. *J Rheumatol* 2008; 35(7): 1288-1293 (VUmc)
627. Lyle KS, Raaijmakers JH, Bruinsma W, Bos JL, de Rooij J. cAMP-induced Epac-Rap activation inhibits epithelial cell migration by modulating focal adhesion and leading edge dynamics. *Cell Signal* 2008; 20: 1104-16 (NKI)
628. Macklis R, Hagenbeek A. Frontline postchemotherapy consolidation with 90Y-Zevalin RIT: Finally an ideal role for RIT in lymphoma management? *Am J Hematol* 2008; 5: 190-192. (AMC)
629. Mandl ES, Dirven CM, Buis DR, Postma TJ, Vandertop WP. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. *Surg Neurol* 2008; 69(5): 506-509 (VUmc)
630. Manohar S, Kharine A, de Vos C, van Hespem JCG, Steenbergen W, van Leeuwen TG (red.): The Twente Photoacoustic Mammoscope: Toward Clinical Trials; In: *Emerging Technology in Breast Imaging and Mammography..* Stevenson Ranch CA USA : American Scientific Publishers, 2008. pp.243-274p. *Emerging Technology in Breast Imaging and Mammography.* J.S. Suri, R. Rangayyan & S. Laxminarayan (eds.). (AMC)
631. Manohar S, Willeminck RG, van Hespem JC, van Leeuwen TG. Hybrid photoacoustic - ultrasound transmission parameter imaging in a miniature photoacoustic imager. *J Acoust Soc America* 2008; 123(5): 3371. (AMC)
632. Marcel JP, Alfa M, Baquero F, Etienne J, Goossens H, Harbarth S, Hryniewicz W, Jarvis W, Kaku M, Leclercq R, Levy S, Mazel D, Nercelles P, Perl T, Pittet D, Vandenbroucke-Grauls CMJE, Woodford N, Jarlier V. Healthcare-associated infections: think globally, act locally. *Clin Microbiol Infect* 2008; 14(10): 895-907 (VUmc)
633. Marchetti S, de Vries NA, Buckle T, Bolijn MJ, van Eijndhoven MA, Beijnen JH, Mazzanti R, van Tellingen O, Schellens JHM. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in vitro and in vivo pharmacokinetic studies employing *Bcrp1-/-/Mdr1a/1b-/-* (triple-knockout) and wild-type mice. *Mol Cancer Ther* 2008; 7: 2280-7 (NKI)
634. Marees T, Moll AC, Imhof SM, de Boer MR, Ringens PJ, van Leeuwen FE. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. *J Natl Cancer Inst* 2008; 100: 1771-9 (NKI)
635. Margadant C, Frijns E, Wilhelmsen K, Sonnenberg A. Regulation of hemidesmosome

- disassembly by growth factor receptors. *Curr Opin Cell Biol* 2008; 20: 589-96 (NKI)
636. Matsushima S, Maeda K, Hayashi H, Debori Y, Schinkel AH, Schuetz JD, Kusuvara H, Sugiyama Y. Involvement of multiple efflux transporters in hepatic disposition of fexofenadine. *Mol Pharmacol* 2008; 73: 1474-83 (NKI)
637. Mauer ME, Bottomley A, Collette L, Slotman BJ. Palliative-care trials; how best to publish findings?. *Lancet Oncol* 2008; 9(5): 411-412 (VUmc)
638. Maurice-Stam H, Oort FJ, Last BF, Brons PPT, Caron HN, Grootenhuis MA. Longitudinal assessment of health-related quality of life in preschool children with non-CNS cancer after the end of successful treatment. *Pediatr Blood & Cancer* 2008; 50(5): 1047-1051. (AMC)
639. Maurice-Stam H, Oort FJ, Last BF, Grootenhuis MA. Emotional functioning of parents of children with cancer: the first five years of continuous remission after the end of treatment. *Psycho-Oncol* 2008; 17(5): 448-459. (AMC)
640. Mauritz R, Peters GJ, Kathmann I, Teshale H, Noordhuis P, Comijn EM, Pinedo HM, Jansen G. Dynamics of antifolate transport via the reduced folate carrier and the membrane folate receptor in murine leukaemia cells in vitro and in vivo. *Cancer Chemother Pharmacol* 2008; 62(6): 937-948 (VUmc)
641. Mayer R, Sminia P. Reirradiation tolerance of the human brain. *Int J Radiat Oncol Biol Phys* 2008; 70(5): 1350-1360 (VUmc)
642. Mazur A, Figurski S, Płoskoń A, Meijer J, Zoetekouw L, Wątróbska S, Sykut-Cegielska J, Gradowska W, van Kuilenburg ABP. Dihydropyrimidine dehydrogenase deficiency presenting with psychomotor retardation in the first Polish patient. *Acta Biochimica Polonica* 2008; 55(4): 787-790. (AMC)
643. McDermott LN, Wendling M, Nijkamp J, Mans A, Sonke JJ, Mijneer BJ, van Herk M. 3D in vivo dose verification of entire hypo-fractionated IMRT treatments using an EPID and cone-beam CT. *Radiother Oncol* 2008; 86: 35-42 (NKI)
644. McGill J, van Rooijen N, Legge KL. Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. *J Exp Med* 2008; 205(7): 1635-1646 (VUmc)
645. Meijer AH, van der Sar AM, Cunha C, Lamers GE, Laplante MA, Kikuta H, Bitter W, Becker TS, Spaink HP. Identification and real-time imaging of a myc-expressing neutrophil population involved in inflammation and mycobacterial granuloma formation in zebrafish. *Dev Comp Immunol* 2008; 32(1): 36-49 (VUmc)
646. Meijer CJLM, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DAM, Snijders PJF. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. *Int J Cancer* 2008; 124(3): 516-520 (VUmc)
647. Meijer CJLM, Berkhof J, Heideman DAM, Snijders PJF. Cervical cancer prevention: who should receive vaccination?. *Nat Clin Pract Oncol* 2008; 5(1): 12-13 (VUmc)
648. Meijer CJLM, Berkhof J, van Kemenade FJ, Snijders PJF. Testen op hoogrisico-HPV-typen. *SOA-AIDS magazine* 2008; 2(5): 24-25 (VUmc)
649. Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation. *Cancer Res* 2008; 68: 4701-8 (NKI)
650. Meijer J, Ogink J, Roos E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. *Br J Cancer* 2008; 99: 1493-501 (NKI)
651. Meijer OW, Vandertop WP, Lagerwaard FJ, Slotman BJ. Linear accelerator-based stereotactic radiosurgery for bilateral vestibular schwannomas in patients with neurofibromatosis type 2. *Neurosurgery* 2008; 62(5 Suppl): A37-A42 (VUmc)
652. Meijer OW, Weijmans EJ, Knol DL, Slotman BJ, Barkhof F, Vandertop WP, Castelijns JA. Tumor-volume changes after radiosurgery for vestibular schwannoma: implications for follow-up MR imaging protocol. *Am J Neuroradiol* 2008; 29(5): 906-910 (VUmc)
653. Meijerink MR, van Waesberghe JH, van der Weide L, van den Tol P, Meijer S, van Kuijk C. Total-liver-volume perfusion CT using 3-D image fusion to improve detection and characterization of liver metastases. *Eur Radiol* 2008; 18(10): 2345-2354 (VUmc)
654. Meijerman I, Beijnen JH, Schellens JHM. Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer. *Cancer Treat Rev* 2008; 34: 505-20 (NKI)
655. Meijnen P, Gilhuijs KGA, Rutgers EJT. The effect of margins on the clinical management of ductal carcinoma in situ of the breast. *J Surg Oncol* 2008; 98: 579-84 (NKI)
656. Meijnen P, Oldenburg HSA, Peterse JL, Bartelink H, Rutgers EJT. Clinical Outcome after Selective Treatment of Patients Diagnosed with Ductal Carcinoma In Situ of the Breast. *Ann Surg Oncol* 2008; 15: 235-43 (NKI)
657. Meijnen P, Peterse JL, Antonini N, Rutgers EJT, van de Vijver MJ. Immunohistochemical categorisation of ductal carcinoma in situ of the breast. *Br J Cancer* 2008; 98(1): 137-142. (AMC / NKI)
658. Meinhardt W, Valdés Olmos RA, van der Poel HG, Bex A, Horenblas S. Laparoscopic sentinel node dissection for prostate carcinoma: Technical and anatomical observations. *BJU Int* 2008; 102: 714-7 (NKI)
659. Meissner M, Whiteside TL, van Kuik-Romein P, Valesky EM, van den Elsen PJ, Kaufmann R, Seliger B. Loss of interferon-gamma inducibility of

- the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation. *Br J Dermatol* 2008; 158(5): 930-940 (VUmc)
660. Meleti M, Baart JA, van der Waal I. Gepigmenteerde laesies in de mondholte in: de Baat C, Aps JKM, Brands WFG, Carels CEL, Jacobs R, Vissink A, van Welsen W, (eds): *Het Tandheelkundig Jaar 2008*. Houten, Bohn Stafleu, Van Loghum. 2008; : 165-171 (VUmc)
661. Meleti M, Leemans CR, de Bree R, Vescovi P, Sesenna E, van der Waal I. Head and neck mucosal melanoma. Experience with 42 patients, with emphasis on the role of postoperative radiotherapy. *Head Neck* 2008; 30(12): 1543-1551 (VUmc)
662. Meleti M, Vescovi P, Mooi WJ, van der Waal I. Pigmented lesions of the oral mucosa and perioral tissues: a flow-chart for the diagnosis and some recommendations for the management. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; 105(5): 606-616 (VUmc)
663. Menko FH, Kneepkens CM, de Leeuw N, Peeters EA, van Maldergem L, Kamsteeg EJ, Davidson R, Rozendaal L, Lasham CA, Peeters-Scholte CM, Jansweijer MC, Hilhorst-Hofstee Y, Gille JJP, Heins YM, Nieuwint AW, Sistermans EA. Variable phenotypes associated with 10q23 microdeletions involving the PTEN and BMPR1A genes. *Clin Genet* 2008; 74(2): 145-154 (VUmc)
664. Merks JHM, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RCM. Prevalence and patterns of morphological abnormalities in patients with childhood cancer. *Jama-J Am Med Assoc* 2008; 299(1): 61-69. (AMC)
665. Messick TE, Russell NS, Iwata AJ, Sarachan KL, Shiekhattar R, Shanks JR, Reyes-Turcu FE, Wilkinson KD, Marmorstein R. Structural basis for ubiquitin recognition by the Otu1 ovarian tumor domain protein. *J Biol Chem* 2008; 283: 11038-49 (NKI)
666. Meuleman W, Engwegen JYMN, Gast MCW, Beijnen JH, Reinders MJT, Wessels LFA. Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data. *BMC Bioinformatics* 2008; 9: 88 (11pp) (NKI)
667. Meurs-Szojda MM, Terhaar sive Droste JS, Kuik DJ, Mulder CJJ, Felt-Bersma RJF. Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. *Int J Colorectal Dis* 2008; 23(10): 979-984 (VUmc)
668. Michael LE, Westerman BA, Ermilov AN, Wang A, Ferris J, Liu J, Blom M, Ellison DW, van Lohuizen M, Dlugosz AA. Bmi1 is required for hedgehog pathway-driven medulloblastoma expansion. *Neoplasia* 2008; 10: 1343-9 (NKI)
669. Michaloglou C, Soengas MS, Mooi WJ, Peeper DS. Comment on "Absence of senescence-associated beta-galactosidase activity in human melanocytic nevi in vivo". *J Invest Dermatol* 2008; 128(6): 1582-1583 (VUmc)
670. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. *Oncogene* 2008; 27(7): 877-895 (NKI / VUmc)
671. Michel MC, Fliers E, van Noorden CJF. Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism? *Naunyn-Schmiedeberg's Arch Pharmacol* 2008; 377(3): 205-207. (AMC)
672. Michel MC, Wetterauer U, Vogel M, de La Rosette JJMCH. Cardiovascular safety and overall tolerability of solifenacin in routine clinical use: a 12-week, open-label, post-marketing surveillance study. *Drug Safety* 2008; 31(6): 505-514. (AMC)
673. Middeldorp JM, Pegtel DM. Multiple roles of LMP1 in Epstein-Barr virus induced immune escape. *Semin Cancer Biol* 2008; 18(6): 388-396 (VUmc)
674. Mijnheer B. State of the art of in vivo dosimetry. *Radiat Prot Dosimetry* 2008; 131: 117-22 (NKI)
675. Milano F, Jorritsma T, Rygiel AM, Bergman JJ, Sondermeijer C, ten Brinke A, Vanham SM, Krishnadath KK. Expression pattern of immune suppressive cytokines and growth factors in oesophageal adenocarcinoma reveal a tumour immune escape-promoting microenvironment. *Scand J Immunol* 2008; 68(6): 616-623. (AMC)
676. Milano F, Krishnadath KK. Novel therapeutic strategies for treating esophageal adenocarcinoma: The potential of dendritic cell immunotherapy and combinatorial regimens. *Hum Immunol* 2008; 69(10): 614-624. (AMC)
677. Minnee RC, Bemelman F, Kox C, Surachno S, ten Berge IJM, Bemelman WA, Idu MM. Comparison of hand-assisted laparoscopic and open donor nephrectomy in living donors. *Int J Urol* 2008; 15(3): 206-209. (AMC)
678. Minnee RC, Bemelman WA, Maartense S, Bemelman FJ, Gouma DJ, Idu MM. Left or right kidney in hand-assisted donor nephrectomy? A randomized controlled trial. *Transplantation* 2008; 85(2): 203-208. (AMC)
679. Minnee RC, Bemelman WA, Polle SW, van Koperen PJ, ter Meulen S, Donselaar-van der Pant KA, Bemelman FJ, Idu MM. Older living kidney donors: Surgical outcome and quality of life. *Transplantation* 2008; 86(2): 251-256. (AMC)
680. Miselis NR, Wu ZJ, van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. *Mol Cancer Ther* 2008; 7(4): 788-799 (VUmc)
681. Miyazaki M, Miyazaki K, Itoi M, Katoh Y, Guo Y, Kanno R, Katoh-Fukui Y, Honda H, Amagai T, van Lohuizen M, Kawamoto H, Kanno M. Thymocyte Proliferation Induced by Pre-T Cell Receptor Signaling Is Maintained through Polycomb Gene

- Product Bmi-1-Mediated Cdkn2a Repression. *Immunity* 2008; 28: 231-45 (NKI)
682. Mokkink LB, van der Lee JH, Grootenhuys MA, Offringa M, Heymans HSA. Defining chronic diseases and health conditions in childhood (0-18 years of age): national consensus in the Netherlands. *Eur J Pediatr* 2008; 167(12): 1441-1447. (AMC)
683. Mol AJ, Geldof AA, Meijer GA, van der Poel HG, van Moorselaar RJ. New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration. *J Cancer Res Clin Oncol* 2007; 133: 687-95 (NKI)
684. Molenaar JJ, Ebus ME, Koster J, van Sluis P, van Noesel CJM, Versteeg R, Caron HN. Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. *Cancer Res* 2008; 68(8): 2599-2609. (AMC)
685. Molenkamp BG, Sluijter BJ, van Leeuwen PAM, Santegoets SJAM, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJM, Scheper RJ, de Gruijl TD. Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. *Clin Cancer Res* 2008; 14(14): 4532-4542 (VUmc)
686. Molling JW, Moreno M, De Groot J, van der Vliet HJ, von Blumberg BME, van den Eertwegh AJM, Scheper RJ, Bontkes HJ. Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastases. *Immunol Lett* 2008; 118(1): 36-43 (VUmc)
687. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJM, Scheper RJ, von Blumberg BME, Bontkes HJ. Invariant natural killer T cells and immunotherapy of cancer. *Clin Immunol* 2008; 129(2): 182-194 (VUmc)
688. Molloy T, van 't Veer LJ. Recent advances in metastasis research. *Curr Opin Genet Dev* 2008; 18: 35-41 (NKI)
689. Molloy TJ, Bosma AJ, van't Veer LJ. Towards an optimized platform for the detection, enrichment, and semi-quantitation circulating tumor cells. *Breast Cancer Res Treat* 2008; 112: 297-307 (NKI)
690. Mols F, Aquarius AE, Essink-Bot ML, Aaronson NK, Kil PJ, van de Poll-Franse LV. Does diabetes mellitus as a comorbid condition affect the health-related quality of life in prostate cancer survivors? Results of a population-based observational study. *BJU Int* 2008; 102: 1594-600 (NKI)
691. Monsuur AJ, de Bakker PI, Zhernakova A, Pinto D, Verduijn W, Romanos J, Auricchio R, Lopez A, van Heel DA, Crusius JBA, Wijmenga C. Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single nucleotide polymorphisms. *PLoS ONE* 2008; 3(5): e2270 (VUmc)
692. Mook OR, van Marle J, Jonges R, Vreeling-Sindelarova H, Frederiks WM, van Noorden CJF. Interactions between colon cancer cells and hepatocytes in rats in relation to metastasis. *J Cell Mol Med* 2008; 12(5B): 2052-2061. (AMC)
693. Mook ORF, Jonker A, Strang AC, Veltien A, Gambarota G, Frederiks WM, Heerschap A, van Noorden CJF. Noninvasive magnetic resonance imaging of the development of individual colon cancer tumors in rat liver. *Biotechniques* 2008; 44(4): 529-535. (AMC)
694. Moraes LB, Murakami AH, Fontes B, Poggetti RS, van Rooijen N, Younes RN, Heimbecker AM, Birolini D. Gut ischemia/reperfusion induced acute lung injury is an alveolar macrophage dependent event. *J Trauma* 2008; 64(5): 1196-1200 (VUmc)
695. Moreno M, Mol BM, Mensdorff-Pouilly SV, Verheijen RH, van Blumberg BM, van den Eertwegh AJ, Scheper RJ, Bontkes HJ. Toll-like receptor agonists and invariant natural killer T-cells enhance antibody-dependent cell-mediated cytotoxicity (ADCC). *Cancer Lett* 2008; 272: 70-76 (VUmc)
696. Moreno M, Molling JW, von Mensdorff-Pouilly S, Verheijen RHM, Hooijberg E, Kramer D, Reurs AW, van den Eertwegh AJM, von Blumberg BME, Scheper RJ, Bontkes HJ. IFN-gamma-producing human invariant NKT cells promote tumor-associated antigen-specific cytotoxic T cell responses. *J Immunol* 2008; 181(4): 2446-2454 (VUmc)
697. Moreno M, Molling JW, von Mensdorff-Pouilly S, Verheijen RHM, von Blumberg BME, van den Eertwegh AJM, Scheper RJ, Bontkes HJ. In vitro expanded human invariant natural killer T-cells promote functional activity of natural killer cells. *Clin Immunol* 2008; 129(1): 145-154 (VUmc)
698. Morre SA, Ouburg S, van Agtmael MA, de Vries HJ. Lymphogranuloma venereum diagnostics: from culture to real-time quadriplex polymerase chain reaction. *Sex Transm Infect* 2008; 84(4): 252-253 (VUmc)
699. Morschhauser F, Radford J, van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez DM, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten WL, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. *J Clin Oncol* 2008; 26(32): 5156-5164 (AMC / VUmc)
700. Moshaver B, van der Pol MA, Westra AH, Ossenkuppele GJ, Zweegman S, Schuurhuis GJ. Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival. *Leuk Lymphoma* 2008; 49(1): 134-148 (VUmc)
701. Moshaver B, van Rhenen A, Kelder A, van der Pol M, Terwijn M, Bachas C, Westra AH, Ossenkuppele GJ, Zweegman S, Schuurhuis GJ. Identification of a small subpopulation of

- candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. *Stem Cells* 2008; 26(12): 3059-3067 (VUmc)
702. Mostert SM, Sitaesmi MN, Gundy CM, Sutaryo, Veerman AJP. Parental experiences of childhood leukemia treatment in Indonesia. *J Pediatr Hematol Oncol* 2008; 30(10): 738-743 (NKI / VUmc)
703. Mostert SM, Sitaesmi MN, Gundy CM, Veerman AJP. Attitude of health-care providers toward childhood leukemia patients with different socio-economic status. *Pediatr Blood Cancer* 2008; 50(5): 1001-1005 (NKI / VUmc)
704. Mourad N, Mounier N, Briere J, Raffoux E, Delmer A, Feller A, Meijer CJLM, Emile JF, Bouabdallah R, Bosly A, Diebold J, Haioun C, Coiffier B, Gisselbrecht C, Gaulard P. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. *Blood* 2008; 111(9): 4463-4470 (VUmc)
705. Mous R, Savage P, Eldering E, Teeling P, van Oers MH, van Lier RA. Adequate synapse formation between leukemic B cells and effector T cells following stimulation with artificial TCR ligands. *Leukemia & Lymphoma* 2008; 49(8): 1592-602. (AMC)
706. Mousavi SF, Soroosh P, Takahashi T, Yoshikai Y, Shen H, Lefrancois L, Borst J, Sugamura K, Ishii N. OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. *J Immunol* 2008; 181: 5990-6001 (NKI)
707. Muir G, Gomez Sancha F, Bachmann A, Choi B, Collins E, de la Rosette J, Reich O, Tabatabaei S, Woo H. Techniques and training with greenlight HPS120-W laser therapy of the prostate: Position paper. *Eur Urol Suppl* 2008; 7(4): 370-377. (AMC)
708. Mulier S, Ni Y, Jamart J, Michel L, Marchal G, Ruers T. Radiofrequency Ablation Versus Resection for Resectable Colorectal Liver Metastases: Time for a Randomized Trial? *Ann Surg Oncol* 2008; 15: 144-57 (NKI)
709. Muris J, Kleverlaan CJ, Feilzer AJ, Rustemeyer T. Sodium tetrachloropalladate (Na₂[PdCl₄]) as an improved test salt for palladium allergy patch testing. *Contact Dermatitis* 2008; 58(1): 42-46 (VUmc)
710. Murphy EA, Davis JM, Brown AS, Carmichael MD, Carson JA, van Rooijen N, Ghaffar A, Mayer EP. Benefits of oat beta-glucan on respiratory infection following exercise stress: role of lung macrophages. *Am J Physiol Regul Integr Comp Physiol* 2008; 294(5): R1593-R1599 (VUmc)
711. Nabatov AA, de Jong MAWP, de Witte L, Bulgheresi S, Geijtenbeek TBH. C-type lectin Mermaid inhibits dendritic cell mediated HIV-1 transmission to CD4+ T cells. *Virology* 2008; 378(2): 323-328 (VUmc)
712. Nagasawa M, Schmidlin H, Hazekamp MG, Schotte R, Blom B. Development of human plasmacytoid dendritic cells depends on the combined action of the basic helix-loop-helix factor E2-2 and the Ets factor Spi-B. *Eur J Immunol* 2008; 38: 2389-400 (NKI)
713. Nagel R, le Sage C, Diosdado B, van der Waal M, Oude Vrielink JA, Bolijn A, Meijer GA, Agami R. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer. *Cancer Res* 2008; 68(14): 5795-5802 (NKI / VUmc)
714. Naik SH. Demystifying the development of dendritic cell subtypes, a little. *Immunol Cell Biol* 2008; 86: 439-52 (NKI)
715. Nery FC, Zeng J, Niland BP, Hewett J, Farley J, Irimia D, Li Y, Wiche G, Sonnenberg A, Breakefield XO. TorsinA binds the KASH domain of nesprins and participates in linkage between nuclear envelope and cytoskeleton. *J Cell Sci* 2008; 121: 3476-86 (NKI)
716. Neve S, de Groot AC, Stoof TJ. Retrospectief onderzoek naar de gastro-intestinale en serologische bevindingen bij patiënten met dermatitis herpetiformis in het VUmc. *Ned Tijdschr Derm Venereol* 2008; 18: 389-393 (VUmc)
717. Nieboer P, de Vries EGE, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WT. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. *Bone Marrow Transplant* 2008; 42: 475-81 (NKI)
718. Nierkens S, den Brok MH, Suttmuller RPM, Grauer OM, Bennink E, Morgan ME, Figdor CG, Ruers TJ, Adema GJ. In vivo colocalization of antigen and cytidyl guanosyl within dendritic cells is associated with the efficacy of cancer immunotherapy. *Cancer Res* 2008; 68: 5390-6 (NKI)
719. Nieuwdorp M, van Nood E, Speelman P, van Heukelem HA, Jansen JM, Visser CE, Kuijper EJ, Bartelsman JFWM, Keller JJ. Behandeling van recidiverende Clostridium difficile-geassocieerde diarree met een suspensie van donorfeces. *NTVG* 2008; 152(35): 1927-1932. (AMC)
720. Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, Horenblas S. Urinary Diversions after Cystectomy: The Association of Clinical Factors, Complications and Functional Results of Four Different Diversions. *Eur Urol* 2008; 53: 834-44 (NKI)
721. Nieuwenhuijzen JA, Meinhardt W, Horenblas S. Clinical outcomes after sexuality preserving cystectomy and neobladder (prostate sparing cystectomy) in 44 patients. *J Urol* 2008; 179: S35-S38 (NKI)
722. Nieweg OE. Een fellow en zijn PET. In: Hoekstra HJ, Wobbes T, editors. *Groninger chirurgische oncologica*. Groningen: UMCG, 2008: 112-114 (NKI)

723. Nijkamp J, Pos FJ, Nuver TT, Jong RD, Remeijer P, Sonke JJ, Lebesque JV. Adaptive Radiotherapy for Prostate Cancer Using Kilovoltage Cone-Beam Computed Tomography: First Clinical Results. *Int J Radiat Oncol Biol Phys* 2008; 70: 75-82 (NKI)
724. Nipshagen MD, Hage JJ, Beekman WH. Use of 2-octyl-cyanoacrylate skin adhesive (Dermabond) for wound closure following reduction mammoplasty: a prospective, randomized intervention study. *Plast Reconstr Surg* 2008; 122: 10-8 (NKI)
725. Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. *Biochem Pharmacol* 2008; 76(1): 53-61 (VUmc)
726. Noskin GA, Rubin RJ, Schentag JJ, Kluytmans J, Hedblom EC, Jacobson C, Smulders M, Gemmen E, Bharmal M. Budget impact analysis of rapid screening for *Staphylococcus aureus* colonization among patients undergoing elective surgery in US hospitals. *Infect Control Hosp Epidemiol* 2008; 29(1): 16-24 (VUmc)
727. Nurmohamed MT, Dijkmans BAC. Are biologics more effective than classical disease-modifying antirheumatic drugs?. *Arthritis Res Ther* 2008; 10(5): 118 (VUmc)
728. Nuyten DSA, Hastie T, Chi JT, Chang HY, van de Vijver MJ. Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification. *Eur J Cancer* 2008; 44: 2319-29 (AMC / NKI)
729. Nuyten DSA, van de Vijver MJ. Using Microarray Analysis as a Prognostic and Predictive Tool in Oncology: Focus on Breast Cancer and Normal Tissue Toxicity. *Semin Radiat Oncol* 2008; 18: 105-14 (AMC / NKI)
730. Nygaard V, Liu F, Holden M, Kuo WP, Trimarchi J, Ohno-Machado L, Cepko CL, Frigessi A, Glad IK, Wiel MA, Hovig E, Lyng H. Validation of oligoarrays for quantitative exploration of the transcriptome. *BMC Genomics* 2008; 9: 258 (VUmc)
731. Ockhuysen-Vermeij CF, Henneman L, van Asperen CJ, Oosterwijk JC, Menko FH, Timmermans DR. Design of the BRISC study: a multicentre controlled clinical trial to optimize the communication of breast cancer risks in genetic counselling. *BMC Cancer* 2008; 8: 283 (VUmc)
732. Oei AL, Moreno M, Verheijen RHM, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S. Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer. *Int J Cancer* 2008; 123(8): 1848-1853 (VUmc)
733. Oei AL, Sweep FC, Geurts-Moespot A, van Tienhoven D, von Mensdorff-Pouilly S, Thomas CM, Massuger LF. Human anti-mouse IgM and IgG responses in ovarian cancer patients after radioimmunotherapy with 90Y-muHMFG1. *Anticancer Res* 2008; 28(5A): 2721-2725 (VUmc)
734. Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Hoefner K. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. *Eur Urol* 2008; 54(2): 419-426. (AMC)
735. Oelke M, Wijkstra H. Bladder wall thickness in healthy school-aged children. *Urology* 2008; 72(1): 233-234. (AMC)
736. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL, Debipersad K, Vojtekova K, Lemos C, van der Heijden JW, Ylstra B, Peters GJ, Kaspers GJL, Dijkmans BAC, Scheper RJ, Jansen G. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. *Blood* 2008; 112(6): 2489-2499 (VUmc)
737. Okamoto A, Fujio K, van Rooijen N, Tsuno NH, Takahashi K, Tsurui H, Hirose S, Elkon KB, Yamamoto K. Splenic phagocytes promote responses to nucleosomes in (NZB x NZW) F1 mice. *J Immunol* 2008; 181(8): 5264-5271 (VUmc)
738. Oldenburg RA, Kroeze-Jansema KH, Houwing-Duistermaat JJ, Bayley JP, Dambrot C, van Asperen CJ, van den Ouweland AM, Bakker B, van Beers EH, Nederlof PM, Vasen H, Hoogerbrugge N, Cornelisse CJ, Meijers-Heijboer HE, Devilee P. Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-22 as a putative breast cancer susceptibility locus. *Genes Chromosomes Cancer* 2008; 47(11): 947-956 (NKI / VUmc)
739. Olivier BJ, Schoenmaker T, Mebius RE, Everts V, Mulder CJJ, van Nieuwkerk KM, de Vries TJ, van der Merwe SW. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia. *Hepatology* 2008; 47(1): 259-267 (VUmc)
740. Omloo JM, Sloof GW, Boellaard R, Hoekstra OS, Jager PL, van Dulleman HM, Fockens P, Plukker JT, van Lanschot JJ. Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. *Endoscopy* 2008; 40(6): 464-471 (VUmc)
741. Omloo JM, Westerterp M, Sloof GW, Hoekstra OS, van Lanschot JJ. [The value of positron emission tomography in the diagnosis and treatment of oesophageal cancer]. *Ned Tijdschr Geneesk* 2008; 152(7): 365-370 (VUmc)
742. Oomen LC, Sacher R, Brocks HH, Zwier JM, Brakenhoff GJ, Jalink K. Immersion oil for high-resolution live-cell imaging at 37 degrees C: optical and physical characteristics. *J Microsc* 2008; 232: 353-61 (NKI)
743. Oosterling SJ, van der Bij GJ, Bogels M, ten Raa S, Post JA, Meijer GA, Beelen RHJ, van Egmond M. Anti-beta1 integrin antibody reduces surgery-

- induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces. *Ann Surg* 2008; 247(1): 85-94 (VUmc)
744. Op den Brouw ML, de Jong MAWP, Ludwig IS, van der Molen RG, Janssen HL, Geijtenbeek TBH, Woltman AM. Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. *J Viral Hepat* 2008; 15(9): 675-683 (VUmc)
745. Oskam IM, Hoebbers F, Balm AJM, van Coevorden F, Bais EM, Hart AAM, Van Den Brekel MWM. Neck management in medullary thyroid carcinoma. *Eur J Surg Oncol* 2008; 34: 71-6 (AMC / NKI)
746. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, Beelen RHJ, van de Winkel JG, van Egmond M. Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. *J Immunol* 2008; 181(10): 6829-6836 (VUmc)
747. Oudejans JJ, Muris JJ, Cillessen SAGM, Meijer CJLM. T-cell response in B-cell lymphomas: favorable or unfavorable?. *Clin Cancer Res* 2008; 14(8): 2514-2516 (VUmc)
748. Oudshoorn AM, van den Dungen FA, Bach KP, Koomen I, Fetter WP, Catsburg A, Savelkoul PHM, van Elburg RM. Mannose-binding lectin in term newborns and their mothers: genotypic and phenotypic relationship. *Hum Immunol* 2008; 69(6): 344-348 (VUmc)
749. Ouwehand K, Santegoets SJAM, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S. CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis. *Eur J Immunol* 2008; 38(11): 3050-3059 (VUmc)
750. Ovaa H, van Leeuwen F. Chemical Biology Approaches to Probe the Proteome. *Chembiochem* 2008; 9: 2913-9 (NKI)
751. Overbeek LI, Hoogerbrugge N, van Krieken JH, Nagengast FM, Ruers TJM, Ligtenberg MJL, Hermens RP. Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. *Dis Colon Rectum* 2008; 51: 1249-54 (NKI)
752. Overbeek MJ, Lankhaar JW, Westerhof N, Voskuyl AE, Boonstra A, Bronzwaer JG, Marques KM, Smit EF, Dijkmans BAC, Vonk-Noordegraaf A. Right ventricular contractility in systemic sclerosis-associated and idiopathic pulmonary arterial hypertension. *Eur Respir J* 2008; 31(6): 1160-1166 (VUmc)
753. Overmeer RM, Henken FE, Snijders PJF, Claassen-Kramer D, Berkhof J, Helmerhorst TJ, Heideman DAM, Wilting SM, Murakami Y, Ito A, Meijer CJLM, Steenbergen RDM. Association between dense CADM1 promoter methylation and reduced protein expression in high-grade CIN and cervical SCC. *J Pathol* 2008; 215(4): 388-397 (VUmc)
754. Paessens LC, Fluitsma DM, van Kooyk Y. Haematopoietic antigen-presenting cells in the human thymic cortex: evidence for a role in selection and removal of apoptotic thymocytes. *J Pathol* 2008; 214(1): 96-103 (VUmc)
755. Paessens LC, Singh SK, Fernandes RJ, van Kooyk Y. Vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) provide co-stimulation in positive selection along with survival of selected thymocytes. *Mol Immunol* 2008; 45(1): 42-48 (VUmc)
756. Panbianco C, Weinkove D, Zanin E, Jones D, Divecha N, Gotta M, Ahringer J. A Casein Kinase 1 and PAR Proteins Regulate Asymmetry of a PIP2 Synthesis Enzyme for Asymmetric Spindle Positioning. *Dev Cell* 2008; 15: 198-208 (NKI)
757. Pandey JP, Nietert PJ, von Mensdorff-Pouilly S, Klaamas K, Kurtenkov O. Immunoglobulin allotypes influence antibody responses to mucin 1 in patients with gastric cancer. *Cancer Res* 2008; 68(11): 4442-4446 (VUmc)
758. Pannekoek Y, Morelli G, Kusecek B, Morre SA, Ossewaarde JM, Langerak AA, van der Ende A. Multi locus sequence typing of Chlamydiales: clonal groupings within the obligate intracellular bacteria *Chlamydia trachomatis*. *BMC Microbiol* 2008; 8: 42 (VUmc)
759. Pantarotto JR, Senan S. Radiotherapy for Locally Advanced Lung Cancer: IIIA/B in: Pass, Carbone, Johnson, Minna, Turrisi, Scagliotti, (eds): *Lung Cancer*. Lippincott Williams & Wilkins. 2008; : (VUmc)
760. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. *Nat Rev Cancer* 2008; 8(5): 329-340 (VUmc)
761. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. *J Clin Virol* 2008; 42(4): 343-352 (VUmc)
762. Park JR, Eggert A, Caron H. Neuroblastoma: Biology, prognosis, and treatment. *Pediatric Clinics Of North America* 2008; 55(1): 97. (AMC)
763. Patil CA, Bosschaart N, Keller MD, van Leeuwen TG, Mahadevan-Jansen A. Combined Raman spectroscopy and optical coherence tomography device for tissue characterization. *Optics Letters* 2008; 33(10): 1135-1137. (AMC)
764. Peeters AJ, Dijkmans BAC, Sedney MI. Total atrioventricular block following a tick bite. *Ned Tijdschr Geneesk* 2008; 152(5): 293 (VUmc)
765. Peeters CF, de Waal RM, Wobbes T, Ruers TJM. Metastatic dormancy imposed by the primary tumor: does it exist in humans? *Ann Surg Oncol* 2008; 15: 3308-15 (NKI)
766. Peninga SE, Bruynzeel DP, Rustemeyer T. Een kok die allergisch is voor zijn eigen gerechten. *Ned Tijdschr Allergie* 2008; 8: 132-135 (VUmc)
767. Peninga SE, Bruynzeel DP, Rustemeyer T. Een kok die allergisch is voor zijn eigen gerechten.

- Ned Tijdschr Allergie Huisarts 2008; 3: 37-40 (VUmc)
768. Pentinga SE, Rustemeyer T. Immunopathofysiologie en huidbeeld van contactallergie. Ned Tijdschr Allergie 2008; 8: 122-126 (VUmc)
769. Perez-Calle JL, Marin-Jimenez I, Lopez-Serrano P, Gisbert JP, Pena AS, Fernandez-Rodriguez C. Prevalence of macrocreatinkinase type 1 in patients with inflammatory bowel disease. Dig Dis Sci 2008; 53(2): 486-489 (VUmc)
770. Peric-Hupkes D, van Steensel B. Linking cohesin to gene regulation. Cell 2008; 132: 925-8 (NKI)
771. Perk LR, Stigter-van WM, Visser GWM, Kloet RW, Vosjan MJWD, Leemans CR, Giaccone G, Albano R, Comoglio PM, van Dongen GAMS. Quantitative PET imaging of Met-expressing human cancer xenografts with (89)Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging 2008; 35(10): 1857-1867 (VUmc)
772. Perrakis A, Romier C. Assembly of protein complexes by coexpression in prokaryotic and eukaryotic hosts: an overview. Methods Mol Biol 2008; 426: 247-56 (NKI)
773. Peters AL, van Noorden CJF. Diagnostiek van glucose-6-fosfaatdehydrogenase deficiëntie in ontwikkelingslanden. Nederl Tijdschr Klin Chemie Laboratoriumgen 2008; 33(2): 104-109. (AMC)
774. Peters FP, Brakenhoff KPM, Curvers WL, Rosmolen WD, Fockens P, ten Kate FJW, Krishnadath KK, Bergman JJGHM. Histologic evaluation of resection specimens obtained at 293 endoscopic resections in Barrett's esophagus. Gastrointest Endoscop 2008; 67(4): 604-609. (AMC)
775. Peters FP, Curvers WL, Rosmolen WD, de Vries CE, ten Kate FJW, Krishnadath KK, Fockens P, Bergman JJGHM. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophag 2008; 21(6): 475-479. (AMC)
776. Peters GJ, Bijnsdorp IV, Fukushima M. Thymidine phosphorylase as a target for antiangiogenesis treatment. Nucleic Acids Symp Ser (Oxf) 2008; (52): 629 (VUmc)
777. Peters GJ. Pharmacogenomics of cancer chemotherapy. Recent Adv Res Updates 2008; 9: 27-36 (VUmc)
778. Peters MJL, van Halm V, Nurmohamed MT, Damoiseaux J, Tervaert JW, Twisk JW, Dijkmans BAC, Voskuyl AE. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008; 35(8): 1495-1499 (VUmc)
779. Peters NAJB, Richel DJ, Verhoeff JJC, Stalpers LJA. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008; 26(14): 2405-2406. (AMC)
780. Peters PJ, Pierson J. Immunogold labeling of thawed cryosections. Methods Cell Biol 2008; 88: 131-49 (NKI)
781. Pham TV, van de Wiel MA, Jimenez CR. Support vector machine approach to separate control and breast cancer serum samples. Stat Appl Genet Mol Biol 2008; 7: Article11 (VUmc)
782. Piek JM, van Diest PJ, Verheijen RHM. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol 2008; 622: 79-87 (VUmc)
783. Piet AH, Hulshof MC, Pieters BR, Pos FJ, de Reijke TM, Koning CC. Clinical Results of a Concomitant Boost Radiotherapy Technique for Muscle-Invasive Bladder Cancer. Ergebnisse nach primärer perkutaner Radiotherapie mittels konkomitanter Boost-Technik nach transurethraler Resektion muskelinvasiver Harnblasenkarzinome. Strahlenther Onkol 2008; 184: 313-8 (AMC / NKI)
784. Pieters BR, van de Kamer JB, van Herten YRJ, van Wieringen N, D'Olieslager GM, van der Heide UA, Koning CCE. Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy. Radiother Oncol 2008; 88(1): 46-52. (AMC)
785. Pieterse AH, Baas-Thijssen MCM, Marijnen CAM, Stiggelbout AM. Clinician and cancer patient views on patient participation in treatment decision-making: a quantitative and qualitative exploration. Br J Cancer 2008; 99: 875-82 (NKI)
786. Pietersen AM, Evers B, Prasad AA, Tanger E, Cornelissen-Steijger P, Jonkers J, van Lohuizen M. Bmi1 Regulates Stem Cells and Proliferation and Differentiation of Committed Cells in Mammary Epithelium. Curr Biol 2008; 18: 1094-9 (NKI)
787. Pietersen AM, Horlings HM, Hauptmann M, Langerod A, Ajouaou A, Cornelissen-Steijger P, Wessels LFA, Jonkers J, van de Vijver MJ, van Lohuizen M. EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res 2008; 10: R109 (12pp) (AMC / NKI)
788. Pietersen AM, van Lohuizen M. Stem cell regulation by polycomb repressors: postponing commitment. Curr Opin Cell Biol 2008; 20: 201-7 (NKI)
789. Piriou E, van Dort K, Otto S, van Oers MHJ, van Baarle D. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection. Clin Infectious Dis 2008; 46(2): 313-316. (AMC)
790. Pisteia A, Bakker EN, Spaan JA, Hardeman MR, van Rooijen N, Vanbavel E. Small artery remodeling and erythrocyte deformability in L-NAME-induced hypertension: role of transglutaminases. J Vasc Res 2008; 45(1): 10-18 (VUmc)

791. Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, Giai V, Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones-Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. *Blood* 2008; 111: 2765-75 (NKI)
792. Planelles L, Medema JP, Hahne M, Hardenberg G. The Expanding Role of APRIL in Cancer and Immunity. *Curr Mol Med* 2008; 8(8): 829-844. (AMC)
793. Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, Hogervorst FBL, Hoogerbrugge N, Spurdle AB, Tavtigian SV. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. *Hum Mutat* 2008; 29: 1282-91 (NKI)
794. Polle SW, van Berge Henegouwen MI, Slors JFM, Cuesta MA, Gouma DJ, Bemelman WA. Total laparoscopic restorative proctocolectomy: are there advantages compared with the open and hand-assisted approaches? *Dis Colon Rectum* 2008; 51(5): 541-548. (AMC)
795. Poortmans PM, Collette L, Bartelink H, Struikmans H, Van den Bogaert WF, Fourquet A, Jager JJ, Hoogenraad W, Muller RP, Dubois JB, Bolla M, Van Der Hulst M, Warlam-Rodenhuis CC, Pierart M, Horiot JC. The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. *Cancer Radiother* 2008; 12: 565-70 (NKI)
796. Postmus PE. Screening and early diagnosis in lung cancer. *Expert Rev Anticancer Ther* 2008; 8(10): 1529-1531 (VUmc)
797. Postmus PE. Screening for lung cancer, an ongoing debate. *Ann Oncol* 2008; 19 Suppl 7: vii25-vii27 (VUmc)
798. Pouw RE, Gondrie JJ, Curvers WL, Sondermeijer CM, ten Kate FJ, Bergman JJ. Successful balloon-based radiofrequency ablation of a widespread early squamous cell carcinoma and high-grade dysplasia of the esophagus: a case report. *Gastrointestinal Endoscopy* 2008; 68(3): 537-541. (AMC)
799. Pouw RE, Gondrie JJ, Sondermeijer CM, ten Kate FJ, van Gulik TM, Krishnadath KK, Fockens P, Weusten BL, Bergman JJ. Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. *J Gastrointest Surg* 2008; 12(10): 1627-1636. (AMC)
800. Prasad GA, Wang KK, Halling KC, Buttar NS, Wongkeesong LM, Zinsmeister AR, Brankley SM, Fritcher EGB, Westra WM, Krishnadath KK, Lutzke LS, Borkenhagen LS. Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. *Gastroenterol* 2008; 135(2): 370-379. (AMC)
801. Prevo W, van den Bosch MA, Horenblas S. Radiofrequency ablation for treatment of sporadic angiomyolipoma. *Urology* 2008; 72: 188-91 (NKI)
802. Prieur A, Peeper DS. Cellular senescence in vivo: a barrier to tumorigenesis. *Curr Opin Cell Biol* 2008; 20: 150-5 (NKI)
803. Puschendorf M, Terranova R, Boutsma E, Mao X, Isono KI, Brykczynska U, Kolb C, Otte AP, Koseki H, Orkin SH, van Lohuizen M, Peters AHFM. PRC1 and Suv39h specify parental asymmetry at constitutive heterochromatin in early mouse embryos. *Nat Genet* 2008; 40: 411-20 (NKI)
804. Qiu H, Fan Y, Joyee AG, Wang S, Han X, Bai H, Jiao L, van Rooijen N, Yang X. Type I IFNs enhance susceptibility to Chlamydia muridarum lung infection by enhancing apoptosis of local macrophages. *J Immunol* 2008; 181(3): 2092-2102 (VUmc)
805. Quaak SG, van den Berg JH, Toebes M, Schumacher TNM, Haanen JBAG, Beijnen JH, Nuijen B. GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial. *Eur J Pharm Biopharm* 2008; 70: 429-38 (NKI)
806. Raijmakers PG, Paul MA, Lips P. Sentinel node detection in patients with thyroid carcinoma: a meta-analysis. *World J Surg* 2008; 32(9): 1961-1967 (VUmc)
807. Raijmakers R, Berkers CR, de Jong A, Ovaa H, Heck AJ, Mohammed S. Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity. *Mol Cell Proteomics* 2008; 7: 1755-62 (NKI)
808. Rajan V, Varghese B, van Leeuwen TG, Steenbergen W. Influence of tissue optical properties on laser Doppler perfusion imaging, accounting for photon penetration depth and the laser speckle phenomenon. *J Biomed Optics* 2008; 13(2): 024001. (AMC)
809. Rajan V, Varghese B, van Leeuwen TG, Steenbergen W. Speckle size and decorrelation time; space-time correlation analysis of coherent light dynamically scattered from turbid media. *Optics Communications* 2008; 281: 1755-1760. (AMC)
810. Rami-Porta R, Postmus PE, Goldstraw P. Reply to the Letter to the Editor entitled: The IASLC lung cancer staging project: Revision proposal of pleural effusion and contralateral nodule staging, by V. Barbeiri, P. Tassone and P. Tagliaferri. *J Thorac Oncol* 2008; 3: 317 (VUmc)
811. Raterman HG, van Halm V, Voskuyl AE, Simsek S, Dijkmans BAC, Nurmohamed MT. Rheumatoid arthritis is associated with a high prevalence of hypothyroidism that amplifies its cardiovascular risk. *Ann Rheum Dis* 2008; 67(2): 229-232 (VUmc)

812. Raterman HG, van Halm V, Voskuyl AE, Simsek S, Dijkman BAC, Nurmohamed MT. Increased prevalence of antithyroid antibodies in rheumatoid arthritis (RA) patients with a low prevalence of hormonal alterations. *Autoimmunity* 2008; 41(5): 337 (VUmc)
813. Raychaudhuri S, Remmers EF, Lee AT, Hackett R, Guiducci C, Burt NP, Gianniny L, Korman BD, Padyukov L, Kurreeman FA, Chang M, Catanese JJ, Ding B, Wong S, van der Helm-van Mil AH, Neale BM, Coby J, Cui J, Tak PP, Wolbink GJ, Crusius JBA, van der Horst-. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. *Nat Genet* 2008; 40(10): 1216-1223 (VUmc)
814. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neuoverexpressing breast cancer: current experience and future strategies. *Annals Oncol* 2008; 19(9): 1530-1539. (AMC)
815. Rebolj M, van Ballegooijen M, van Kemenade FJ, Looman C, Boer R, Habbema JD. No increased risk for cervical cancer after a broader definition of a negative Pap smear. *Int J Cancer* 2008; 123(11): 2632-2635 (VUmc)
816. Reesink HW, Mohammadi T, Pietersz RN, Savelkoul PHM. Rapid screening by real-time 16S rDNA PCR for bacterial contamination of blood products. *Clin Chem Lab Med* 2008; 46(7): 954-962 (VUmc)
817. Reijerkerk A, Kooij G, van der Pol SM, Leyen T, van het Hof B, Couraud PO, Vivien D, Dijkstra CD, de Vries HE. Tissue-type plasminogen activator is a regulator of monocyte diapedesis through the brain endothelial barrier. *J Immunol* 2008; 181(5): 3567-3574 (VUmc)
818. Reker Hadrup S, Toebes M, Rodenko B, Bakker AH, Egan DA, Ovaas H, Schumacher TNM. High-Throughput T-Cell Epitope Discovery Through MHC Peptide Exchange. *Epitope Mapping Protocols: Second Edition*. New York / Heidelberg: Springer, 2008: 383-405 (NKI)
819. Retel VP, Hummel MJ, Van Harten WH. Early phase Technology Assessment of nanotechnology in oncology. *Tumori* 2008; 94: 284-90 (NKI)
820. Revet I, Huizenga G, Chan A, Koster J, Volckmann R, van Sluis P, Øra I, Versteeg R, Geerts D. The MSX1 homeobox transcription factor is a downstream target of PHOX2B and activates the Delta-Notch pathway in neuroblastoma. *Exp Cell Res* 2008; 314(4): 707-719. (AMC)
821. Reyat F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LFA. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of Proliferation, Immune response and RNA splicing modules in breast cancer. *Breast Cancer Research* 2008; 10: R93 (AMC / NKI)
822. Riegman PHJ, Llombart Bosch A, Dinjens WNM, Oomen MHA, Spatz A, Ratcliffe C, Knox K, Mager R, Kerr D, Pezzella F, Van Damme B, Van De Vijver M, van Boven H, Morente MM, Alonso S, Kerjaschki D, Pammer J, Lopez-Guerrero JA, Carbone A, Gloghini A, Teodorovic I, Isabelle M, Oldenburg HSA, Passiukov A, Lejeune S, Therasse P, Van Veen EB, Lam KH, Oosterhuis JW. OECl TuBaFrost tumor biobanking. *Tumori* 2008; 94: 160-3 (NKI)
823. Rinkel RN, Verdonck-de Leeuw IM, Van Reij EJ, Aaronson NK, Leemans R. Speech handicap index in patients with oral and pharyngeal cancer: Better understanding of patients' complaints. *Head Neck* 2008; 30: 868-74 (NKI)
824. Rinkel RNPM, Leeuw IM, van Reij EJ, Aaronson NK, Leemans CR. Speech Handicap Index in patients with oral and pharyngeal cancer: better understanding of patients' complaints. *Head Neck* 2008; 30(7): 868-874 (VUmc)
825. Rioja J, de La Rosette JJMCH, Wijkstra H, Laguna MP. Advances in diagnosis and follow-up in kidney cancer. *Current Opinion In Urol* 2008; 18(5): 447-454. (AMC)
826. Rioja ZJ, Toutziaris V, Laguna Pes MP, de Reijke TM, de la Rosette JJ. Láser y tumores vesicales. *Archivos Espanoles De Urologia* 2008; 61(9): 994-1003. (AMC)
827. Rival C, Theas MS, Suescun MO, Jacobo P, Guazzone V, van Rooijen N, Lustig L. Functional and phenotypic characteristics of testicular macrophages in experimental autoimmune orchitis. *J Pathol* 2008; 215(2): 108-117 (VUmc)
828. Robertson CM, Perrone EE, McConnell KW, Dunne WM, Boody B, Brahmabhatt T, Diacovo MJ, van Rooijen N, Hogue LA, Cannon CL, Buchman TG, Hotchkiss RS, Coopersmith CM. Neutrophil depletion causes a fatal defect in murine pulmonary Staphylococcus aureus clearance. *J Surg Res* 2008; 150(2): 278-285 (VUmc)
829. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. *EMBO J* 2008; 27: 1-5 (NKI)
830. Roggen E, Aufderheide M, Cetin Y, Dearman RJ, Gibbs S, Hermanns I, Kimber I, Regal JF, Rovida C, Warheit DB, Uhlig S, Casati S. The development of novel approaches to the identification of chemical and protein respiratory allergens. *Altern Lab Anim* 2008; 36(5): 591-598 (VUmc)
831. Rogoza RM, Ferko N, Bentley J, Meijer CJLM, Berkhof J, Wang KL, Downs L, Smith JS, Franco EL. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. *Vaccine* 2008; 26 Suppl 5: F46-F58 (VUmc)
832. Rolf MP, ter Wee R, van Leeuwen TG, Spaan JAE, Streekstra GJ. Diameter measurement from images of fluorescent cylinders embedded in tissue. *Medical & Biological Engineering & Computing* 2008; 46(6): 589-596. (AMC)

833. Rood IGH, Koppelman MH, Pettersson A, Savelkoul PHM. Development of an internally controlled PCR assay for broad range detection of bacteria in platelet concentrates. *J Microbiol Methods* 2008; 75(1): 64-69 (VUmc)
834. Rood IGH, Pettersson A, de Korte D, Savelkoul PHM. Reducing the risk of transfusion-transmitted bacterial infections in platelet concentrates: current status and developments. *Lab Medicine* 2008; 39: 553-558 (VUmc)
835. Roozendaal R, Mebius RE, Kraal G. The conduit system of the lymph node. *Int Immunol* 2008; 20(12): 1483-1487 (VUmc)
836. Roth KM, Oghumu S, Satoskar AA, Gunn JS, van Rooijen N, Satoskar AR. Respiratory infection with *Francisella novicida* induces rapid dystrophic cardiac calcinosis (DCC). *FEMS Immunol Med Microbiol* 2008; 53(1): 72-78 (VUmc)
837. Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. *Proc Natl Acad Sci U S A* 2008; 105: 17079-84 (NKI)
838. Rottenberg S, Jonkers J. Modeling therapy resistance in genetically engineered mouse cancer models. *Drug Resist Updat* 2008; 11: 51-60 (NKI)
839. Rustemeyer T. Contactallergie in: Bruijnzeel-Koomen, van Wijk, Knulst, de Monchy, (eds): *Handboek Allergologie*. Utrecht, De Tijdstroom. 2008; : 73-81 (VUmc)
840. Rutgers EJT. Sentinel node biopsy: Interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases. *J Clin Oncol* 2008; 26: 698-702 (NKI)
841. Rutten HJ, den Dulk M, Lemmens VE, Van de Velde CJ, Marijnen CAM. Controversies of total mesorectal excision for rectal cancer in elderly patients. *Lancet Oncol* 2008; 9: 494-501 (NKI)
842. Rygiel AM, Milano F, ten Kate FJ, de Groot JG, Peppelenbosch MP, Bergman JJGHM, Krishnadath KK. Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett's esophagus brush cytology specimens. *Genes Chromosomes & Cancer* 2008; 47(5): 396-404. (AMC)
843. Rygiel AM, Milano F, ten Kate FJ, Schaap A, Wang KK, Peppelenbosch MP, Bergman JJGHM, Krishnadath KK. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. *Cancer Epidemiology Biomarkers & Prevention* 2008; 17(6): 1380-1385. (AMC)
844. Rygiel TP, Mertens AE, Strumane K, van der Kammen R, Collard JG. The Rac activator Tiam1 prevents keratinocyte apoptosis by controlling ROS-mediated ERK phosphorylation. *J Cell Sci* 2008; 121: 1183-92 (NKI)
845. Saad AG, Yeap BY, Thunnissen FBJM, Pinkus GS, Pinkus JL, Loda M, Sugarbaker DJ, Johnson BE, Chirieac LR. Immunohistochemical markers associated with brain metastases in patients with nonsmall cell lung carcinoma. *Cancer* 2008; 113(8): 2129-2138 (VUmc)
846. Saghatchian M, Hummel H, Otter R, de Valeriola D, van Harten W, Paradiso A, Koot B, Ringborg U, Tursz T. Towards quality, comprehensiveness and excellence. The accreditation project of the Organisation of European Cancer Institutes (OECI). *Tumori* 2008; 94: 164-71 (NKI)
847. Sankatsing SUC, Prins JM, Yong SL, Roelofsen J, van Kuilenburg ABP, Kewn S, Back DJ, Bemelman FJ, ten Berge IJM. : Mycophenolate mofetil inhibits T-cell proliferation in kidney transplant recipients without lowering intracellular dGTP and GTP. *Transplant Internat* 2008; 21(11): 1066-1071. (AMC)
848. Santegoets LA, Van Seters M, Heijmans-Antonissen C, Kleinjan A, van Beurden M, Ewing PC, Kuhne LC, Beckmann I, Burger CW, Helmerhorst TJM, Blok LJ. Reduced local immunity in HPV-related VIN: expression of chemokines and involvement of immunocompetent cells. *Int J Cancer* 2008; 123: 616-22 (NKI)
849. Santegoets SJAM, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJM, Hooijberg E, Scheper RJ, de Gruijl TD. Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model. *J Immunol* 2008; 180(7): 4540-4549 (VUmc)
850. Santegoets SJAM, Gibbs S, Kroeze K, van d, V, Scheper RJ, Borrebaeck CA, de Gruijl TD, Lindstedt M. Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. *J Leukoc Biol* 2008; 84(1): 143-151 (VUmc)
851. Santegoets SJAM, van den Eertwegh AJM, van de Loosdrecht AA, Scheper RJ, de Gruijl TD. Human dendritic cell line models for DC differentiation and clinical DC vaccination studies. *J Leukoc Biol* 2008; 84(6): 1364-1373 (VUmc)
852. Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoché V, Blatter J, Visseren-Grul CM, Manegold C. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemo-naïve patients with malignant pleural mesothelioma: Results of the International Expanded Access Program. *J Thorac Oncol* 2008; 3: 756-63 (NKI)
853. Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyüpoglu IY. Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. *Nat Med* 2008; 14: 629-32 (NKI)

854. Schaaf GJ, van Ruissen F, van Kampen A, Kool M, Ruijter JM. Statistical comparison of two or more SAGE libraries: one tag at the time. Nielsen KL (red.): Serial analysis of gene expression (SAGE). Methods and protocols. Totowa NJ: Humana Press, 2008. p.151-168. (AMC)
855. Schaapveld M, Visser O, Louwman MJ, de Vries EGE, Willemsse PHB, Otter R, van der Graaf WTA, Coebergh JWW, van Leeuwen FE. Risk of new primary nonbreast cancers after breast cancer treatment: A Dutch population-based study. *J Clin Oncol* 2008; 26: 1239-46 (NKI)
856. Schaapveld M, Visser O, Louwman WJ, Willemsse PH, de Vries EGE, van der Graaf WT, Otter R, Coebergh JW, van Leeuwen FE. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. *Breast Cancer Res Treat* 2008; 110: 189-97 (NKI)
857. Schagen FH, Graat HC, Carette JE, Vellinga J, van Geer MA, Hoeben RC, Dermody TS, van Beusechem VW. Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice. *Hum Gene Ther* 2008; 19(8): 783-794 (VUmc)
858. Schagen SB, Boogerd W, Muller MJ, Ten Bokkel Huinink W, Moonen L, Meinhardt W, van Dam FSAM. Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. *Acta Oncol* 2008; 47: 63-70 (NKI)
859. Schallreuter KU, Bahadoran P, Picardo M, Slominski A, Elasiuty YE, Kemp EH, Giachino C, Liu JB, Luiten RM, Lambe T, Le Poole IC, Dammak I, Onay H, Zmijewski MA, Dell'anna ML, Zeegers MP, Cornall RJ, Paus R, Ortonne JP, Westerhof W. Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? *Exp Dermatol* 2008; 17(2): 139-40, discussion 141-60. (AMC)
860. Scheepers JJ, Sietses C, Bos DG, Boelens PG, Teunissen CM, Ligthart-Melis GC, Cuesta MA, van Leeuwen PAM. Immunological consequences of laparoscopic versus open transhiatal resection for malignancies of the distal esophagus and gastroesophageal junction. *Dig Surg* 2008; 25(2): 140-147 (VUmc)
861. Scheepers JJ, Veenhof AA, van der Peet DL, van Groeningen C, Mulder CJJ, Meijer S, Cuesta MA. Laparoscopic transhiatal resection for malignancies of the distal esophagus: outcome of the first 50 resected patients. *Surgery* 2008; 143(2): 278-285 (VUmc)
862. Scheer MGW, Sloots CEJ, Van der Wilt GJ, Ruers TJM. Management of patients with asymptomatic colorectal cancer and synchronous irresectable metastases. *Ann Oncol* 2008; 19: 1829-35 (NKI)
863. Scheer MGW, Stollman TH, Boerman OC, Verrijp K, Sweep FC, Leenders WPJ, Ruers TJM, Oyen WJG. Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. *Eur J Cancer* 2008; 44: 1835-40 (NKI)
864. Scheer MGW, Stollman TH, Vogel WV, Boerman OC, Oyen WJG, Ruers TJM. Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. *J Nucl Med* 2008; 49: 887-91 (NKI)
865. Scheeren FA, Diehl SA, Smit LA, Beaumont T, Naspetti M, Bende RJ, Blom B, Karube K, Ohshima K, van Noesel CJM, Spits H. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. *Blood* 2008; 111(9): 4706-4715. (AMC)
866. Scheeren FA, Nagasawa M, Weijer K, Cupedo T, Kirberg J, Legrand N, Spits H. T cell-independent development and induction of somatic hypermutation in human IgM+IgD+CD27+ B cells. *J Exp Med* 2008; 205: 2033-42 (NKI)
867. Schellens JHM, Grouls R, Guchelaar HJ, Touw DJ, Rongen GA, De Boer A, Van Bortel LM. The Dutch model for clinical pharmacology: Collaboration between physician- and pharmacist-clinical pharmacologists. *Br J Clin Pharmacol* 2008; 66: 146-7 (NKI)
868. Schepers K, Swart E, van Heijst JW, Gerlach C, Castrucci M, Sie D, Heimerikx M, Velds A, Kerkhoven RM, Arens R, Schumacher TNM. Dissecting T cell lineage relationships by cellular barcoding. *J Exp Med* 2008; 205: 2309-18 (NKI)
869. Schilder CMT, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: Cross-sectional findings from the neuropsychological TEAM-side study. *Acta Oncol* 2008; 1-10 (NKI)
870. Schilder CMT, Schagen SB, van Dam FSAM. Effect of hormones and hormonal treatment on cognition. In: Meyers CA, Perry JR, editors. *Cognition and cancer*. Cambridge University Press, 2008: 115-141 (NKI)
871. Schiltz PM, Dillman RO, Korse CM, Cubellis JM, Lee GJ, de Gast GC. Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells. *Cancer Biother Radiopharm* 2008; 23: 214-21 (NKI)
872. Schiphof D, Boers M, Bierma-Zeinstra SM. Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis. *Ann Rheum Dis* 2008; 67(7): 1034-1036 (VUmc)
873. Schlisio S, Kenchappa RS, Vredevelde LCW, George RE, Stewart R, Greulich H, Shahriari K, Nguyen NV, Pigny P, Dahia PL, Pomeroy SL, Maris

- JM, Look AT, Meyerson M, Peeper DS, Carter BD, Kaelin J. The kinesin KIF1B? acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. *Genes Dev* 2008; 22: 884-93 (NKI)
874. Schouten-van Meeteren AY, van d, V, Moll AC, Imhof SM, de Graaf P, Siregar NC, Darmiati S, Asih D, Gatot D, Tehuteru E, Simangunsong LB, Sitorus RS. International retinoblastoma staging system helps to bridge the gap. *Pediatr Blood Cancer* 2008; 50(3): 733 (VUmc)
875. Schrama D, Voigt H, Eggert AO, Xiang R, Zhou H, Schumacher TNM, Andersen MH, Thor Straten P, Reisfeld RA, Becker JC. Immunological tumor destruction in a murine melanoma model by targeted LT? independent of secondary lymphoid tissue. *Cancer Immunol Immunother* 2008; 57: 85-95 (NKI)
876. Schwamborn K, Knipscheer P, van Dijk E, van Dijk WJ, Sixma TK, Meloen RH, Langedijk JP. SUMO assay with peptide arrays on solid support: insights into SUMO target sites. *J Biochem* 2008; 144: 39-49 (NKI)
877. Scott NW, Fayers PM, Aaronson NK, Bottomley A, de Graeff A, Groenvold M, Koller M, Petersen MA, Sprangers MAG. The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database. *J Clin Epidemiol* 2008; 61: 788-95 (NKI)
878. Seigers R, Schagen SB, Beerling W, Boogerd W, van Tellingen O, van Dam FSAM, Koolhaas JM, Buwalda B. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. *Behav Brain Res* 2008; 186: 168-75 (NKI)
879. Senft A, de Bree R, Hoekstra OS, Kuik DJ, Golding RP, Oyen WJ, Pruim J, van den Hoogen FJ, Roodenburg JL, Leemans CR. Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. *Radiother Oncol* 2008; 87(2): 221-229 (VUmc)
880. Seto E, Ooka T, Middeldorp JM, Takada K. Reconstitution of nasopharyngeal carcinoma-type EBV infection induces tumorigenicity. *Cancer Res* 2008; 68(4): 1030-1036 (VUmc)
881. Shanmugham A, Ovaa H. DUBs and disease: activity assays for inhibitor development. *Curr Opin Drug Discov Devel* 2008; 11: 688-96 (NKI)
882. Shear NH, Milpied B, Bruynzeel DP, Phillips EJ. A review of drug patch testing and implications for HIV clinicians. *AIDS* 2008; 22(9): 999-1007 (VUmc)
883. Shivapurkar N, Stastny V, Okumura N, Girard L, Xie Y, Prinsen C, Thunnissen FBJM, Wistuba II, Czerniak B, Frenkel E, Roth JA, Liloglou T, Xinarianos G, Field JK, Minna JD, Gazdar AF. Cytoglobin, the newest member of the globin family, functions as a tumor suppressor gene. *Cancer Res* 2008; 68(18): 7448-7456 (VUmc)
884. Shivapurkar N, Stastny V, Xie Y, Prinsen C, Frenkel E, Czerniak B, Thunnissen FBJM, Minna JD, Gazdar AF. Differential methylation of a short CpG-rich sequence within exon 1 of TCF21 gene: a promising cancer biomarker assay. *Cancer Epidemiol Biomarkers Prev* 2008; 17(4): 995-1000 (VUmc)
885. Siegel-Lakhai WS, Zandvliet AS, Huitema ADR, Tibben MM, Milano G, Girre V, ras V, King A, Richmond E, Wanders J, Beijnen JH, Schellens JHM. A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours. *Br J Cancer* 2008; 98: 1320-6 (NKI)
886. Sigurdson AJ, Ha M, Hauptmann M, Bhatti P, Sram RJ, Beskid O, Tawn EJ, Whitehouse CA, Lindholm C, Nakano M, Kodama Y, Nakamura N, Vorobtsova I, Oestreicher U, Stephan G, Yong LC, Bauchinger M, Schmid E, Chung HW, Darroudi F, Roy L, Voisin P, Barquinerio JF, Livingston G, Blakey D, Hayata I, Zhang W, Wang C, Bennett LM, Littlefield LG, Edwards AA, Kleinerman RA, Tucker JD. International study of factors affecting human chromosome translocations. *Mutat Res Genet Toxicol Environ Mutagen* 2008; 652: 112-21 (NKI)
887. Simkens L, Tol J, Koopman M, Mol L, Antonini N, Van Krieken H, Punt C. Current questions in the treatment of advanced colorectal cancer: The CAIRO studies of the Dutch Colorectal Cancer Group. *Clin Colorectal Cancer* 2008; 7: 105-9 (NKI)
888. Sinclair LV, Finlay D, Feijoo C, Cornish GH, Gray A, Ager A, Okkenhaug K, Hagenbeek TJ, Spits H, Cantrell DA. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. *Nat Immunol* 2008; 9: 513-21 (NKI)
889. Sitaresmi MN, Mostert SM, Gundy CM, Sutaryo S, Veerman AJP. Health-related quality of life assessment in Indonesian childhood acute lymphoblastic leukemia. *Health Qual Life Outcomes* 2008; 6(1): 96 (VUmc)
890. Sitaresmi MN, Mostert SM, Gundy CM, Sutaryo, Veerman AJP. Health-care providers' compliance with childhood acute lymphoblastic leukemia protocol in Indonesia. *Pediatr Blood Cancer* 2008; 51(6): 732-736 (VUmc)
891. Sjogren EV, Van Rossum MA, Langeveld TPM, Voerman MS, Van De Kamp VAH, Friebel MOW, Wolterbeek R, De Jong RJB. Voice outcome in T1a midcord glottic carcinoma. *Arch Otolaryngol Head Neck Surg* 2008; 134: 965-72 (NKI)
892. Skaland I, Ovestad I, Janssen EAM, Klos J, Kjellevoid KH, Helliesen T, Baak JPA. Digital image analysis improves the quality of subjective HER-2 expression scoring in breast cancer. *Appl Immunohistochem Mol Morphol* 2008; 16: 185-190 (VUmc)
893. Skaland I, van Diest PJ, Janssen EAM, Gudlaugsson E, Baak JPA. Prognostic differences of World Health Organization-assessed mitotic activity

- index and mitotic impression by quick scanning in invasive ductal breast cancer patients younger than 55 years. *Hum Pathol* 2008; 39: 584-590 (VUmc)
894. Skolarikos A, de la Rosette J. Prevention and treatment of complications following percutaneous nephrolithotomy. *Cur Opin Urol* 2008; 18(2): 229-234. (AMC)
895. Slotman BJ, Faivre-Finn C, Kramer GW, Rankin E, Snee M, Hatton M, Postmus PE, Collette L, Musat E, Senan S. Profylactische schedelbestraling bij patiënten met uitgebreid kleincellig longcarcinoom dat reageert op chemotherapie: minder symptomatische hersenmetastasen en betere overleving. *Ned Tijdschr Geneesk* 2008; 152: 1000-1004 (VUmc)
896. Smeenk RM, Bruin SC, van Velthuysen MLF, Verwaal VJ. In Brief. *Curr Probl Surg* 2008; 45: 522-5 (NKI)
897. Smeenk RM, Bruin SC, van Velthuysen MLF, Verwaal VJ. Pseudomyxoma Peritonei. *Curr Probl Surg* 2008; 45: 527-75 (NKI)
898. Smeenk RM, van Velthuysen MLF, Verwaal VJ, Zoetmulder FAN. Appendiceal neoplasms and pseudomyxoma peritonei: A population based study. *Eur J Surg Oncol* 2008; 34: 196-201 (NKI)
899. Smelov V, Morre SA, de Vries HJ. Are serological chlamydia-specific markers useful to detect asymptomatic cases of lymphogranuloma venereum proctitis?. *Sex Transm Infect* 2008; 84(1): 77-78 (VUmc)
900. Smit EF. Thymic malignancies. *Ann Oncol* 2008; 19 Suppl 7: vii309-vii312 (VUmc)
901. Smit LH, Nieweg OE, Mooi WJ, Bonfrer JM, Haanen JB, Kroon BB, De Gast GC. Value of serum S-100B for prediction of distant relapse and survival in stage III B/C melanoma. *Anticancer Res* 2008; 28(4C): 2297-2302 (NKI / VUmc)
902. Smit NP, Van Rossum HH, Romijn FP, Sellar KJ, Breetveld M, Gibbs S, van Pelt J. Calcineurin activity and inhibition in skin and (epi)dermal cell cultures. *J Invest Dermatol* 2008; 128(7): 1686-1690 (VUmc)
903. Smitsmans MH, Pos FJ, de Bois J, Heemsbergen WD, Sonke JJ, Lebesque JV, van Herk M. The influence of a dietary protocol on cone beam CT-guided radiotherapy for prostate cancer patients. *Int J Radiat Oncol Biol Phys* 2008; 71: 1279-86 (NKI)
904. Snijders AM, Hermsen MA, Baughman J, Buffart TE, Huey B, Gajduskova P, Roydasgupta R, Tokuyasu T, Meijer GA, Fridlyand J, Albertson DG. Acquired genomic aberrations associated with methotrexate resistance vary with background genomic instability. *Genes Chromosomes Cancer* 2008; 47(1): 71-83 (VUmc)
905. Snijders PJF, Heideman DAM, Hesselink AT, Berkhof J, Meijer CJLM. HPV DNA detection assays for cervical screening. *Central Eur J Publ Health* 2008; 16: s17-s18 (VUmc)
906. Soehnlein O, Oehmcke S, Ma X, Rothfuchs AG, Frithiof R, van Rooijen N, Morgelin M, Herwald H, Lindbom L. Neutrophil degranulation mediates severe lung damage triggered by streptococcal M1 protein. *Eur Respir J* 2008; 32(2): 405-412 (VUmc)
907. Soiland H, Skaland I, Janssen EAM, Gudlaugsson E, Korner H, Varhaug JE, Soreide JA, Baak JPA. Comparison of apolipoprotein D determination methods in breast cancer. *Anticancer Res* 2008; 28: 1151-1160 (VUmc)
908. Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shamma MA, Anderson KC, Balk SP, Exley MA, Munshi NC. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. *Clin Cancer Res* 2008; 14(21): 6955-6962 (VUmc)
909. Sonke GS, Beerepoot LV, Los M. A patient with subdiaphragmatic air. *Neth J Med* 2008; 66: 89-90 (NKI)
910. Sonke GS, Ludwig I, van Oosten H, Baars JW, Meijer E, Kater AP, de Jong D. Poor outcomes of chronic active Epstein-Barr virus infection and hemophagocytic lymphohistiocytosis in non-Japanese adult patients. *Clin Infect Dis* 2008; 47: 105-8 (NKI)
911. Sonke JJ, Lebesque J, van Herk M. Variability of Four-Dimensional Computed Tomography Patient Models. *Int J Radiat Oncol Biol Phys* 2008; 70: 590-8 (NKI)
912. Soolsma J, van den Brekel MW, Ackerstaff AH, Balm AJ, Tan B, Hilgers FJ. Long-Term Results of Provox activevalve, Solving the Problem of Frequent Candida- and "Underpressure"-Related Voice Prosthesis Replacements. *Laryngoscope* 2008; 118(2): 252-257. (AMC)
913. Soolsma J, Van Den Brekel MWM, Ackerstaff AH, Balm AJM, Tan B, Hilgers FJM. Long-term results of Provox ActiValve, solving the problem of frequent candida- and "underpressure"-related voice prosthesis replacements. *Laryngoscope* 2008; 118: 252-7 (NKI)
914. Soreide K, Gudlaugsson E, Skaland I, Janssen EAM, van Diermen B, Korner H, Baak JPA. Metachronous cancer development in patients with sporadic colorectal adenomas - multivariate risk model with independent and combined value of hTERT and survivin. *Int J Colorectal Dis* 2008; 23: 389-400 (VUmc)
915. Sountoulides P, de La Rosette JJMCH. Update on photoselective vaporization of the prostate. *Curr Urol Rep* 2008; 9(2): 106-112. (AMC)
916. Spanier BWM, Stokkers PCF, Bartelsman JFWM. An unusual bleeding duodenal ulcer. *Gut* 2008; 57(3): 373, 382. (AMC)
917. Spanjaard L, Vandenbroucke-Grauls CMJE. Activity of daptomycin against *Listeria monocytogenes* isolates from cerebrospinal fluid.

- Antimicrob Agents Chemother 2008; 52(5): 1850-1851 (VUmc)
918. Sparidans RW, Lagas JS, Schinkel AH, Schellens JHM, Beijnen JH. Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma. *J Chromatogr B Anal Technol Biomed Life Sci* 2008; 872: 77-82 (NKI)
919. Spoelstra FO, Senan S. Novel tools in radiotherapy. *Ann Oncol* 2008; 19 Suppl 7: vii294-vii299 (VUmc)
920. Spoelstra FO, van Sornsen de Koste JR, Cuijpers JP, Lagerwaard FJ, Slotman BJ, Senan S. Analysis of reproducibility of respiration-triggered gated radiotherapy for lung tumors. *Radiother Oncol* 2008; 87(1): 59-64 (VUmc)
921. Spurdle AB, Couch FJ, Hogervorst FBL, Radice P, Sinilnikova OM. Prediction and assessment of splicing alterations: implications for clinical testing. *Hum Mutat* 2008; 29: 1304-13 (NKI)
922. Staffhorst RW, van der Born K, Erkelens CA, Hamelers IH, Peters GJ, Boven E, de Kroon AI. Antitumor activity and biodistribution of cisplatin nanocapsules in nude mice bearing human ovarian carcinoma xenografts. *Anticancer Drugs* 2008; 19(7): 721-727 (VUmc)
923. Stap J, Krawczyk PM, van Oven CH, Barendsen GW, Essers J, Kanaar R, Aten JA. Induction of linear tracks of DNA double-strand breaks by alpha-particle irradiation of cells. *Nature Methods* 2008; 5(3): 261-266. (AMC)
924. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DSA, van de Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. *Br J Cancer* 2008; 99: 1884-90 (AMC / NKI)
925. Steen KSS, Nurmohamed MT, Visman I, Heijerman M, Boers M, Dijkmans BAC, Lems WF. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. *Ann Rheum Dis* 2008; 67(2): 256-259 (VUmc)
926. Steggerda MJ, van der Poel HG, Moonen LMF. An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors. *Radiother Oncol* 2008; 88: 108-14 (NKI)
927. Steggerda MJ, van der Poel HG, Moonen LMF. Predicting urinary morbidity after brachytherapy of localized prostate cancer. *Eur Urol suppl* 2008; 7: 723-31 (NKI)
928. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernardis R, Mills GB, Hennessy BT. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. *Cancer Res* 2008; 68: 6084-91 (AMC / NKI)
929. Stollman TH, Scheer MGW, Leenders WPJ, Verrijp KCN, Soede AC, Oyen WJG, Ruers TJM, Boerman OC. Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. *Int J Cancer* 2008; 122: 2310-4 (NKI)
930. Stortelers C, Kerckhoven R, Moolenaar WH. Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling. *BMC Genomics* 2008; 9: 387 (NKI)
931. Struijk L, van der Meijden E, Kazem S, ter Schegget J, de Gruijl FR, Steenberg RDM, Feltkamp MC. Specific betapapillomaviruses associated with squamous cell carcinoma of the skin inhibit UVB-induced apoptosis of primary human keratinocytes. *J Gen Virol* 2008; 89(Pt 9): 2303-2314 (VUmc)
932. Struijs B, de Bree R, van Groeningen CJ, Mooi WJ, Rene LC. Tonsillar metastasis of oesophageal adenocarcinoma. *Eur Arch Otorhinolaryngol* 2008; 265(1): 127-129 (VUmc)
933. Strumane K, Song JY, Baas I, Collard JG. Increased Rac activity is required for the progression of T-lymphomas induced by Pten-deficiency. *Leuk Res* 2008; 32: 113-20 (NKI)
934. Studer UE, Collette L, Whelan P, Albrecht W, Casselman J, de Reijke T, Knonagel H, Loidl W, Isorna S, Sundaram SK, Debois M, EORTC Genitourinary Group, Horenblas S, 60 collaborators. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). *Eur Urol* 2008; 53: 941-9 (NKI)
935. Stuiver MM, van Wilgen CP, de Boer EM, de Goede CJ, Koolstra M, van Opzeeland A, Venema P, Sterken MW, Vincent A, Dijkstra PU. Impact of shoulder complaints after neck dissection on shoulder disability and quality of life. *Otolaryngol Head Neck Surg* 2008; 139: 32-9 (NKI)
936. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, Kleijn I, Dee R, Hooft L, van Noesel MM, Bierings M, Berthold F, Versteeg R, Caron HN, van der Schoot CE, Tytgat GAM. PHOX2B Is a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma. *J Clin Oncol* 2008; 26(33): 5443-5449. (AMC)
937. Swaneveld FH, van Vugt RM, de Boer JP, Dijkmans BAC, Lems WF. A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma. *Clin Rheumatol* 2008; 27(2): 249-251 (NKI / VUmc)
938. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Sillevs Smitt PAE, Van Es CA, Van Den Bent MJ. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoradiation with temozolomide. *Cancer* 2008; 113: 405-10 (NKI)

939. Taghavi P, Verhoeven E, Jacobs JJ, Lambooi JP, Stortelers C, Tanger E, Moolenaar WH, van Lohuizen M. In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. *Oncogene* 2008; 27: 6806-16 (NKI)
940. Takahashi N, van Kilsdonk JWJ, Ostendorf B, Smeets R, Bruggeman SWM, Alonso A, van de Loo F, Schneider M, van den Berg WB, Swart GWM. Tumor marker nucleoporin 88 kDa regulates nucleocytoplasmic transport of NF- κ B. *Biochem Biophys Res Commun* 2008; 374: 424-30 (NKI)
941. Tanis PJ, Nieweg OE, van den Brekel MWM, Balm AJM. Dilemma of clinically node-negative head and neck melanoma: Outcome of "watch and wait" policy, elective lymph node dissection, and sentinel node biopsy - A systematic review. *Head And Neck-Journal For The Sciences And Specialties Of The Head And Neck* 2008; 30(3): 380-389. (AMC / NKI)
942. Tanis PJ, ten Kate FJW, van Lanschot JJB. No mucosal escape of signet-ring cell carcinoma for ten years in a patient with familial aggregation of gastric cancer. *J Surg Oncol* 2008; 97(3): 294-296. (AMC)
943. Taylor WJ, Schumacher HR, Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, . A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout. *Ann Rheum Dis* 2008; 67(6): 888-891 (VUmc)
944. te Veldhuis EC, te Veldhuis AH, van Dijk FS, Kwee ML, van Hagen JM, Baart JA, van der Waal I. Rendu-Osler-Weber disease: update of medical and dental considerations. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2008; 105(2): e38-e41 (VUmc)
945. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. *Br J Cancer* 2008; 99(5): 750-759 (VUmc)
946. ten Hove CH, Zijlstra JM, Comans EFI, van Elburg RM. An unusual hotspot in a young woman with Hodgkin's lymphoma. *Haematologica* 2008; 93(1): e14-e15 (VUmc)
947. Terhaard CH, van der Schroeff MP, van Schie K, Eerenstein SE, Lubsen H, Kaanders JH, Smeele LE, Burlage FR, van den Ende PL, Baatenburg de Jong RJ. The prognostic role of comorbidity in salivary gland carcinoma. *Cancer* 2008; 113: 1572-9 (NKI)
948. Terranova R, Yokobayashi S, Stadler MB, Otte AP, van Lohuizen M, Orkin SH, Peters AHFM. Polycomb Group Proteins Ezh2 and Rnf2 Direct Genomic Contraction and Imprinted Repression in Early Mouse Embryos. *Dev Cell* 2008; 15: 668-79 (NKI)
949. Theodore C, Skoneczna I, Bodrogi I, Leahy M, Kerst JM, Collette L, Ven K, Marréaud S, Oliver RDT. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). *Ann Oncol* 2008; 19: 1304-7 (NKI)
950. Theurl M, Theurl I, Hochegger K, Obrist P, Subramaniam N, van Rooijen N, Schuemann K, Weiss G. Kupffer cells modulate iron homeostasis in mice via regulation of hepcidin expression. *J Mol Med* 2008; 86(7): 825-835 (VUmc)
951. Thieblemont C, Rolland D, Baseggio L, Felman P, Gazzo S, Callet-Bauchu E, Traverse-Glehen A, Houlgatte R, Fu K, Weisenburger D, de Jong D, Jaffe E, Rosenwald A, Ott G, Coiffier B, Berger F. Comprehensive analysis of GST- γ expression in B-cell lymphomas: Correlation with histological subtypes and survival. *Leuk Lymphoma* 2008; 49: 1403-6 (NKI)
952. Thomas G, Ali S, Hoebbers FJP, Darcy KM, Rodgers WH, Patel M, Abulafia O, Lucci JA, III, Begg AC. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 120 g/dL with erythropoietin vs above 100 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. *Gynecol Oncol* 2008; 108: 317-25 (NKI)
953. Thurlings RM, Wijbrandts CA, Mebius RE, Cantaert T, Dinant HJ, van der Pouw-Kraan CTM, Verweij CL, Baeten D, Tak PP. Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. *Arthritis Rheum* 2008; 58(6): 1582-1589 (VUmc)
954. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, Di Marsico R, Antonuzzo A, Orlandini C, Ricciardi S, del Tacca M, Peters GJ, Falcone A, Danesi R. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. *Clin Cancer Res* 2008; 14(6): 1797-1803 (VUmc)
955. Tijink BM, Laeremans T, Budde M, Stigter-van WM, Dreier T, de Haard HJ, Leemans CR, van Dongen GAMS. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. *Mol Cancer Ther* 2008; 7(8): 2288-2297 (VUmc)
956. Timmer-Bonte JNH, Punt CJA, vd Heijden HFM, van Die CE, Bussink J, Beijnen JH, Huitema ADR, Tjan-Heijnen VCG. Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. *Lung Cancer* 2008; 60: 222-30 (NKI)
957. Timmermans WHM, Stoof TJ. Fluoroscopy-induced ulcer. *Ned Tijdschr Derm Venereol* 2008; 18: 402-403 (VUmc)

958. Timmers GJ, Kessels LW, Wilhelm AJ, Veldkamp AI, Bosch TM, Beijnen JH, Huijgens PC. Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies. *Ther Drug Monit* 2008; 30(3): 301-305 (NKI / VUmc)
959. Tischkowitz M, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, Wong N, Novak D, Quenneville LA, Grist SA, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro AN, Ladas JAA, Foulkes WD. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: A multimodal approach. *Eur J Hum Genet* 2008; 16: 820-32 (NKI)
960. Tjon JM, Verbeek WHM, Kooy-Winkelaar YM, Nguyen BH, van der Slik AR, Thompson A, Heemskerk MH, Schreurs MW, Dekking LH, Mulder CJJ, van Bergen J, Koning F. Defective synthesis or association of T-cell receptor chains underlies loss of surface T-cell receptor-CD3 expression in enteropathy-associated T-cell lymphoma. *Blood* 2008; 112(13): 5103-5110 (VUmc)
961. Todaro M, Perez AM, Scopelliti A, Medema JP, Stassi G. IL-4-mediated drug resistance in colon cancer stem cells. *Cell Cycle* 2008; 7(3): 309-313. (AMC)
962. Toebak MJ, de Rooij J, Moed H, Stoof TJ, von Blomberg BME, Bruynzeel DP, Scheper RJ, Gibbs S, Rustemeyer T. Differential suppression of dendritic cell cytokine production by anti-inflammatory drugs. *Br J Dermatol* 2008; 158(2): 225-233 (VUmc)
963. Toes AC, Daleke MH, Kuenen JG, Muyzer G. Expression of copA and cusA in *Shewanella* during copper stress. *Microbiology* 2008; 154(Pt 9): 2709-2718 (VUmc)
964. Tol J, Cats A, Mol L, Koopman M, Bos MMEM, Van Der Hoeven JJM, Antonini NF, Van Krieken JHJM, Punt CJA. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. *Invest New Drugs* 2008; 26: 393-7 (NKI)
965. Tol J, Koopman M, Rodenburg CJ, Cats A, Creemers GJ, Schrama JG, Erdkamp FLG, Vos AH, Mol L, Antonini NF, Punt CJA. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. *Ann Oncol* 2008; 19: 734-8 (NKI)
966. Tonino SH, Spijker R, Luijckx DMP, van Oers MHJ, Kater AP. No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. *Blood* 2008; 112(3): 840-843. (AMC)
967. Topolnjak R, Vliet-Vroegindeweyj C, Sonke JJ, Minkema D, Remeijer P, Nijkamp J, Elkhuizen P, Rasch C. Breast-Conserving Therapy: Radiotherapy Margins for Breast Tumor Bed Boost. *Int J Radiat Oncol Biol Phys* 2008; 72: 941-8 (NKI)
968. Tournoy KG, Burgers SA, Annema JT, Vermassen F, Praet M, Smits M, Klomp HM, van Meerbeeck JP, Baas P. Transesophageal endoscopic ultrasound with fine needle aspiration in the preoperative staging of malignant pleural mesothelioma. *Clin Cancer Res* 2008; 14: 6259-63 (NKI)
969. Towne CF, York IA, Neijssen J, Karow ML, Murphy AJ, Valenzuela DM, Yancopoulos GD, Neefjes JJ, Rock KL. Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. *J Immunol* 2008; 180: 1704-12 (NKI)
970. Travis LB, Hodgson D, Allen J, van Leeuwen FE. Second cancers. In: De Vita Jr VT, Hellman S, Rosenberg SA, editors. *Cancer principles and practice of oncology*, 8th edition. Philadelphia: Lippincott, 2008: 2718-2742 (NKI)
971. Trompetter M, Smedts F, van der Wijk J, Schoots C, de Jong HJ, Hopman A, de la Rosette J. Keratin profiling in the developing human prostate. A different approach to understanding epithelial lineage. *Anticancer Res* 2008; 28(1A): 237-243. (AMC)
972. Tsakiris P, de la Rosette JJ, Michel MC, Oelke M. Pharmacologic treatment of male stress urinary incontinence: systematic review of the literature and levels of evidence. *Eur Urol* 2008; 53(1): 53-59. (AMC)
973. Tsakiris P, Thüroff S, de la Rosette J, Chaussy C. Transrectal high-intensity focused ultrasound devices: a critical appraisal of the available evidence. *J Endourol* 2008; 22(2): 221-229. (AMC)
974. Turkstra F, Rinkel RNPM, Biermann H, van der Valk P, Voskuyl AE. Tracheobronchomalacia due to amyloidosis in a patient with rheumatoid arthritis. *Clin Rheumatol* 2008; 27(6): 807-808 (VUmc)
975. Tuynman JB, Lagarde SM, ten Kate FJW, Richel DJ, van Lanschot JJB. Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. *Br J Cancer* 2008; 98(6): 1102-1108. (AMC)
976. Tuynman JB, Vermeulen L, Boon EM, Kemper K, Zwinderman AH, Peppelenbosch MP, Richel DJ. Cyclooxygenase-2 inhibition inhibits c-Met kinase activity and Wnt activity in colon cancer. *Cancer Res* 2008; 68(4): 1213-1220. (AMC)
977. Udink Ten Cate FE, ten Hove CH, Nix WM, de Vries JI, van de Loosdrecht AA, van Elburg RM. Transient Neonatal Myelosuppression after Fetal Exposure to Maternal Chemotherapy. Case Report and Review of the Literature. *Neonatology* 2008; 95(1): 80-85 (VUmc)
978. Uitterhoeve ALJ, Belderbos JSA, van Zandwijk N, Koning CCE. Perspectieven in de

- behandeling van het niet-kleincellige longcarcinoom stadium III met radiotherapie en gelijktijdig gegeven laaggedoseerde chemotherapie. *NTVG* 2008; 152(50): 2709-2713. (AMC)
979. Ungureanu C, van Weperen T, Sijl J, Rayavarapu R, Manohar S, Versluis M, van Leeuwen TG. Acoustic signals from gold nanoparticles irradiated with pulsed lasers. *J Acoust Soc America* 2008; 123(5): p.3370. (AMC)
980. Uren AG, Kool J, Matentzoglou K, de Ridder J, Mattison J, Van Uitert M, Lagcher W, Sie D, Tanger E, Cox T, Reinders M, Hubbard TJ, Rogers J, Jonkers J, Wessels L, Adams DJ, van Lohuizen M, Berns A. Large-scale mutagenesis in p19(ARF)- and p53-deficient mice identifies cancer genes and their collaborative networks. *Cell* 2008; 133: 727-41 (NKI)
981. Ursum J, Nielen MM, van Schaardenburg D, van der Horst AR, van de Stadt RJ, Dijkmans BAC, Hamann D. Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. *Arthritis Res Ther* 2008; 10(1): R12 (VUmc)
982. Uzunkoy A, Dilmec F, Ozgonul A, van Kuilenburg ABP, Akkafa F. Investigation of IVS14+1G > A polymorphism of DPYD gene in a group of Turkish patients with colorectal cancer. *Anticancer Res* 2008; 27(6B): 3899-3902. (AMC)
983. Vaccarella S, Herrero R, Snijders PJF, Dai M, Thomas JO, Hieu NT, Ferreccio C, Matos E, Posso H, de Sanjose S, Shin HR, Sukvirach S, Lazcano-Ponce E, Munoz N, Meijer CJLM, Franceschi S. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. *Int J Epidemiol* 2008; 37(3): 536-546 (VUmc)
984. Vainchtein LD, Rosing H, Mirejovsky D, Huynh V, Lenaz L, Schellens JHM, Beijnen JH. Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EO9 given intravesically. *Rapid Commun Mass Spectrom* 2008; 22: 462-70 (NKI)
985. Valdés Olmos RA, Kroon BBR, Hoefnagel CA, Horenblas S. Penile carcinoma - Radionuclide imaging and PET. In: De la Rosette JJMCH, et al., editors. *Imaging in oncological urology*. Springer, 2008: 345-350 (NKI)
986. van Amerongen R, Berns A. Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape. *Cancer Cell* 2008; 13: 5-7 (NKI)
987. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, Kynaston H, Gontero P, Thalmann G, Akdas A, D'Haese S, Aaronson NK. An international field study of the EORTC QLQ-PR25: A questionnaire for assessing the health-related quality of life of patients with prostate cancer. *Eur J Cancer* 2008; 44: 2418-24 (NKI)
988. Van Baal JWPM, Bozikas A, Pronk R, ten Kate FJW, Milano F, Rygiel AM, Rosmolen WD, Peppelenbosch MP, Bergman JJGHM, Krishnadath KK. Cytokeratin and CDX-2 expression in Barrett's esophagus. *Scan J Gastroenterol* 2008; 43(2): 132-140. (AMC)
989. Van Baal JWPM, Krishnadath KK. High throughput techniques for characterizing the expression profile of Barrett's esophagus. *Dis Esophag* 2008; 21(7): 634-640. (AMC)
990. Van Baal JWPM, Milano F, Rygiel AM, Sondermeijer CMT, Spek CA, Bergman JJGHM, Peppelenbosch MP, Krishnadath KK: A comparative analysis by SAGE of gene expression profiles of esophageal adenocarcinoma and esophageal squamous cell carcinoma. *Cell Oncol* 2008; 30(1): 63-75. (AMC)
991. Van Baal JWPM, Rygiel AM, Milano F, Anderson M, Bergman JJGHM, Spek CA, Wang KK, Peppelenbosch MP, Krishnadath KK. Gene expression profile comparison of Barrett's esophagus epithelial cell cultures and biopsies. *Dis Esophag* 2008; 21(7): 628-633. (AMC)
992. van Baarsen LG, Vosslamber S, Tijssen M, Baggen JM, van d, V, Killestein J, van der Pouw-Kraan CTM, Polman CH, Verweij CL. Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. *PLoS ONE* 2008; 3(4): e1927 (VUmc)
993. van Beek GJ, Roodenburg JL, van der Waal I. Oncologie in de tandheelkundige praktijk. Voorwoord. *Ned Tijdschr Tandheelkd* 2008; 115: 179 (VUmc)
994. van Beek S, De Jaeger K, Mijnheer B, Vliet-Vroegindeweyj C. Evaluation of a single-isocenter technique for axillary radiotherapy in breast cancer. *Med Dosim* 2008; 33: 191-8 (NKI)
995. Van Beem RT, Noort WA, Voermans C, Kleijer M, ten Brinke A, van Ham SM, van der Schoot CE, Zwaginga JJ. The presence of activated CD4(+) T cells is essential for the formation of colony-forming unit-endothelial cells by CD14(+) cells. *J Immunol* 2008; 180(7): 5141-5148. (AMC)
996. Van Blitterswijk WJ, Verheij M. Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. *Curr Pharm Des* 2008; 14: 2061-74 (NKI)
997. Van Bree C, Rodermond HM, Leen R, Medema JP, van Kuilenburg ABP. Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells. *Br J Cancer* 2008; 98(7): 1226-1233. (AMC)
998. Van Bree C, Rodermond HM, ten Cate R, de Vos J, Stalpers LJA, Haveman J, Medema JP, Franken NAP. G0 cell cycle arrest alone is insufficient for enabling the repair of ionizing

- radiation-induced potentially lethal damage. *Rad Res* 2008; 170(2): 184-191. (AMC)
999. Van Bree C, van Kuilenburg ABP. Will cyclopentenyl cytosine (CPEC) ever have a future in the clinic? *Leukemia Res* 2008; 32(2): 201-202. (AMC)
1000. van Cruijnsen H, van der Veldt AAM, Vroling L, Oosterhoff D, Broxterman HJ, Scheper RJ, Giaccone G, Haanen JB, van den Eertwegh AJM, Boven E, Hoekman K, de Gruijl TD. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients. CD1c+ dendritic cell frequency predicts progression-free survival. *Clin Cancer Res* 2008; 14(18): 5884-5892 (NKI / VUmc)
1001. Van Dalen EC, Caron HN, Dickinson HO, Kremer LCM. Cardioprotective interventions for cancer patients receiving anthracyclines. *Cochrane Database Of Systematic Reviews* 2008; (2) p.CD003917. (AMC)
1002. van de Loosdrecht AA, Westers TM, Ossenkoppele GJ. Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication?. *Leuk Res* 2008; 32(2): 205-207 (VUmc)
1003. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der Velden V, Ossenkoppele GJ. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. *Blood* 2008; 111(3): 1067-1077 (VUmc)
1004. van de Ven R, Scheffer GL, Reurs AW, Lindenberg JJ, Oerlemans R, Jansen G, Gillet JP, Glasgow JN, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD. A role for multidrug resistance protein 4 (MRP4: ABCC4) in human dendritic cell migration. *Blood* 2008; 112(6): 2353-2359 (VUmc)
1005. van de Weerd BCM, Littler DR, Klompmaker R, Huseinovic A, Fish A, Perrakis A, Medema RH. Polo-box domains confer target specificity to the Polo-like kinase family. *Biochim Biophys Acta Mol Cell Res* 2008; 1783: 1015-22 (NKI)
1006. van den Ancker W, Westers TM, Ossenkoppele GJ, van de Loosdrecht AA. Back to basics: in search of the optimal dendritic cell for vaccination in AML. *Leuk Res* 2008; 32(11): 1641-1643 (VUmc)
1007. van den Berg R, Buis DR, Lagerwaard FJ, Lycklama a Nijeholt GJ, Vandertop WP. Extensive white matter changes after stereotactic radiosurgery for brain arteriovenous malformations: a prognostic sign for obliteration?. *Neurosurgery* 2008; 63(6): 1064-1069 (VUmc)
1008. van den Berg RM, Teertstra HJ, van Zandwijk N, van Tinteren H, Visser C, Pasic A, Sutedja TG, Baas P, Golding RP, Postmus PE, Smit EF. CT detected indeterminate pulmonary nodules in a chemoprevention trial of fluticasone. *Lung Cancer* 2008; 60(1): 57-61 (NKI / VUmc)
1009. van den Bout I, van Rheenen J, van Angelen AA, de Rooij J, Wilhelmsen K, Jalink K, Divecha N, Sonnenberg A. Investigation into the mechanism regulating MRP localization. *Exp Cell Res* 2008; 314: 330-41 (NKI)
1010. Van den Brekel M, Hilgers FJM. Preoperative workup of the neck in head and neck squamous cell carcinoma. In: Cernea CR, editor. *Pearls and pitfalls in head and neck surgery: practical tips to minimize complications*. Basel: Karger, 2008: 34-35 (NKI)
1011. van den Brekel MWM, Castelijns JA. Ultrasound surveillance for Head and Neck Cancer in: Orloff L, (ed): *Head and Neck Ultrasonography*. 2008; : (VUmc)
1012. Van Den Broek E, Richard W, Van Tinteren H, de Vries N. UPPP combined with radiofrequency thermotherapy of the tongue base for the treatment of obstructive sleep apnea syndrome. *Eur Arch Oto-Rhino-Laryngol* 2008; 265: 1361-5 (NKI)
1013. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum. *Rapid Commun Mass Spectrom* 2008; 22: 2915-28 (NKI)
1014. van den Broek I, Sparidans RW, Schellens JHM, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. *J Chromatogr B Anal Technol Biomed Life Sci* 2008; 872: 1-22 (NKI)
1015. Van den Broek W, Barneveld P, Lemstra C, Van Urk P. *Tumoren. Leerboek Nucleaire geneeskunde*. Elsevier, 2008: 505-557 (NKI)
1016. van den Heuvel MM, Korse CM, Bonfrer JMG, Baas P. Non-invasive diagnosis of pleural malignancies: The role of tumour markers. *Lung Cancer* 2008; 59: 350-4 (NKI)
1017. van den Heuvel-Eibrink MM, Grundy P, Graf N, Pritchard-Jones K, Bergeron C, Patte C, Van Tinteren H, Rey A, Langford C, Anderson JR, de Kraker J. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. *Pediatr Blood Cancer* 2008; 50: 1130-4 (NKI)
1018. van den Hoorn T, Neefjes J. Activated pDCs: open to new antigen-presentation possibilities. *Nat Immunol* 2008; 9: 1208-10 (NKI)
1019. Van den Tweel XW, Hatzmann J, Ensink E, van der Lee JH, Peters M, Fijnvandraat K, Grootenhuis M. Quality of life of female caregivers of children with sickle cell disease: a survey. *Haematologica-Hematol J* 2008; 93(4): 588-593. (AMC)
1020. van der Bij GJ, Oosterling SJ, Bogels M, Bhoelan F, Fluitsma DM, Beelen RHJ, Meijer S, van Egmond M. Blocking alpha2 integrins on rat CC531s colon carcinoma cells prevents operation-induced

- augmentation of liver metastases outgrowth. *Hepatology* 2008; 47(2): 532-543 (VUmc)
1021. van der Deen M, Homan S, Timmer-Bosscha H, Scheper RJ, Timens W, Postma DS, de Vries EG. Effect of COPD treatments on MRP1-mediated transport in bronchial epithelial cells. *Int J Chron Obstruct Pulmon Dis* 2008; 3(3): 469-475 (VUmc)
1022. van der Drift MA, Prinsen CF, Hol BE, Bolijn AS, Jeunink MA, Dekhuijzen PN, Thunnissen FBJM. Can free DNA be detected in sputum of lung cancer patients?. *Lung Cancer* 2008; 61(3): 385-390 (VUmc)
1023. Van der Gaag NA, ten Kate FJW, Gouma DJ. Authors' reply: Prognostic significance of extracapsular lymph node involvement in patients with adenocarcinoma of the ampulla of Vater (*Br J Surg* 2008; 95 : 735-743). *Br J Surg* 2008; 95(9): 1188-1189. (AMC)
1024. Van der Gaag NA, ten Kate FJW, Lagarde SM, Busch ORC, van Gulik TM, Gouma DJ. Prognostic significance of extracapsular lymph node involvement in patients with adenocarcinoma of the ampulla of Vater. *Br J Surg* 2008; 95(6): 735-743. (AMC)
1025. van der Geld YG, van Triest B, Verbakel WF, van Sornsen de Koste JR, Senan S, Slotman BJ, Lagerwaard FJ. Evaluation of four-dimensional computed tomography-based intensity-modulated and respiratory-gated radiotherapy techniques for pancreatic carcinoma. *Int J Radiat Oncol Biol Phys* 2008; 72(4): 1215-1220 (VUmc)
1026. van der Groep P, Bouter A, Menko FH, van der Wall E, van Diest PJ. High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. *Breast Cancer Res Treat* 2008; 111(3): 475-480 (VUmc)
1027. van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP, van Diest PJ. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. *Breast Cancer Res Treat* 2008; 107(1): 41-47 (VUmc)
1028. van der Kooij SM, Allaart CF, Dijkmans BAC, Breedveld FC. Innovative treatment strategies for patients with rheumatoid arthritis. *Curr Opin Rheumatol* 2008; 20(3): 287-294 (VUmc)
1029. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Peeters AJ, van Krugten MV, Breedveld FC, Dijkmans BAC, Allaart CF. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis* 2008; 67(2): 266-269 (VUmc)
1030. Van der Krogt GNM, Ogink J, Ponsioen B, Jalink K. A comparison of donor-acceptor pairs for genetically encoded FRET sensors: Application to the Epac cAMP sensor as an example. *PLoS ONE* 2008; 3: e1916 (9pp) (NKI)
1031. van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CFM, van der Heijden JW, Maruyama K, Boellaard R, Dijkmans BAC, Lammertsma AA, Voskuyl AE. Noninvasive imaging of macrophages in rheumatoid synovitis using (11)C-(R)-PK11195 and positron emission tomography. *Arthritis Rheum* 2008; 58(11): 3350-3355 (VUmc)
1032. van der Laken CJ, Voskuyl AE, Roos JC, Stigter van WM, de Groot ER, Wolbink GJ, Dijkmans BAC, Aarden LA. [The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients]. *Ned Tijdschr Geneesk* 2008; 152(30): 1672-1677 (VUmc)
1033. van der Meij EH, de Visscher JG, van der Waal I. Diagnostiek en behandeling van premaligne afwijkingen van het mondslijmvlies. *ACTA Quality Practice* 2008; 4: 28-33 (VUmc)
1034. van der Ploeg HP, Streppel KR, van der Beek AJ, van der Woude LH, Van Harten WH, Van Mechelen W. Underlying mechanisms of improving physical activity behavior after rehabilitation. *Int J Behav Med* 2008; 15: 101-8 (NKI)
1035. van der Ploeg IMC, Kroon BBR, Antonini N, Valdés Olmos RA, Rutgers EJT, Nieweg OE. Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration. *Ann Surg Oncol* 2008; 15: 1025-31 (NKI)
1036. van der Ploeg IMC, Nieweg OE, Van Rijk MC, Valdés Olmos RA, Kroon BBR. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: A systematic review and meta-analysis of the literature. *Eur J Surg Oncol* 2008; 34: 1277-84 (NKI)
1037. van der Ploeg IMC, Tanis PJ, Valdes Olmos RA, Kroon BBR, Rutgers EJT, Nieweg OE. Breast Cancer Patients with Extra-Axillary Sentinel Nodes Only may be Spared Axillary Lymph Node Dissection. *Ann Surg Oncol* 2008; 15: 3239-43 (NKI)
1038. van der Ploeg IMC, Valdés Olmos RA, Kroon BBR, Nieweg OE. The Hybrid SPECT/CT as an Additional Lymphatic Mapping Tool in Patients with Breast Cancer. *World J Surg* 2008; 32: 1930-4 (NKI)
1039. van der Ploeg IMC, Valdés Olmos RA, Kroon BBR, Nieweg OE. Tumor-positive sentinel node biopsy of the groin in clinically node-negative melanoma patients: Superficial or superficial and deep lymph node dissection? *Ann Surg Oncol* 2008; 15: 1485-91 (NKI)
1040. van der Ploeg IMC, Van Rijk MC, Nieweg OE, Kroon BBR. Sentinel lymph node. *Encyclopedia of Cancer*, 2nd ed.; part 19. 2009: (NKI)
1041. van der Poel HG, de Blok W, Bex A, Meinhardt W, Horenblas S. Peroperative transrectal ultrasonography-guided bladder neck dissection eases the learning of robot-assisted laparoscopic prostatectomy. *BJU Int* 2008; 102: 849-52 (NKI)
1042. van der Poel HG, Moonen L, Horenblas S. Sequential treatment for recurrent localized prostate cancer. *J Surg Oncol* 2008; 97: 377-82 (NKI)

1043. van der Pouw-Kraan CTM, van Baarsen LG, Wijbrandts CA, Voskuyl AE, Rustenburg F, Baggen JM, Dijkmans BAC, Tak PP, Verweij CL. Expression of a pathogen-response program in peripheral blood cells defines a subgroup of rheumatoid arthritis patients. *Genes Immun* 2008; 9(1): 16-22 (VUmc)
1044. van der Pouw-Kraan CTM, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. *Ann Rheum Dis* 2008; 67(4): 563-566 (VUmc)
1045. van der Putten L, Hoekstra OS, de Bree R, Kuik DJ, Comans EFI, Langendijk JA, Leemans CR. 2-deoxy-2-[F-18]FDG-PET for detection of recurrent laryngeal carcinoma after radiotherapy: interobserver variability in reporting. *Mol Imaging Biol* 2008; 10(5): 294-303 (VUmc)
1046. Van Der Schoot SC, Vainchtein LD, Nuijen B, Gore A, Mirejovsky D, Lenaz L, Beijnen JH. Purity profile of the indoloquinone anticancer agent EO-9 and chemical stability of EO-9 freeze dried with 2-hydroxypropyl-beta-cyclodextrin. *Pharmazie* 2008; 63: 796-805 (NKI)
1047. Van der Sluijs Veer L, Kempers MJE, Last BF, Vulmsa T, Grootenhuys MA. Quality of life, developmental milestones, and self-esteem of young adults with congenital hypothyroidism diagnosed by neonatal screening. *J Clin Endocrinol Metabol* 2008; 93(7): 2654-2661. (AMC)
1048. van der Stoop P, Boutsma EA, Hulsman D, Noback S, Heimerikx M, Kerkhoven RM, Voncken JW, Wessels LFA, van Lohuizen M. Ubiquitin E3 ligase Ring1b/Rnf2 of polycomb repressive complex 1 contributes to stable maintenance of mouse embryonic stem cells. *PLoS ONE* 2008; 3: e2235 (NKI)
1049. van der Veldt AAM, Boven E, Helgason HH, van Wouwe M, Berkhof J, De Gast GC, Mallo H, Tillier CN, van den Eertwegh AJM, Haanen JB. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. *Br J Cancer* 2008; 99(2): 259-265 (NKI / VUmc)
1050. van der Veldt AAM, Buist MR, van Baal MW, Comans EF, Hoekstra OS, Molthoff CF. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET. *J Nucl Med* 2008; 49: 1936-1943 (VUmc)
1051. van der Veldt AAM, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized Treatment Planning in Oncology. Role of PET and Radiolabelled Anticancer Drugs in Predicting Tumour Resistance. *Curr Pharm Des* 2008; 14(28): 2914-2931 (VUmc)
1052. van der Veldt AAM, Meijerink MR, van den Eertwegh AJM, Bex A, De Gast GC, Haanen JB, Boven E. Sunitinib for treatment of advanced renal cell cancer: primary tumor response. *Clin Cancer Res* 2008; 14(8): 2431-2436 (NKI / VUmc)
1053. van der Veldt AAM, van Wouwe M, van den Eertwegh AJM, van Moorselaar RJA, van Geijn HP. Metastatic renal cell cancer in a 20-year-old pregnant woman. *Urology* 2008; 72(4): 775-777 (VUmc)
1054. van der Vliet HJ, Lefevre P, van Groeningen CJ. [A patient with very high serum level of human chorionic gonadotrophin: the diagnosis is not always a germ-cell tumour]. *Ned Tijdschr Geneesk* 2008; 152(12): 705-709 (VUmc)
1055. van der Waal I, Reichart PA. Oral proliferative verrucous leukoplakia revisited. *Oral Oncol* 2008; 44(8): 719-721 (VUmc)
1056. van der Waal I. De mond als spiegel van de algemene gezondheid. *ACTA Quality Practice* 2008; 4: 8-16 (VUmc)
1057. van der Waal I. Een wit vlekje in de mond in: Graamans P, van de Heyning P, de Vries N, (eds): *Keel-neus-oorheelkunde en hoofd-halschirurgie. Casu ´stiek uit de dagelijkse praktijk.* Houten, Bohn Stafleu Van Loghum. 2008; : 105-107 (VUmc)
1058. van der Waal RI, van der Waal I. Knobbels op de tong. *Ned Tijdschr Derm* 2008; 18: 21 (VUmc)
1059. van der Weide L, van Sornsen de Koste JR, Lagerwaard FJ, Vincent A, van Triest B, Slotman BJ, Senan S. Analysis of Carina Position as Surrogate Marker for Delivering Phase-Gated Radiotherapy. *Int J Radiat Oncol Biol Phys* 2008; 71: 1111-7 (NKI)
1060. van der Weide L, van Sornsen de Koste JR, Lagerwaard FJ, Vincent A, van Triest B, Slotman BJ, Senan S. Analysis of carina position as surrogate marker for delivering phase-gated radiotherapy. *Int J Radiat Oncol Biol Phys* 2008; 71(4): 1111-1117 (VUmc)
1061. Van der Wijk J Jr, van der Wijk J Sr, Horn T, Nyengaard JR, Wijkstra H, Nordling J, Smedts F, de la Rosette J. Three-dimensional stereology as a tool for evaluating bladder outlet obstruction. *Scan J Urol Nephrol* 2008; 42(1); 40-46. (AMC)
1062. Van der Zee AG, Oonk MH, de Hullu JA, Ansink AC, Vergote I, Verheijen RHM, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, van d, V, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol* 2008; 26(6): 884-889 (VUmc)
1063. Van der Zee CE, Kreft M, Beckers G, Kuipers A, Sonnenberg A. Conditional deletion of the Itgb4 integrin gene in Schwann cells leads to delayed peripheral nerve regeneration. *J Neurosci* 2008; 28: 11292-303 (NKI)
1064. van der Zwet WC, Catsburg A, van Elburg RM, Savelkoul PHM, Vandenbroucke-Grauls CMJE. Mannose-binding lectin (MBL) genotype in relation to risk of nosocomial infection in pre-term

- neonates in the neonatal intensive care unit. *Clin Microbiol Infect* 2008; 14(2): 130-135 (VUmc)
1065. van der Zwet WC, Vandenbroucke-Grauls CMJE. Nosocomiale infecties in: van Furth AM, Hartwig NG, Wolfs THFW, (eds): *Werkboek Infectieziekten bij kinderen*. 2008; : 224-240 (VUmc)
1066. van Deutekom AW, Nurmohamed MT, Peters MJL, van Eijk I, Dijkmans BAC, Hamann D, Heine RJ, Simsek S. Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus. *Ann Rheum Dis* 2008; 67(7): 1051-1052 (VUmc)
1067. van Diermen DE, Hoogstraten J, van der Waal I. [Dental procedures for patients using oral anticoagulation: new insights]. *Ned Tijdschr Tandheelkd* 2008; 115(4): 225-229 (VUmc)
1068. van Dijk EM, van Dulmen-den BE, Kaspers GJL, van Dam EW, Braam KI, Huisman J. Psychosexual functioning of childhood cancer survivors. *Psychooncology* 2008; 17(5): 506-511 (VUmc)
1069. van Dijk FS, Meijers-Heijboer HE, Pals G. Angiotensin II blockade in MarfanÆs syndrome. *N Engl J Med* 2008; 359(16): 1733-1734 (VUmc)
1070. van Dijk J, Oostrom KJ, Imhof SM, Moll AC, Schouten-van Meeteren AY, Bezemer DP, Huisman J. Behavioural functioning of retinoblastoma survivors. *Psychooncology* 2008; 18(1): 87-95 (VUmc)
1071. Van Dijk M, Bongers MEJ, de Vries GJ, Grootenhuis MA, Last BF, Benninga MA. Behavioral therapy for childhood constipation: a randomized, controlled trial. *Pediatrics* 2008; 121(5): 1334-e1341. (AMC)
1072. van Eggermond MC, Tezcan I, Heemskerk MH, van den Elsen PJ. Transcriptional silencing of RFXAP in MHC class II-deficiency. *Mol Immunol* 2008; 45(10): 2920-2928 (VUmc)
1073. van Elmpt W, McDermott L, Nijsten S, Wendling M, Lambin P, Mijnheer B. A literature review of electronic portal imaging for radiotherapy dosimetry. *Radiother Oncol* 2008; 88: 289-309 (NKI)
1074. van Elmpt W, Nijsten S, Mijnheer B, Dekker A, Lambin P. The next step in patient-specific QA: 3D dose verification of conformal and intensity-modulated RT based on EPID dosimetry and Monte Carlo dose calculations. *Radiother Oncol* 2008; 86: 86-92 (NKI)
1075. van Elmpt W, Ollers M, Velders M, Poels K, Mijnheer B, Ruyscher DD, Dekker A, Lambin P, Boersma L. Transition from a simple to a more advanced dose calculation algorithm for radiotherapy of non-small cell lung cancer (NSCLC): Implications for clinical implementation in an individualized dose-escalation protocol. *Radiother Oncol* 2008; 88: 326-34 (NKI)
1076. van Furth AM. Infecties van het centraal zenuwstelsel. *VU uitgeverij*. 2008; : (VUmc)
1077. van Galen JC, Hoefnagel JJ, Vermeer MH, Willemze R, Dijkman R, Tensen CP, de Boer WP, Meijer CJLM, Oudejans JJ. Profiling of apoptosis genes identifies distinct types of primary cutaneous large B cell lymphoma. *J Pathol* 2008; 215(3): 340-346 (VUmc)
1078. van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJLM, Oudejans JJ. Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. *Histopathology* 2008; 52(5): 578-584 (VUmc)
1079. Van Gent R, Kater AP, Otto SA, Jaspers A, Borghans JAM, Vrisekoop N, Ackermans MAT, Ruiter AFC, Wittebol S, Eldering E, van Oers MHJ, Tesselaar K, Kersten MJ, Miedema F. In vivo Dynamics of Stable Chronic Lymphocytic Leukemia Inversely Correlate with Somatic Hypermutation Levels and Suggest No Major Leukemic Turnover in Bone Marrow. *Cancer Res* 2008; 68(24): 10137-10144. (AMC)
1080. van Gerven MAJ, Taal BG, Lucas PJF. Dynamic Bayesian networks as prognostic models for clinical patient management. *J Biomed Informatics* 2008; 41: 515-29 (NKI)
1081. van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJP, van Noesel MM, Pieters R. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. *Leukemia* 2008; 22(1): 124-131 (VUmc)
1082. van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, van Noesel MM, Kamps WA, Veerman AJP, Pieters R, Meijerink JP. CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia. *Pediatr Blood Cancer* 2008; 51(6): 737-740 (VUmc)
1083. Van Haaren PMA, Hulshof MCCM, Kok HP, Oldenburg S, Geijsen ED, van Lanschot JJB, Crezee J. Relation between body size and temperatures during locoregional hyperthermia of oesophageal cancer patients. *Int J Hyperthermia* 2008; 24(8): 663-674. (AMC)
1084. van Heijl M, Omlou JM, van Berge Henegouwen MI, Busch OR, Tilanus HW, Bossuyt PM, Hoekstra OS, Stoker J, Hulshof MC, van der Gaast A, Nieuwenhuijzen GA, Bonenkamp HJ, Plukker JT, Bilgen EJ, ten Kate FJ, Boellaard R, Pruijm J, Sloof GW, van Lanschot JJ. NEOadjuvant therapy monitoring with PET and CT in Esophageal Cancer (NEOPEC-trial). *BMC Med Phys* 2008; 8: 3 (AMC / VUmc)
1085. Van Heijl M, van Lanschot JJB, Koppert LB, van Berge Henegouwen MI, Muller K, Steyerberg EW, van Dekken H, Wijnhoven BPL, Tilanus HW, Richel DJ, Busch ORC, Bartelsman JF, Koning CCE, Offerhaus GJ, van der Gaast A. Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or

- squamous cell carcinoma of the esophagus (CROSS). *BMC Surg* 2008; 8(1): 21. (AMC)
1086. Van Hoof JE, Fockens P, Marinelli AW, Timmer R, van Berkel AM, Bossuyt PM, Bemelman WA. Early closure of a multicenter randomized clinical trial of endoscopic stenting versus surgery for stage IV left-sided colorectal cancer. *Endoscopy* 2008; 40(3): 184-191. (AMC)
1087. Van Hoof JE, Fockens P, Marinelli AW, Timmer R, van Berkel AM, Bossuyt PM, Bemelman WA. Early Closure of a Multicenter Randomized Clinical Trial of Endoscopic Stenting versus Surgery for Stage IV Left-sided Colorectal Cancer. *Endoskopie Heute* 2008; 21(2): 123-131. (AMC)
1088. van Houdt I, Sluijter BJ, Moesbergen LM, Vos WM, de Gruijl TD, Molenkamp BG, van den Eertwegh AJM, Hooijberg E, van Leeuwen PAM, Meijer CJLM, Oudejans JJ. Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T-lymphocytes and preserved MHC class I antigen expression. *Int J Cancer* 2008; 123(3): 609-615 (VUmc)
1089. van Kemenade FJ. Een onterecht geruststellend cervixuitstrijkje bij een adenocarcinoom van de baarmoedermond. *Ned Tijdschr Geneesk* 2008; 152: 1751-1752 (VUmc)
1090. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. *Nat Immunol* 2008; 9(6): 593-601 (VUmc)
1091. van Kooyk Y. C-type lectins on dendritic cells: key modulators for the induction of immune responses. *Biochem Soc Trans* 2008; 36(Pt 6): 1478-1481 (VUmc)
1092. Van Koperen PJ, Bemelman WA, Bossuyt PM, Gerhards MF, Eijsbouts QAJ, van Tets WF, Janssen LWM, Dijkstra FR, van Dalsen AD, Slors JFM. The Anal Fistula Plug versus the mucosal advancement flap for the treatment of Anorectal Fistula (PLUG trial). *BMC Surgery* 2008; 8(1): 11. (AMC)
1093. Van Koperen PJ, Horsthuis K, Bemelman WA, Stoker J, Slors JFM. Perianale fistels: veranderde inzichten met betrekking tot classificatie en diagnostiek, en een nieuwe behandelstrategie. *NTVG* 2008; 152(51-52): 2774-2780. (AMC)
1094. Van Koperen PJ, van Berge Henegouwen MI, Slors JFM, Bemelman WA. Endo-sponge treatment of anastomotic leakage after ileo-anal pouch anastomosis: report of two cases. *Colorectal Dis* 2008; 10(9): 943-944. (AMC)
1095. Van Koperen PJ, Wind J, Bemelman WA, Bakx R, Reitsma JB, Slors JFM. Long-term functional outcome and risk factors for recurrence after surgical treatment for low and high perianal fistulas of cryptoglandular origin. *Dis Colon & Rectum* 2008; 51(10): 1475-1481. (AMC)
1096. Van Koperen PJ, Wind J, Bemelman WA, Slors JFM. Fibrin glue and transanal rectal advancement flap for high transsphincteric perianal fistulas; is there any advantage? *Int J Colorect Dis* 2008; 23(7): 697-701. (AMC)
1097. Van Kuilenburg ABP, Klumpen HJ, Westermann AM, Zoetekouw L, Bakker PJM, Guchelaar HJ, Richel DJ. Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy. *Nucleosides Nucleotides & Nucleic Acids* 2008; 27(6): 726-732. (AMC)
1098. Van Kuilenburg ABP, Maring JG, Schalthorn A, Terborg C, Schmalenberg H, Behnke D, Schwabe W, Jabschinsky K, Hausler P. Pharmacokinetics of 5-fluorouracil in patients heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene. *Nucleosides Nucleotides & Nucleic Acids* 2008; 27(6): 692-698. (AMC)
1099. Van Kuilenburg ABP, Meijer J, Dobritzsch D, Lohkamp B, Ruitenbeek W, Roelofsen J, Abeling NGGM, Duran M, Buzing C. Identification of two novel mutations C79X and R235Q in the dihydropyrimidine dehydrogenase gene in a patient presenting with hematuria. *Nucleosides Nucleotides & Nucleic Acids* 2008; 27(6): 809-815. (AMC)
1100. Van Kuilenburg ABP, Stroomeer AEM, Bosch AM, Duran M. Beta-alanine and beta-aminoisobutyric acid levels in two siblings with dihydropyrimidinase deficiency. *Nucleosides Nucleotides & Nucleic Acids* 2008; 27(6): 825-829. (AMC)
1101. Van Kuilenburg ABP, van Cruchten AG, Abeling NGGM. Screening for Disorders of Purine and Pyrimidine Metabolism using HPLC-Electrospray Tandem Mass Spectrometry. Blau Nenad, Duran Marinus, Gibson Michael K. (red.): *Laboratory Guide to the Methods in Biochemical Genetics*. S.l.: Springer, 2008. p.725-737. (AMC)
1102. van Leuken R, Clijsters L, Wolthuis R. To cell cycle, swing the APC/C. *Biochim Biophys Acta (Rev Cancer)* 2008; 1786: 49-59 (NKI)
1103. van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM, Medema RH. Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. *Cell Cycle* 2008; 7: 2710-9 (NKI)
1104. Van Maldegem F, de Wit M, Morsink F, Musler A, Weegeenaar J, van Noesel CJM. Effects of processing delay, formalin fixation, and immunohistochemistry on RNA Recovery From Formalin-fixed Paraffin-embedded Tissue Sections. *Diagn Mol Pathol* 2008; 17(1): 51-58. (AMC)
1105. Van Maldegem F, van Dijk R, Wormhoudt TAM, Kluin PM, Willemze R, Cerroni L, van Noesel CJM, Bende RJ. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment. *Blood* 2008; 112(8): 3355-3361. (AMC)
1106. Van Meeteren LA, Brinkmann V, Saulnier-Blache JS, Lynch KR, Moolenaar WH. Anticancer

- activity of FTY720: Phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D. *Cancer Lett* 2008; 266: 203-8 (NKI)
1107. van Montfrans C, Lagendijk J, Hayes D, Bousema M. Two cases of spontaneous stellate scars. *Pediatr Dermatol* 2008; 25(2): 245-246 (VUmc)
1108. Van Oers MHJ. Chronisch Lymfatische Leukemie (hoofdstuk 25). In: Löwenberg Bob, Ossenkoppele Gert J. (red.): *Handboek Hematologie*. Utrecht: De Tijdstroom, 2008. p.337-351. (AMC)
1109. Van Poppel H, Tombal B, de la Rosette JJ, Persson BE, Jensen JK, Kold OT. Degarelix: A Novel Gonadotropin-Releasing Hormone (gnrh) Receptor Blocker-Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer. *Eur Urol* 2008; 54(4): 805-815. (AMC)
1110. van Rietschoten JG, Gal-Yam EN, Jeong S, Cortez CC, Verweij CL, Jones PA. Epigenetic regulation and nucleosome positioning in the human TATA-less IL-1 alpha promoter. *Genes Immun* 2008; 9(7): 582-590 (VUmc)
1111. Van Rij CM, Oughlane-Heemsbergen WD, Ackerstaff AH, Lamers EA, Balm AJM, Rasch CRN. Parotid gland sparing IMRT for head and neck cancer improves xerostomia related quality of life. *Rad Oncol* 2008; 3(1): 41. (AMC)
1112. van Rijen MM, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev* 2008; (4): CD006216 (VUmc)
1113. van Rijen MM, Bonten M, Wenzel RP, Kluytmans JA. Intranasal mupirocin for reduction of *Staphylococcus aureus* infections in surgical patients with nasal carriage: a systematic review. *J Antimicrob Chemother* 2008; 61(2): 254-261 (VUmc)
1114. van Rijen MM, Kluytmans JA. New approaches to prevention of staphylococcal infection in surgery. *Curr Opin Infect Dis* 2008; 21(4): 380-384 (VUmc)
1115. van Rijen MM, van Keulen PH, Kluytmans JA. Increase in a Dutch hospital of methicillin-resistant *Staphylococcus aureus* related to animal farming. *Clin Infect Dis* 2008; 46(2): 261-263 (VUmc)
1116. van Rooijen N. Liposomes for targeting of antigens and drugs: immunoadjuvant activity and liposome-mediated depletion of macrophages. *J Drug Target* 2008; 16(7): 529-534 (VUmc)
1117. van Rossum TG, de Melker HE, Houweling H, Voordouw AC, Meijer CJLM, Helmerhorst TJ, Kretzschmar M, Berkhof J, van der Noordaa J. Vaccines against human papillomavirus (HPV): between registration and implementation. *Ned Tijdschr Geneesk* 2008; 152(17): 987-992 (VUmc)
1118. Van Ruissen F, Schaaf GJ, Kool M, Baas F, Ruijter JM. Scaling of gene expression data allowing the comparison of different expression platforms. Nielsen K. L. (red.): *Serial analysis of gene expression (SAGE)*. Methods and protocols. Totowa NJ: Humana Press, 2008. p.169-184. (AMC)
1119. Van Sandick JW, Kappers I, Baas P, Haas RL, Klomp HM. Surgical treatment in the management of malignant pleural mesothelioma: A single institution's experience. *Ann Surg Oncol* 2008; 15: 1757-64 (NKI)
1120. van Schaardenburg D, Bos WH, Ursum J, van de Stadt RJ, van Denderen JC, Dijkmans BAC. [The diagnostic accuracy of anti-citrulline antibody assessment in the diagnosis of patients suspected of rheumatoid arthritis by a general practitioner]. *Ned Tijdschr Geneesk* 2008; 152(21): 1244-1246 (VUmc)
1121. Van Seters M, Beckmann I, Heijmans-Antonissen C, van Beurden M, Ewing PC, Zijlstra FJ, Helmerhorst TJ, Kleinjan A. Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. *Cancer Res* 2008; 68: 6617-22 (NKI)
1122. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJLM, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. *N Engl J Med* 2008; 358(14): 1465-1473 (AMC / NKI / VUmc)
1123. Van Slambrouck S, Hilkens J, Steelant WFA. Ether lipid 1-O-octadecyl-2-O-methyl-3-glycerophosphocholine inhibits cell-cell adhesion through translocation and clustering of E-cadherin and episialin in membrane microdomains. *Oncol Rep* 2008; 19: 123-8 (NKI)
1124. van Tilburg EW, Mooijer MP, Brinkhorst J, van der Meij M, Windhorst AD. Improved and semi-automated GMP-compliant radiosynthesis of [¹¹C]docetaxel. *Appl Radiat Isot* 2008; 66: 1414-1418 (VUmc)
1125. van Tuyl LH, Lems WF, Voskuyl AE, Kerstens PJ, Garnero P, Dijkmans BAC, Boers M. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. *Ann Rheum Dis* 2008; 67(11): 1574-1577 (VUmc)
1126. van Tuyl LH, Plass AM, Lems WF, Voskuyl AE, Kerstens PJ, Dijkmans BAC, Boers M. Discordant perspectives of rheumatologists and patients on COBRA combination therapy in rheumatoid arthritis. *Rheumatology (Oxford)* 2008; 47(10): 1571-1576 (VUmc)
1127. Van Uitert M, Meuleman W, Wessels L. Biclustering sparse binary genomic data. *J Comput Biol* 2008; 15: 1329-45 (NKI)
1128. van Velden FH, Kloet RW, van Berckel BN, Molthoff CFM, de Jong HW, Lammertsma AA, Boellaard R. Impact of attenuation correction strategies on the quantification of High Resolution

- Research Tomograph PET studies. *Phys Med Biol* 2008; 53(1): 99-118 (VUmc)
1129. van Velden FH, Kloet RW, van Berckel BN, Molthoff CFM, Lammertsma AA, Boellaard R. Gap filling strategies for 3-D-FBP reconstructions of High-Resolution Research Tomograph scans. *IEEE Trans Med Imaging* 2008; 27(7): 934-942 (VUmc)
1130. van Velden FH, Kloet RW, van Berckel BN, Wolfensberger SP, Lammertsma AA, Boellaard R. Comparison of 3D-OP-OSEM and 3D-FBP reconstruction algorithms for High-Resolution Research Tomograph studies: effects of randoms estimation methods. *Phys Med Biol* 2008; 53(12): 3217-3230 (VUmc)
1131. Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP. The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. *Blood* 2008; 111: 4668-80 (NKI)
1132. van Vliet MH, Reyat F, Horlings HM, van de Vijver MJ, Reinders MJT, Wessels LFA. Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability. *BMC Genomics* 2008; 9: 375 (22pp) (AMC / NKI)
1133. van Vliet SJ, Garcia-Vallejo JJ, van Kooyk Y. Dendritic cells and C-type lectin receptors: coupling innate to adaptive immune responses. *Immunol Cell Biol* 2008; 86(7): 580-587 (VUmc)
1134. van Vliet SJ, Paessens LC, Broks-van den Berg VC, Geijtenbeek TBH, van Kooyk Y. The C-type lectin macrophage galactose-type lectin impedes migration of immature APCs. *J Immunol* 2008; 181(5): 3148-3155 (VUmc)
1135. van Vliet SJ, Saeland E, van Kooyk Y. Sweet preferences of MGL: carbohydrate specificity and function. *Trends Immunol* 2008; 29(2): 83-90 (VUmc)
1136. van Vugt RM, Rijken PJ, Rietveld AG, van Vugt AC, Dijkmans BAC. Antioxidant intervention in rheumatoid arthritis: results of an open pilot study. *Clin Rheumatol* 2008; 27(6): 771-775 (VUmc)
1137. van Vulpen M, van der Heide UA, van Moorselaar JR. How quality influences the clinical outcome of external beam radiotherapy for localized prostate cancer. *BJU Int* 2008; 101(8): 944-947 (VUmc)
1138. van Waterschoot RA, van Herwaarden AE, Lagas JS, Sparidans RW, Wagenaar E, van der Kruijssen CM, Goldstein JA, Zeldin DC, Beijnen JH, Schinkel AH. Midazolam metabolism in Cytochrome P450 3A knockout mice can be attributed to upregulated CYP2C enzymes. *Mol Pharmacol* 2008; 73: 1029-36 (NKI)
1139. van Welssem T, Frederiks F, Verzijlbergen KF, Faber AW, Nelson ZW, Egan DA, Gottschling DE, van Leeuwen F. Synthetic lethal screens identify gene silencing processes in yeast and implicate the acetylated amino terminus of Sir3 in recognition of the nucleosome core. *Mol Cell Biol* 2008; 28: 3861-72 (NKI)
1140. van Wieringen WN, van de Wiel MA, van der Vaart AW. A test for partial differential expression. *J Am Statist Assoc* 2008; 103: 1039-1049 (VUmc)
1141. van Wieringen WN, van de Wiel MA, Ylstra B. Weighted clustering of called array CGH data. *Biostatistics* 2008; 9(3): 484-500 (VUmc)
1142. van Zeeburg HJ, Snijders PJF, Wu T, Gluckman E, Soulier J, Surrallés J, Castella M, van der Wal JE, Wennerberg J, Califano J, Velleuer E, Dietrich R, Ebell W, Bloemena E, Joenje H, Leemans CR, Brakenhoff RH. Clinical and Molecular Characteristics of Squamous Cell Carcinomas From Fanconi Anemia Patients. *J Natl Cancer Inst* 2008; 100(22): 1649-1653 (VUmc)
1143. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. *Nature* 2008; 452: 564-70 (NKI)
1144. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. *Ann Oncol* 2008; 19: 623-9 (NKI)
1145. Varghese B, Rajan V, van Leeuwen TG, Steenbergen W. High angle phase modulated low coherence interferometry for path length resolved Doppler measurements of multiply scattered light. *Optics Communications* 2008; 281(3): 494-498. (AMC)
1146. Veenhof AA, Engel AF, van der Peet DL, Sietses C, Meijerink WJ, de Lange-de Klerk ES, Cuesta MA. Technical difficulty grade score for the laparoscopic approach of rectal cancer: a single institution pilot study. *Int J Colorectal Dis* 2008; 23(5): 469-475 (VUmc)
1147. Veenhof AA, van der Peet DL, Meijerink WJ, Cuesta MA. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. *Ann Surg* 2008; 247(4): 718-719 (VUmc)
1148. Vekony H, Raaphorst FM, Otte AP, van Lohuizen M, Leemans CR, van der Waal I, Bloemena E. High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma. *J Clin Pathol* 2008; 61(6): 744-749 (NKI / VUmc)
1149. Vekony H, Roser K, Loning T, Raaphorst FM, Leemans CR, van der Waal I, Bloemena E. Deregulated expression of p16INK4a and p53 pathway members in benign and malignant myoepithelial tumours of the salivary glands. *Histopathology* 2008; 53(6): 658-666 (VUmc)
1150. Vellenga E, van Putten WL, van 't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, Verdonck LF, Wijermans PW, van Imhoff GW, Lugtenburg PJ,

- Huijgens PC. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. *Blood* 2008; 111(2): 537-543 (AMC / VUmc)
1151. Veltkamp SA, Beijnen JH, Schellens JHM. Prolonged versus standard gemcitabine infusion: Translation of molecular pharmacology to new treatment strategy. *Oncologist* 2008; 13: 261-76 (NKI)
1152. Veltkamp SA, Jansen RS, Callies S, Pluim D, Visseren-Grul CM, Rosing H, Kloeker-Rhoades S, Andre VA, Beijnen JH, Slapak CA, Schellens JHM. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. *Clin Cancer Res* 2008; 14: 3477-86 (NKI)
1153. Veltkamp SA, Pluim D, van Eijndhoven MA, Bolijn MJ, Ong FH, Govindarajan R, Unadkat JD, Beijnen JH, Schellens JHM. New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine. *Mol Cancer Ther* 2008; 7: 2415-25 (NKI)
1154. Veltkamp SA, Pluim D, van Tellingen O, Beijnen JH, Schellens JHM. Extensive metabolism and hepatic accumulation of gemcitabine following multiple oral and intravenous administration in mice. *Drug Metab Dispos* 2008; 36: 1608-15 (NKI)
1155. Veltkamp SA, Witteveen EO, Capriati A, Crea A, Animati F, Voogel-Fuchs M, van den Heuvel IJ, Beijnen JH, Voest EE, Schellens JHM. Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors. *Clin Cancer Res* 2008; 14: 7535-44 (NKI)
1156. Verbeek WHM, Goerres MS, von Blumberg BME, Oudejans JJ, Scholten PE, Hadithi M, Al-Toma AB, Schreurs MW, Mulder CJJ. Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease. *Clin Immunol* 2008; 126(1): 48-56 (VUmc)
1157. Verbeek WHM, Mulder CJJ. [A changing spectrum: mucosal damage and the clinical picture of adult celiac disease]. *Gastroenterol Clin Biol* 2008; 32(3): e3-e4 (VUmc)
1158. Verbeek WHM, Schreurs MW, Visser OJ, von Blumberg BME, Al-Toma AB, Mulder CJJ. Novel approaches in the management of refractory celiac disease. *Expert Rev Clin Immunol* 2008; 4(2): 205-219 (VUmc)
1159. Verbeek WHM, van de Water JMW, Al-Toma AB, Oudejans JJ, Mulder CJJ, Coupe VM. Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based registry in The Netherlands. *Scand J Gastroenterol* 2008; 43(11): 1322-1328 (VUmc)
1160. Verbeek WHM, von Blumberg BME, Scholten PE, Kuik DJ, Mulder CJJ, Schreurs MW. The presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated with lymphoma development in refractory celiac disease. *Am J Gastroenterol* 2008; 103(12): 3152-3158 (VUmc)
1161. Verbrugge I, de Vries E, Tait SW, Wissink EH, Walczak H, Verheij M, Borst J. Ionizing radiation modulates the TRAIL death-inducing signaling complex, allowing bypass of the mitochondrial apoptosis pathway. *Oncogene* 2008; 27: 574-84 (NKI)
1162. Verbrugghe P, Kujala P, Waelput W, Peters PJ, Cuvelier CA. Clusterin in human gut-associated lymphoid tissue, tonsils, and adenoids: localization to M cells and follicular dendritic cells. *Histochem Cell Biol* 2008; 129: 311-20 (NKI)
1163. Verhaar HJ, Lems WF. PTH analogen: comparable or different?. *Tijdschr Gerontology en Geriatrie* 2008; : 176-181 (VUmc)
1164. Verhagen A, Bierma-Zeinstra SM, Lambeck J, Cardoso JR, de Bie R, Boers M, de Vet HC. Balneotherapy for osteoarthritis. A cochrane review. *J Rheumatol* 2008; 35(6): 1118-1123 (VUmc)
1165. Verheij M, Bartelink H. Chemoradiotherapy. In: Schwab M, editor. *Encyclopedia of Cancer*, 2nd ed.; part C. Springer, 2009: 625-628 (NKI)
1166. Verheij M, van Blitterswijk W. Sphingomyelin metabolism: Implications for cell signaling and drug uptake. In: Kasis UN, Notario V, Haimowitz-Friedman A, Bar-Eli M, editors. *Reviews in cancer biology & therapeutics*. Kerala: Transworld Research Network, 2008: 55-71 (NKI)
1167. Verheij M. Clinical biomarkers and imaging for radiotherapy-induced cell death. *Cancer Metastasis Rev* 2008; 27: 471-80 (NKI)
1168. Verheul HM, Salumbides B, van Erp K, Hammers H, Qian DZ, Sanni T, Atadja P, Pili R. Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors. *Clin Cancer Res* 2008; 14(11): 3589-3597 (VUmc)
1169. Verkooijen HM, Koot VC, Fioretta G, van der Heiden M, Schipper ME, Rapiti E, Peeters PHM, Peterse JL, Bouchardey C. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: an ecological study comparing two European populations. *Breast Cancer Res Treat* 2008; 107: 389-95 (NKI)
1170. Vermaat H, Kirtschig G. Prevention and treatment of glucocorticoid-induced osteoporosis in daily dermatologic practice. *Int J Dermatol* 2008; 47(7): 737-742 (VUmc)
1171. Vermaat H, Smienk F, Rustemeyer T, Bruynzeel DP, Kirtschig G. Anogenital allergic contact dermatitis, the role of spices and flavour allergy. *Contact Dermatitis* 2008; 59(4): 233-237 (VUmc)
1172. Vermaat H, van Meurs T, Rustemeyer T, Bruynzeel DP, Kirtschig G. Vulval allergic contact

- dermatitis due to peppermint oil in herbal tea. *Contact Dermatitis* 2008; 58(6): 364-365 (VUmc)
1173. Vermeulen C, Verwijs-Janssen M, Begg AC, Vens C. Cell cycle phase dependent role of DNA polymerase γ in DNA repair and survival after ionizing radiation. *Radiother Oncol* 2008; 86: 391-8 (NKI)
1174. Vermeulen L, Sprick MR, Kemper K, Stassi G, Medema JP. Cancer stem cells--old concepts, new insights. *Cell Death And Differentiation* 2008; 15(6): 947-958. (AMC)
1175. Vermeulen L, Todaro M, Mello De Sousa F, Sprick MR, Kemper K, Alea Perez M, Richel DJ, Stassi G, Medema JP. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. *Proceedings Of The National Academy Of Sciences Of The United States Of America* 2008; 105(36): 13427-13432. (AMC)
1176. Versteeg HH, Borensztajn KS, Kerver ME, Ruf W, Reitsma PH, Spek CA, Peppelenbosch MP. TF:fviiia-specific activation of CREB upregulates proapoptotic proteins via protease-activated receptor-2. *J Thromb Haemostasis* 2008; 6(9): 1550-1557. (AMC)
1177. Verstege MI, Ten Kate FJ, Reinartz SM, van Drunen CM, Slors FJ, Bemelman WA, Vyth-Dreese FA, Te Velde AA. Dendritic Cell Populations in Colon and Mesenteric Lymph Nodes of Patients With Crohn's Disease. *J Histochem Cytochem* 2008; 56: 233-41 (AMC / NKI)
1178. Verstrepen BE, Bins AD, Rollier CS, Mooij P, Koopman G, Sheppard NC, Sattentau Q, Wagner R, Wolf H, Schumacher TNM, Heeney JL, Haanen JBAG. Improved HIV-1 specific T-cell responses by short-interval DNA tattooing as compared to intramuscular immunization in non-human primates. *Vaccine* 2008; 26: 3346-51 (NKI)
1179. Verwaal VJ, Bruin S, Boot H, van Slooten G, Van Tinteren H. 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer. *Ann Surg Oncol* 2008; 15: 2426-32 (NKI)
1180. Verwaal VJ, Kusamura S, Baratti D, Deraco M. The eligibility for local-regional treatment of peritoneal surface malignancy. *J Surg Oncol* 2008; 98: 220-3 (NKI)
1181. Veteläinen R, Erdogan D, de Graaf W, ten Kate F, Jansen PLM, Gouma DJ, van Gulik TM. Liver adenomatosis: re-evaluation of aetiology and management. *Liver Internat* 2008; 28(4): 499-508. (AMC)
1182. Videtic GM, Belderbos JSA, Spring Kong FM, Kepka L, Martel MK, Jeremic B. Report from the International Atomic Energy Agency (IAEA) consultants' meeting on elective nodal irradiation in lung cancer: small-cell lung cancer (SCLC). *Int J Radiat Oncol Biol Phys* 2008; 72: 327-34 (NKI)
1183. Vis M, Bos WH, Wolbink G, Voskuyl AE, Twisk JW, van de Stadt R, Hamann D, Dijkman BAC, Lems WF. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. *J Rheumatol* 2008; 35(3): 425-428 (VUmc)
1184. Visser M, Jiwa M, Horstman A, Brink AA, Pol RP, van Diest PJ, Snijders PJF, Meijer CJLM. Intra-operative rapid diagnostic method based on CK19 mRNA expression for the detection of lymph node metastases in breast cancer. *Int J Cancer* 2008; 122(11): 2562-2567 (VUmc)
1185. Vissers JH, Nicassio F, van Lohuizen M, Di Fiore PP, Citterio E. The many faces of ubiquitinated histone H2A: insights from the DUBs. *Cell Div* 2008; 3: 8 (14pp) (NKI)
1186. Vlaming ML, Pala Z, van Esch A, Wagenaar E, van Tellingen O, de Waart DR, Oude Elferink RP, Van De Wetering K, Schinkel AH. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. *Clin Cancer Res* 2008; 14: 8152-60 (NKI)
1187. Vliem MJ, Ponsioen B, Schwede F, Pannekoek WJ, Riedl J, Kooistra MR, Jalink K, Genieser HG, Bos JL, Rehmann H. 8-pCPT-2'-O-Me-cAMP-AM: An Improved Epac-Selective cAMP Analogue. *Chembiochem* 2008; 9: 2052-4 (NKI)
1188. Voermans R, van Berge Henegouwen MI, Bemelman WA, Fockens P. Endoscopische abdominale chirurgie via natuurlijke lichaamsopeningen. *NTVG* 2008; 152(19): 1091-1096. (AMC)
1189. Voermans RP, Worm AM, van Berge Henegouwen MI, Breedveld P, Bemelman WA, Fockens P. In vitro comparison and evaluation of seven gastric closure modalities for natural orifice transluminal endoscopic surgery (NOTES). *Endoscopy* 2008; 40(7): 595-601. (AMC)
1190. Vogel WV. *Beeldfusie. Leerboek Nucleaire geneeskunde*. Elsevier, 2008: 107-122 (NKI)
1191. Volman MN, van Rossem MC, de Winter JP, van Houten MA. [Outbreak of coxsackievirus infection in children]. *Ned Tijdschr Geneesk* 2008; 152(8): 413-417 (VUmc)
1192. Vondenhoff MF, Desanti GE, Cupedo T, Bertrand JY, Cumano A, Kraal G, Mebius RE, Golub R. Separation of splenic red and white pulp occurs before birth in a L α 1phbeta-independent manner. *J Leukoc Biol* 2008; 84(1): 152-161 (VUmc)
1193. Vormer TL, Fojjer F, Wielders CL, Te Riele H. Anchorage-independent growth of pocket protein-deficient murine fibroblasts requires bypass of G2 arrest and can be accomplished by expression of TBX2. *Mol Cell Biol* 2008; 28: 7263-73 (NKI)
1194. Vos J, Otten W, van Asperen C, Jansen A, Menko FH, Tibben A. The counsellors' view of an

- unclassified variant in BRCA1/2: recall, interpretation, and impact on life. *Psychooncology* 2008; 17(8): 822-830 (VUmc)
1195. Vos MR, Bomans PH, Frederik PM, Sommerdijk NA. The development of a glove-box/Vitrobot combination: Air-water interface events visualized by cryo-TEM. *Ultramicroscopy* 2008; 108: 1478-83 (NKI)
1196. Voskuil DW, Vrieling A, Korse CM, Beijnen JH, Bonfrer JMG, van Doorn J, Kaas R, Russell NS, Rutgers EJT, van Leeuwen FE, van 't Veer LJ, Rookus MA. Effects of lycopene on the Insulin-like Growth Factor (IGF) system in breast cancer survivors and women at high familial breast cancer risk. *Nutr Cancer* 2008; 60: 342-53 (NKI)
1197. Vrieling A, Rookus MA, Kampman E, Bonfrer JMG, Bosma A, Cats A, van Doorn J, Korse CM, Witteman BJ, van Leeuwen FE, van't Veer LJ, Voskuil DW. No effect of red clover-derived isoflavone intervention on the insulin-like growth factor system in women at increased risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 2585-93 (NKI)
1198. Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BMP. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. *Radiother Oncol* 2008; 87: 405-11 (NKI)
1199. Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, Pink R, Buckley SM, Greig JA, Denby L, Custers J, Morita T, Francischetti IM, Monteiro RQ, Barouch DH, van Rooijen N, Napoli C, Havenga MJ, Nicklin SA, Baker AH. Adenovirus serotype 5 hexon mediates liver gene transfer. *Cell* 2008; 132(3): 397-409 (VUmc)
1200. Wagenaar-Bos IGA, Drouet C, Aygoeren-Pursun E, Bork K, Bucher C, Bygum A, Farkas H, Fust G, Gregorek H, Hack CE, Hickey A, Joller-Jemelka HI, Kapusta M, Kreuz W, Longhurst H, Lopez-Trascasa M, Madalinski K, Naskalski J, Nieuwenhuys E, Ponard D, Truedsson L, Varga L, Nielsen EW, Wagner E, Zingale L, Cicardi M, van Ham SM. Functional C1-inhibitor diagnostics in hereditary angioedema: Assay evaluation and recommendations. *J Immunol Methods* 2008; 338(1-2): 14-20. (AMC)
1201. Wakelee H, Langer C, Vokes E, Schiller J, Baas P, Saijo N, Adjei A, Shepherd F, Choy H, Gandara DR. Cooperative group research efforts in lung cancer: Focus on early-stage non-small-cell lung cancer. *Clin Lung Cancer* 2008; 9: 9-15 (NKI)
1202. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T cell activation in nonlymphoid tissues. *Science* 2008; 319(5860): 198-202 (VUmc)
1203. Wapenaar MC, Monsuur AJ, van Bodegraven AA, Weersma RK, Bevova MR, Linskens RK, Howdle P, Holmes G, Mulder CJJ, Dijkstra G, van Heel DA, Wijmenga C. Associations with tight junction genes PARD3 and MAGI2 in Dutch patients point to a common barrier defect for coeliac disease and ulcerative colitis. *Gut* 2008; 57(4): 463-467 (VUmc)
1204. Watchmaker PB, Urban JA, Berk E, Nakamura Y, Mailliard RB, Watkins SC, van Ham SM, Kalinski P. Memory CD8(+) T cells protect dendritic cells from CTL killing. *J Immunol* 2008; 180(6): 3857-3865. (AMC)
1205. Weichselbaum RR, Ishwaran H, Yoon T, Nuyten DSA, Baker SW, Khodarev N, Su AW, Shaikh AY, Roach P, Kreike B, Roizman B, Bergh J, Pawitan Y, van de Vijver MJ, Minn AJ. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. *Proc Natl Acad Sci U S A* 2008; 105: 18490-5 (AMC / NKI)
1206. Weigelt B, Horlings HM, Kreike B, Hayes MM, Hauptmann M, Wessels LFA, de Jong D, van de Vijver MJ, van't Veer LJ, Peterse JL. Refinement of breast cancer classification by molecular characterization of histological special types. *J Pathol* 2008; 216: 141-50 (AMC / NKI)
1207. Weijers M, ten Hove I, Allard RH, Bezemer DP, van der Waal I. Patients with oral cancer developing from pre-existing oral leukoplakia: do they do better than those with de novo oral cancer?. *J Oral Pathol Med* 2008; 37(3): 134-136 (VUmc)
1208. Weinkove D, Bastiani M, Chessa TA, Joshi D, Hauth L, Cooke FT, Divecha N, Schuske K. Overexpression of PPK-1, the *Caenorhabditis elegans* Type I PIP kinase, inhibits growth cone collapse in the developing nervous system and causes axonal degeneration in adults. *Dev Biol* 2008; 313: 384-97 (NKI)
1209. Westerterp M, Sloof GW, Hoekstra OS, ten Kate FJ, Meijer GA, Reitsma JB, Boellaard R, van Lanschot JJ, Molthoff CFM. 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. *J Cancer Res Clin Oncol* 2008; 134(2): 227-236 (AMC / VUmc)
1210. Wijbrandts CA, Dijkgraaf MG, Kraan MC, Vinkenoog M, Smeets TJ, Dinant H, Vos K, Lems WF, Wolbink GJ, Sijpkens D, Dijkmans BAC, Tak PP. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. *Ann Rheum Dis* 2008; 67(8): 1139-1144 (VUmc)
1211. Wijkstra H, de La Rosette JJMCH. Editorial comment on: comparison of contrast-enhanced color Doppler imaging (CDI), computerized tomography (CT), and magnetic resonance imaging (MRI) for the detection of crossing vessels in patients with ureteropelvic junction obstruction (UPJO). *Eur Urol* 2008; 53(6): 1260-1261. (AMC)
1212. Willeminck GH, Manohar S, van der Heijden F, Slump CH, van Leeuwen TG (red.): Imaging of acoustic attenuation and speed of sound maps using photoacoustic measurement.. S.l. : Proc SPIE 692013, 2008(Medical Imaging 2008, Ultrasonic Imaging & Signal Processing; 692013). (AMC)
1213. Willeminck RG, Manohar S, Slump KH, van der Heijden F, van Leeuwen TG. A maximum likelihood

- method for obtaining integrated attenuation from ultrasound transmission mode measurements. *J Acoust Soc Am* 2008; 123(5): 3641. (AMC)
1214. Willemsen I, Mooij M, van der Wiel M, Bogaers D, van der Bijl M, Savelkoul PHM, Kluytmans J. Highly resistant microorganisms in a teaching hospital: the role of horizontal spread in a setting of endemicity. *Infect Control Hosp Epidemiol* 2008; 29(12): 1110-1117 (VUmc)
1215. Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, Canninga-van Dijk MR, Carlotti A, Geerts ML, Hahtola S, Hummel M, Jeskanen L, Kempf W, Massone C, Ortiz-Romero PL, Paulli M, Petrella T, Ranki A, Peralto JL, Robson A, Senff NJ, Vermeer MH, W. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors. an EORTC Cutaneous Lymphoma Group Study of 83 cases. *Blood* 2008; 111(2): 838-845 (VUmc)
1216. Wilting SM, de Wilde J, Meijer CJLM, Berkhof J, Yi Y, van Wieringen WN, Braakhuis BJM, Meijer GA, Ylstra B, Snijders PJF, Steenbergen RDM. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer. *Genes Chromosomes Cancer* 2008; 47(10): 890-905 (VUmc)
1217. Wind J, Safiruddin F, van Berge Henegouwen MI, Slors JFM, Bemelman WA. Staple line failure using the Proximate (R) 100 mm linear cutter. *Dis Colon Rectum* 2008; 51(8): 1275-1278. (AMC)
1218. Wind J, ten Kate FJW, Kiewiet JJS, Lagarde SM, Slors JFM, van Lanschot JJB, Bemelman WA. The prognostic significance of extracapsular lymph node involvement in node positive patients with colonic cancer. *EJSO* 2008; 34(4): 390-396. (AMC)
1219. Windhorst AD, Klein PJ, Eisenbarth J, Oeser T, Kruijjer PS, Eisenhut M. 3'-Sulfonylestere of 2,5'-anhydro-1-(2-deoxy-beta-d-threo-pentofuranosyl)thymine as precursors for the synthesis of [18F]FLT: syntheses and radiofluorination trials. *Nucl Med Biol* 2008; 111: 537-543 (VUmc)
1220. Wink M, Frauscher F, Cosgrove D, Chapelon JY, Palwein L, Mitterberger M, Harvey C, Rouvière O, de la Rosette J, Wijkstra H. Contrast-Enhanced Ultrasound and Prostate Cancer; A Multicentre European Research Coordination Project. *Eur Urol* 2008; 54(5): 982-993. (AMC)
1221. Wink MH, Laméris JS, de la Rosette JJMCH. Ultrasound in diagnosis and follow-up of renal cell cancer. In: de La Rosette JJMCH, van Poppel H, Sternberg C (red.): *Renal Cell Cancer: Diagnosis and Therapy*. London: Springer-Verlag, 2008. p.71-80. (AMC)
1222. Witte Lambertus PW, Chapple CR, de La Rosette JJMCH, Michel MC. Cholinergic innervation and muscarinic receptors in the human prostate. *Eur Urol* 2008; 54(2): 326-334. (AMC)
1223. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, van't Veer LJ, Ramaswamy S. Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. *Clin Cancer Res* 2008; 14: 2988-93 (NKI)
1224. Wolbink GJ, Dijkmans BAC, Aarden LA. The formation of infliximab and anti-infliximab immune complexes as an explanation for non-responding to infliximab treatment of rheumatoid arthritis: observational study in 4 patients. *Ned Tijdschr Geneesk* 2008; 152(30): 1672-1677 (VUmc)
1225. Wolthaus JWH, Sonke JJ, van Herk M, Belderbos JSA, Rossi MMG, Lebesque JV, Damen EMF. Comparison of Different Strategies to Use Four-Dimensional Computed Tomography in Treatment Planning for Lung Cancer Patients. *Int J Radiat Oncol Biol Phys* 2008; 70: 1229-38 (NKI)
1226. Wolthaus JWH, Sonke JJ, van Herk M, Damen EMF. Reconstruction of a time-averaged midposition CT scan for radiotherapy planning of lung cancer patients using deformable registration. *Med Phys* 2008; 35: 3998-4011 (NKI)
1227. Wolthuis R, Clay-Farrace L, Van Zon W, Yekezare M, Koop L, Ogink J, Medema R, Pines J. Cdc20 and Cks direct the spindle checkpoint-independent destruction of cyclin A. *Mol Cell* 2008; 30: 290-302 (NKI)
1228. Wondergem MJ, Stevens SJ, Janssen JJWM, Oudejans JJ, Ossenkoppele GJ, Middeldorp JM, Zweegman S. Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. *Blood* 2008; 111(3): 1739-1740 (VUmc)
1229. Wong DJ, Nuyten DSA, Regev A, Lin M, Adler AS, Segal E, van de Vijver MJ, Chang HY. Revealing targeted therapy for human cancer by gene module maps. *Cancer Res* 2008; 68: 369-78 (AMC / NKI)
1230. Woo H, Reich O, Bachmann A, Choi B, Collins E, de la Rosette J, Gomez Sancha F, Muir G, Tabatabaei S. Outcome of greenlight HPS 120-w laser therapy in specific patient populations: Those in retention, on anticoagulants, and with large prostates (>= 80 ml). *Eur Urol Suppl* 2008; 7(4): 378-383. (AMC)
1231. Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S: C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. *Exp Op Biol Ther* 2008; 8(8): 1225-1240. (AMC)
1232. Wouters MW, van Geel AN, Menke-Pluimers M, de Kanter AY, de Bruin HG, Verhoog L, Eggermont AMM. Should internal mammary chain (IMC) sentinel node biopsy be performed? Outcome in 90 consecutive non-biopsied patients with a positive IMC scintigraphy. *Breast* 2008; 17: 152-8 (NKI)
1233. Wouters MW, van Geel AN, Nieuwenhuis L, Van Tinteren H, Verhoef C, van Coevorden F, Klomp HM. Outcome After Surgical Resections of Recurrent Chest Wall Sarcomas. *J Clin Oncol* 2008; 26: 5113-8 (NKI)

1234. Wouters MW, Wijnhoven BP, Karim-Kos HE, Blaauwgeers HG, Stassen LP, Steup WH, Tilanus HW, Tollenaar RA. High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. *Ann Surg Oncol* 2008; 15: 80-7 (NKI)
1235. Wulf MWH, Tiemersma E, Kluytmans J, Bogaerts D, Leenders ACAP, Jansen MWH, Berkhout J, Ruijters E, Haverkate D, Isken M, Voss A. MRSA carriage in healthcare personnel in contact with farm animals. *J Hosp Infect* 2008; 70: 186-190 (VUmc)
1236. Xiao Y, Peperzak V, Keller AM, Borst J. CD27 instructs CD4+ T cells to provide help for the memory CD8+ T cell response after protein immunization. *J Immunol* 2008; 181: 1071-82 (NKI)
1237. Xu B, Geerts D, Qian K, Zhang H, Zhu n: Myeloid ecotropic viral integration site 1 (MEIS) 1 involvement in embryonic implantation. *Hum Reprod* 2008; 23(6): 1394-1406. (AMC)
1238. Yanez-Mo M, Barreiro O, Gonzalo P, Batista A, Megias D, Genis L, Sachs N, Sala-Valdes M, Alonso MA, Montoya MC, Sonnenberg A, Arroyo AG, Sanchez-Madrid F. MT1-MMP collagenolytic activity is regulated through association with tetraspanin CD151 in primary endothelial cells. *Blood* 2008; 112: 3217-26 (NKI)
1239. Yapliito-Lee J, Pitt J, Meijer J, Zoetekouw L, Meinsma R, van Kuilenburg ABP. Beta-ureidopropionase deficiency presenting with congenital anomalies of the urogenital and colorectal systems. *Mol Gen Metabolism* 2008; 93(2): 190-194. (AMC)
1240. Zafrakas M, Tarlatzis BC, Streichert T, Pournaropoulos F, Wolfle U, Smeets SJ, Witteck B, Grimbizis G, Brakenhoff RH, Pantel K, Bontis J, Gunes C. Genome-wide microarray gene expression, array-CGH analysis, and telomerase activity in advanced ovarian endometriosis: a high degree of differentiation rather than malignant potential. *Int J Mol Med* 2008; 21(3): 335-344 (VUmc)
1241. Zandvliet AS, Schellens JHM, Beijnen JH, Huitema ADR. Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology. *Clin Pharmacokinet* 2008; 47: 487-513 (NKI)
1242. Zandvliet AS, Siegel-Lakhai WS, Beijnen JH, Copalu W, Etienne-Grimaldi MC, Milano G, Schellens JHM, Huitema ADR. PK/PD Model of Indisulam and Capecitabine: Interaction Causes Excessive Myelosuppression. *Clin Pharmacol Ther* 2008; 83: 829-39 (NKI)
1243. Zeilstra J, Joosten SPJ, Dokter M, Verwiel E, Spaargaren M, Pals ST. Deletion of the WNT target and cancer stem cell marker CD44 in Apc(Min/+) mice attenuates intestinal tumorigenesis. *Cancer Res* 2008; 68(10): 3655-3661. (AMC)
1244. Zerp SF, Vink SR, Ruiters GA, Koolwijk P, Peters E, van der Luit AH, de Jong D, Budde M, Bartelink H, Van Blitterswijk WJ, Verheij M. Alkylphospholipids inhibit capillary-like endothelial tube formation in vitro: antiangiogenic properties of a new class of antitumor agents. *Anticancer Drugs* 2008; 19: 65-75 (NKI)
1245. Zhang H, Langeslag M, Breukels V, Jenks BG, Roubos EW, Scheenen WJMM. Calcium channel kinetics of melanotrope cells in *Xenopus laevis* depend on environmental stimulation. *Gen Comp Endocrinol* 2008; 156: 104-12 (NKI)
1246. Zhao A, Urban JF, Jr, Anthony RM, Sun R, Stiltz J, van Rooijen N, Wynn TA, Gause WC, Shea-Donohue T. Th2 cytokine-induced alterations in intestinal smooth muscle function depend on alternatively activated macrophages. *Gastroenterology* 2008; 135(1): 217-225 (VUmc)
1247. Zheng Q, van Die IM, Cummings RD. A novel alpha1,2-fucosyltransferase (CE2FT-2) in *Caenorhabditis elegans* generates H-type 3 glycan structures. *Glycobiology* 2008; 18: 290-302 (VUmc)
1248. Zhernakova A, Festen EM, Franke L, Trynka G, van Diemen CC, Monsuur AJ, Bevova M, Nijmeijer RM, van 't Slot R, Heijmans R, Boezen HM, van Heel DA, van Bodegraven AA, Stokkers PC, Wijmenga C, Crusius JBA, Weersma RK. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. *Am J Hum Genet* 2008; 82(5): 1202-1210 (VUmc)
1249. Zhou Z, Barrett RP, McClellan SA, Zhang Y, Szliter EA, van Rooijen N, Hazlett LD. Substance P delays apoptosis, enhancing keratitis after *Pseudomonas aeruginosa* infection. *Invest Ophthalmol Vis Sci* 2008; 49(10): 4458-4467 (VUmc)
1250. Zimmermann C, Van De Wetering K, van de Steeg E, Wagenaar E, Vens C, Schinkel AH. Species-dependent transport and modulation properties of human and mouse multidrug resistance protein 2 (MRP2/Mrp2, ABCC2/Abcc2). *Drug Metab Dispos* 2008; 36: 631-40 (NKI)
1251. Ziol M, Barbu V, Rosmorduc O, Frassati-Biaggi A, Barget N, Hermelin B, Scheffer GL, Bennouna S, Trinchet JC, Beaugrand M, Ganne-Carrie N. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. *Gastroenterology* 2008; 135(1): 131-141 (VUmc)
1252. Zlotorynski E, Agami R. A PASport to cellular proliferation. *Cell* 2008; 134: 208-10 (NKI)
1253. Zucali PA, Ruiz MG, Giovannetti E, Destro A, Varella-Garcia M, Floor K, Ceresoli GL, Rodriguez JA, Garassino I, Comoglio P, Roncalli M, Santoro A, Giaccone G. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. *Ann Oncol* 2008; 19(9): 1605-1612 (VUmc)
1254. Zuo J, Thomas W, van Leeuwen D, Middeldorp JM, Wiertz EJ, Rensing ME, Rowe M. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. *J Virol* 2008; 82(5): 2385-2393 (VUmc)

1255. Zuur CL, Simis YJ, Verkaik RS, Schornagel JH, Balm AJM, Dreschler WA, Rasch CRN. Hearing loss due to concurrent daily low-dose cisplatin chemoradiation for locally advanced head and neck cancer. *Radiother Oncol* 2008; 89: 38-43 (AMC / NKI)

1256. Zuur JK, Muller SH, Vincent A, Sinaasappel M, de Jongh FH, Hilgers FJM. Assessment of tracheal temperature and humidity in laryngectomized individuals and the influence of a heat and moisture exchanger on tracheal climate. *Head Neck* 2008; 30: 1072-82 (NKI)

1257. Zwier JM, Oomen L, Brocks L, Jalink K, Brakenhoff GJ. Quantitative image correction and calibration for confocal fluorescence microscopy using thin reference layers and SIPchart-based calibration procedures. *J Microsc* 2008; 231: 59-69 (NKI)

1258. Zwiers A, Fuss IJ, Leijen S, Mulder CJJ, Kraal G, Bouma G. Increased expression of the tight junction molecule claudin-18 A1 in both experimental colitis and ulcerative colitis. *Inflamm Bowel Dis* 2008; 14(12): 1652-1659 (VUmc)